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ABSTRACT 
NAFLD is characterized by simple steatosis, which can progress to chronic inflammation and 
fibrosis. Vascular Adhesion Protein-1 (VAP-1) is an adhesion molecule with semicarbazide- 
sensitive amine oxidase (SSAO) activity, which is also expressed as a soluble protein in 
serum (sVAP-1) and elevated in inflammatory liver diseases such as NAFLD. VAP-1 has 
been shown to modulate glucose and lipid uptake in muscle and adipose tissue and thus we 
investigated whether it may contribute to glucose and lipid homeostasis in human liver tissue.  
Recreating the multicellular liver environment using an ex-vivo model we have shown that 
activation of VAP-1 by its substrate methylamine leads to activation of NF-κB, glucose 
uptake and lipid accumulation in the human liver with changes in transporter expression of 
GLUT4, GLUT10 and GLUT13, as well as FABP2, LRP1, FATP2, FATP3, FATP4 and 
FATP6. We have also documented changes in transporter expression profiles in human 
disease. In conclusion, we demonstrate for the first time global alterations in cellular 
expression of glucose and lipid transporter proteins in NASH. We confirm that VAP-1 is 
elevated in disease and that SSAO activity of VAP-1 results in enhanced hepatic glucose and 
lipid accumulation with changes in transporter expression. Thus we propose that bioactive 
metabolites of SSAO activity contribute to the metabolic derangement evident in fatty liver 
disease. 
 
 
 
 
 
 
 
 
 
Work arising from this thesis 
 
Published Manuscripts 
 
An in vitro model of human acute ethanol exposure that incorporates CXCR3 and 
CXCR4 dependent recruitment of immune cells, 
Sumera Karim, Evaggelia Liaskou, Samuel Hadley, Janine Youster, Jeffrey Faint, David H 
Adams, Patricia F Lalor, Toxicological Sciences, January 2013 132 (1): 131-141 
 
Hepatic expression and cellular distribution of the glucose transporter family, Sumera 
Karim, David H Adams, Patricia F Lalor, World Journal of Gastroenterology, 2012 
December 14; 18 (46): 6771-6781 
 
 
 
Published Abstracts 
 
Digestive Disorders Federation (DDF) combined meeting for BSG, AUGIS, BAPEN and 
BASL.  Joint Meeting, June 7–20 2012, Arena and Convention Centre (ACC), Liverpool, 
UK.  Poster presentation.  (Awarded poster of distinction), published in Gut 2012; 61:Suppl 
2 A86-A87.  
 
The liver meeting, 62nd annual meeting of the American association for the study of 
liver diseases (ASSLD), November 4-8 2011, Moscone West Convention Center, San 
Francisco, CA.  Poster presentation.  Published in Hepatology, 2011, Volume 54, Number 4, 
1174A. 
 
 
British association for the study of liver (BASL), 7-9 September 2011, Royal College of 
physicians, London.  Poster presentation.  Published in special addition of GUT 2011; 60: 
Supplement 2, A40-A41 
 
American society for Mass Spectrometry, 59
th
 Annual Meeting.  June 5-9th 2011, Denver, 
Colorado. (Poster presentation).  Published in Journal for the American Society for Mass 
Spectrometry, Volume 22, Supplement 1. 
 
 
International presentations 
 
 
International society for Hepatic Sinusoidal Research, 16
th
 International Symposium on 
cells of the Hepatic Sinusoid, Sinusoidal cells and the metabolic syndrome. September 22-
24, 2011.  Florence, Italy.  
 
 
 
 
Manuscripts In preparation 
 
 
Dysregulated hepatic expression of glucose transporters in NASH: The contribution of 
amine oxidase activity to hepatic glucose uptake. 
Sumera Karim, Evaggelia Liaskou, Janine Fear, Abhilok Garg, Lee Claridge, Gary 
Reynolds, Sirpa Jalkanen, David H Adams, Philip N. Newsome and Patricia F Lalor. 
 
 
Use of MALDI Image analysis to determine disease-specific expression of variant forms 
of L-FABP in non-alcoholic fatty liver disease. 
Josephine Bunch, Sumera Karim, Joscelyn Sarsby, Anna Bradford, Evangelia Liaskou, 
Janine Fear, Patricia F. Lalor. 
 
 
The formation of atheroma is linked to steatohepatitis and hyper triglyceridaemia by 
inflammatory signalling through the lymphotoxin-β receptor.   
Mathew J. Harrison, Cécile Bénézech, Sumera Karim, Carl F. Ware, Patricia. F. Lalor, Jorge 
H. Caamaño, G. Ed Rainger. 
 
 
Multivariate and correlation analysis of MALDI mass spectrometry imaging data 
reveals features in human Non-Alcoholic Steatohepatitis (NASH) liver samples. 
Andrew D. Palmer, Alan M. Race, Rian L. Griffiths, Rory T. Steven, Sumera Karim, 
Patricia F Lalor, Iain Styles, Josephine Bunch. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Learn from yesterday, live for today, hope for tomorrow.  The important thing is not to stop 
questioning. 
 
 
Albert Einstein  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedication 
 
 
I dedicate this thesis to mum and my late father Abdul Karim. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENTS 
 
 
I would like to take this opportunity and show my gratitude to my supervisor Dr PF Lalor and 
co supervisor Professor P Newsome who gave me the opportunity to do this PhD and also to 
Professor DH Adams.  In particular I would like to say a special thank you to Dr PF Lalor for 
her excellent guidance throughout my PhD and for supporting me not only academically but 
also personally.  I am eternally grateful to her.  Thank you also to my past and present 
industrial supervisors for their support and advice on microarrays. 
 
This PhD would not have been possible without my funding bodies, so a special thank you to 
BBSRC and my industrial sponsors for funding my PhD.  Professor S Jalkanen for providing 
VAP-1 constructs and our collaborators from chemistry Dr J Bunch and Rian Griffiths.  A big 
thank you to everyone in the liver labs for all their support in particular Ben James and Dr 
Evangelia Liaskou who showed me many of the techniques when I started and Dr Lee 
Claridge for providing the mouse samples used in this study.    
 
I feel I have had an amazing journey both scientifically and personally and although there are 
many lows and highs during a PhD the highs certainly make up for the lows.  Last but not 
least I would like to thank my family, firstly my mum who has always been there for me, who 
has never let me down and who’s supported me in everything I have ever done.  I would like 
to thank my husband and my best friend Naveed Liaquat who has believed in me and has 
supported me and has always found a way to cheer me up, to the rest of my family thank you 
for your continued support and encouragement and finally thank you to my beautiful son 
Ismaeel Sabih Naveed for being a good little boy whilst mummy was writing up.   
 
TABLE OF CONTENTS 
 
CHAPTER 1: GENERAL INTRODUCTION ...................................................................... 1 
1.1 Overview ...................................................................................................................... 2 
1.1.1 The Human Liver ................................................................................................... 2 
1.1.2 The Liver Acinus .................................................................................................... 3 
1.1.3 Liver cells ............................................................................................................... 5 
1.1.4 Functions of the liver ............................................................................................ 10 
1.1.5 The role of the liver in glucose homeostasis ........................................................ 10 
1.1.6 The role of carbohydrate transporters in glucose metabolism ............................. 15 
1.1.7 The role of the liver in lipid homeostasis ............................................................. 16 
1.1.8 The role of fatty acid transporters in lipid metabolism ........................................ 18 
1.1.9 Obesity and the Metabolic Syndrome .................................................................. 20 
1.1.10 Non-Alcoholic Fatty Liver Disease ...................................................................... 21 
1.1.11 Vascular Adhesion Protein- 1 .............................................................................. 30 
1.1.12 VAP-1 is a multifunctional protein ...................................................................... 32 
CHAPTER 2: MATERIALS & METHODS ....................................................................... 36 
2.1 Human Tissue .............................................................................................................. 37 
2.2 Murine Tissue .............................................................................................................. 37 
2.3 Generation of Precision-Cut Liver Slices (PCLS) ...................................................... 38 
2.4 Preparation of tissue sections for immunochemistry .................................................. 40 
2.5 Sectioning of liver tissues for Matrix Assisted Laser Desorption Ionization Mass 
Spectrometry Imaging (MALDI-MSI) ................................................................................. 40 
2.6 Immunohistochemical staining of human liver specimens ......................................... 40 
2.6.1 Immunofluorescent staining ................................................................................. 41 
2.7 Histological staining to investigate liver morphology, steatosis and fibrosis ............. 43 
2.8 Cell Isolation, Culture and Maintenance ..................................................................... 45 
2.8.1 Isolation and culture of HSEC, BEC and Fibroblasts from human liver tissue ... 45 
2.8.2 Isolation and culture of primary hepatocytes ....................................................... 47 
2.8.3 Isolation and culture of peripheral blood mononuclear cells (PBMC) ................ 48 
2.9 Culture and maintenance of hepatocyte cell lines ....................................................... 48 
2.10 Maintenance of cells by freezing and storing ........................................................... 49 
2.11 Adenoviral Transfection of Human HSEC with VAP-1 Constructs ......................... 49 
2.12 Single Color Flow Cytometry ................................................................................... 50 
2.13 Determination of cell and PCLS function and viability in culture ........................... 51 
2.13.1 Treatment of cells and PCLS with palmitic and oleic acid .................................. 51 
2.13.2 Quantification of lipid accumulation in fatty acid treated cells and PCLS using 
ORO labelling ................................................................................................................... 52 
2.13.3 Use of MTT to assess viability of PCLS and cultured cells ................................. 52 
2.14 Assessment of lipid accumalation in PCLS and hepatic cells after VAP-1 treatment
 53 
2.15 Assessment of triglyceride secretion from PCLS after VAP-1 interventions ........... 54 
2.16 Assessment of glucose uptake in PCLS and hepatic cells after VAP-1 treatment 
using 2- Deoxy-D- Glucose [3H (G)] uptake assay ............................................................. 54 
2.17 Validation of Hoechst dye for cell quantification ..................................................... 55 
2.18 Determination of PCLS function and viability in culture ......................................... 56 
2.18.1 Quantification of Albumin production for the assessment of hepatocyte synthetic 
function in PCLS .............................................................................................................. 56 
2.18.2 Assessment of glycogen storage in PCLS ............................................................ 57 
2.18.3 Assessment of nuclear integrity in PCLS using Hoechst dye .............................. 58 
2.19 Determination of the enzymatic activity of VAP-1 in whole tissues by the Amplex 
Ultra Red method ................................................................................................................. 58 
2.20 Analysis of gene expression in cultured cells and whole liver using microarrays and 
quantitative PCR (qPCR) ..................................................................................................... 60 
2.20.1 RNA extraction .................................................................................................... 60 
2.20.2 cDNA synthesis .................................................................................................... 62 
2.20.3 Microarray Analysis ............................................................................................. 62 
2.20.4 Quantitative real-time PCR .................................................................................. 64 
2.21 Whole tissue lipid analysis using Mass Spectrometry (MS) and Gas 
Chromatography (GC) .......................................................................................................... 67 
2.22 Extraction of lipids from liver tissue and PCLS for analysis by GC and MALDI-MS 
dried droplet analysis ............................................................................................................ 67 
2.23 Identification of lipid species in tissue extracts using MALDI-MS dried droplet 
analysis ................................................................................................................................. 68 
2.24 Identification and localization of lipids in tissue extracts using MALDI imaging ... 69 
2.25 Statistical Analysis .................................................................................................... 70 
CHAPTER 3: HEPATOCELLULAR EXPRESSION OF GLUCOSE AND LIPID 
TRANSPORTERS .................................................................................................................. 71 
3.1 Introduction ............................................................................................................... 72 
3.1.1 Hepatic expression and function of carbohydrate transporters ............................ 73 
3.1.2 Hepatic expression and function of lipid transporters .......................................... 80 
3.2 Methods ...................................................................................................................... 89 
3.3 Results ........................................................................................................................ 90 
3.3.1 Microarray analysis reveals expression of GLUT receptors in human liver ........ 90 
3.3.2 qPCR confirms expression of GLUT family receptors in human liver ................ 93 
3.3.3 Liver epithelial cells express a varied GLUT receptor profile ............................. 96 
3.3.4 GLUT receptor profile in non-epithelial cells ...................................................... 98 
3.3.5 Immunohistochemical detection of GLUT protein expression in normal and 
diseased livers ................................................................................................................. 100 
3.3.6 Microarray analysis reveals expression of lipid trafficking proteins in human 
liver 110 
3.3.7 qPCR confirms expression of FABP receptors in human liver .......................... 114 
3.3.8 Liver epithelial cells express FABP ................................................................... 117 
3.3.9 FABP receptor profile in non-epithelial cells .................................................... 119 
3.3.10 Immunohistochemical detection of fatty acid trafficking protein expression in 
normal and diseased livers. ............................................................................................. 121 
3.3.11 qPCR confirms expression of FATPs in human liver ........................................ 126 
3.3.12 Liver epithelial cells express FATP receptors .................................................... 128 
3.3.13 Liver non-epithelial cells express FATP receptors ............................................ 130 
3.4 Discussion ................................................................................................................. 132 
3.4.1 Hepatocellular expression of GLUT proteins .................................................... 134 
3.4.2 Hepatocellular expression of fatty acid trafficking proteins .............................. 145 
3.4.3 Mechanisms explaining changes in lipid transporter proteins ........................... 156 
3.4.4 Future work ........................................................................................................ 158 
CHAPTER 4: IS THERE A ROLE FOR VAP-1 IN GLUCOSE HOMEOSTASIS IN 
THE LIVER? ........................................................................................................................ 162 
4.1 Introduction ............................................................................................................. 163 
4.1.1 Could VAP-1 activity be of significance in hepatic glucose homeostasis? ....... 164 
4.2 Methods .................................................................................................................... 167 
4.3 Results ...................................................................................................................... 168 
4.3.1 VAP-1 expression and functional activity is increased in diseased liver ........... 168 
4.3.2 VAP-1 and its substrate methylamine regulate glucose uptake in Hepatic cells175 
4.3.3 Use of PCLS to model glucose and lipid homeostasis in human liver .............. 179 
4.3.4 VAP-1 and its substrate methylamine regulate glucose uptake in liver tissue ... 185 
4.3.5 SSAO activity causes activation of NF-κB in PCLS ......................................... 187 
4.3.6 VAP1 and its substrate methylamine may alter the expression of GLUT proteins 
in PCLS .......................................................................................................................... 190 
4.3.7 VAP-1 null mice show altered glucose responses ............................................. 191 
4.4 Discussion ................................................................................................................. 193 
4.4.1 VAP-1/SSAO expression and functional activity is upregulated in diseased livers
 193 
4.4.2 The role of amine oxidases in the pathogenesis of NASH ................................. 195 
4.4.3 Activation of VAP-1 stimulates glucose uptake in hepatic cells ....................... 198 
4.4.4 Development of an ex vivo human model of liver for the functional study of 
VAP-1 in glucose and lipid homeostasis ........................................................................ 200 
4.4.5 Activated VAP-1 regulates glucose uptake in PCLS ......................................... 202 
4.4.6 The role of GLUT4 and other glucose transporters in VAP-1 stimulated glucose 
transport .......................................................................................................................... 204 
4.4.7 VAP-1 KO mice show altered glucose responses .............................................. 207 
4.4.8 The Functional significance of VAP-1 in chronic liver disease ......................... 209 
CHAPTER 5: IS THERE A ROLE FOR VAP-1 IN HEPATIC LIPID 
HOMEOSTASIS? ................................................................................................................. 212 
5.1 Introduction ............................................................................................................. 213 
5.2 Methods .................................................................................................................... 216 
5.3 Results ...................................................................................................................... 217 
5.3.1 Quantification of lipid accumulation in cultured cells ....................................... 217 
5.3.2 Expression of Lipid transporters alters after treatment of cells with free fatty 
acids 225 
5.3.3 VAP-1 regulates lipid accumulation in Huh7.5 ................................................. 227 
5.3.4 Lipid deposits can be visualized in freshly harvested tissue specimens ............ 230 
5.3.5 Use of PCLS to model lipid homeostasis in human liver .................................. 232 
5.3.6 VAP-1 deficient animals exhibit reduced steatosis in response to a high fat diet
 246 
5.3.7 VAP-1 and methylamine alter the expression of fatty acid trafficking proteins in 
PCLS 248 
5.4 Discussion ................................................................................................................. 250 
5.4.1 Free fatty acids induce altered levels of steatosis .............................................. 250 
5.4.2 FFA induce expression of fatty acid trafficking proteins in Huh7.5 .................. 252 
5.4.3 The activity of VAP-1 regulates lipid accumulation in Huh7.5 ......................... 253 
5.4.4 The role of VAP-1 in altering lipid accumulation in PCLS ............................... 255 
5.4.5 Activity of VAP-1 alters expression of lipid trafficking proteins ...................... 258 
CHAPTER 6: USE OF MASS SPECTROMETRY AND MALDI IMAGING TO 
DETECT PATHOLOGICAL CHANGES IN NASH ....................................................... 263 
6.1 Introduction ............................................................................................................. 264 
6.1.1 MALDI ............................................................................................................... 265 
6.1.2 Use of mass spectrometry in the study of human liver disease .......................... 269 
6.2 Methods .................................................................................................................... 271 
6.3 Results ...................................................................................................................... 272 
6.3.1 Identification of lipid species in normal and diseased livers using Gas 
Chromatography  (GC) ................................................................................................... 272 
6.3.2 Can Gas Chromatography identify any lipid compositional change in PCLS 
treated with VAP-1? ....................................................................................................... 276 
6.3.3 Identification of lipid species in normal and diseased livers using Matrix Assisted 
Laser Desorption Ionization-Mass Spectrometry (MALDI-MS) ................................... 278 
6.3.4 Identification of lipid species in wild type and VAP-1 KO mice using Matrix 
Assisted Laser Desorption Ionization-Mass Spectrometry (MALDI-MS) ..................... 289 
6.3.5 Imaging of lipid species in normal and diseased livers using Matrix Assisted 
Laser Desorption Ionization-Mass Spectrometry Imaging (MALDI-MSI) ................... 296 
6.4 Discussion ................................................................................................................. 299 
6.4.1 Gas chromatography reveals compositional lipid differences in normal and 
diseased livers. ................................................................................................................ 299 
6.4.2 Gas chromatography reveals compositional lipid differences in PCLS treated 
with VAP-1 and its metabolites ...................................................................................... 301 
6.4.3 Use of MALDI-MS to detect pathological changes in normal and diseased livers
 302 
6.4.4 Use of MALDI-MSI to detect changes in lipid species in wild type and VAP-1 
knock out mice ............................................................................................................... 304 
6.4.5 MALDI-MSI allows visualization of lipid species in distinct anatomical locations 
in normal and diseased livers ......................................................................................... 306 
CHAPTER 7: CONCLUSIONS & FUTURE WORK ...................................................... 309 
7.1 Overview .................................................................................................................. 310 
7.1.1 Physiological relevance of VAP-1 derived glucose and lipid accumulation in 
NASH 311 
7.1.2 Hepatic expression of glucose and fatty acid trafficking transporter proteins and 
implications in NASH .................................................................................................... 316 
7.1.3 Use of GC and MALDI-MS/MSI in diagnosis and biomarker discovery in NASH
 319 
7.1.4 Future work ...................................................................................................... 320 
 
 
 
 
 
 
LIST OF FIGURES 
 
Figure 1.1: Structure and morphology of the liver ..................................................................... 4 
Figure 1.2: Localization of hepatic cells in the liver lobule ....................................................... 9 
Figure 1.3: Insulin secretion and effect of insulin on peripheral tissues .................................. 13 
Figure 1.4: Schematic showing the interrelationships between glucose and lipid metabolism 19 
Figure 1.5: Schematic showing disease progression from the healthy liver to HCC ............... 22 
Figure 1.6: Histology of NAFLD disease progression ............................................................. 27 
Figure 1.7: Structure of VAP-1 ................................................................................................ 31 
Figure 2.1: Functional components of the Krumdieck tissue slicer ......................................... 39 
Figure 2.2: Protocol for histological staining procedures for H&E, ORO and Sirius Red 
staining. ............................................................................................................................ 44 
Figure 2.3: Representative phase contrast pictures of HSEC, BEC and fibroblast cells in 
culture. .............................................................................................................................. 46 
Figure 3.1: Roles of GLUT and fatty acid trafficking proteins ................................................ 79 
Figure 3.2: Microarray analysis of GLUT receptor expression in normal liver ....................... 91 
Figure 3.3: Microarray analysis of GLUT receptor expression in HSEC and Huh7.5............. 92 
Figure 3.4: Analysis of GLUT receptor expression in human liver by quantitative qPCR 
analysis ............................................................................................................................. 94 
Figure 3.5: Analysis of GLUT receptor expression in human diseased liver by quantitative 
qPCR analysis ................................................................................................................... 95 
Figure 3.6: Analysis of GLUT receptor expression in human liver epithelial cells by 
quantitative qPCR analysis ............................................................................................... 97 
Figure 3.7: Analysis of GLUT receptor expression in human liver non-epithelial cells and 
PBMCs by quantitative qPCR analysis ............................................................................ 99 
Figure 3.8: Immunohistochemical analysis of GLUT1 protein expression in normal human 
and diseased livers .......................................................................................................... 101 
Figure 3.9: Immunohistochemical analysis of GLUT2 protein expression in normal and 
diseased livers ................................................................................................................. 103 
Figure 3.10: Immunohistochemical analysis of GLUT4 protein expression in normal and 
diseased livers ................................................................................................................. 105 
Figure 3.11: Immunofluorescence analysis of GLUT4 protein expression in normal liver ... 106 
Figure 3.12: Immunohistochemical analysis of GLUT9 protein expression in normal and 
diseased livers ................................................................................................................. 108 
Figure 3.13: Immunohistochemical analysis of GLUT10 protein expression in normal and 
diseased livers ................................................................................................................. 109 
Figure 3.14: Microarray analysis of lipid trafficking receptor expression in normal liver .... 111 
Figure 3.15: Microarray analysis of lipid trafficking receptor expression in HSEC and Huh7.5
 ........................................................................................................................................ 112 
Figure 3.16: Lipid trafficking receptors are differential regulated in HSEC and Huh7.5 ...... 113 
Figure 3.17: Analysis of fatty acid trafficking protein receptor expression in human liver by 
quantitative qPCR analysis ............................................................................................. 115 
Figure 3.18: Analysis of fatty acid trafficking protein receptor expression in human liver by 
quantitative qPCR analysis ............................................................................................. 116 
Figure 3.19: Analysis of fatty acid trafficking protein receptor expression in human liver 
epithelial cells by quantitative qPCR analysis ................................................................ 118 
Figure 3.20: Analysis of fatty acid trafficking protein receptor expression in human liver non-
epithelial cells and PBMCs by quantitative qPCR analysis ........................................... 120 
Figure 3.21: Immunohistochemical analysis of Caveolin 1 protein expression in normal 
human and diseased livers .............................................................................................. 122 
Figure 3.22: Immunohistochemical analysis of FABP1 protein expression in normal human 
and diseased livers .......................................................................................................... 123 
Figure 3.23: Immunohistochemical analysis of FABP4 protein expression in normal human 
and diseased livers .......................................................................................................... 124 
Figure 3.24: Immunohistochemical analysis of LRP8 protein expression in normal human and 
diseased livers ................................................................................................................. 125 
Figure 3.25: Analysis of FATP expression in human liver by quantitative qPCR analysis ... 126 
Figure 3.26: Analysis of FATP receptor expression in human liver by quantitative qPCR 
analysis ........................................................................................................................... 127 
Figure 3.27: Analysis of FATP receptor expression in human liver epithelial cells by 
quantitative qPCR analysis ............................................................................................. 129 
Figure 3.28: Analysis of FATP receptor expression in human liver non-epithelial cells and 
PBMCs by quantitative qPCR analysis .......................................................................... 131 
Figure 4.1: Schematic showing VAP-1/SSAO related glucose uptake .................................. 165 
Figure 4.2: Analysis of SSAO and MAO by quantitative qPCR analysis .............................. 169 
Figure 4.3: Analysis of SSAO and MAO in human liver epithelial cells by quantitative qPCR 
analysis ........................................................................................................................... 170 
Figure 4.4: Analysis of SSAO and MAO in human liver non-epithelial cells and PBMCs by 
quantitative qPCR analysis ............................................................................................. 171 
Figure 4.5: Immunohistochemical analysis of VAP-1 protein expression in normal and 
diseased livers ................................................................................................................. 173 
Figure 4.6: Analysis of SSAO activity in normal and diseased human liver lysates ............. 174 
Figure 4.7: Assessment of glucose uptake after VAP-1 stimulation in HSEC ...................... 176 
Figure 4.8: Assessment of glucose uptake after VAP-1 stimulation in Huh7.5 and HepG2 cells
 ........................................................................................................................................ 178 
Figure 4.9: Generation of PCLS using a Krumdieck tissue slicer .......................................... 179 
Figure 4.10: Assessment of PCLS reproducibility and viability ............................................ 181 
Figure 4.11: H&E staining of Cultured PCLS confirms loss of morphology over time ........ 182 
Figure 4.12: Functional assessment of cultured PCLS ........................................................... 183 
Figure 4.13: Assessment of PCLS viability in different media .............................................. 184 
Figure 4.14: Assessment of glucose uptake after VAP-1 stimulation in PCLS ..................... 186 
Figure 4.15: Analysis of NF-κB signaling pathway after VAP-1 treatment in PCLS ........... 188 
Figure 4.16: Analysis of NF-κB signaling pathway after VAP-1 treatment in PCLS ........... 189 
Figure 4.17: Analysis of GLUT mRNA in PCLS after VAP-1 stimulation by quantitative 
qPCR analysis ................................................................................................................. 190 
Figure 4.18: Assessment of glucose uptake after VAP-1 stimulation in PCLS from livers of 
WT and VAP-1 KO mice ............................................................................................... 192 
Figure 4.19: Schematic showing VAP-1/SSAO related glucose uptake in the human liver .. 211 
Figure 5.1: Accumulation of free fatty acids in Huh7.5 cells ................................................. 218 
Figure 5.2: Dose and time dependent accumulation of free fatty acids in Huh7.5 ................ 219 
Figure 5.3: Accumulation of oleic acid in HSEC ................................................................... 220 
Figure 5.4: Dose and time dependent accumulation of oleic acid in HSEC .......................... 221 
Figure 5.5: Determination of cell number using Hoechst dye ................................................ 222 
Figure 5.6: Quantification of free fatty acids in Huh7.5 ........................................................ 224 
Figure 5.7: Quantification of oleic acid in HSEC .................................................................. 225 
Figure 5.8: Analysis of fatty acid trafficking proteins in Huh7.5 after treatment with free fatty 
acids by quantitative qPCR analysis ............................................................................... 226 
Figure 5.9: Assessment of oleic acid accumulation after VAP-1 stimuli ............................... 228 
Figure 5.10: Visual assessment of oleic acid accumulation after VAP-1 stimulation ........... 229 
Figure 5.11: Morphological appearance of normal and diseased liver tissue. ....................... 231 
Figure 5.12: Image J analysis of lipid in normal and diseased tissue ..................................... 232 
Figure 5.13: Viability of PCLS after free fatty acid treatment ............................................... 234 
Figure 5.14: Assessment of lipid accumulation in PCLS ....................................................... 235 
Figure 5.15: Morphological appearance of PCLS after 250μm oleic acid treatment ............. 236 
Figure 5.16: Morphological appearance of PCLS after 500μm oleic acid treatment ............. 237 
Figure 5.17: Morphological appearance of Cultured PCLS after VAP-1 stimulation ........... 238 
Figure 5.18: Assessment of 250μm oleic and palmitic acid accumulation after VAP-1 
stimulation. ..................................................................................................................... 240 
Figure 5.19: Assessment of oleic acid accumulation after VAP-1 activation ........................ 242 
Figure 5.20: Assessment of palmitic acid accumulation after VAP-1 activation ................... 244 
Figure 5.21: Assessment of triglyceride secretion after VAP-1 stimulation in PCLS ........... 245 
Figure 5.22: Assessment of lipid accumulation in WT and VAP-1 KO mice........................ 247 
Figure 5.23: Analysis of fatty acid trafficking proteins in PCLS after methylamine treatment 
by quantitative qPCR analysis ........................................................................................ 249 
Figure 5.24: Schematic showing the hypothesized role of lipid transporters in liver, which are 
elevated as a result of VAP-1 activity ............................................................................ 261 
Figure 6.1: Schematic representation of workflow and of data acquired by gas 
chromatography .............................................................................................................. 273 
Figure 6.2: Analysis of fatty acid components of lipids in normal and diseased livers using 
GC ................................................................................................................................... 275 
Figure 6.3: GC analysis of fatty acid components in PCLS after stimulation of VAP-1 ....... 277 
Figure 6.4: Schematic representation of workflow and of data acquired using MALDI-MS and 
MALDI-MSI ................................................................................................................... 279 
Figure 6.5: Typical analysis of abundantly detected phosphocholines in normal liver lipid 
extracts using MALDI-MS ............................................................................................. 281 
Figure 6.6: Analysis of normal and diseased liver lipid extracts using MALDI-MS ............. 283 
Figure 6.7: Principle component analysis of normal and diseased liver lipid extracts .......... 285 
Figure 6.8: Analysis of m/z peak 304 and 326 in normal and disease lipid extracts using 
MALDI-MS .................................................................................................................... 286 
Figure 6.9: Analysis of m/z peak 478 and 502 in normal and disease lipid extracts using 
MALDI-MS .................................................................................................................... 287 
Figure 6.10: Analysis of m/z peak 734 and 810 in normal and disease lipid extracts using 
MALDI-MS .................................................................................................................... 288 
Figure 6.11: MALDI-MS Analysis of phosphocholine lipids present in normal mouse liver 
lipid extracts ................................................................................................................... 290 
Figure 6.12: MALDI-MS analysis of hepatic lipid composition of WT and VAP-1 KO mice in 
m/z region 50-1000 ......................................................................................................... 293 
Figure 6.13: MALDI-MS analysis of hepatic lipid composition of wild type and VAP-1 KO 
mice in m/z region 400-880 ............................................................................................ 294 
Figure 6.14: Principle component analysis of wild type and VAP-1 KO mice liver lipid 
extracts ............................................................................................................................ 295 
Figure 6.15: MALDI-MS and MALDI-MSI analysis of m/z 734 peak in normal and diseased 
liver extracts ................................................................................................................... 298 
Figure 7.1: The hypothesized role of VAP-1 in the spectrum of NAFLD ............................. 313 
 
 
LIST OF TABLES 
Table 1.1: Substrates and Inhibitors of Amine Oxidase Enzymes ........................................... 34 
Table 2.1: Antibodies used for immunohistochemial detection of proteins ............................. 42 
Table 2.2: Adenoviral constructs used for HSEC transfection ................................................. 50 
Table 2.3: Antibodies used for single color flow cytometry .................................................... 51 
Table 2.4: Reagents used for glucose and lipid uptake assays ................................................. 54 
Table 2.5: Preamp reaction mix ................................................................................................ 65 
Table 2.6: Probe identifiers for Fluidigm
®
 96.96 Dynamic Array
TM
 and Agilent microarrays66 
Table 3.1: Summary of reported human and animal hepatic expression of GLUT proteins .... 74 
Table 3.2: Summary of reported human and animal hepatic expression of fatty acid trafficking 
proteins. ............................................................................................................................ 86 
Table 6.1: Table of m/z peaks present in WT and VAP-1 KO mice ...................................... 292 
 
 
 
 
 
 
 
 
 
 
 
LIST OF ABBREVIATIONS 
AA Amino Acid 
Acetyl-CoA Acetyl Coenzyme A 
ACS Acyl CoA Activity 
AFLD Alcoholic Fatty Liver Disease 
ALD Alcoholic Liver Disease 
ALT Alanine Transaminase 
AMP Adenosine Monophosphate 
AO Amine Oxidase 
ASH Alcoholic Steatohepatitis 
AST Aspartate Transaminase 
ATP Adenosine Triphosphate 
BACS Bile Acid CoA Synthetase 
BAPN β-Aminopropanitrile 
BEA 2-Bromoethylamine 
BEC Biliary Epithelial Cells 
BMI Body Mass Index 
BSA Bovine Serum Albumin 
C Chlorgyline 
CAV1 Caveolin 1  
CHCA α-Cyano-4-Hydroxycinnamic Acid  
ChREPP Carbohydrate-Responsive Element-Binding Protein 
CPS1 Carbamoyl Phosphate Synthase 1 
CPT1 Carnitine Palmitoyltransferase I 
DAB 3,3'Diaminobenzidine Tetrahydrochloride 
DCA Deoxycholic Acid 
DHB 2,5,Dhydroxybenzoic acid  
DMEM Dulbecco's Modiﬁed Eagle's Medium 
DMSO Dimethyl Sulfoxide 
DNL De Novo Lipogenesis 
DPM  Disintegrations Per Minute  
DPX Depex 
ECM Extra Cellular Matrix 
EDTA Ethylene Diaminotetraacetic Acid  
EGF Epidermal Growth Factor 
EGTA Ethylene Glycol Tetraacetic Acid 
ELISA Enzyme-Linked Immunosorbent Assay 
ER Endoplasmic Reticulum  
FA Fatty Acid 
FABP Fatty Acid Binding Protein 
FATP Fatty Acid Transporter Protein 
FCS Fetal Calf Serum 
FFA Free Fatty Acid 
FAD Flavin-Adenine-Dinucleotide 
FOXO-1 Forkhead Box Protein O1 
FP Focusing Potential 
FXRα Farnesoid X Receptor Alpha 
G-6-P Glucose-6-Phosphate 
GC Gas Chromatography 
GLP-1 Glucagon-Like-Peptide-1 
GLP-2 Glucagon Like Peptide-2 
GRP78 Glucose Regulated Protein  
GS Glycogen Synthase 
GSC Group Specific Component 
GSK3 Glycogen Synthase Kinase 3 
H&E Hematoxylin and Eosin 
HCC Hepatocellular Carcinoma 
HDL High Density Lipoproteins 
HEA Human Epithelial Antibody 
HEPES 4-(2-hydroxyethyl)-1-Piperazineethanesulfonic Acid 
HFD High Fat Diet 
HFE Hemochromatosis 
HGF Hepatocyte Growth Factor 
HIAA 5-Hydroxyindoleacetic Acid 
HSC Hepatic Stellate Cells 
HSEC Hepatic Sinusoidal Endothelial Cells 
HSL Hormone-Sensitive Lipase 
IBD Inflammatory Bowel Disease 
ICAM-1 Intercellular Adhesion Molecule 1 
IFC Integrated Fluidic Circuit  
IL-8 Interleukin 8 
IL-6 Interleukin-6 
IR Insulin Resistance 
IRS Insulin Receptor Substrates 
JAK-STAT Janus Kinase Signal Transducer and Activator of Transcription 
JNK Jun N-terminal Kinase 
K Potassium 
kDA kiloDalton 
KO Knock Out 
LCFA Long Chain Fatty Acid  
LCP1 Lymphocyte Cytosolic Protein 1 
LDL Low-Density Lipoprotein 
LESA Liquid Extraction Surface Analysis Mass Spectrometry  
LOX Lysyl Oxidase 
LPS Lipopolysaccharide 
LRPs Receptor Related Proteins 
MAdCAM-1 Mucosal Addressin Cell Adhesion Molecule-1 
MALDI-MS Matrix-Assisted Laser Desorption Ionisation - Mass Spectrometry Imaging 
MALDI-
MSI Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging 
MAOA Monoamine Oxidase A 
MAOB Monoamine Oxidase B 
MetS Metabolic Syndrome 
MnSOD Manganese Superoxide Dismutase 
MRI Magnetic Resonance Imaging 
MTP Mitochondrial Transfer Protein 
MTT Methyl Thiazol Tetrazolium  
NADPH Nicotinamide Adenine Dinucleotide Phosphate 
NAFLD Non-Alcoholic Fatty Liver Disease 
NASH Non-Alcoholic Steatohepatitis 
NEFA Non-Esterified Fatty Acid 
NF-κB Nuclear Factor kappa B  
NK Natural Killer 
NO Nitrogen Oxide 
OA Oleic Acid 
OCT Optimal Cutting Temperature Polymer 
P Pargyline  
PA Palmitic acid 
PBC Primary Biliary Cirrhosis 
PBMC Peripheral Blood Mono Nuclear Cells 
PBS Phosphate Buffered Saline 
PC Phosphocholine 
PCA Principal Components Analysis 
PCLS Precision Cut Liver Slices  
PEPCK Phosphoenolpyruvate Carboxykinase 
PI3-K Phosphoinositide 3-Kinase 
PM Plasma Membrane 
PPARGC1A Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-Alpha 
PPARα Peroxisome Proliferator-Activated Receptor Alpha 
PPARδ Peroxisome Proliferator-Activated Receptor Delta 
RBC Red Blood Cells 
ROS Reactive Oxygen Species 
RT Retention Times 
RTC Rat Tail Collagen 
SA 3,5,dimethoxy-4-Hydroxycinnamic Acid 
sCD36 Soluble CD36 
SLC2A Solute Carrier 2A Protein 
SREBP Sterol Regulatory Element-Binding Protein 
SSAO Semicarbazide-Sensitive Amine Oxidase 
sVAP-1 Soluble Vascular Adhesion Protein 
TAG Triglyceride 
TBS Tris-Buffered Saline 
TCA Tricarboxylic Acid Cycle 
TGFβ Transforming Growth Factor β 
TMB Tetramethylbenzidine 
TNFα Tumour Necrosis Factor-Alpha 
TPQ Topa Quinone 
UDCA Ursodeoxycholic Acid 
UK United Kingdom 
VAP-1 Vascular Adhesion Protein 1 
VEGF Vascular Endothelial Growth Factor 
VLDLPs Very Low Density Lipoproteins 
VSMC Vascular Smooth Muscle Cells  
WHO World Health Organisation 
WT Wild Type 
 
 1 
 
 
 
 
 
 
CHAPTER 1 
 
1 GENERAL INTRODUCTION 
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1.1 Overview 
1.1.1 The Human Liver  
The liver is the largest visceral organ in the body weighing approximately 1.5kg in an average 
adult and a remarkable organ with regenerative capacity.  It is enclosed in a coating of the 
visceral peritoneum and wrapped in a tough fibrous capsule (Martini, 2006).  It lies just under 
the diaphragm protected by the rib cage in the right upper quadrant of the abdominal cavity 
(Sheila Sherlock, 2002).  The liver consists of two lobes the right and left, which are 
separated on the anterior, posterior and inferior surface by the falciform ligament, ligamentum 
venosum and ligamentum teres (Martini, 2006).  The right lobe is the largest lobe of the two, 
which is further, subdivided in to two smaller lobes the caudate lobe on the posterior surface 
and the quadrate lobe on the inferior surface (Sheila Sherlock, 2002). 
 
Each lobe of the liver is further divided in to approximately 100,000 liver lobules forming the 
functional units of the liver (Martini, 2006).  The liver has a dual blood supply arising from 
the hepatic artery which carries approximately 20-30% of blood flow to the liver and is rich in 
oxygen (Greenway and Stark, 1971) and the hepatic portal vein which supplies almost 70-
80% of blood which is rich in nutrients from the small intestine (Greenway and Stark, 1971).  
These branch into smaller vessels allowing the blood to flow through the sinusoids and 
subsequently to the central vein of a single lobule before drainage into the hepatic vein.   
 
In a cross section of the liver the lobules appear to be hexagonal in shape and at each corner 
there is the hepatic triad consisting of a branch of the hepatic artery, branch of the portal vein 
and a branch of the bile duct, which is lined with Biliary Epithelial Cells (BEC).  The portal 
triad also contains the lymphatic vessels and the Vagus nerve.  
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1.1.2 The Liver Acinus  
The liver acinus (Figure 1.1) is the main metabolic functional unit of the liver (Rappaport et 
al., 1954)  and is best described as a diamond shape as it lies along two portal triads and 
spreads away towards two central veins.  It is divided in to three zones based on the flow of 
blood. Thus, Zone 1 is closest to the flow of blood from the portal triad (periportal) rich in 
oxygen, nutrients and hormones, Zone 2 is located between Zone 1 and Zone 3 (transition 
zone) and Zone 3 is closest to blood leaving the hepatocytes via the central vain (centrilobular 
Zone) low in oxygen and rich in waste products for example metabolites and carbon dioxide.  
This zonation of the liver can change, based on metabolic alterations such as post birth, in the 
fetal liver and during starvation (Katz, 1992).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 
 
Figure 1.1: Structure and morphology of the liver 
The liver is made up of two lobes the right and left that the falciform ligament separates.  The 
right lobe is subdivided in to two smaller lobes the caudate lobe on the posterior surface and 
the quadrate lobe on the inferior surface (not shown).  The liver has a dual blood supply 
arising from the hepatic portal vein and the hepatic artery.  The lobes of the liver are further 
divided in to smaller lobules, which are hexagonal in shape at each corner there is the hepatic 
triad consisting of a branch of the hepatic artery, branch of the portal vein and a branch of the 
bile duct.  The liver acinus is a diamond shape (shown in red) it lays along two portal triads 
and spreads away towards two central veins.  Image adapted from:  
http://medcell.med.yale.edu/systems_cell_biology/liver_and_pancreas/images/liver_cartoon.j
pg 
 
 
 
The liver lobule/acinus contains many cell types, which can be classified into parenchymal 
epithelial cells, the hepatocytes which compromise approximately 80% of the liver volume 
(Wisse et al., 1996) and non-parenchymal cells which include non epithelial cells which 
occupy 6.5% of the liver volume (Wisse et al., 1996).  
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1.1.3 Liver cells  
The different cell types are distinctly located in the liver for example each lobule consists of 
hepatocytes arranged in plates, and each plate is separated by sinusoids lined with Hepatic 
Sinusoidal Endothelial Cells (HSEC).  The Kupffer Cells (KC) are attached to the 
endothelium and the Hepatic Stellate Cells (HSCs) reside between the hepatocytes and HSEC 
in the space of Disse (space between the hepatocytes and HSEC).   Lymphocytes, dendritic 
and other immune cells are often present in the sinusoidal lumen and within the parenchyma 
and the functions of each in the normal liver and pathological conditions are discussed below. 
 
1.1.3.1 Hepatocytes and Biliary epithelium 
Hepatocytes are multifaceted cells, which are found in layers packed on top of each other, 
with microvilli on their sinusoidal face.  Hepatocytes are the predominant and main functional 
cells of the liver containing large amounts of mitochondria, which provide energy for their 
numerous functions.  There is a functional heterogeneity of these cells across the acinus, for 
example there are respectively more mitochondria in Zone 1 hepatocytes compared to Zone 3 
(Loud, 1968) and increased activities of gluconeogenic and amino acid metabolism enzymes 
(Katz et al., 1977a), (Katz et al., 1977b), (Welsh, 1972), (Katz, 1992).  In contrast Zone 3 
hepatocytes have high expression of glycolytic and liponeogenic enzymes (Katz, 1992).  Thus 
it has been proposed Zone 1 hepatocytes have a main role in oxidative energy metabolism 
whilst Zone 3 have a favored role in glucose uptake, glycolysis and liponeogenesis 
(Jungermann, 1988).  Hepatocytes are in close contact with HSEC, which line the sinusoids.   
 
The other major epithelial component of the liver is the biliary epithelium. These cells are 
BEC and function to modify bile and are also involved in the immune response by secreting 
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chemokines (Wu et al., 2004).  BEC are affected in Primary Biliary Cirrhosis (PBC) which is 
a destructive autoimmune disease targeting the biliary ducts and is associated with 
inflammation and fibrosis (Popov and Popova, 1986), (Reshetnyak, 2006).  Furthermore bile 
acids have been considered as signaling molecules and have been implicated in glucose and 
lipid homeostasis by activating Farnesoid X Receptor α (FXRα) (Houten et al., 2006).   
 
1.1.3.2 Hepatic Sinusoidal Endothelial cells  
HSEC are thin flat shaped cells, and are the first hepatic cells to come into contact with 
sinusoidal blood. They are considered unique and specialized compared to other endothelial 
cells as they lack a basement membrane (Wisse, 1970), allowing the free movement of fluid 
and substances from the sinusoids (Wisse et al., 1996).  They contain fenestrations which are 
approximately 100-200 nm in diameter (Cogger et al., 2006) which behave like “sieves” as 
they allow only the movement of particles which are less than the diameter of the fenestrae. 
These are involved in clearance of chylomicron remnants (Fraser et al., 1978), and HSEC 
have roles as scavengers by engulfing pathogens by receptor mediated endocytosis and also in 
immune modulation (Connolly et al., 2010), (Lalor et al., 2002).   
 
HSEC fenestrations are important in regulating lipoprotein transfer from the blood into 
hepatocytes and defenestration can affect systemic lipoprotein levels and prevent steatosis in 
hepatocytes (Cogger et al., 2006).  Furthermore chronic exposure to alcohol impairs the 
fenestrae in alcoholic cirrhosis (Horn et al., 1987) leading to hyperlipoproteinaemia  (Clark et 
al., 1988).  HSEC have roles in controlling vascular tone (Iwakiri and Groszmann, 2006) and 
thus damage can lead to portal hypertension.  Furthermore Reactive Oxygen Species (ROS) 
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can deplete levels of Nitrogen Oxide (NO) released by endothelial cells and thus have impact 
on vascular tone (Gryglewski et al., 1986), and subsequent HSEC dysfunction.   
 
1.1.3.3 Hepatic Stellate Cells (HSCs) 
HSCs are described as star shaped cells and in the quiescent state have a role in vitamin A 
regulation and storage (Blomhoff and Blomhoff, 2006), they are involved in liver 
regeneration (Chen et al., 2012), regulation of blood flow in the sinusoids (Reynaert et al., 
2008), and regulate the extracellular matrix (ECM) turnover.  As a result of liver injury HSCs 
transform from the quiescent to the activated state, which disrupts normal ECM turnover as 
HSCs produce and deposit increased collagen, which eventually leads to fibrosis, and 
cirrhosis (Bataller and Brenner, 2005).  They also exacerbate the immune response by 
secreting cytokines and chemokines and induce KC activation (Chang et al., 2012).   
 
1.1.3.4 Kupffer cells  
Kupffer cells are asymmetrical in shape possessing filopodia which spike through HSEC 
fenestrae and anchor on to the sinusoidal lining (McCuskey and McCuskey, 1990).  They are 
liver macrophages and are involved in engulfing foreign material or toxic material such as 
bacteria in the liver and are also involved in the breakdown of old Red Blood Cells (RBCs).  
Activation of KC by bacteria or for example by cytokines or chemokines secreted by 
activated HSCs can lead to secretion of pro-inflammatory cytokines such as Tumor Necrosis 
Factor α (TNFα) which in turn can activate HSCs. This ability means that KC have been 
implicated in the pathogenesis of Alcoholic Liver Disease (ALD) (Tsukamoto and Lu, 2001) 
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and Non Alcoholic Fatty Liver Disease (NAFLD) (Solga and Diehl, 2003) and have also been 
proposed to play a role in liver regeneration (Xu et al., 2012).   
 
1.1.3.5 Lymphocytes and other immune cells  
The liver contains resident populations of lymphocytes including ‘Pit cells’ which are 
regarded as large granulocyte lymphocytes and as liver exclusive Natural Killer (NK) cells 
(Wisse et al., 1997).  They have defense roles against virally infected cells and have been 
suggested to be the first line of defense against metastatic cells (Bouwens and Wisse, 1992).  
Importantly the liver is regarded as an immunologic organ (Racanelli and Rehermann, 2006) 
and contains additional immune cells such as dendritic cells, macrophages and monocytes 
(Liaskou et al., 2012).   
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Figure 1.2: Localization of hepatic cells in the liver lobule 
In the liver lobule hepatocytes are arranged in plates, and each plate is separated by sinusoids 
lined with HSEC, which are the first hepatic cells to come into contact with sinusoidal blood.  
The KC are attached to the endothelium and the quiescent HSCs containing Vitamin A 
granules (depicted in orange) reside between the hepatocytes and HSEC in the space of Disse 
(space between the hepatocytes and HSEC).   Hepatic lymphocytes or ‘Pitt cells’ are also 
often present in the sinusoidal lumen and function as NK cells, along with macrophages and 
monocytes (not shown).   Figure adapted from (Hui and Friedman, 2003). 
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1.1.4 Functions of the liver 
The liver is a central organ in metabolic homeostasis and has many functions.  It synthesis 
and secretes bile, stores vitamins and minerals, it is involved in drug inactivation and waste 
product removal it also has the ability to absorb, store, metabolize and produce carbohydrates, 
lipids and amino acids (AAs) and control their subsequent redistribution to other peripheral 
organs (Martini, 2006). These functions are tightly regulated by hormones insulin, glucagon, 
glucocorticoids and catecholamines (adrenaline, noradrenaline, dopamine) (Fritsche et al., 
2008).   
 
This thesis will consider the role of the liver in glucose and lipid homeostasis, two metabolic 
pathways which are intricately linked and share mutual metabolites. An imbalance in this 
system due to insulin resistance (IR) can lead to and contribute to the metabolic syndrome 
(MetS) and subsequent liver damage and so these functions are discussed in more detail in 
this thesis. 
 
1.1.5 The role of the liver in glucose homeostasis  
1.1.5.1 The postprandial state  
During the post and pre-prandial state the pancreas is the major organ involved in secretion of 
insulin and glucagon from β and α cells, two hormones, which work antagonistically to 
regulate glucose and lipid homeostasis.  As the blood glucose levels raise, glucose passes into 
the β cells of the pancreas via the glucose transporter GLUT2 (Jorns et al., 1996).  Glucose is 
then phosphorylated by the enzyme glucokinase, and is eventually metabolized via glycolysis, 
the Tricarboxylic Acid Cycle (TCA) and the electron transport chain to generate Adenosine 
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Triphosphate (ATP).  As the levels of ATP rise, ATP sensitive potassium (K) channels close 
causing the influx of positive K
+
 ions to enter and depolarize the cell.  Depolarization of the 
cell causes an influx of calcium ions, which cause the activation of synaptotagmin, which in 
turn helps granules containing insulin to fuse with the Plasma Membrane (PM) and secrete 
insulin in to the bloodstream (Grodsky and Bennett, 1966).  Glucagon-like-peptide-1 (GLP-1) 
can also stimulate insulin secretion.   
 
When insulin binds to its receptor on the plasma membrane of target cells, the insulin 
receptor, which is a receptor tyrosine kinase, becomes activated and uses insulin receptor 
substrates (IRS) to initiate signaling.  The net result of insulin signaling in target organs such 
as the liver, muscle and adipose tissue are that it causes peripheral tissue such as muscle and 
adipose tissue to clear glucose and stops liver producing glucose and releasing it through 
GLUT2 via internalization of GLUT2 and IRS (Grodsky and Bennett, 1966).  Insulin exerts 
its actions via nuclear transcription factors Sterol Element Regulatory Binding Protein 
(SREBP)-1c and Carbohydrate Response Element Binding Protein (ChREBP) (Kawaguchi et 
al., 2001) by increasing the expression of genes involved in lipogenesis (Canbay et al., 2007), 
(Sirek et al., 2009) and phosphorylating Forkhead Box Protein-O1 (FOXO-1) thus inhibiting 
gluconeogenesis and glycogenolysis (Puigserver et al., 2003).    
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1.1.5.2 Hepatic glucose metabolism  
1.1.5.2.1 Glycolysis  
Glycolysis occurs in the cytosol of cells and essentially involves splitting of sugar glykos 
“sugar” and lysis “splitting”. It is the essential stage in glucose metabolism providing energy 
for subsequent metabolic reactions.  The initial stage involves phosphorylation of glucose 
catalyzed by the enzyme glucokinase forming the intermediate Glucose-6-Phosphate (G-6-P), 
which can be used for glycogen synthesis via glycogenesis, or further metabolized producing 
two molecules of pyruvate and generation of ATP and Nicotinamide Adenine Dinucleotide 
Phosphate (NADPH).  Pyruvate then enters mitochondria were it becomes Acetyl coenzyme 
A (Acetyl-CoA), a carrier molecule which is further metabolized in the TCA cycle generating 
energy for cellular processes.   
 
1.1.5.2.2 Glycogenesis  
When glucose exceeds requirement, surplus glucose present in the bloodstream, is used to 
generate or replenish hepatic glycogen stores, via the conversion of G-6-P to glycogen.  G-6-P 
is an allosteric regulator of Glycogen Synthase (GS), the key enzyme involved in conversion 
of G-6-P to glycogen.  Insulin inhibits glucose synthesis and output by promoting storage of 
glucose as glycogen within hepatocytes. Glycogenesis is primed by insulin causing 
dephosphorylation and activation of GS by inactivation of Glycogen Synthase Kinase 3 
(GSK3). This leads to inhibition of other key enzymes involved in gluconeogenesis such as 
Phosphoenolpyruvate Carboxy Kinase (PEPCK) and glucose-6-phosphatase by 
phosphorylation and subsequent nuclear exclusion of the transcription factor FOXO-1 
(Barthel et al., 2005).  
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Figure 1.3: Insulin secretion and effect of insulin on peripheral tissues 
In the postprandial state, glucose levels rise and glucose enters β cells of the pancreas through 
GLUT2 and is phosphorylated by glucokinase, and is eventually metabolized generating ATP.  
As the levels of ATP rise, ATP sensitive potassium (K) channels close, causing the influx of 
positive K
+
 ions to enter which depolarize the cell.  Depolarization of the cell causes an influx 
of calcium ions, causing the activation of synaptotagmin, which in turn helps granules 
containing insulin to fuse with the plasma membrane and secrete insulin in to the 
bloodstream.  The net effects of insulin when it binds to its receptors on the plasma membrane 
of target cells are that it promotes muscle glycogenesis, adipose tissue lipogenesis and inhibits 
lipolysis.  Whilst in the liver it promotes glycolysis, glycogenesis, DNL and inhibits 
gluconeogenesis and glycogenolysis.  Figure adapted from 
http://2011.igem.org/wiki/images/d/da/Insulin_production_model.jpg.  
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Approximately 400kcal (1700kJ) of glycogen can be stored in the liver (Jeremy M Berg, 
2002).  However when glycogen stores are fully replenished, excess G-6-P has a variety of 
fates. It is either metabolized to Acetyl-CoA which is used for De Novo Lipogenesis (DNL) 
(Bechmann et al., 2012) and the anabolism of bile salts and cholesterol (Jeremy M Berg, 
2002), or it enters the pentose-phosphate pathway to generate reducing power in the form of 
NADPH for the reductive biosynthesis of the above (Jeremy M Berg, 2002).  These pathways 
work intrinsically to restore glucose homeostasis in the fed state. 
 
1.1.5.3 The pre-prandial state  
In the pre-prandial state (between meals) when blood glucose levels fall the liver is the main 
organ involved in glucose release providing energy to peripheral organs.  Although muscle 
has the largest reserves of glycogen it does not possess glucose 6 phosphatase and thus cannot 
export free glucose out of myocytes (Jeremy M Berg, 2002).  Instead, glucagon works 
antagonistically to insulin by increasing breakdown of fats in the adipose tissue to free fatty 
acids (FFA) and initiates glycogenolysis and gluconeogenesis.  Glucagon stimulates the cyclic 
Adenosine Monophosphate (AMP) cascade which causes the activation of the enzyme 
phosphorylase and the inhibition of GS inhibiting glycogen synthesis (Jeremy M Berg, 2002).  
It also initiates gluconeogenesis and inhibits glycolysis by decreasing levels of fructose-2-6-
bisphosphate, an intermediate metabolite that allosterically activates expression of key 
enzymes involved in glycolysis and thus inhibits Fatty Acid (FA) synthesis by inhibition of 
pyruvate formation. 
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1.1.5.3.1 Glycogenolysis  
Glycogen phosphorylase is the main enzyme involved in the catalysis of glycogen to glucose-
1-phosphate.  Glucose-1-phosphate is then converted to G-6-P for glycolysis and 
glycogenesis, catalyzed by the enzyme phosphoglucomutase (Bechmann et al., 2012).  
Glucose-6-phosphatase then catalyzes the reaction releasing free glucose out of the 
hepatocytes available to other peripheral organs for energy.  When glycogen stores are 
exhausted the liver provides glucose via gluconeogenesis. 
 
1.1.5.3.2 Gluconeogenesis  
During sustained starvation the liver forms glucose from alternate precursors such a lactate 
(Raddatz and Ramadori, 2007).  For example during strenuous exercise muscle obtains energy 
via glycogenolysis however this can lead to production of lactate, which cannot be utilized for 
energy.  Thus its transported out of myocytes to the liver were it is converted back to pyruvate 
and used in the TCA cycle to generate energy in the form of ATP or used for the synthesis of 
glucose.  This is also known as the Cori cycle named after the Nobel prize winners who 
discovered it (Raju, 1999). 
 
1.1.6 The role of carbohydrate transporters in glucose metabolism  
To date 14 members of the GLUT family have been identified which facilitate entry of 
glucose into and out of cells.  These GLUT proteins are required in hepatocytes to facilitate 
glucose uptake in the post-absorptive state and to permit the exit of glucose formed by 
glycogenolysis and gluconeogenesis. Moreover glucose has the ability to regulate ChREBP 
(Yamashita et al., 2001) and thus drive lipogenesis.  Despite importance of these in glucose 
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homeostasis and liver metabolism the significance of these transporters, and their expression 
patterns in the diseased liver have not been clearly defined (Karim et al., 2012) and thus these 
transporters are discussed in more detail in Chapter 3.   
 
1.1.7 The role of the liver in lipid homeostasis  
1.1.7.1 Hepatic lipid metabolism  
As discussed earlier, when the liver glycogen stores reach approximately 5% of the total liver 
mass (Postic and Girard, 2008) excess glucose is used for synthesis of FAs.  The liver also 
receives Non Esterified Fatty Acids (NEFA) liberated from adipose tissue in plasma via 
specific transporter proteins as well as chylomicron remnants containing cholesterol, FA, and 
glycerol (Cooper, 1997).  These remnants, are taken up by Low Density Lipoprotein (LDL) 
receptor related proteins (LRP)s.  Cholesterol can be used for membranes, as a precursor for 
bile acid synthesis, or exported out of the hepatocytes as Very Low-Density Lipoproteins 
(VLDLs). FAs can be stored within hepatocytes as triglycerides (TAG), in lipid droplets or if 
surplus to requirement are esterified to TAG, which are exported out of the hepatocytes as 
VLDLs for transport to adipose tissue.  FAs can also be oxidized to produce fuel via β 
oxidation in mitochondria. 
 
The role of the liver in lipid metabolism begins with emulsification of fats in the small 
intestine by bile secreted by the liver (Oude Elferink and Groen, 2000).  Once in the liver the 
fate of lipids follows one of two metabolic pathways, esterification or oxidation.  Lipids are 
subject to esterification in the Endoplasmic Reticulum (ER) and β oxidation in the 
mitochondria.  Lipids can also undergo both α and β oxidation in peroxisomes.   
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Whether lipids undergo esterification or oxidation depends on the nutritional state of the 
individual.  In the fed state, insulin prevents breakdown of fats (Rautou et al., 2010), (Yang et 
al., 2010) furthermore oxidation of FAs is limited and this is primarily regulated by the 
concentration of malonyl CoA.  In addition during starvation lipoautophagy can liberate FAs 
from lipid droplets within the hepatocyte (Rautou et al., 2010), (Wang et al., 2010), (Singh et 
al., 2009), (Liu and Czaja, 2013).  In order to be oxidized a FA needs to be able to transverse 
from the outer membrane of mitochondria to the matrix of the inner membrane of the 
mitochondria, which contains the enzymes for β oxidation (Reddy and Hashimoto, 2001).  
Very long chain FAs consisting of >C20 undergo β oxidation in the peroxisomes to shorten the 
carbon length before entering further oxidation in the mitochondria. In mitochondria, the 
initial stage in β oxidation involves the dehydrogenation of acyl-CoA by acyl-CoA 
dehydrogenases, and mice lacking these enzymes have been shown to develop micro and 
macrovesicular steatosis in the liver (Tolwani et al., 2005).  The FA then attaches to a 
carnitine molecule, which facilitates its move to the matrix aided by a carnitine carrier 
protein.  The enzyme carnitine palmitoyltransferase I (CPT 1) then supports the transfer of FA 
from the cytoplasmic side to the mitochondrial side (Reddy and Hashimoto, 2001).  The next 
stage of β oxidation involves the Mitochondrial Trifunctional Protein (MTP).  This protein 
consists of three enzymes, 2-enoyl-CoA hydratase, 3- hydroxyacyl-CoA dehydrogenase and 
3-ketoacyl-CoA thiolase, which further catalyze the oxidation of FAs.  
 
When levels of malonyl CoA are low during the fasting state, β oxidation is favored and this 
is aided by the flux of FAs through the CPT 1 reaction.  Similarly when levels are high as in 
the fed state esterification is favored (Reddy and Hashimoto, 2001) due to a decrease in FA 
delivery as a result of CPT 1 inhibition (Reddy and Hashimoto, 2001).    
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In addition to hormonal control, lipid and glucose metabolism can be directly regulated by FA 
themselves through regulation of nuclear transcription factors such as Peroxisome Proliferator 
Activated Receptor δ (PPARδ) which is involved in activating glycolysis by regulating 
SREBP-1c and Peroxisome Proliferator Activated Receptor α (PPARα), which increases 
expression of FA transporters, leading to FA uptake, usage and breakdown (Rakhshandehroo 
et al., 2010).   
 
1.1.8 The role of fatty acid transporters in lipid metabolism  
FAs gain entry into the hepatocytes via facilitated carrier proteins such as the Fatty Acid 
Binding Proteins (FABP), Fatty Acid Transporter Proteins (FATP), Caveolin 1 (CAV1) and 
CD36 (Musso et al., 2009) also known as Fatty acid Translocase (FAT), whilst the 
chylomicron remnants gain entry via receptor mediated endocytosis by attaching to LRP 
proteins (Fritsche et al., 2008).  Furthermore these proteins are involved in the intracellular 
shuttling of FAs to target organelles for oxidation or storage.  These transporters are 
fundamentals for lipid entry and thus metabolism, and yet their role in the liver and liver 
disease has been under appreciated.  This thesis will consider the expression patterns of these 
proteins in liver cells and their implications in liver disease and therefore they are discussed in 
more detail in Chapter 3.   
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Figure 1.4: Schematic showing the interrelationships between glucose and lipid 
metabolism 
Glucose enters hepatocytes through GLUT proteins it is then metabolized via glycolysis to G-
6-P which is an intermediate metabolite which can be used for storage of glucose in the form 
of glycogen via glycogenesis, and reverted back to free glucose via glycogenolysis depending 
on the nutritional status for example during starvation or exercise.  Hepatocytes can form 
glucose from lactate released by myocytes during exercise (Cori cycle), this process is known 
as gluconeogenesis.  Further metabolism of G-6-P can produce Acetyl Co-A, which can 
further be processed in the TCA cycle for generating energy in the form of ATP or used for 
DNL of FAs, these can be used as precursors for bile salts, cholesterol synthesis or storage as 
lipid droplets.  The hepatocytes can also receive FAs liberated from adipocytes or from the 
diet; these are taken up via facilitator proteins FABPs, FATPs, CAV1 and CD36.  Internalized 
FAs can be used for synthesis of VLDLPs, which can be exported out of the hepatocyte to 
peripheral tissues such as adipose tissue, stored as lipid droplets within the hepatocyte or enter 
β-oxidation.  Chylomicron remnants are internalized via receptor mediated endocytosis and 
subjected to lysosomal degradation releasing FAs, cholesterol and TAG.    
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1.1.9 Obesity and the Metabolic Syndrome  
The prevalence of obesity in the United Kingdom (UK) and across the world is increasing due 
to poor dietary habits and a sedentary lifestyle.  The world health organization (WHO) reports 
a doubling in worldwide obesity since 1980, with shocking statistics revealed in 1998: 200 
million adult males and 300 million adult females were classified as obese.  In 2010 the WHO 
reported 40 million children (under 5) to be overweight 
(http://www.who.int/mediacentre/factsheets/fs311/en/index.html). The rising trend in obesity 
is alarming and has led to many health complications, which include the MetS also commonly 
referred to as syndrome X (Reaven, 1988), (Reaven, 1993).  The MetS includes a spectrum of 
diseases including hypertension, presence of low high-density lipoproteins (HDL), high 
fasting glucose and an increased abdomen circumference (2001).  It is associated with 
inflammatory markers such as TNFα and Interleukin 6 (IL6) (Sutherland et al., 2004), (Hardy 
et al., 2013) along with IR which is considered a hallmark of this condition (Alberti and 
Zimmet, 1998), (Balkau and Charles, 1999). However it must be noted that IR has also been 
reported in non obese individuals (Ruderman et al., 1998).  MetS alarmingly has also been 
reported in children (Sung et al., 2003), (Wang et al., 2013), (Pastucha et al., 2013).  
Furthermore individuals with the MetS are more likely to develop cardiovascular disorders, 
type II diabetes and NAFLD which is becoming a growing problem in the western world and 
is one of the leading causes of end stage liver disease (Blachier et al., 2013).  
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1.1.10 Non-Alcoholic Fatty Liver Disease 
NAFLD is increasing rapidly in the developing world, with 25%-30% of the general 
population in western countries said to be suffering from the condition (Bhala et al., 2013).  
NALFD has also been reported in children, (Franzese et al., 1997), (Akcam et al., 2013), with 
an estimated prevalence of 2.6% in some cohort studies (Tominaga et al., 1995).  NAFLD 
encompasses hepatic steatosis, which is the accumulation of lipid in the liver and can occur in 
the absence of alcohol consumption or due to excessive alcohol consumption and is referred 
as Alcoholic Fatty Liver Disease (AFLD) or ALD (Reddy and Rao, 2006).  
 
NAFLD encompasses a spectrum of diseases, which includes the presence of simple steatosis 
which is benign (Day, 2005), to the more aggressive form Non Alcoholic Steatohepatitis 
(NASH) (Ludwig et al., 1980) where inflammation is present.  The prevalence of NASH in 
the general population is said to be around 3%-5% (Vernon et al., 2011).  NASH is 
characterized by steatosis and inflammation which is also characteristic in Alcoholic Steato 
Hepatitis (ASH); which can progress to fibrosis and eventually cirrhosis and is an important 
risk factor for the development of Hepatocellular Carcinoma (HCC), (Torres and Harrison, 
2012), (Starley et al., 2010), (Tacke and Yoneyama, 2013).   
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Figure 1.5: Schematic showing disease progression from the healthy liver to HCC 
Obesity leads to an overload of FFA in the adipose tissue, and in the IR this leads to increased 
lipolysis, along with DNL leads to steatosis in the liver.  Obesity leads to a rise in TNFα in 
adipocytes further increasing IR and lipolysis.  Overload of FAs leads to formation of ROS, 
which leads to inflammation and thus development of NASH.  Activation of HSCs and 
Kupffer cells further exacerbates liver damage by deposition of collagen, which leads to 
fibrosis and cirrhosis through Jun Terminal Kinase (JNK), Janus Kinase Signal Transducer 
and Activator of Transcription JAK/STAT and Nuclear Factor kappa B (NF-κB) pathways.  
Figure adapted from (Bechmann et al., 2012) 
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1.1.10.1 Pathogenesis of NAFLD  
The precise causes of NALFD are poorly understood but disease progression has been coined 
a “two hit hypothesis” with the first hit, were the hepatocytes fill with lipid droplets in the 
form of TAG.  Precursors for these are the FFAs, which can arise from the breakdown of 
TAG from the diet, from adipose tissue due to inhibition of lipolysis or from DNL from 
substrates such as glucose (Cazanave and Gores, 2010).  The net accumulation is due to 
increase delivery of substrate to the hepatocytes, increased DNL (Postic and Girard, 2008), 
decreased oxidation of FAs and decreased export of VLDLPs. The first hit is fairly benign 
and is often regarded as a protective mechanism where toxic FFAs are esterified to neutral 
TAG (Yamaguchi et al., 2007).  However overload of lipid can eventually prime the liver for 
the “second hit” or rather “multiple hits” which includes inflammation, oxidative stress, lipid 
peroxidation and mitochondrial dysfunction impairing lipid oxidation (Fromenty et al., 2004).  
Furthermore FFAs have been reported to induce oxidative stress (Feldstein et al., 2004).  
Various factors have been considered to drive disease onset and progression and these are 
discussed below.   
 
1.1.10.1.1 Free Fatty Acids  
Adipose tissue in the fed state can increase in mass, which may lead to increased 
concentrations of FFAs in serum. These can also increase due to prohibition of lipolysis in the 
IR state, and thus have been implicated in the pathogenesis of NAFLD.  FFA have been 
shown to cause lipotoxicity by activating JNK dependent apoptosis (Malhi et al., 2006), 
(Cazanave et al., 2009), inducing endoplasmic reticulum stress (Wei et al., 2006), (Wang et 
al., 2006), (Wei et al., 2009) and altered lysosomal metabolism (Feldstein et al., 2004), 
(Feldstein et al., 2006).  It is has also been shown that FAs can induce β oxidation enzymes by 
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binding to PPAR- α, and mice lacking this receptor during starvation have been shown to 
develop severe liver steatosis (Rao et al., 2002).  The nature of available lipids and FFAs also 
impacts upon pathology. The circulating FFA lipid profile observed in NASH patients (Fong 
et al., 2000), (Diraison et al., 2003) is principally composed of saturated and monounsaturated 
FAs Palmitic Acid (PA) and Oleic Acid (OA) (de Almeida et al., 2002).  A recent report has 
shown that medium chain triglycerides reduce lipid content in a rat model of NAFLD by 
activating PPAR- α and hence stimulating β and ω oxidation (Ronis et al., 2013). Importantly 
lipids such as ceramides have been implicated in IR (Summers, 2006), (Holland et al., 2007) 
whilst free cholesterol has been implicated in the pathogenesis of NASH (Van Rooyen et al., 
2011) thus esterification of lipids is an important detoxifying mechanism of the liver.    
 
1.1.10.1.2 Adipokines  
Adipocytes in addition to secreting FFA also secrete signaling molecules such as cytokines 
known as adipokines which can exert their own biological effects meaning adipose tissue has 
also been considered as an endocrine organ (Ahima and Flier, 2000), (Galic et al., 2010), 
(Duan et al., 2013).  For example leptin and adiponectin have been considered as insulin 
sensitizers, whilst TNF-α, IL-6 and resistin as insulin suppressors (Pittas et al., 2004).  Leptin 
has been reported to have a role in regulating the immune system (Lord, 2002), energy intake 
and usage and to increase insulin sensitivity in muscle and liver (Unger et al., 1999), 
(Minokoshi et al., 2002).  Hence leptin has been implicated in obesity. In mice for example 
addition of leptin has shown to decrease weight in the ob/ob mice with a deletion in the leptin 
gene (Friedman et al., 1991) whilst in human obesity  leptin levels are increased (Considine et 
al., 1996).  Leptin is elevated in NASH and associated with steatosis rather than inflammation 
and fibrosis (Chitturi et al., 2002), whilst levels of adiponectin have been shown to be low in 
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NASH (Jarrar et al., 2008), (Hui et al., 2004), (Shimada et al., 2007), (Younossi et al., 2008).  
Lower levels have also been correlated with increased histological severity of disease (Aller 
et al., 2008), (Targher et al., 2006), furthermore adiponectin expression has been detected in 
murine hepatocytes, HSEC and HSCs in response to fibrotic stimuli and hence hepatic 
damage (Wolf et al., 2006), (Yoda-Murakami et al., 2001).  Its levels are suppressed by TNF-
α (Bruun et al., 2003) whilst adiponectin itself suppresses TNF-α (Xu et al., 2003).  In 
addition elevated levels of resistin and IL-6 have been reported in NASH compared to simple 
steatosis alone (Senates et al., 2012), (Wieckowska et al., 2008).  
 
1.1.10.1.3 Glucocorticoids  
Glucocorticoid hormones have a role in gluconeogenesis (Nordlie et al., 1999), (Pilkis and 
Granner, 1992) and have been implicated in NAFLD pathogenesis. For example patients with 
Cushing’s syndrome have elevated levels of cortisol (Hatipoglu, 2012) and some of these 
Cushing’s patients have been reported to have hepatic steatosis (Rockall et al., 2003).  
Enzymes which inactivate cortisol have been reported to be increased in IR states (Tomlinson 
et al., 2008) and NAFLD (Konopelska et al., 2009) and it has been postulated these enzymes 
are upregulated in order to retain insulin sensitivity, thereby serving as a protective 
mechanism (Tomlinson et al., 2008).  Certainly a recent report has shown that glucocorticoids 
enhance the insulin response in hepatocytes (Hazlehurst et al., 2013).   
 
1.1.10.1.4 Genetic factors  
Although many factors of the MetS are common in NAFLD, not all NAFLD patients progress 
to NASH suggesting there are environmental and genetic factors, which may lead to increased 
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susceptibility of disease progression in some individuals.  Certainly ethnic differences in 
histological severity of NAFLD have been reported. African Americans have less steatosis 
than Caucasians whilst Asians and Hispanics demonstrate increased severity of disease 
(Mohanty et al., 2009).  Recently genetic polymorphisms in Lymphocyte Cytosolic Protein-1 
(LCP1) and Group Specific Component (GSC) have been associated with NAFLD (Adams et 
al., 2013) and polymorphism of Peroxisome Proliferator-Activated Receptor-γ Coactivator 
(PGC)-1α gene (PPARGC1A) have been reported to increase the risk of developing NAFLD 
in obese children (Lin et al., 2013).  Similarly gene polymorphisms in MTP, PPAR-α, 
adiponectin, Manganese Superoxide Dismutase (MnSOD), Hormone Sensitive Lipase (HSL) 
have also been reported in NASH (Namikawa et al., 2004), (Dongiovanni and Valenti, 2013), 
(Merriman et al., 2006).   
 
1.1.10.2 Pathophysiology of NAFLD  
Hepatic steatosis can exist as macrovesicular steatosis where a large lipid droplet can displace 
the nuclei of hepatocytes, or co-exist with microvesicular steatosis characterized by multiple 
lipid droplets in the hepatocyte with a centrally located nuclei (Crabb et al., 2004), (Ludwig et 
al., 1980), (Schwimmer et al., 2005).  Mixed steatosis has been reported for both ASH and 
NASH (Brunt, 2001) but microvesicular steatosis is considered to be increasingly severe.  
NASH compromises both steatosis and inflammation (Lee, 1995), with presence of fibrosis, 
hepatocellular injury and necroinflammation present mainly in Zone 3 (Schwimmer et al., 
2005), (Brunt, 2001), (Cortese and Brunt, 2002).  Inflammation can be mixed with prescence 
of neutrophils (Brunt, 2001) and some forms of NASH can also include Mallory bodies 
(Brunt, 2001).  Portal inflammation has been asscoiated with increased disease progression in 
ALD and NAFLD (Rakha et al., 2010).  Despite the underlying causes of ASH and NASH 
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being different, it is usually difficult to distinguish between the two types histologically. 
Studies have attempted to differentiate between the two types and have reported glycogenated  
nuclei to be present in NASH (Itoh et al., 1987) but not ASH (MacSween and Burt, 1986), 
(French et al., 1993), whilst others have reported features such as cholestasis (French et al., 
1993) and sclerosing hyaline necrosis (Goodman and Ishak, 1982) as more prominent in ASH 
than NASH.   
 
 
Figure 1.6: Histology of NAFLD disease progression 
Arrow in (A) indicate presence of TAG, whilst in (B) circle indicates presence of 
inflammatory cells as disease progresses there is appearance of ballooning degeneration, 
Mallory bodies and (D) the progressive form encompassing both steatosis and fibrosis, central 
vein is depicted as CV (Parekh and Anania, 2007).   
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1.1.10.3 Diagnosis of NALFD  
Most patients with NAFLD are asymptomatic; although some common conditions include 
right upper quadrant pain, fatigue, malaise and hepatomegaly on physical examination (Lewis 
and Mohanty, 2010).  Thus diagnosis of NAFLD is often difficult or accidental as a result of 
routine liver function checks in susceptible individuals.  Presence of altered Alanine 
Transaminase (ALT) and Aspartate Transaminase (AST) levels can indicate liver damage and 
thus an underlying cause, however some individuals with NAFLD have been reported to have 
normal levels of these enzymes (Browning et al., 2004).  Imaging such as ultrasound can be 
used to identify presence of fat in the liver, but may not permit a clinician to distinguish 
between simple fatty liver and NASH (Obika and Noguchi, 2012). Furthermore some imaging 
techniques such as Magnetic Resonance Imaging (MRI) are expensive (Obika and Noguchi, 
2012).  Thus the gold standard for diagnosing NAFLD, and assessing disease severity and 
prognosis is the liver biopsy, which is an invasive procedure.  However on histology it is 
difficult to distinguish between ALD, NAFLD and ASH versus NASH as discussed earlier.  
Thus there is a need for specific biomarkers, which could be less invasive than a biopsy and 
which could distinguish between NAFLD and NASH.  Recent attempts using Gas 
Chromatography (GC) and exhaled breath samples have been used to distinguish patients with 
NASH (Verdam et al., 2013), furthermore techniques such as Matrix Assisted Laser 
Desorption Ionization Mass Spectrometry (MALDI-MS)  have been used to identify disease 
pathogenesis (Gorden et al., 2011), (Feldstein et al., 2010), (Wattacheril et al., 2013) and 
these are discussed in more detail in Chapter 5.    
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1.1.10.4 Treatment strategy for NAFLD  
Current options for preventing or ameliorating NAFLD include lifestyle modifications such as 
diet, weight loss and improving insulin sensitivity by taking drugs such as metformin which 
decreases hepatic glucose release and increases β oxidation (Nakajima, 2012), or GLP-1 
analogues which can increase insulin secretion (Cuthbertson et al., 2012), (Iltz et al., 2006).  
For ALD, abstinence from alcohol is recommended.  Treatments targeting NASH include 
anti-inflammatory and antioxidant therapies such as vitamin E which decreases lipid 
peroxidation (Chang et al., 2006), and ursodeoxycholic acid (Ratziu et al., 2011).  For patients 
with NASH associated fibrosis, anti fibrotic drugs such as PPARϒ agonists are used (Aithal 
et al., 2008), (Belfort et al., 2006), whilst for patients with cirrhosis, liver transplantation is 
the only treatment option.   In all many of the treatment strategies currently employed in the 
management of NAFLD and its related conditions are either associated with side effects or 
show little benefit (Lago et al., 2007), (Lavine et al., 2011), (Musso et al., 2012), (Adinolfi 
and Restivo, 2011), (Miller et al., 2005a), (Duvnjak et al., 2009), (Keech et al., 2005).  Thus 
an excellent treatment option for NAFLD would be a target directly in the liver, which would 
prevent oxidant stress, inflammation and subsequent fibrosis.  
 
One potential molecule, which may be involved in the pathogenesis of NASH, is Vascular-
Adhesion Protein-1 (VAP-1), which has adhesive properties, Semicarbazide Sensitive Amine 
Oxidase  (SSAO) activity, and has a reported role in glucose, lipid modulation. This may 
present a novel target for therapeutic intervention in NAFLD and is the focus of this thesis 
and so is introduced below with further detail in Chapters 4 and 5.   
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1.1.11 Vascular Adhesion Protein- 1  
VAP-1 (AOC3, EC 1.4.3.6) is a 180 Kilo Dalton (kDA) protein.  It is multifunctional and 
expressed on diverse cell types including endothelial cells, adipocytes, smooth muscle and 
heart. It localizes within cytoplasmic vesicles (Enrique-Tarancon et al., 1998) and a soluble 
form is also found in serum (sVAP-1) (Stolen et al., 2004a), (Morin et al., 2001), (Salmi and 
Jalkanen, 1992), (Salmi et al., 1993), (Salmi and Jalkanen, 2006).  The soluble form is 
cleaved and shed from membrane bound VAP-1 which is controlled by TNFα and insulin in 
some cells (Abella et al., 2004) and levels increase in inflammatory liver disease (Kurkijarvi 
et al., 1998), (Kurkijarvi et al., 2000), obesity (Meszaros et al., 1999), diabetes (Salmi et al., 
2002), (Boomsma et al., 1999) and congestive heart failure (Boomsma et al., 1997), 
(Boomsma et al., 2000).  Furthermore in experimental diabetes sVAP-1 appears to be shed by 
endothelial cells and adipose tissue (Stolen et al., 2004b).   
 
VAP-1 is an Amine Oxidase (AO) enzyme.  Amine oxidases are classified into two groups 
depending on the co factor they possess.  For example the Flavin-Adenine-Dinucleotide 
(FAD) containing AO and the copper and 6-Hydroxy-Topa Quinone (TPQ) containing AO.  
The FAD containing AO include the Mono Amine Oxidase- A (MAO-A) and Mono Amine 
Oxidase-B (MAO-B), which are found in the outer mitochondrial membrane (Strolin 
Benedetti et al., 2007).  Cloning of VAP-1 revealed it had similarity to the copper containing 
amine oxidases (Smith et al., 1998).  These AO such as Lysyl Oxidase (LOX) are sensitive to 
inhibition by semicarbazide and thus are also referred to as SSAO (Jalkanen and Salmi, 
2001).  Thus VAP-1/SSAO is a membrane bound protein, which has one transmembrane 
spanning domain, the extracellular domain has the active site containing the two co factors 
copper and TPQ (Jakobsson et al., 2005) and contains multiple glycosylation sites whilst the 
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intracellular domain is much shorter (Smith et al., 1998), (Salmi and Jalkanen, 1992).  The X 
ray crystal structure of this enzyme revealed that the entrance of substrates to the active site 
may be regulated by a Leu469 residue which blocks the active site functioning rather like a 
gate (Airenne et al., 2005), (Jakobsson et al., 2005).  A recent study has reported substrates 
with a long aliphatic chain are better substrates for VAP-1 as the enzyme has higher affinity 
and catalytic efficiency for them (Bonaiuto et al., 2010).   
 
 
 
Figure 1.7: Structure of VAP-1 
VAP-1 is a homodimeric protein and the figure shows an overall fold of the active domain of 
VAP-1.  Blue and red indicate the monomers, which contain the active site, which is indicated 
by the black arrow in the red colored monomer on the left. Figure adapted from (Salmi and 
Jalkanen, 2001).   
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VAP-1 and other AO generally catalyze the deamination of endogenous and exogenous 
amines producing an aldehyde and hydrogen peroxide.  For example VAP-1 catalyzes the 
oxidative deamination of both endogenous (methylamine and aminoacetone) (Bonaiuto et al., 
2010) and exogenous (benzylamine) primary amines generating aldehydes, ammonia and 
hydrogen peroxide as products based on the reaction:  
 
RCH2NH2  +O2  + H20       SSAO        RCHO  +NH3  +H202 
(Reviewed in (Klinman and Mu, 1994), (Wilmot et al., 1999)).   
 
These products have been shown to exert biological affects. For example the aldehydes 
formaldehyde and methylglyoxal produced from methylamine and aminoacetone and also 
ammonia have been shown to fuel glycation and produce protein cross linking (Yu et al., 
1997), (Mathys et al., 2002), (Seiler, 2002), (Yang and Butler, 2002).  Furthermore hydrogen 
peroxide can act as a signaling molecule and also as a ROS (Veal and Day, 2011), 
(Muzykantov, 2001) (Muzykantov, 2001) and has been shown to mimic the effects of insulin 
(Mahadev et al., 2001).  
 
1.1.12 VAP-1 is a multifunctional protein 
VAP-1 was initially identified in endothelium where it has been reported as an adhesion 
molecule supporting lymphocyte recruitment to the liver (Salmi and Jalkanen, 1992), (Lalor et 
al., 2002) and its role as an immunomodulatory molecule is well known. For example in 
HSEC, the SSAO activity of VAP-1 activates the NF-κB pathway leading to the upregulation 
of Intracellular Adhesion Molecule-1 (ICAM-1), Vascular Cell Adhesion Molecule-1 
(VCAM-1) and E selectin (Lalor et al., 2007) hence supporting leukocyte recruitment.  VAP- 
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1 has also been reported to be involved in neutrophil extravasation during inflammation 
(Tohka et al., 2001).  In addition VAP-1 has been shown to induce expression of Mucosal 
Addressin Cell Adhesion Molecule-1 (MAdCAM-1) a molecule involved in Inflammatory 
Bowel Disease (IBD) (Liaskou et al., 2011).  Other reported roles include implications in 
atherogenesis (Yu et al., 2002), angiogenesis (Langford et al., 1999), and the most intriguing 
in glucose and lipid modulation, the specifics of which are discussed in Chapters 4 and 5 
respectively.  
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Amine Oxidase (AO) Substrates Inhibitors  
VAP-1/SSAO Methylamine  2-Bromethylamine (BEA) 
 Aminoacetone  Semicarbazide 
 Allylamine  Hydroxylamine  
 Benzylamine Propargylamine  
 Beta-Phenyl-Ethylamine Pyridoxamine  
 Tyramine  (+) Mexiletine  
 Dopamine  B-24 
 Mescaline FLA 336 
 Tryptamine  MDL-72145 
 Histamine  MDL-72974A 
  Iproniazid 
  Phenelzine 
  Procarbazine 
  Hydralazine 
  Carbidopa 
  Benserazide 
  Aminoguanidine  
MAO-A Benzylamine Chlorgyline (C) 
 Tyramine  
 Beta-Phenyl-Ethylamine  
 Serotonin   
 Dopamine   
Norepinephrine  
Epinephrine 
MAO-B Benzylamine Pargyline (P) 
 Tyramine MDL-72974A 
 Beta-Phenyl-Ethylamine MDL-72145 
 Dopamine   
LOX Lysine  β-Aminopropionitrile 
(BAPN) 
Table 1.1: Substrates and Inhibitors of Amine Oxidase Enzymes 
Table 1.1 shows the preferred substrates and inhibitors of SSAO/VAP-1, MAO-A, MAO-B 
and LOX.  (K Magyar, 2001), (Ochiai et al., 2006), (Jalkanen and Salmi, 2001), (Kagan and 
Li, 2003). 
 
 
 
In all, the mechanisms leading to NAFLD and subsequent progression to NASH fibrosis and 
in some cases to HCC remain elusive, although initial stages are likely to involve IR, 
increased flux of FFAs and decreased lipid oxidation.  Since the rather benign simple steatosis 
can develop to the more aggressive NASH leading to chronic inflammation and fibrosis, it is 
important to understand and elucidate the molecular mechanisms leading to NAFLD so that 
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therapeutic interventions can be developed.  Since VAP-1 is expressed in the hepatic 
microenvironment, and has been involved in the inflammatory response, glucose and lipid 
modulation in extra-hepatic tissues and is upregulated in inflammatory liver disease, obesity 
and type II diabetes it poses as a potential molecule, which may be involved in disease 
progression. Thus, just as adipose tissue has its own compensatory mechanisms in the form of 
leptin and adiponectin, VAP-1 may be the livers compensator.  
 
Thus we hypothesized that VAP-1 is able to modulate glucose and lipid uptake in the liver 
through specific GLUT and possibly lipid transporters and at the same time due to its multiple 
functions such as immune modulation exacerbates disease pathogenesis. Thus the major aims 
of this thesis were: 
 
(I) To investigate the expression patterns of genes involved in glucose and lipid 
transport in hepatic cells and hepatic disease. 
(II) To develop an ex-vivo model and investigate the role of VAP-1 in glucose 
modulation in the liver. 
(III) To investigate the role of VAP-1 in lipid modulation in the liver using an ex-vivo 
model. 
(IV) To use mass spectrometry in the identification of possible lipid biomarkers and 
disease pathogenesis.   
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CHAPTER 2 
2 MATERIALS & METHODS 
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2.1 Human Tissue  
All human liver tissue used in this study was obtained from patients attending the Liver Unit 
at the Queen Elizabeth Hospital Birmingham, UK. Normal tissue was collected from donor 
material surplus to transplantation requirements or from excised non-diseased margin samples 
from tumor resection specimens. On occasion normal samples were rejected on the basis of 
excessive steatosis and these samples were designated steatotic.  Diseased tissue was also 
obtained from explanted livers collected during transplantation surgery for, NASH, PBC and 
ALD. Liver tissue was cut into 2cm
3
 cubes and immediately snap frozen in liquid nitrogen, 
before storage at -80°C prior to cryosectioning or fixed in formal saline (10%, Adams, 
Healthcare) for paraffin embedded tissue blocks.  Alternately fresh tissue was processed 
immediately for cell isolation (see section 2.8) or generation of Precision Cut Liver Slices 
(PCLS), (see section 2.3).  Kidney, breast melanoma and adipose tissue were used as positive 
controls for immunohistochemistry and were obtained from routine clinical procedures 
surplus to requirement with appropriate ethical approval. Whole blood from patients with 
hemochromatosis (HFE) attending clinic at the Queen Elizabeth Hospital was collected for 
isolation of peripheral blood mononuclear cells (PBMC).  All human material was collected 
with local research ethics committee approval (Walsall LREC) and written informed patient 
consent.    
2.2 Murine Tissue 
Murine tissue used in this study was obtained from C57BL/6 Wild Type (WT) (Charles River, 
UK) and VAP-1 Knock Out (KO) (Taconic, Denmark) mice fed on a High Fat Diet (HFD) 
(Special Diets Services, Essex, UK) for 12 weeks (Project License 40/3201).  Mice were 
sacrificed and the liver was removed and used for the generation of PCLS (see section 2.3) or 
staining and quantifying steatosis.  
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2.3 Generation of Precision-Cut Liver Slices (PCLS)  
To generate PCLS, 8mm tissue cores were aseptically obtained and placed in DMEM 
(Invitrogen, UK) at 4°C prior to slicing.  A Krumdieck tissue slicer (Alabama Research and 
Development, USA), (Figure 2.1) was set up aseptically in a class II microflow tissue safety 
hood according to the manufacturers instructions.  Tissue cores were placed into the 
Krumdieck tissue slicer assembly and aseptic 240μm thick PCLS were cut with a blade cycle 
speed ranging from 20-70/min depending on the type of tissue used (cirrhotic or normal).  
PCLS were then immediately transferred to tissue culture media consisting of Williams E 
media (Sigma, UK) supplemented with 2% Fetal Calf Serum (FCS, Invitrogen, UK), 0.1μM 
dexamethasone (Sigma, UK), and 0.5μM insulin (Novo-Nordisk) unless otherwise noted for 
specific assays.  PCLS were cultured for up to 48 hours ex vivo in static culture at 37°C in 5% 
CO2 in a humidified atmosphere (Karim et al., 2013).  
 
In order to assess functional integrity of PCLS before or after specific treatments, slices were 
fixed in formal saline (10%, Adams, Healthcare) for three days followed by a three-day 
incubation in 30% sucrose (Sigma) made up in Phosphate Buffered Saline (PBS, Oxoid, UK).  
PCLS were then embedded in Tissue-Tek® Optimal Cutting Temperature polymer
 TM
 (OCT) 
compound (Sakura Finetek, UK) in a foil boat, and snap frozen in liquid nitrogen prior to -
80°C storage until they were cryosectioned at 15μm for immunohistochemical staining. 
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Figure 2.1: Functional components of the Krumdieck tissue slicer 
(A) Krumdieck tissue slicer, (B) components of the Krumdieck tissue slicer include the 
electrical housing indicated by arrow, which rotates to allow the tissue core to be cut and is 
placed in the microtome assembly (indicated by arrow) which sits in the reservoir assembly to 
be cut.  The reservoir assembly contains sterile PBS and allows cut PCLS to flow in to the 
glass funnel for collection.  (C) Components of the microtome assembly.  Figure adapted 
from (Estes et al., 2007). 
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2.4 Preparation of tissue sections for immunochemistry 
For immunohistochemical staining procedures sections were produced from previously snap 
frozen human or mouse liver tissue cubes.  Tissue blocks were mounted and cut on a 
BRIGHT (model-OTF) cryostat into 5-10μm sections which were then mounted on glass 
microscope slides (Xtra Slides, Leica UK), fixed in acetone (Fisher Scientific, Loughborough, 
UK) and stored at -20°C wrapped in foil.  Some tissue sections were also taken from formalin 
fixed paraffin embedded tissue blocks which had been fixed in formal saline (10%, Adams, 
Healthcare) and tissue was embedded in paraffin and sectioned into 5-10μm sections using a 
rotary microtome (Leica microsystems) tissue was floated in a water bath and transferred on 
to glass slides and stored at room temperature.     
 
2.5 Sectioning of liver tissues for Matrix Assisted Laser Desorption Ionization Mass 
Spectrometry Imaging (MALDI-MSI) 
Serial tissue sections of normal, steatotic, NASH, ALD and PBC liver samples or WT and 
VAP-1 KO mice livers were cut using a cryostat (Leica) at 5μm and were mounted with water 
rather than OCT compound.  Sections were placed on glass slides (Xtra Slides, Leica UK) for 
Hematoxylin and Eosin (H&E) staining.  Sections were also placed on steel MALDI plates 
(AB Sciex, Warrington, UK) for MALDI imaging (section 2.29). 
 
2.6 Immunohistochemical staining of human liver specimens 
Fixed liver sections from patients stored at -20°C were defrosted at room temperature in foil 
for 15 minutes.  The sections were then fixed in acetone for five minutes and endogenous 
peroxidase activity was blocked with 1-2 drops of peroxidase block (Dako) for 20 minutes or 
0.3% H202 (diluted in methanol) for 10 minutes.  This was carried out in a humidified 
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chamber to prevent evaporation of solutions.  The sections were washed twice with Tris 
Buffered Saline pH 7.6  (TBS) + Tween 20 (Sigma) and treated with 1- 2 drops of horse 
serum (Vector ImmPress Kit, Vector labs UK) for 30 minutes.  The horse serum was drained 
and the sections were incubated for 1 hour with 100µl of primary antibody or respective 
control antibodies diluted in TBS pH 7.6 as indicated in Table (2.1).  Sections were washed 
twice with TBS pH 7.6 and incubated with 100µl of secondary antibody (Vector ImmPress 
Kit, Vector labs UK) for 30 minutes, and were further washed twice with TBS pH 7.6 and 
incubated in 3,3’ diaminobenzidine tetrahydrochloride (DAB) substrate (Vector, laboratories) 
for five minutes.  The sections were washed in distilled water for 5 minutes, counterstained 
with Mayer’s haematoxylin (Leica, Biosystems, Peterborough) for 1 minute and then washed 
in running tap water.  The sections were mounted with Depex (DPX) mountant (Shandon, 
UK) and were left to dry for 24 hours before microscopic observation. On occasion paraffin-
embedded, formalin-fixed human liver sections were used for immunohistochemical staining.  
Here all staining methods were as above with the addition of a dewaxing step and antigen 
retrieval.  Briefly slides were deparaffinised in xylene (Sigma) (2 washes, 3 minutes each) and 
rehydrated through a series of alcohol changes (100% ethanol, 2 washes three minutes each, 
95% ethanol three minutes, 70% ethanol three minutes) and finally washed in running tap 
water.  To unmask the antigenic epitope, heat mediated antigen retrieval was performed were 
slides where incubated in warm Ethylenediaminetetraacetic acid (EDTA) buffer for 
approximately 10 minutes to allow exposure of antigenic sites.   
 
2.6.1 Immunofluorescent staining  
Analyses of protein expression in formalin-fixed sections cut from PCLS were demonstrated 
using immunofluorescent staining.  Firstly antigen retrieval was carried out in EDTA buffer 
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(as described above, section 2.6).  Sections were then washed in EnVision buffer (Dako) and 
non-specific binding to sections was inhibited by treatment with 2% casein blocking solution 
for 10 minutes (Vector Laboratories).  Primary antibody or appropriate isotype-matched 
negative control antibody was applied for 1 hour, followed by a 5-minute wash with Envision 
buffer.  The appropriate FITC-conjugated secondary antibody was then added for 30 minutes.  
The sections were then washed twice with buffer and mounted using VECTASHIELD 
mounting media (VECTOR Laboratories).  Images were obtained using Zeiss LSM Zen 
conofocal.   
Antigen Isotype Concentration Source 
GLUT1
1
 IgG2a 1μg/ml- 5μg/ml ABCAM 
GLUT2
2 
IgG 5μg/ml ABCAM 
GLUT4
1
 IgG2b 10μg/ml ABCAM 
GLUT9
2
 IgG 10μg/ml ABCAM 
GLUT10
2
 IgG 2.5μg/ml ABCAM 
FABP1
1
 IgG1 1μg/ml Cambridge 
Bioscience 
FABP4
1
 IgG1 10μg/ml ABCAM 
LRP8
2
 IgG 2μg/ml Cambridge 
Bioscience  
Caveolin 1
1
 IgG2b 0.2μg/ml ABCAM 
VAP-1
1
 IgG2a 5μg/ml Biotie 
therapeutics 
  Negative control antibodies   
 IgG2a 1μg/ml-5μg/ml R&D 
 IgG2b 0.2μg/ml R&D 
 IgG 2.5μg/ml-10μg/ml ABCAM 
  Secondary antibodies  
Immunopress 
secondary 
antibodies  
 1-2 drops on tissue section Vector 
laboratories 
2° Antibody, 
Anti mouse 
Alexa 488 FITC 
green  
IgG2b 1/500 Invitrogen  
 
Table 2.1: Antibodies used for immunohistochemial detection of proteins 
Antibodies used in frozen and paraffin embedded human tissues.  
1 
denotes mouse anti human 
monoclonal antibodies whilst 
2
 denotes rabbit anti human polyclonal antibodies.  
Immunopress secondary antibodies contained both mouse and rabbit antibodies.   
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2.7 Histological staining to investigate liver morphology, steatosis and fibrosis  
Fresh frozen, unfixed liver sections from normal, steatotic, NASH, ALD and PBC patients or 
from WT and VAP-1 KO mice fed on a HFD stored at -20°C were defrosted at room 
temperature in foil for 30 minutes.  For morphological analysis, they were stained using 
standard H&E methodology (Leica, UK) with sequential baths in the reagent series indicated 
in Figure 2.2 for various time points as indicated. 
 
To examine samples for the degree of steatosis present, we used lysochrome Oil Red O 
(ORO). Here a working solution of ORO made fresh in isopropanol (5g/L, Sigma UK) was 
further diluted to 60% v/v in distilled water. Sections were defrosted at room temperature in 
foil for 30 minutes, fixed in formal saline for 5 minutes, and were then washed in distilled 
water for 10 minutes before staining as illustrated in Figure 2.2.   
 
Serial acetone-fixed frozen sections from the same patients were also stained with Sirius Red, 
(0.1% w/v, Sigma Aldrich in 1.3% saturated picric acid, Sigma) to allow visualisation of the 
extent of fibrosis present, according to standard protocols. Sections were defrosted at room 
temperature and then subjected to Sirius Red staining as illustrated in Figure 2.2.  
  
Following completion of staining protocols, the slides were then mounted using DPX 
(Shandon, UK) and a 24x40mm coverslip (SurgiPath, UK) was placed on the sections.  The 
sections were left to dry for 24 hours before visualising using a Zeiss Axiovert microscope, 
and representative images were captured using Axiovision software.  
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Figure 2.2: Protocol for histological staining procedures for H&E, ORO and Sirius Red 
staining.     
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•Haematoxylin 4 
minutes 
•Water 2 minutes 
•Acid alcohol 30 
seconds 
•Water 5 minutes 
•Eosin 30 seconds 
•Water 2 minutes 
•70% ethanol 5 
minutes 
•100% ethnol 5 
minutes  
•Xylene 5 minutes 
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•60% Isopropanol 5 
minutes 
•ORO 15 minutes 
•60% Isopropanol 5 
minutes 
•Distilled water x2 
•Haematoxylin 5 
minutes 
•Tap water 10 
minutes 
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•Acetone 5 minutes 
•100% ethanol 2 
minutes 
•70% ethanol 2 
minutes 
•Distilled water 5 
minutes 
•0.5% 
Phosphomolybdic 
acid 5 minutes 
(Sigma Aldrich) 
•0.1% Sirius Red 2 
hours (Sigma 
Aldrich) 
•Dip in 0.01M HCL 
•Distilled water 5 
minutes 
•Haematoxylin 30 
seconds 
•Distilled water 5 
minutes 
•70% ethanol 2 
minutes 
•95% ethanol 2 
minutes 
•100% ethanol 2 
minutes 
•Xylene 5 minutes 
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2.8 Cell Isolation, Culture and Maintenance 
2.8.1 Isolation and culture of HSEC, BEC and Fibroblasts from human liver tissue 
In order to isolate cells from tissue samples, 5-10cm thick (approximately 50g) slices of 
human liver tissue were used.  The tissue was chopped finely using scalpels and transferred to 
a sterile beaker containing 20ml of PBS.  5ml of 0.2% Collagenase solution (Sigma, Poole 
UK) was added and the tissue slice was incubated for 20 minutes in 5% CO2 at 37°C until the 
tissue was well digested.  The liver suspension was then passed through a fine mesh and 
washed with 200ml of PBS.  The filtrate was then divided in to eight universal tubes and 
centrifuged at 550g for five minutes.  The supernatant was discarded and the pellets were 
rewashed in PBS until the supernatants were relatively clear.  To obtain the non-parenchymal 
cell populations the cell pellets were then resuspended in 3ml of PBS and layered over a 77% 
and 33% Percoll
TM 
(Amersham Biosciences) gradient and subjected to density gradient 
centrifugation at 869g, for 25 minutes.  The non-parenchymal cell population was collected 
from the gradient
 
interface, washed in PBS and centrifuged at 550g for 5 minutes.   
 
Next the BEC were magnetically selected using positive selection by addition of mouse anti 
Human Epithelial Antibody (HEA) (50µg/ml, Progen, Biotec) and pan mouse Dynabeads ® 
(4 x 10
8
 beads/ml, Dynal, UK). These were then seeded in to a Rat Tail Collagen (RTC, 
Sigma) coated T25cm
2
 flask (Corning, UK) and cultured in BEC media consisting of:  equal 
volumes of complete Dulbecco’s Modified Eagle Medium (DMEM, GIBCO®, Invitrogen) 
and HAMS-F1 (GIBCO®, Invitrogen) containing 2mM L-Glutamine, 100U/ml Penicillin and 
100µg/ml Streptomycin (Sigma, Dorset, UK).  The medium was supplemented with 10% 
human serum (H+D supplies, UK), 2μg/ml hydrocortisone (Solu- Cortef Pharmacia), 125μl 
insulin (per 100ml) and 10ng/ml of cholera toxin (Sigma), Hepatocyte Growth Factor (HGF) 
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and Vascular Endothelial Growth Factor (VEGF), (both Peprotech, UK).  This was then 
followed by positive selection of HSEC using mouse anti-human CD31 antibody (10µg/ml, 
Dako, ELY, UK) with magnetic selection using Dynabeads as above.  HSEC were then 
seeded in to an RTC-coated T25cm
2
 flask (Corning, UK).  HSEC were maintained in a 
humidified atmosphere at 5% CO2 in complete endothelial basal media (Invitrogen, Paisley, 
UK) containing 2mM L-Glutamine, 100U/ml Penicillin and 100µg/ml Streptomycin (Sigma, 
Dorset, UK).  The medium was supplemented with 10% human serum (H+D supplies, UK) 
and 10ng/ml of both HGF and VEGF (both Peprotech, UK).  The HSEC and BEC depleted 
supernatant from the cell preparation was then centrifuged at 550g for 5 minutes. The pellet 
which contained predominantly hepatic fibroblasts was resuspended in fibroblast growth 
media consisting of complete DMEM (GIBCO®, Invitrogen) containing 2mM L-Glutamine, 
100U/ml Penicillin and 100µg/ml Streptomycin (Sigma, Dorset, UK) and supplemented with 
16% FCS (H+D supplies, UK) seeded in to a T25cm
2
 flask (Corning, UK) and cultured at 
37°C in humidified atmosphere at 5% CO2.  
 
 
 
Figure 2.3: Representative phase contrast pictures of HSEC, BEC and fibroblast cells in 
culture.  
Typical images of (A) HSEC, (B) BEC and (C) Fibroblasts isolated from human liver. Images 
taken using canon camera, connected to a phase contrast microscope, original magnification 
X10. 
 
 
A  B  C  
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2.8.2 Isolation and culture of primary hepatocytes  
Hepatocyte isolation was carried out according to established protocols within our laboratory 
(Bhogal et al., 2011).  Briefly liver wedges (50-413g) were cut and placed in cold DMEM 
(Gibco, Paisley, UK).  The wedge was perfused with PBS to remove blood from the liver and 
for the identification of two suitable vessels for cannulation and perfusion of buffers.   Two 
20-gauge cannulae (Becton-Dickinson, UK) were sutured into the vessels using a 3/0 prolene 
(Covidien, Hampshire, UK) purse string suture.  The liver wedge was then perfused with 
wash buffer 10mM 4-(2-hydroxylethyl)-1-piperazineethanesulfonic acid  (HEPES) pH7.2 
(Sigma, Dorset, UK) at room temperature using a flow rate of 75ml/min.  The liver wedge 
was then perfused with a chelating solution consisting of 10mM HEPES, 0.5mM Ethylene 
Glycol Tetra-Acetic Acid (EGTA) pH7.2, (Sigma), followed by a further perfusion with wash 
buffer.  The liver wedge was then perfused with a recirculating enzymatic buffer at 37°C for 
1-19min at a flow rate of 75ml/min consisting of 0.5% w/v Collagenase A from Clostridium 
Histolyticum (Roche, UK), 0.25% w/v 4.5units/mg Protease type XIV from Streptomyces 
Griseus (Sigma), 0.125% w/v 451units/mg Hyaluronidase from bovine testes (Sigma) and 
0.05% w/v 552units/mg Deoxyribonuclease from bovine pancreas (Sigma).  All enzymes 
were dissolved in Hank’s Balanced Salt Solution (HBSS) (Gibco, Paisley, UK) supplemented 
with 5mM calcium and magnesium chloride.  The liver was then mechanically disrupted and 
the suspension was filtered through a nylon mesh of 250μm (John Staniar Ltd, UK) followed 
by a nylon mesh of 60μm (John Staniar Ltd, UK).  Cell suspensions were washed three times 
at 50xg for 10 minutes at 4°C in supplemented media, and cells were plated on to type 1 RTC 
plates for two hours after which the media was removed and replaced with Arginine-free 
Williams E media (Sigma) supplemented with hydrocortisone (2μg/ml), Insulin (0.124U/ml), 
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Glutamine (2mM), Penicillin (20,000units/l), streptomycin (20mg/l) and Ornithine (0.4 
mmol/l), (Bhogal et al., 2011).    
 
2.8.3 Isolation and culture of peripheral blood mononuclear cells (PBMC) 
Approximately 25mls of blood from patients with HFE attending clinic at the Queen 
Elizabeth Hospital was layered on to 25mls of lympholyte (Cedarlane laboratories) separation 
gradient and centrifuged for 20 minutes at 900g with the brake at zero. Mixed PBMC were 
collected from the gradient interface and washed three times in PBS, centrifuged for 550g for 
5 minutes.  The pellet was resuspened in PBS and centrifuged further at 88g for 10 minutes to 
remove platelets.  PBMCs were used fresh for isolation of RNA using the RNEasy mini kit 
(Qiagen, Crawley, UK) according to the manufacturers instructions. 
 
2.9 Culture and maintenance of hepatocyte cell lines 
The human hepatoma-derived hepatocyte cell lines Huh7.5 and HepG2 were used in this 
study and were available in house.  The Huh7.5 and HepG2 cell line were resuscitated from 
liquid nitrogen storage and thawed using warm FCS to prevent any toxic effects from 
dimethyl sulfoxide (DMSO), which was a constituent of the freezing medium used.  The cell 
suspension was then topped up with PBS and centrifuged at 550g for 5 minutes.  The cell 
pellet was seeded in to a T75cm
2
 flask (Corning, UK) cultured in complete DMEM, 
(GIBCO®, Invitrogen) containing 2mM L-Glutamine, 100U/ml Penicillin and 100µg/ml 
Streptomycin (Sigma, Dorset, UK).  The medium was also supplemented with 10% FCS 
(Invitrogen, Paisley, UK) and 1ml of non-essential AAs (GIBCO®, Invitrogen).   The cells 
were maintained in a 5% CO2 humidified atmosphere at 37°C.   
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2.10 Maintenance of cells by freezing and storing  
Primary cells or cell lines were stored long term in liquid nitrogen at the gaseous phase.  
Cultured cells were detached enzymatically with trypsin (Invitrogen), centrifuged at 550g for 
5 minutes and resuspended in 95%FCS+5%DMSO (Sigma-Aldrich).  The cell suspension 
was then placed in cryovials (Corning), which were placed in a Mr Frosty
TM
 (Wessington 
Cryogenics, Tyne & Wear, UK) containing isopropanol (Sigma).  The Mr Frosty
TM 
was then 
transferred to -80°C for 24 hours which allowed gradual freezing of cells at a rate of 1°C per 
minute.   After 24 hours the cryovials were stored at the gaseous phase of liquid nitrogen at -
157°C. On requirement cells were removed from nitrogen storage and placed on ice to thaw, 
and the cell pellet was diluted in PBS, centrifuged at 550g for 5 minutes and seeded and 
cultured in the appropriate cell media.   
 
2.11 Adenoviral Transfection of Human HSEC with VAP-1 Constructs 
To stably express VAP-1 in HSEC, adenoviral constructs encoding WT hVAP-1 
(enzymatically active), hVAP-1 (Y471F), which is enzymatically inactive, and a LacZ control 
virus (see table 2.2) were transfected in HSEC according to established protocols (Liaskou et 
al., 2011).  HSEC were grown to confluency in 12 well plates.  Media containing human 
serum was removed prior to transfection, cells were washed with PBS and cells were 
incubated in endothelial basal media containing 10% (v/v) FCS for one hour.  The medium 
was discarded, cells washed again before adenoviral transfection at a multiplicity of infection 
of 600 for four hours. Cell numbers in confluent wells were calculated according to the 
formula below: 
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N= Average number of cells from 2 fields X 100cm
2
 X 3.8cm
2 *
  
                                                 0.1496 
*
 
* Approximate growth area in single well of a 12 well plate (Corning, UK) 
* Cells counted in a field of 0.1496mm
2
 at X10 magnification  
 
After incubation with viruses, the media was removed; cells washed again and complete 
HSEC media was added to the cells overnight.  The cells were then incubated at 37°C in a 
humidified atmosphere containing 5% CO2.  The next day cells were washed prior to 
experimental use.  To confirm the presence of hVAP-1, single color flow cytometry was 
performed. 
 
Adenoviral Constructs Concentration (PFU/ml) Lot number  
Padre hVAP-1 1.4 x 10
10 
842 
Padre hVAP-1 1.2 x 10
10
 1252 
hVAP-1_Y471F 2.6 x 10
10
 1025 
hVAP-1_Y471F 2.2 x 10
10
 1241 
LacZ 4.2 x 10
10
 950 
LacZ 1.4 x 10
10
 1156 
 
Table 2.2: Adenoviral constructs used for HSEC transfection 
* Constructs were a kind gift from Professor Sirpa Jalkanen, Medcity laboratory, Turku, 
Finland.  
 
 
2.12 Single Color Flow Cytometry  
To confirm the presence of hVAP-1 positivity after transfection, single color flow cytometry 
was performed.  Transfected HSEC were washed in PBS, detached with trypsin and spun at 
550g for 5 minutes.  The pellets were resuspended in Fluorescence Activated Cell Sorting 
(FACS) buffer (PBS + 10% FCS) and incubated with mouse anti human VAP-1 antibody 
(TK8-14 FITC conjugated) and matched isotype control (IgG1 FITC) conjugated antibodies 
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for approximately 40 minutes in the dark at 4°C, washed in FACS buffer and samples were 
run on the Cyan FACS analyzer.   
 
Antibody 
(FITC conjugated)  
Clone Concentration  Source  
VAP-1 TK8-14 10μg/ml Biotie, Finland 
IgG1 DAK-G01 10μg/ml Dako 
Table 2.3: Antibodies used for single color flow cytometry 
 
2.13 Determination of cell and PCLS function and viability in culture 
2.13.1 Treatment of cells and PCLS with palmitic and oleic acid  
Huh7.5 and HSEC were liberated from a confluent T75cm
2 
flask using Trypsin (Invitrogen) 
and seeded in to a 24 well or 48 well plate as required.  They were cultured in the appropriate 
media (see sections 2.8 and 2.9) for 24 hours until confluent.  Cells or PCLS were then treated 
with PA or OA (both Sigma, UK) at 250μm, 500μm or 1500μm (PA made up in methanol and 
OA in ethanol 25mM and stored under nitrogen gas) for 3, 6 and 24 hours.  Control wells 
were treated with methanol or ethanol alone.  For cells duplicate plates were treated 
identically and then fixed and stained with Hoechst dye  (2.5μg/ml, Invitrogen, UK) to permit 
cell quantification and signal normalisation after treatment. Cell counts were calculated 
according to the methodology described below in section 2.17. The data from cells treated 
with ORO and Hoechst dye was manipulated to express the amount of ORO normalised to 
amount of lipid taken up per 100,000 cells.  Treated cells were fixed in formal saline for 5 
minutes, washed in PBS three times and then stored in PBS at 4ºC until use for analysis whilst 
PCLS were fixed in formal saline (10%, Adams, Healthcare) for three days followed by a 
three-day incubation in 30% sucrose (Sigma) made up in PBS.   
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2.13.2 Quantification of lipid accumulation in fatty acid treated cells and PCLS using 
ORO labelling 
Following FA treatment, cells or PCLS were treated with ORO to permit quantification of 
lipid accumulation.  Cells or PCLS were treated with 60% isopropanol (Sigma) for five 
minutes followed by a 45-minute incubation with ORO; this was then followed by a 5-minute 
incubation with 60% isopropanol (Sigma) and then cells and PCLS were washed in distilled 
water.  Finally the ORO reagent was solubilised out of treated cells or PCLS, in order for 
spectrophotometric quantification, 300µl of isopropanol (Sigma) was added to each well, and 
the plate was placed on a plate shaker for 5 minutes. 100µl of solubilised supernatant from 
each well or an isopropanol control was added to triplicate wells in a 96 well plate, and the 
plate was read at an absorbance of 520nm.  Each PCLS was weighed and results normalised 
and expressed as amount of lipid taken up per 500mg of tissue.  For cells the data was 
manipulated to express the amount of ORO normalised to amount of lipid taken up per 
100,000 cells as described in section (2.17).   
 
2.13.3 Use of MTT to assess viability of PCLS and cultured cells 
In order to assess the viability of either cells cultured in 24 well plates or PCLS in culture a 
Methyl Thiazol Tetrazolium (MTT) assay was used (Sigma).  Control or pretreated cultured 
cells seeded in to a 24 well plate at a density of 1.0x 10
5 
per well, or PCLS were incubated 
with MTT.  PCLS were cultured for 1.5 hours at 37°C Williams E media containing 2mg/ml 
MTT, whilst cells were treated with 300µl of 0.4mg/ml MTT made up in DMEM without 
phenol red (Invitrogen UK) and incubated for 1 hour until the development of a purple 
insoluble formazan product was visualised.  Thereafter PCLS and cells were washed with 
PBS and the resulting formazan product was extracted by treatment with DMSO (Sigma 
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Aldrich) for 5 minutes.  Absorbance of replicate samples was read at 570nm using a 
microplate reader (Biotek Proview) using KC4
TM 
software, (Wolf Laboratories).  The 
absorbance of DMSO alone was also read as a background control.  All results were 
expressed as means of replicate samples. Signal from PCLS was normalized to per 500mg of 
tissue, and percentage viability of cultured cells and PCLS was calculated using the following 
formula: 
 
% Viability =  Mean absorbance of sample    X 100 
             Mean absorbance of control  
 
2.14 Assessment of lipid accumalation in PCLS and hepatic cells after VAP-1 treatment  
In order to study the effects of VAP-1 activity on lipid uptake in an intact organ culture 
system and isolated cells PCLS and Huh7.5 were used.  PCLS were cultured in Williams E 
media (Sigma, UK) supplemented with 2% FCS (Invitrogen, UK).  Insulin and 
dexamethasone were removed from the culture media unless added as treatments separately.  
Huh7.5 cells were cultured in the appropriate media as described (section 2.9).  PCLS and 
Huh7.5 cells were stimulated with treatments alone as indicated in Table 2.4 or in 
combination with each other for approximately 18 hours followed by a 6-hour incubation with 
either 250μm OA or 250μm PA.  Media alone was added in as a control.  
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Reagent  Concentration  Source  
Insulin  0.10IU Novo-nordisk 
Methylamine  200μm Sigma 
Benzylamine  200μm Sigma 
rVAP-1 500ng Biotie therapeutics 
H202 10μm ProLABO BDH 
BEA 400μm Sigma 
BAPN 250μm Sigma 
Chlorgyline  200μm Sigma 
Pargyline  200μm Sigma 
Table 2.4: Reagents used for glucose and lipid uptake assays 
 
2.15 Assessment of triglyceride secretion from PCLS after VAP-1 interventions  
To quantify and detect secretion of TAG after VAP-1 interventions and subsequent treatment 
with PA at 250μm, a TAG secretion assay (Cayman chemical calorimetric assay 
(CAT10010303) was carried out according to the manufacturers instructions.   
 
2.16 Assessment of glucose uptake in PCLS and hepatic cells after VAP-1 treatment 
using 2- Deoxy-D- Glucose [3H (G)] uptake assay  
In order to study the effects of VAP-1 treatment on glucose uptake in the intact liver and 
isolated liver cell populations, PCLS and single populations of HSEC (transfected see section 
2.11), Huh7.5 and HepG2 were used. PCLS were cultured and stimulated in 500μl of low 
glucose DMEM (Invitrogen) (glucose concentration 1000mg/L) media consisting of 2% FCS 
(Invitrogen, UK) for approximately 2.5 hours.  Cells were cultured for 24 hours in the 
appropriate media as indicated in sections 2.11 and 2.9 in 12 or 24 well plates.  Thereafter the 
complete media was removed; cells were washed with PBS and incubated with treatments for 
2.5 hours in low glucose DMEM (Invitrogen) containing growth factors or FCS as 
appropriate for each cell type.  For HSEC human serum was replaced with 0.5% Bovine 
Serum Albumin (BSA) as human serum contains VAP-1.  Treatments used are as indicated in 
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Table 2.4 were PCLS or cells were treated alone with each reagent or in combination with 
other treatments as indicated in specific figures.  PCLS and cells were then washed in PBS at 
least three times and were further incubated for 30 minutes in low glucose DMEM containing 
0.1mM 2 Deoxy-glucose (Sigma) and 2μci/ml 2-Deoxy-D-Glucose [3H (G)] (Sigma).  PCLS 
and cells were washed three times with ice cold PBS to stop the reaction and each PCLS was 
lysed in approximately 400μl of 1N NaOH (Sigma) for 30 minutes on a plate shaker, whilst 
cells were lysed in 400µl of 0.2% Triton X-100 (Sigma) and visualised microscopically to 
ensure cell liberation.  The lysates were then mixed with 4ml of scintillation fluid (Fisher 
Scientific, UK) and sent for scintillation counting on a Packard T2500 liquid scintillation 
counter (Perkin Elmer).  Samples were run on a five-minute program to give tritium 
Disintegrations Per Minute (DPM) values.  Each PCLS was weighed and results expressed 
and normalized to 500mg of tissue.   
 
2.17 Validation of Hoechst dye for cell quantification  
Here cells were seeded at densities ranging from 8.0 x 10
3 
-8.0 x 10
5 
in 24 well plates and 
fixed with methanol for five minutes. Hoechst dye (Bisbenzamide 33342, Invitrogen UK) 
which specifically incorporates in AT rich regions of double stranded DNA in cell nuclei was 
used to determine cell number at a final concentration of 2.5µg/ml.  500µl of Hoechst dye was 
added to each well for five minutes, cells were washed and fluorescence was measured on a 
plate reader (excitation 355nm, emission 465nm) as above.  Background fluorescence signals 
were also determined from control wells containing PBS alone.  Plotting an XY scatter graph 
of the absorbance values obtained for each cell density generated a standard curve.  A 
regression equation was generated so that in future experiments cell number could be 
determined from the cell number calibration. Experiments were repeated three times using 
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different cell isolates and in each case the standard curve was used only if the R
2
 value was ≥ 
0.9.     
 
These calibration curves were then used in conjunction with ORO staining to express the 
amount of ORO taken per 100,000 cells.  Graphical representations showing ORO uptake per 
100,000 cells were plotted by dividing the cell number by 100,000.  The absorbance values 
were then multiplied by this corrected value as were the SEM values and a graph showing 
ORO uptake per 100,000 cells plotted.  
 
2.18 Determination of PCLS function and viability in culture  
2.18.1 Quantification of Albumin production for the assessment of hepatocyte synthetic 
function in PCLS  
Hepatocyte function was assessed by measuring albumin production by Enzyme-Linked 
Immunosorbent Assay (ELISA) using optimal concentrations of coating antibody (0.5mg/ml 
goat anti-human albumin antibody) and detection antibody (1mg/ml HRP-conjugated goat 
anti-human albumin antibody: both Bethyl Industries, USA) and albumin standards (Bethyl 
Industries, USA).  Briefly the coating antibody was diluted 1/200 in coating buffer 0.05M 
(5.3g/l) Na2CO3 pH 9.6 and 100μl was applied to each well of a Nunc 96 well maxisorp 
immunoplate and incubated for 1 hour at room temperature.  The wells were then washed 
three times with 400μl of wash solution (Tween20 containing 0.2% FCS), prior to the 
addition of 200μl of blocking solution to prevent unspecific binding of primary antibody 
(50mM Tris. 0.14M NaCl, 1% BSA) pH 8.  The wells were incubated at room temperature for 
30 minutes, followed by three washes with washing buffer.   
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Standards (ranging from 400ng/ml-6.25ng/ml), samples and a negative control (uPA-SCID 
plasma) were diluted in sample buffer (50mM Tris. 0.14M NaCl, 1% BSA, 0.05% Tween20) 
pH 8 and 100μl of each was placed in triplicates on the plate and incubated for 1 hour at room 
temperature.  This was then followed by five washes with washing buffer prior to the addition 
of the detection antibody which was diluted 1/100 in sample buffer and 100μl was added to 
each well for 1 hour at room temperature.  The wells were washed a further five times with 
washing buffer and the binding of detection antibody was visualized with 
Tetramethylbenzidine (TMB) substrate (Sigma).  The reaction was stopped with the addition 
of 100μl of 1M sulphuric acid (H2SO4) and the plate was read at an absorbance of 490nm on a 
Synergy HT plate reader using the KC4 program.  The albumin concentration in samples was 
determined by comparison to the standard concentration curve.   
 
2.18.2 Assessment of glycogen storage in PCLS  
PCLS were cultured in complete media for up to 48 hours before representative samples were 
cryopreserved and sectioned (see section 2.3). For assessment of glycogen content, sections 
were stained using ready-made working concentrations of Periodic Acid Schiff Stain (Leica, 
UK) using standard methodology. Briefly the sections were washed in excess distilled water, 
followed by a 5-minute incubation in 500μl of periodic acid, rinsed in tap water and incubated 
with 500ul of Schiff’s reagent for ten minutes.  The sections were then rinsed twice with distilled 
water for up to 5 minutes before being dehydrated through graded alcohol twice for 3 minutes 
and clearance series three times, for two minutes.  Sections were mounted using a non-aqueous 
mountant (Thermoscientific) and left to day for 24 hours before microscopic observation 
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using a Zeiss Axiovert microscope and representative images were captured using Axiovision 
software.  
 
2.18.3 Assessment of nuclear integrity in PCLS using Hoechst dye  
Nuclear integrity was assessed using Bisbenzimide (Hoescht dye, 2.5ug/ml, Sigma UK) 
staining followed by fluorescent microscopic imaging.  PCLS frozen sections were incubated 
for five minutes with 500l of 2.5ug/ml Hoechst dye.  The sections were then rinsed with 
PBS and mounted with VECTASHIELD mounting media (VECTOR Laboratories) and 
imaged by fluorescent microscopy.  Image J was used to assess the percentage of staining as a 
proportion of that seen at control time points.   
 
 
2.19 Determination of the enzymatic activity of VAP-1 in whole tissues by the Amplex 
Ultra Red method  
In order to quantify endogenous VAP-1 activity in normal and diseased tissue, approximately 
2cm/2cm tissue blocks of normal, steatotic, NASH, ALD and PBC livers were snap frozen in 
liquid nitrogen and stored at -80°C.  Frozen tissue blocks were then digested in 0.2% Triton 
X-100 (Sigma-Aldrich) containing protease inhibitor cocktail using gentleMACS
TM
 tubes 
(Miltenyi Biotec).  Tissue lysates were briefly spun at 13148g for 20 minutes, and the 
supernatant was collected and placed on ice whilst protein concentration in a sample of the 
lysate was measured using a Bio-Rad DC Protein Assay according to the manufacturers 
instructions.  A protein standard curve using dilutions of BSA (Sigma) was generated to 
calculate the concentration of protein in each sample.  Total protein samples from all tissues 
were then diluted to a final protein concentration of 8mg/ml and stored at -20°C.  
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The Amplex ultra red assay was then used to quantify VAP-1 activity in these protein lysates.  
Briefly the reaction works as follows: upon addition of substrates such as MA or BA to VAP-
1, enzymatic activity leads to the production of formaldehyde, ammonia and hydrogen 
peroxide.  The hydrogen peroxide produced in this reaction reacts with the Amplex Red 
reagent (10-acetyl-3, 7-dihydroxyphenoxazine) in the presence of horseradish peroxidase 
(HRP) in a 1:1 stoichiometric ratio, producing Amplex UltroxRed, a brightly fluorescent 
product with a long wavelength spectrum, which can be quantified spectrophotometrically. 
Protein lysates were added in triplicates to a 96 well flat bottom plate.  Benzylamine (2mM) 
was added in the presence or absence of the specific VAP-1 inhibitor BEA (400μM). 
Chlorgyline and Pargyline inhibitors for MAOA and MAOB were also added in to wells 
containing BA alone to block non-specific activity.  The fluorometric reaction was initiated 
by the addition of the Amplex red reagent consisting of 1/100 Amplex ultra red (20mM stock, 
Invitrogen) and 1/100 HRP (200U/ml stock, Invitrogen).  The reaction was measured 
continuously in a fluorescence microplate reader (Biotek Proview) for approximately 3 hours 
using excitation of 530nm and emission detection at 590nm using KC4
TM 
software, (Wolf 
Laboratories).  PBS was added as a negative control to some wells and 30% hydrogen 
peroxide as a positive control. 
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2.20 Analysis of gene expression in cultured cells and whole liver using microarrays 
and quantitative PCR (qPCR) 
2.20.1 RNA extraction 
2.20.1.1 RNA extraction from primary cells and cell lines 
Microarray analysis and qPCR was carried out to see what the basal expression of glucose 
and fatty acid transporters was in cultures of primary hepatocytes, HSEC, Huh7.5, HepG2, 
BEC, fibroblasts and PBMC cells and in normal, steatotic, NASH, ALD and PBC patients to 
see whether firstly what the expression patterns were and weather these changed in disease, 
and between different cell types.  In addition to see whether the activity of VAP-1 altered 
expression of any of these transporters.  Specific arrays such as the human NF-κB signaling 
pathway PAHS-025A (Qiagen) was used to analyze the expression of genes involved in the 
NF-κB signal transduction pathway in PCLS which had been treated with VAP-1+MA for 2.5 
hours.    
 
For the microarray analysis Huh7.5 and HSEC were grown in culture and total cellular RNA 
from samples was extracted from all cell populations, whilst for qPCR analysis total RNA 
was isolated from HSEC, BEC, fibroblasts, primary hepatocytes, HepG2, PBMC cells and 
normal, steatotic, NASH, ALD and PBC explanted livers.  To determine whether there were 
any changes in lipid transporter expression after FA treatment RNA was also extracted from 
Huh7.5, which had been treated with 250μm OA or PA using the RNEasy mini kit (Qiagen, 
Crawley, UK) according to the manufacturers instructions.   
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Briefly Media from confluent T75cm2 flasks containing cells was removed and the flasks 
were washed with 10ml of PBS.  Then 5ml of trypsin (Invitrogen) was added to the flask to 
detach cells.  The detachment of cells was visualized under a phase contrast microscope.  The 
trypsin was neutralised with 20ml of PBS and the cell suspension was centrifuged at 550g for 
5 minutes.  The pellet was resuspended in PBS and then further centrifuged to remove 
residual trypsin; the pellet was resuspended in 200µl of PBS and 1ml in RNA later (Ambion).  
The sample was stored at 4°C for 24 hours and then transferred to -80°C storage. The RNA 
samples were also treated with DNAase treatment with RNAase free DNAase (Qiagen, UK) 
as part of the protocol instructions.  This was done to eliminate possible genomic 
contamination, which may interfere with downstream reactions.   
 
2.20.1.2 RNA extraction from human liver tissue 
Tissue blocks from normal, steatotic, NASH, ALD and PBC patients, roughly 2cm/2cm, had 
previously been preserved in RNA later and stored at -80°C.  Tissue blocks were removed 
from -80°C storage and placed on ice, approximately 30mg of tissue was excised and used to 
isolate RNA as previously described (see section 2.20.1.1).   RNA was also extracted from 
untreated PCLS and PCLS treated with 200μm MA for approximately 4.5hours; here the 
PCLS were submerged in buffer RLT+β-mercaptoethanol immediately after treatment for 
RNA extraction.  The concentration of the eluted RNA from all samples was checked as well 
as the purity and integrity before further use using the NanoDrop spectrophotometer (Thermo 
Fisher Scientific).  The 260/280nm and 260/230nm ratios were calculated and samples with a 
value of 2 at 260/280nm ratio were indicative of relatively pure RNA.  For samples, which 
were used for microarray analysis, the RNA integrity was confirmed using Agilent 2100 
Bioanalyser (Palo Alto, CA, USA).  
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2.20.2 cDNA synthesis  
All RNA samples were transcribed into cDNA with approximately 1µg of total RNA using 
the first strand cDNA synthesis kit (Roche) according to the manufacturer’s protocol unless 
otherwise stated for example for specific arrays such as the Fluidigm ® 96.96 Dynamic Array 
TM 
Integrated Fluidic Circuit; the minimum amount of RNA which could be used was 
125ng/ul and all RNA samples were diluted to 125ng/μl and approximately 1μl of total RNA 
was transcribed to cDNA using the superscript TM III first strand synthesis supermix kit 
(Invitrogen) according to the manufactures instructions.  Samples used for the human NF-κB 
signaling pathway PAHS-025A (Qiagen) were transcribed using the RT
2 
First Strand Kit 
(SABiosciences, Qiagen) according to the manufacturers instructions.  The concentration of 
cDNA from all samples was checked as well as the purity and integrity before further use, 
using the NanoDrop spectrophotometer (Thermo Fisher Scientific).   
 
2.20.3 Microarray Analysis  
Transcriptome analysis was carried out for all samples using Agilent Human Whole Genome 
Oligo Arrays (catalogue number G4112F) in accordance with the Agilent One-Color 
Microarray-Based Gene Expression Analysis Protocol. Key consumables were purchased 
from Agilent Technologies UK Ltd (Wokingham, Berkshire, UK) unless otherwise stated. 
 
2.20.3.1 Labelling 
RNA from each sample (200 to 1000ng depending on amount and concentration available) 
and the appropriate amount of Agilent One-Color RNA Spike-In RNA were labeled with 
reagents supplied in the Agilent Quick Amp one-color Labeling Kit, according to 
manufacturer’s instructions, and with final reagent concentrations and volumes as follows:  
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Primers were annealed to template by mixing 1.2 µl T7 Promoter Primer, RNA and spike-in 
control in a volume of 11.5µl. Samples were then denatured at 65ºC for 10min followed by 
incubation at 4ºC for 5min. First Strand Buffer (1X stock), DTT (10mM), dNTP (0.5mM), 
MMLV (1µl) and RNaseOut (0.5 µl) were then added to make up the cDNA synthesis 
reaction (20µl), which was incubated for 2h at 40 ºC. After 15 min denaturation at 65ºC, the 
reaction was made up to 80µl with the addition of Cyanine 3-CTP (0.3mM), Transcription 
Buffer (1X), DTT (10mM), NTP (8µl), PEG (4%), RNaseOUT (0.5µl), Inorganic 
Phosphatase (0.6µl), and T7 RNA Polymerase (0.8µl) and incubated for 2h at 40ºC to 
synthesize the fluorescently- labeled cRNA.  The labeled cRNA was then purified with the 
RNeasy Mini Kit (Qiagen Ltd, Crawley, UK) according to the manufacturer’s protocol. 
 
2.20.3.2 Hybridisation and Scanning   
The labeled cRNA was then hybridized to the Agilent human whole genome Oligo Array 
slides (Agilent array ID 014850) using reagents from the Agilent Hybridization Kit (catalogue 
number 5188-5242) with a slight modification to manufacturer’s protocol: 2μg (instead of 
1.65μg) of the labeled sample RNA was used for hybridization.  Hybridization was performed 
for 17 hours at 65ºC with 10-rpm rotation on a mixer platform. Slides were washed for 1 min 
at 22ºC in Wash Solution 1 (catalogue number 5188-5325), followed by 1 minute in Wash 
Solution 2, which was pre-warmed, to 37ºC (catalogue number 5188-5326), 30 seconds in 
acetonitrile (Fisher catA/0630/PB15), and 30 seconds in Agilent Stabilization and Drying 
Solution (catalogue number 5185-5979). Slides were then scanned with the Agilent 
Microarray Scanner System. Data was extracted using the Agilent Feature Extraction 
Software (v.9.1), and analyzed using Gene Spring (GX.12.5).   
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2.20.3.3 Data analysis  
Genes or spots, which were not reliably detected, were filtered/removed and the data sets 
were normalized based on percentile shift normalization.  Percentile shift normalization is a 
global normalization, where all the spot intensities in an array are adjusted to enable 
comparison with other arrays. This normalization computes the 75
th
 percentile of the log 
transformed expression values for each array independently, across all spots, then subtracts 
this value from the log transformed expression value of each spot.  To detect GLUT and fatty 
acid transporters, heat maps were generated for genes which were detected in >75% of all 
samples tested.  Heat maps, are a visual tool to aid assessment of the expression patterns of 
genes across different samples.   
Data was represented by the per gene normalization method.  For example the median 
expression of a given gene is found across all samples and then expression is relative to the 
median expression of that gene in all samples tested.   
 
2.20.4 Quantitative real-time PCR 
2.20.4.1 Pre amplification of cDNA for Fluidigm® 96.96 Dynamic ArrayTM Integrated 
Fluidic Circuit 
To validate our results from the microarray data the Fluidigm ® 96.96 Dynamic Array 
TM 
Integrated Fluidic Circuit (IFC) was used.  Here all cDNA samples had to be preamplified 
with the TaqMan PreAmp Master Mix (Applied Biosystems).  Briefly all 20X Taqman assays 
to be used in the array were pooled and diluted to 0.2X in Tris-EDTA buffer 100X (Sigma).  
High expressers such as the house keeping genes β-actin and GAPDH were excluded from the 
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preamp stage.  Taqman fluorogenic 5’ nuclease assays using gene-specific 5’FAM labeled 
probes were used in this array.  
 
Reagent μl/reaction 
TaqMan PreAmp Master mix (2X) 
(Applied Biosystems) 
2.5 
0.2X pooled TaqMan assay  1.25 
cDNA  1.25 
Final volume (μl) 5 
Table 2.5: Preamp reaction mix 
 
The Preamp thermocycling parameters were as follows: 95°C for 10 minutes, 14 cycles at 
95°C for 15 seconds followed by 60°C for 4 minutes.  The PreAmplified template was diluted 
(at least 1:5 dilution) with 20μl of 1X Tris-EDTA buffer 100X (Sigma) and stored at -20°C 
until further use.  
 
2.20.4.2 Fluidigm® 96.96 Dynamic ArrayTM Integrated Fluidic Circuit chip preparation  
The 96.96 syringes containing 150μl of control line fluid were gently inserted into the 
dynamic array.  The plate was then primed for 20 minutes on the IFC loader (136X script), 
before 5μl of each sample and probe were dispensed on to the 96.96 dynamic array on 
respective inlets on the plate.  The plate was loaded on the IFC for 1 hour and 30 minutes on 
the load mix (136x) script.  When the load mix script had finished the plate was removed 
from the IFC controller, the blue protective film from the underside of the plate was removed, 
any dust particles or debris on the plate were removed and the plate was then run in the 
fluidigm for two hours and 10 minutes.  All samples were run in triplicate and therefore three 
96.96 Dynamic Array plates were used.  
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Gene Gene symbol Taqman Assay ID  Agilent Probe ID  
GLUT1 SLC2A1 Hs00892681_m1* A_23_P571 
GLUT2 SLC2A2 Hs01096904_m1* A_24_P405705 
GLUT3 SLC2A3 Hs00359840_m1* A_24_P81900 
GLUT4 SLC2A4 Hs00168966_m1* A_32_P151263 
GLUT5 SLC2A5 Hs00161720_m1* A_24_P111054 
GLUT6 SLC2A6 Hs01115485_m1* A_23_P169249 
GLUT7 SLC2A7 Hs01013553_m1*             - 
GLUT8 SLC2A8 Hs00205863_m1* A_24_P175435 
GLUT9 SLC2A9 Hs01115485_m1* A_24_P118211 
GLUT10 SLC2A10 Hs00368843_m1* A_24_P271323 
GLUT11 SLC2A11 Hs00368843_m1* A_23_P404565 
GLUT12 SLC2A12 Hs00376943_m1* A_23_P395001 
GLUT13 SLC2A13 Hs00369423_m1* A_23_P10211 
FABP1 FABP1 Hs00155026_m1* A_23_P79562 
FABP2 FABP2 Hs01573164_g1* A_23_P391711 
FABP3 FABP3 Hs00269758_m1* A_24_P62783 
FABP4 FABP4 Hs01086177_m1* A_23_P8820 
FABP5 FABP5 Hs02339439_g1 A_24_P673063 
FABP6 FABP6 Hs01031183_m1* A_23_P43846 
FABP7 FABP7 Hs00361426_m1* A_23_P134139 
FATP1 SLC27A1 Hs01587917_m1* A_24_P382489 
FATP2 SLC27A2 Hs00186324_m1* A_23_P140450 
FATP3 SLC27A3 Hs00225680_m1* A_24_P179816 
FATP4 SLC27A4 Hs00192700_m1 A_24_P257971 
FATP5 SLC27A5 Hs00202073_m1* A_23_P4611 
FATP6 SLC27A6 Hs00204034_m1* A_23_P41789 
CAV1 CAV1 Hs00971716_m1* A_23_P134454 
CD36 CD36 Hs00169627_m1* A_24_P925505 
LRP1 LRP1 Hs00233856_m1* A_23_P124837 
LRP2 LRP2 Hs00189742_m1* A_23_P28295 
LRP8 LRP8 Hs00182998_m1* A_23_P200222 
Table 2.6: Probe identifiers for Fluidigm
®
 96.96 Dynamic Array
TM
 and Agilent 
microarrays 
*All Taqman probes from Applied Biosystems 
 
For the human NF-κB signaling pathway PAHS-025A (Qiagen) the RT2 SYBR® green qPCR 
Mastermix (SABiosciences, Qiagen) was used according to the manufacturers instructions 
and the PCR conditions were 95°C for 10 minutes required to activate hotstart taqDNA 
Polymerase, followed by 95°C for 15 seconds and 40 cycles at 60°C for 1 minute, qPCR was 
performed using the 700HT (Applied Biosystems) real time PCR machine.   
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2.21 Whole tissue lipid analysis using Mass Spectrometry (MS) and Gas 
Chromatography (GC)  
Mass spectrometric techniques were used in order to assess spatial location and distribution of 
phospholipids and FFA in normal, steatotic, NASH, ALD and PBC livers as well as PCLS 
treated with VAP-1 and its substrates.  In order to assess whether certain lipids were 
associated with disease pathogenesis such as in NASH livers and whether these correlate to 
mouse models of steaotohepatitis and fatty liver disease (WT and VAP-1 KO mice fed on a 
HFD), and acute treatments of PCLS with VAP-1 were investigated.   
 
2.22 Extraction of lipids from liver tissue and PCLS for analysis by GC and MALDI-
MS dried droplet analysis 
Tissue blocks from normal, steatotic, NASH, ALD and PBC explanted livers or PCLS treated 
with VAP-1 interventions which had previously been snap frozen in liquid nitrogen were 
removed from -80°C storage.  Each block of tissue was weighed and approximately 0.13-
0.15g of tissue was removed from each block for lipid extraction using a modified version of 
the Folch’s methodology (Folch et al., 1957).  Briefly, each block of tissue was finely 
chopped on a glass petri dish on ice and transferred to 1ml of 2:1 (CHCl3: MeOH) (Fisher 
Scientific, Leicestershire, UK) mixture.  The tissue and chloroform: methanol mixture was 
then made up to 20 fold its volume with 2:1 (CHCl3: MeOH) and homogenized vigorously.  
The samples were then filtered into a separating funnel through fat free filter paper 
(Whatman
®
).  The organic extract containing the lipids were washed in deionized distilled 
water, which formed two separate phases, the aqueous phase at the top, and the organic phase 
(chloroform: methanol containing lipid) formed the bottom layer.  The organic phase was 
decanted and retained whilst the aqueous phase was discarded.  The organic phase was then 
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rewashed for a second time with deionized distilled water.  This method was also used for the 
extraction of lipids from treated PCLS samples. The final extracts were then collected and 
stored in glass vials at -80°C until further use.   
 
For GC analysis the 2:1 (CHCl3: MeOH) solvent was evaporated off from 500μl of each liver 
lipid extract sample.  750μl of hexane (Fisher Scientific, Leicestershire, UK) was added 
followed by 500μl of 250mM KOH in MeOH (Fisher Scientific, Leicestershire, UK).  This 
mixture was then shaken for two minutes and left to stand for two minutes.  This resulted in 
the formation of two layers of which the upper layer was pipetted into a vessel for GC 
injection.  Samples along with a standard containing 37 methyl esters were run on a DB225 
column and GC was performed with Rian Griffiths (Chemistry Department, University of 
Birmingham) using established methodology.  Chromatograms for each sample were obtained 
with Retention Times (RT); these were then compared to retention times to the known 
standard to assign a lipid identity to each peak.   
 
 
2.23 Identification of lipid species in tissue extracts using MALDI-MS dried droplet 
analysis  
MALDI-MS dried droplet analysis allows acquisition of lipid spectra from digested lipid 
extracts, here 10 replicate spots (approximately 0.5μl) of lipid sample from each liver were 
pipetted on to a steel MALDI multi-well plate (AB Sciex, Warrington, UK) and allowed to 
dry.  This was then followed by the addition of 0.5μl α-Cyano-4-Hydroxycinnamic Acid 
(CHCA) matrix (25mg/ml, Sigma) which was prepared in 80% MeOH with 0.1% TFA (both 
Sigma).  Complex extract samples were analyzed on a hybrid quadrupole time of flight mass 
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spectrometer (Qstar XL, Applied Biosystems, Warrington, UK), fitted with an orthogonal 
MALDI ion source (pulsed N2 laser, 337nm, operated at 20Hz, 200μm core diameter fiber 
delivered).  All data were acquired in positive refelectron mode.  Spot analyses were 
interrogated using a circular laser pattern, summing 30 scans per spectrum.  Ion transmission 
was optimized and a Focusing Potential (FP) of 60 and declustering potential DP2 of 20 were 
used in all experiments.  Data processing was performed using MATLAB (MathWorks Inc), 
and Principle Component Analysis (PCA) was performed to reduce the dimensionality of the 
data.  For all MALDI data sets the spectra were collated to generate a total spectrum and peak 
intensities of interest were extracted from each individual spectrum.  Lipid maps 
(http://www.lipidmaps.org) and lipid libraries were used to identify lipid species as well as 
MS/MS fragmentation analysis to confirm lipid identities.  Experiments where performed by 
Sumera Karim and Rian Griffiths.   
 
2.24 Identification and localization of lipids in tissue extracts using MALDI imaging  
MALDI imaging was used to visualize the spatial distribution of lipids within intact tissue 
sections.  Liver sections (5μm) from normal, steatotic, NASH, ALD and PBC explanted livers 
or from WT and VAP-1 KO mice livers were cut onto steel MALDI plates (AB Sciex, 
Warrington, UK) for MALDI imaging as described in section 2.5.  CHCA matrix (see above) 
was then applied to each tissue section using an artist’s brush (Draper Air Tools Airbrush kit, 
Hampshire, UK) with Badger Airbrush propellant (Badger, Illinois, USA).  Tissue samples 
were analyzed on a hybrid quadrupole time of flight mass spectrometer (Qstar XL, Applied 
Biosystems, Warrington, UK), as described above.  For all MALDI imaging data sets, the 
spectra were collated to generate a total spectrum and peak ion images for peaks of interest 
were generated in MATLAB.   H&E and MALDI ion image overlays were produced to see if 
 70 
lipids correlated to anatomical regions, these were generated using GNU image manipulation 
program 2.6.   
 
2.25 Statistical Analysis  
Data was analyzed using students T test to compare means of two samples unless otherwise 
stated for specific assays for example a two way ANOVA with no replication was used to 
examine differences between time and concentration in the lipid uptake assays using 
Graphpad Prism version 5.0a, for gene array data a one-way ANOVA (unequal variance) with 
Benjamini Hochberg was used with a p value cut of at p<0.05 using gene spring (GX.12.5) 
and are indicated in specific figures.  Statistical significance accepted as * ≤0.05,  **≤0.01, 
***≤0.001. 
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CHAPTER 3 
 
 
3 HEPATOCELLULAR EXPRESSION OF GLUCOSE 
AND LIPID TRANSPORTERS 
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3.1 Introduction 
In a climate of rising obesity and increasing incidence of fatty liver disease in the Western 
world, this thesis sets out to examine potential roles of novel mediators that may impact upon 
hepatic glucose and lipid homeostasis. As stated in the introductory chapter, factors which 
may give rise to excess TAG within the hepatocyte leading to NALFD, include: 
 
 Increased uptake of FFAs and glucose by liver cells. This may occur in response to an 
overload of dietary fats and possibly due to altered expression of FA and carbohydrate 
transport proteins.   
 Decreased β-oxidation in mitochondria (Nakamuta et al., 2005)  
 Increased DNL  
 Decreased FA efflux caused by decrease in the production of apolipoprotein B which 
is involved in the transport of cholesterol low-density lipoproteins (LDL) and 
triglycerides to the rest of the body (Utzschneider and Kahn, 2006), (Chitturi and 
Farrell, 2001).  
 
This thesis will consider lipid and glucose uptake paths, and also how disease induced 
alterations in transporter proteins may impact on pathogenesis. Upon investigation, of 
published data regarding basal expression of carbohydrate and lipid transporters in the human 
liver, we were surprised by the lack of available information. Therefore we begin by 
documenting expression in health and disease.  Since both glucose and lipid uptake requires 
presence of active transport systems, we felt it was important to look at expression patterns of 
each.  
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Hepatocytes and other non-parenchymal cells require energy for cellular processes and this 
energy can be generated from carbohydrates and FFAs entering the cell. Carbohydrates enter 
using members of a specific family of 14 integral membrane transporter proteins also known 
as solute carrier 2A (SLC2A) proteins. These proteins are divided in to three classes (class 1-
3) (Olson and Pessin, 1996), (Joost and Thorens, 2001), class I consisting of GLUT1, 2, 3, 4 
and 14, class II GLUT5, 7, 9, 11 and class III 6, 8, 10, 12, 13.  The GLUT proteins are 
classified according to their transport characteristics whether they are inducible or intrinsic 
and sequence similarities (Bell et al., 1990) and some are sensitive to stimuli such as insulin. 
 
3.1.1 Hepatic expression and function of carbohydrate transporters 
To date the expression of GLUT1, GLUT2 (Wu et al., 2008), (Nordlie et al., 1999), GLUT9 
(Keembiyehetty et al., 2006) and GLUT10 (McVie-Wylie et al., 2001) has been reported on 
the hepatocytes (Karim et al., 2012). However it is clear that expression patterns of the 
different family members differs between species, and tissue and cell type specific differences 
have been described (Karim et al., 2012) and are summarized in Table 3.1.  
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 Class 
GLUT 
Isoform 
Human subcellular expression/localization  Animal/other hepatic expression References  
Class I GLUT1 Cytoplasmic hepatocyte expression in some HCC 
Expressed on hepatocytes, endothelial 
cells KC and rat cholangiocytes.  Also 
found on sinusoidal membrane of rat 
and porcine hepatocytes 
(Spolarics et al., 1993, Lazaridis et al., 1997, 
Aschenbach et al., 2009, Shinoda et al., Roh et al., 
2004, Bilir et al., 1993) 
  GLUT2 Human liver  
In rats localises on sinusoidal 
membrane+ malignant hepatocytes  
(Axelrod and Pilch, 1983, Thorens et al., 1990), 
(Leturque et al., 2009)  
  GLUT3  Human liver  
Porcine liver, rat hepatocyte plasma 
membrane  
(Aschenbach et al., 2009), (Ciaraldi et al., 1995, 
Kurata et al., 1999, Shinoda et al.) 
  GLUT4 
 
Porcine liver. Rat HSCs  (Aschenbach et al., 2009, Tang and Chen, 2010) 
Class II GLUT5 Normal liver tissue hepatocytes (cytoplasmic)  Porcine livers (Aschenbach et al., 2009, Godoy et al., 2006) 
  GLUT9 
Majority of expression in hepatocytes of normal 
liver and HCC with granular cytoplasmic 
expression more in pericentral areas 
 
(Takanaga et al., 2008) 
  GLUT11   Porcine liver (Aschenbach et al., 2009) 
Class III GLUT6   Hepatoma cell lines (Kayano et al., 1990) 
 
GLUT8 
 
Mouse perivenous hepatocytes, 
porcine liver 
(Aschenbach et al., 2009, Gorovits et al., 2003) 
  GLUT10  Human liver Porcine liver, zebra fish livers  
(Aschenbach et al., 2009, Chiarelli et al., 2011, 
McVie-Wylie et al., 2001) 
  GLUT12  Normal and cirrhotic human liver lysates  Bovine liver  
(Miller et al., 2005b), 
(http://www.abcam.com/GLUT12-antibody-
ab100993.html) 
 
Table 3.1: Summary of reported human and animal hepatic expression of GLUT proteins  
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GLUT1 expression is suggested to be low in hepatocytes compared to endothelium and KC in 
animal models (Spolarics et al., 1993). Cholangiocytes also express GLUT1 to facilitate the 
absorption of glucose from bile (Lazaridis et al., 1997).  Cellular distribution remains 
controversial however, with hepatocyte sinusoidal membrane localization reported in rat and 
porcine hepatocytes (Aschenbach et al., 2009), (Shinoda et al.) and zonal expression patterns 
(Tal et al., 1991) and membrane localization reported under basal conditions restricted to 
hepatocytes proximal to the hepatic venule (Bilir et al., 1993).  In contrast cytoplasmic 
GLUT1 expression has been noted in some HCC, with suggestions that this may be used as a 
marker for distinguishing cholangiocarcinomas from HCC (Roh et al., 2004).   
 
Whilst some degree of GLUT1 expression in the liver is likely, GLUT2 is considered the 
major GLUT transporter in the liver (Axelrod and Pilch, 1983), (Gould and Holman, 1993).  
In rats it has been reported to localize to the sinusoidal membrane domain of normal 
(Leturque et al., 2009), (Thorens et al., 1990) and malignant hepatocytes.  GLUT2 is more 
important for glucose efflux during gluconeogenesis (Leturque et al., 2009) than  glucose 
uptake, and this is supported by studies in murine hepatocytes where upon insulin stimulation 
both GLUT2 and the insulin receptor co localize and internalize in the endosomal fraction 
(Leturque et al., 2009), (Eisenberg et al., 2005), (Gonzalez-Rodriguez et al., 2008).  There is 
also evidence to suggest that other GLUTS may play a role in the exit of glucose from the 
liver since in mice lacking GLUT2 the rate of hepatic glucose production is not impaired 
(Guillam et al., 1998).  
 
GLUT3 is expressed in porcine livers (Aschenbach et al., 2009), and in rat hepatocytes it is 
localized to the plasma membrane with the bile canicular membrane being more enriched 
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with GLUT3 than the sinusoidal membrane (Shinoda et al.).  In humans 
immunohistochemical staining of primary and metastatic lesions suggests an increase in 
hepatic expression during carcinogenesis (Kurata et al., 1999).  Although there has been some 
speculation that the low level of human GLUT3 expression in the liver reflects expression 
upon a specific subset of cells (Ciaraldi et al., 1995) to date there is no data documenting 
specific cellular expression.   
 
GLUT5 is localized to the cytoplasmic regions of human hepatocytes (Godoy et al., 2006), as 
is GLUT9 which is found as granular structures in HCC (Godoy et al., 2006) and in normal 
liver is found in pericentral hepatocytes.  Hepatocytic expression is supported by data from 
the tumor cell line HepG2 cells where GLUT9 together with GLUT1 has been found in the 
plasma membrane. The membranous distribution in cancer cells suggests a transport role in 
glucose influx (Takanaga et al., 2008), and studies showing that GLUT9 inactivation in 
mouse leads to hyperuricosuria suggest a wider substrate specificity (Preitner et al., 2009) 
with confirmed ability to transport urate (Vitart et al., 2008).  In contrast GLUT10 may have 
roles in antioxidant defense. It is expressed in liver of several species (McVie-Wylie et al., 
2001), (Aschenbach et al., 2009), (Chiarelli et al., 2011) but its cellular localization is yet to 
be confirmed. Its localization in mitochondria of smooth muscle cells and adipocytes, ability 
to transport antioxidant vitamin C (Lee et al., 2010) and contribution towards mitochondrial 
respiration in the cardiovascular system (Willaert et al., 2012) suggest it may play important 
protective roles in the fatty liver. 
 
The expression patters of GLUT1, GLUT2, GLUT3, GLUT5, GLUT9 and GLUT10 in the 
liver are reasonably well documented; in contrast there is little information on GLUT4, 
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GLUT6, GLUT7, GLUT11, GLUT12, GLUT13 and GLUT14 expression in the liver.  
GLUT4 is the main inulin sensitive member of the family and hence this property 
distinguishes it from other members of the GLUT family.  It is mainly expressed in insulin 
sensitive tissues such as skeletal, cardiac, brown and white adipose tissue (Zhao and Keating, 
2007), whilst the liver is generally considered to lack significant expression of GLUT4 
(Nevado et al., 2006) its mRNA has been detected in porcine liver (Aschenbach et al., 2009).  
In contrast, GLUT6 mRNA has been documented in hepatoma cell lines with a lack in normal 
liver (Kayano et al., 1990) whilst GLUT7 was initially reported as a hepatic microsomal 
glucose transporter found in the endoplasmic reticulum, which facilitated the release of 
glucose formed in the process of gluconeogenesis and glycogenolysis for export into the 
blood (Gould and Holman, 1993), (Waddell et al., 1992).  However this long standing view 
has recently been challenged by Ann Burchell who has shown that neither human nor rat liver 
contain mRNA comparable to the clone termed GLUT7 (Burchell, 1998). Similarly GLUT8 
mRNA has only been described in porcine (Aschenbach et al., 2009) and mouse livers were it 
is detected in perivenous hepatocytes (Gorovits et al., 2003)  and might function in regulating 
glycolytic flux.  
 
Finally whilst there are some reports of mammalian hepatic mRNA expression for GLUT11 
(Aschenbach et al., 2009) and GLUT12 (Miller et al., 2005b), and a single report of GLUT12 
protein expression in human liver tissue (http://www.abcam.com/GLUT12-antibody-
ab100993.pdf) there is little convincing data for expression patterns of these, and none for 
GLUT13 and GLUT14 in the human liver. Therefore this chapter will focus on documenting 
disease specific and cellular expression of the GLUT transporters 1-13.   
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Over the last two decades the identification of lipid transport systems such as the FABP 
family, FATP family and the lipoprotein binding CD36/FAT have been reported.  Its 
important to understand which proteins regulate FA uptake in the liver.  In obesity related 
conditions such as the MetS, IR leads to inhibition of lipolysis in adipose tissue this leads to 
an increase in circulating FFA, which are taken up by cells.  There is a fine balance between 
FFA uptake, storage and oxidation, which is regulated by specific transport proteins.  These 
proteins also direct intracellular trafficking of FA (FABPs and FATPs).  For FA to be targeted 
for storage or β-oxidation to the mitochondria they need to be activated via FATPs by their 
Acyl CoA activity- (ACS).  When there is a deregulation in these proteins it can lead to 
excess storage of lipids within cells, which eventually can cause IR, ER stress and apoptosis.  
Furthermore these transport proteins have tissue specific expression and function for example 
in the liver they are involved in storage and oxidation of lipids, in the intestine they aid in 
absorption of dietary lipids, in macrophages and adipose tissue they order storage and lipid 
mediated gene expression and in neuronal tissue maintain the phospholipid bilayer.  In 
addition other proteins such as CD36 have been found to localize with GLUT4 in caveolae 
rich regions and (Lisanti et al., 1994), (Gonzalez-Munoz et al., 2009) the LRPs have been 
associated with elevated TAG levels (Shen et al., 2012).   
 
It is likely that these FATP and FABP may play an important role in the pathogenesis of 
metabolic diseases such as NASH and so we were also interested to study them in this 
chapter.  Multiple families and classes of receptors play a role in fatty acid homeostasis and a 
brief detail of the major family members is below.   
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Figure 3.1: Roles of GLUT and fatty acid trafficking proteins 
In the post prandial state, insulin stimulation triggers CD36 and GLUT4 mobilization to the 
cell surface from intracellular storage sites, this leads to glucose and lipid uptake.  CD36 is 
also found at the cell membrane.  FA can also be taken up by FABPs, which are found on the 
cell membrane and also intracellularly were they can transport FAs activated by FATPs to 
either the mitochondria for β-oxidation or storage in lipid droplets.  Activated FA can also be 
transported to nuclear receptors such as PPARs and NF-κB hence regulating genes which are 
involved in metabolic and inflammatory processes (Musso et al., 2009), (Tan et al., 2002), 
(Helledie et al., 2000), (Wolfrum et al., 2001). 
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3.1.2 Hepatic expression and function of lipid transporters 
3.1.2.1 Fatty Acid Transport Proteins (FATPs)  
The FATP family (SLC27A) contains 6 integral membrane proteins involved in long chain 
fatty acid uptake (LCFA) uptake.  These are found in all tissues, although the distribution at 
different sites varies (Musso et al., 2009). Therefore we begin by reviewing the current 
literature on specific expression of lipid transporters in the liver.   
 
FATP1 expression is insulin regulated in adipose tissue were it translocates and colocalises 
with GLUT4 on the cell membrane to facilitate LCFA uptake (Stahl et al., 2002). Thus the 
protein is predominant in white adipose tissue, skeletal muscle and the heart (Musso et al., 
2009).  However a recent study has reported FATP1 mRNA expression in chicken liver 
(Wang et al., 2011) and it is expressed in HepG2 cells although to lesser extent than the other 
FATP (Sandoval et al., 2008).  In contrast FATP2 is abundantly expressed in the liver (Musso 
et al., 2009), (Moya et al., 2012) consistent with a role in peroxisomal FA processing (Falon 
2010). However it is likely a multifunctional protein with roles in LCFA transport and FA 
biosynthesis, in peroxisomes of mouse liver (Falcon et al., 2010).  In Huh7.5 and HepG2 cells 
its found only in the endoplasmic reticulum (Krammer et al., 2011) whist the most abundant 
expression appears to be in the adrenal gland, brain, ovary, and testis.  
 
In the context of hepatic lipid transport, FATP5 is the predominant isoform expressed in the 
liver (Auinger et al., 2010), and found on the plasma membrane of hepatocytes most proximal 
to the sinusoids (Musso et al., 2009) consistent with a role in uptake of circulating lipids. A 
further member of the family, FATP6 is reported as being absent in liver (Gimeno et al., 
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2003) and is rather selectively expressed in the heart (Musso et al., 2009) where it transports 
LCFA (Auinger et al., 2012).  
 
3.1.2.2 Fatty Acid Binding Proteins (FABPs)  
The second family of fatty acid trafficking proteins considered in this thesis is the FABP 
family, which consists of nine membrane transport proteins that can bind FA as well as 
eicosanoids (Makowski and Hotamisligil, 2005), (Makowski and Hotamisligil, 2004).  They 
are also found in the cytosol were its speculated they may aid in FA transport to nuclear 
receptors such as PPARs and NF-κB hence regulating genes which are involved in metabolic 
and inflammatory processes (Musso et al., 2009), (Tan et al., 2002), (Helledie et al., 2000), 
(Wolfrum et al., 2001).  Again differential cell and tissue specific expression patterns have 
been reported and are linked to organ-specific functions. 
 
FABP1/L-FABP is expressed in the pancreas, small intestine, kidney and the liver (Musso et 
al., 2009) were its reported to constitute 2-5% of total cytosolic protein (Atshaves et al., 
2010).  Moreover in mice lacking FABP1 there is strong association with IR, increased 
lipogenesis and TAG secretion (Newberry et al., 2003).  Similarly a recent study has shown 
that polymorphisms of FABP1 make an individual more susceptible to NAFLD (Peng et al., 
2012b) and also to developing type II diabetes (Mansego et al., 2012).   
 
FABP2 is reported to be mainly expressed in the small intestine and has been considered as a 
candidate gene for diabetes (Humphreys et al., 1994).  It binds saturated LCFA with high 
affinity and unsaturated LCFA with lower affinity and is involved in the intracellular 
transport of LCFA and their acyl CoA esters (Bass et al., 1985), (www.uniprot.org).  There 
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are no studies documenting liver specific expression of FABP2 although certain 
polymorphisms of the gene have been associated with NAFLD.  Certainly mice lacking 
FABP2 are more susceptible to dietary induced fatty liver disease, independent of FABP1 
expression (Agellon et al., 2007).    
 
No human hepatic protein expression data exists for FABP3 which is considered the ‘heart 
specific’ isoform, however mRNA expression of FABP3 has been reported in porcine livers 
(Li et al., 2010) and is also found at lower levels in mammary gland, skeletal muscle and 
blastocyts (Musso et al., 2009).  In contrast FABP4 is expressed in adipocytes and 
macrophages (Musso et al., 2009) and has also been documented in the nucleus and 
cytoplasm of murine endothelial cells and in hepatic and portal vein branches (Elmasri et al., 
2009b).   
 
FABP5 is expressed in the liver and is also found in abundance in the skin and to a lesser 
extent in the mammary gland, eyes, tongue, adipocytes and kidney (Musso et al., 2009).  It 
binds LCFA with high affinity and has a lower affinity for short chain FAs and those 
containing double bonds (www.uniprot.org).  
 
FABP6 and FABP7 are both expressed in the ileum (Musso et al., 2009), but whilst a role for 
bile acid transport is attributed to FABP6, decreased lipid uptake occurs in response to 
FABP7 blockade in murine cells (Ahn et al., 2012). Hepatic expression of these proteins is 
less well documented although FABP6 mRNA is present in zebra fish livers with a 55.3% 
sequence homology to human FABP6 and FABP7, mRNA is present in murine kupffer cells 
(Abdelwahab et al., 2003). The remaining members of this family are also little studied, with  
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FABP8 expression documented in myelin and FABP9 in testis (Musso et al., 2009) and the 
suggestion that hepatic expression of FABP10 increases in response to food intake in 
chickens (Hughes and Piontkivska, 2011). However a mammalian orthologue of this gene 
does not exist and similarly FABP11 mRNA has only been documented in fish (Agulleiro et 
al., 2007), (Karanth et al., 2008), (Torstensen et al., 2011).   
 
3.1.2.3 Additional transport proteins  
We also felt it was important to look at other transport proteins like the LRPs since LRPs 
have been associated with elevated TAG levels and fibrogenesis in the liver (Pieper-Furst et 
al., 2011), (Shen et al., 2012) and also CAV1 and CD36 as there is growing evidence 
suggesting these proteins work jointly together to aid FA and glucose uptake (Souto et al., 
2003).  Since caveolae contain VAP-1, which regulates glucose and lipid uptake through 
GLUT4 and CD36 translocation (Pilch et al., 2007), (Karlsson et al., 2002) we considered 
documentation of CD36 and Caveolin expression may be of benefit.  Caveolins are 
constituents of caveolae, the small infoldings of plasma membranes, which have multiple 
roles including endocytosis and intracellular signaling.  Caveolins are important for the 
formation of the caveoli, can bind cholesterol and FAs (Dugail and Postic, 2010), (Trigatti et 
al., 1999), (Murata et al., 1995) and are important in lipid droplet formation, cell signaling 
and protein trafficking (Pol et al., 2004).  There are three caveolin family members which all 
localize with caveoli plasma membrane facing the cytoplasmic interface of the cell, but the 
distribution varies with cell type although Caveolin 1 and Caveolin 2 are normally co-
expressed (Dugail and Postic, 2010).  Epithelial, endothelial cells and adipocytes express 
Caveolin 1 with Caveolin 3 expressed in cardiac and skeletal myocytes (Dugail and Postic, 
2010). Within the liver, Caveolin 1 is expressed at low levels in endothelium and HSCs and 
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increases in cirrhotic liver. (Yokomori et al., 2002).  In particular, fatty hepatocytes have 
increased expression inside and around the lipid droplets as well as increased expression in 
the inner membrane of their mitochondria (Mastrodonato et al., 2011).  
 
CD36/FAT is ubiquitously expressed (Greenwalt et al., 1992), (Febbraio et al., 2001).  Within 
the liver however, its expression in hepatocytes has been reported to be low (Musso et al., 
2009), but it is expressed on HSEC were it acts as a scavenger receptor (class B) for oxidized 
lipid (Lalor et al., 2006).  Two properties discriminate it from the FABP and FATP family, 
firstly there are no tissue specific isoforms and secondly it has diverse functions other than 
FA uptake (Musso et al., 2009). CD36 allows FAs bound to albumin to dissociate and 
sequester on the outer side of the plasma membrane, creating a diffusion gradient which 
allows the FA to flip flop across the inner leaflet, and it has been suggested the movement of 
these FA through the plasma membrane and to the cytosol is through contact with FABP 
(Glatz and Storch, 2001).  CD36 has been shown to localize in caveolae (Lisanti et al., 1994) 
and in murine fibroblasts Caveolin1 is needed for CD36 translocation to the cell membrane 
(Ring et al., 2006).  Furthermore decreased expression of Caveolin 1 in adipocytes has been 
shown to result in decreased caveolae on the plasma membrane resulting in decreased 
expression of IRS and GLUT4 leading to decreased glucose uptake (Gonzalez-Munoz et al., 
2009).  Muscle CD36 localizes with Caveolin 3 (Vistisen et al., 2004) and in the heart insulin 
stimulation causes simultaneous GLUT4 and CD36  translocation (Schwenk et al., 2010).  
Furthermore a soluble form of CD36 (sCD36) has been found to positively correlate with IR, 
fatty liver and atherosclerosis in non diabetic subjects (Handberg et al., 2012).  
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The final types of receptors we where interested in are the LRP family. LRP1, LRP2 and 
LRP8 are endocytic receptors, which bind multiple ligands (Lillis et al., 2008) and are 
involved in cholesterol homeostasis.  LRP1/CD29 is expressed in the liver parenchymal and 
KC (Lillis et al., 2008) and in rat HSEC (Oie et al., 2011).  It binds apolipoprotein E 
(Beisiegel et al., 1989) and is involved in clearance of  chylomicron particles and their 
degradation (Lillis et al., 2008) and reduced hepatic LRP1 has been associated with 
atherosclerosis (Espirito Santo et al., 2004). LRP2/Megalin C has been associated with 
fibrogenesis in mice liver (Pieper-Furst et al., 2011)  and LRP8 polymorphisms are related to 
increased TAG levels in patients with coronary artery disease (Shen et al., 2012). However as 
with the proteins we have discussed previously, little evidence of hepatocellular expression 
and changes in disease have been reported. We have summarized the current state of 
knowledge in Table 3.2 below: 
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Fatty acid 
transport 
protein family 
Isoform Substrates Human Subcellular 
expression/ 
localization 
Animal/other hepatic 
expression 
References 
FATP FATP1 LCFA  HepG2 cells, chicken livers  (Stahl et al., 2002, Wang et al., 2011, 
Sandoval et al., 2008) 
 FATP2 Activates Long and branched chain FA Hepatocytes in HepG2 
and Huh7 cells is only 
found in the ER 
Peroxisomes of mouse liver (Musso et al., 2009, Moya et al., 2012, 
Krammer et al., 2011), www.uniprot.org 
(Falcon et al., 2010) 
 FATP4 FFA, very LCFA ER of Huh7 and HepG2  (Herrmann et al., 2001, Krammer et al., 
2011) 
 FATP5  Cell membrane of 
hepatocytes facing HSEC  
Hepatocytes of mice (Auinger et al., 2010, Musso et al., 2009, 
Doege et al., 2006) 
 FATP6 Translocation of LCFA across PM    (Gimeno et al., 2003) 
FABP FABP1 FA and eicosanoids  Hepatocytes, also found 
as a cytosolic protein  
 (Atshaves et al., 2010, Charlton et al., 
2009a) 
 FABP2 Intracellular transport of LCFA and their 
acyl CoA esters.  High affinity for saturated 
LCFA and low affinity for unsaturated 
LCFA 
  www.uniprot.org 
 FABP3   Porcine livers (Li et al., 2010) 
 FABP4 Binds LCFA and retinoic acid  Human fatty liver Mice, hepatic portal vein 
branches, endothelial cell 
cytoplasm and nucleus  
www.uniprot.org (Elmasri et al., 2009b), 
(Westerbacka et al., 2007) 
 FABP5 High affinity for FA, especially long chain 
compared to short and those containing 
double bonds. 
Human fatty liver  (Musso et al., 2009), www.uniprot.org, 
(Westerbacka et al., 2007) 
 FABP6   Zebra fish livers  (Alves-Costa et al., 2008) 
 FABP7   Mice kupffer cell cytoplasm  (Abdelwahab et al., 2003) 
CD36  Oxidized lipid, HDL, cholesterol esters Hepatocytes, HSEC   (Lalor et al., 2006) (Musso et al., 2009) 
Caveolin Caveolin1 Cholesterol and FA HSEC, HSCs  (Yokomori et al., 2002), (Dugail and 
Postic, 2010) 
 
LRPs 
LRP1 Chylomicron particles  Parenchymal and 
Kupffer cells  
Rat HSEC (Lillis et al., 2008), (Oie et al., 2011)  
 
Table 3.2: Summary of reported human and animal hepatic expression of fatty acid trafficking proteins. 
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In summary, we are interested in novel mechanisms linked to glucose and lipid uptake 
in the liver such as VAP-1/SSAO, which may contribute to hepatic steatosis.  
Currently there is little detailed description of the expression patterns of GLUT 
proteins or indeed fatty acid trafficking proteins in normal or diseased livers (see 
summary Tables 3.1 and 3.2).  These proteins have vital roles in glucose and lipid 
uptake for example GLUT5 is important in the transport of fructose and has been 
associated with NAFLD (Vila et al., 2008).  Decreased Caveolin 1 expression is 
linked to GLUT4 which results in decreased glucose uptake (Gonzalez-Munoz et al., 
2009).  FABP4 and FABP5, are associated with IR and NAFLD (Westerbacka et al., 
2007) and polymorphisms in FABP1 have been linked to NAFLD (Peng et al., 
2012b). CD36 null mice show increased insulin sensitivity and decreased muscle 
TAG content (Goudriaan et al., 2003), (Hajri et al., 2002) and LRP2 has been 
associated with fibrogenesis in mice liver (Pieper-Furst et al., 2011).  Furthermore 
there is evidence to suggest these proteins work together to achieve glucose and lipid 
homeostasis, for example GLUT4 and its association with FATP1 and CD36 (Stahl et 
al., 2002),  (Schwenk et al., 2010).  Taken together it is clear that these transporters 
have significant implications in disease pathogenesis and yet their hepatic expression 
in disease is unknown.    
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Therefore the major aims of this chapter were: 
 
Aims: 
I) To document the expression of GLUT transporters GLUT1-13 in normal and 
diseased liver tissue. 
 
II) To document the expression of lipid trafficking proteins FATP, FABP, CD36, 
Caveolin 1 and LRPs in normal and diseased liver tissue. 
 
III) To characterize the specific hepatocellular expression of GLUT transporters and 
lipid trafficking proteins by using histological and cell-based transcriptome analysis. 
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3.2 Methods  
For methods pertinent to this chapter please refer to the general methods p60-65. 
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3.3 Results  
3.3.1 Microarray analysis reveals expression of GLUT receptors in human liver 
In this thesis we wanted to examine the expression patterns of carbohydrate and fatty 
acid trafficking proteins in human liver, parenchymal and non-parenchymal cells.  We 
began by using microarrays to measure gene expression in normal liver, HSEC and 
hepatocytes (represented by the cell line Huh7.5). Heat maps were generated using 
GeneSpring (GX.12.5) which showed transcripts were present for all GLUTS in 
normal liver, HSEC and Huh7.5 with the exception of GLUT7 (Figure 3.2 and Figure 
3.3A), which was not present.  For each heatmap the color code is shown as a key 
indicating average gene intensity change for all genes sampled. Data for our genes of 
interest is expressed relative to the median expression of a given gene in all samples 
tested, and the colour key at zero (Figure 3.2B) indicates median expression of all 
genes across all samples whilst blue coloration indicates expression lower than 
median expression and red coloration indicates expression higher than the median.   
 
We found that expression of eight of our key genes significantly (P<0.05) differed by 
more than two-fold between HSEC and Huh.7.5.  Thus GLUT2, 53.8fold (p<3.17E-
0.4), GLUT4 2.9fold (p<0.018), GLUT8 10.13fold (p<6.09E-05), GLUT11 3.49 
(p<0.026) were down regulated on HSEC compared to hepatocytes and GLUT3 
9.78fold (p<0.001), GLUT6 3.99fold (p<0.004), GLUT10 7.17fold (p<6.35E-04), 
GLUT12 37.70fold (p<0.004) were more abundant in HSEC (Figure 3.3C).  
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Figure 3.2: Microarray analysis of GLUT receptor expression in normal liver 
(A) RNA was extracted from normal livers using Qiagen RNeasy mini kit and 
assessed for purity and integrity using an Agilent bioanalyser before being run on 
human oligo arrays (Agilent array ID  014850).  Extracted data was analyzed using 
Gene Spring (GX.12.5). Column represents liver type and rows are the gene of 
interest, data is expressed relative to the median expression of a given gene in all 
samples tested. (B) Color key indicates log values (log base 2) were zero indicates 
median expression of all genes across all samples whilst blue coloration indicates 
expression lower than median expression and red coloration indicates expression 
higher than the median.  Representative data from N=14 normal livers.  
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Figure 3.3: Microarray analysis of GLUT receptor expression in HSEC and 
Huh7.5 
(A) RNA was extracted from HSEC and Huh7.5 using Qiagen RNeasy mini kit and 
assessed for purity and integrity using an Agilent bioanalyser before being run on 
human oligo arrays (Agilent array ID 014850).  Extracted data was analyzed using 
Gene Spring (GX.12.5). Columns represent cell type and rows are the gene of interest, 
data is expressed relative to the median expression of a given gene in all samples 
tested. (B) Color key indicates log values (log base 2) were zero indicates median 
expression of all genes across all samples whilst blue coloration indicates expression 
lower than median expression and red coloration indicates expression higher than the 
median (C) Table of GLUT probes which were >2-fold and p<0.05 different between 
HSEC compared to Huh7.5 using one way ANOVA with Benjamini Hochberg 
correction, data representative from N=5 HSEC and N=3 Huh7.5. 
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3.3.2 qPCR confirms expression of GLUT family receptors in human liver 
We then used qPCR to measure the mRNA transcript levels of the glucose 
transporters GLUT1-13 in normal and diseased human liver tissue, and relative 
expression compared to the averaged pooled CT values of β-actin and GAPDH 
housekeeping genes was calculated using the Livak method (Livak and Schmittgen, 
2001, Schmittgen and Livak, 2008).  The use of multiple house keeping genes 
allowed for accurate quantification and normalization, as the expression patterns of 
both GAPDH and β-actin were unchanged in disease (for example the average CT 
values for pooled GAPDH and β-actin were 24.5 in normal and 24.11 in steatotic 
livers).  In agreement with our microarray data, mRNA for all GLUT receptors bar 
GLUT7 was present in normal liver  (Figure 3.4) with GLUT2, GLUT8, GLUT9 and 
GLUT10 most abundantly expressed. GLUT7 was only expressed in one normal liver 
and only in two cases of ALD.    
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Figure 3.4: Analysis of GLUT receptor expression in human liver by quantitative 
qPCR analysis 
mRNA expression of glucose transporters GLUT1-13 in normal human liver 
determined using a fluidigm qPCR array
®
.  Results are expressed as means of five 
normal livers +/- SEM, run on triplicate arrays and normalized to pooled endogenous 
controls β-actin and GAPDH and log transformed using 2-ΔCt. 
 
Analysis of the fold change in GLUT expression in disease compared to normal liver  
(Figure 3.5) shows that relative abundance of some receptors significantly changes 
with disease. Thus whilst there was no dramatic change in the steatotic livers (Figure 
3.5A), in contrast for diseased and inflamed livers (eg NASH and ALD) the majority 
of GLUTS were significantly up regulated compared to normal.  GLUT1, GLUT3, 
GLUT5 and GLUT12 were up regulated in NASH (fold change 4.76, 3.29, 4.20, 3.21 
respectively) and in ALD (fold change 7.49, 7.38, 11.24, 4.75 respectively).  In 
contrast in PBC only GLUT1 and GLUT5 were up regulated (fold change 1.75 and 
3.62).  
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Figure 3.5: Analysis of GLUT receptor expression in human diseased liver by 
quantitative qPCR analysis 
(A) mRNA expression of glucose transporters GLUT1-13 in steatotic liver, (B) 
NASH, (C) ALD and (D) PBC, using a fluidigm qPCR array
®
 and run on triplicate 
arrays.  Results are expressed as the mean fold change in gene expression normalized 
to pooled endogenous controls β-actin and GAPDH relative to normal livers defined 
as 1 +/- SEM with means from five normal livers, four steatotic, three NASH, four 
ALD and four PBC.  Dotted line represents normal expression at 1. Significance 
expressed as * p<0.05, ***p<0.001 using a one way ANOVA with Bonferroni 
correction.   
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3.3.3 Liver epithelial cells express a varied GLUT receptor profile  
Changes in total mRNA expression in tissue can reflect either disease-related changes 
in proportions of cells, which express a particular receptor, or an up regulation in 
signal on specific cells. Therefore we then went on to assess the receptor expression 
profile on isolated cultured liver epithelial and non-epithelial cells using qPCR.   
Primary hepatocytes abundantly expressed GLUT1, GLUT2, GLUT6, GLUT8, 
GLUT9 and GLUT10, (Figure 3.6A).  The hepatocyte cell lines Huh7.5 and HepG2 
reflected GLUT expression seen in primary hepatocytes to some extent with abundant 
GLUT1, GLUT2, GLUT6 and GLUT8 present. However cell lines expressed more 
GLUT4, Huh.7.5 had lower GLUT6 and GLUT9 than primary cells (Figure 3.6A) and 
HepG2 cells had higher GLUT1, GLUT3, GLUT9 and GLUT10 (Figure 3.6A). In 
contrast primary BEC, Figure 3.6B did not express GLUT2, GLUT4, GLUT7 or 
GLUT12 with GLUT1, GLUT3 and GLUT6 being most abundant in this cell type.  
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Figure 3.6: Analysis of GLUT receptor expression in human liver epithelial cells 
by quantitative qPCR analysis 
(A) mRNA expression of glucose transporters GLUT1-13 in primary hepatocytes, 
Huh7.5 and HepG2 and (B) BEC determined using a fluidigm qPCR array
®
.  Results 
are expressed as means of three primary hepatocytes, three Huh7.5, three HepG2 and 
three BEC +/- SEM, run on triplicate arrays and normalized to pooled endogenous 
controls β-actin and GAPDH log transformed using 2-Δct.  
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3.3.4 GLUT receptor profile in non-epithelial cells 
Finally we assessed GLUT family expression in, non-epithelial (non-parenchymal) 
cells. HSEC most abundantly expressed GLUT1, GLUT3, and GLUT6 (Figure 3.7A), 
and in contrast to hepatocytes had higher GLUT3 and GLUT12 and decreased 
GLUT9 expression.  This pattern was similar in liver-derived fibroblasts, although 
these had lower signals for GLUT12 and GLUT8 compared to HSEC. We also 
assessed expression in peripheral blood leukocytes, since diseased livers would 
contain elevated numbers of inflammatory cells.  These cells expressed GLUT1, 
GLUT2 and interestingly GLUT5, which was present at negligible levels in primary 
hepatocytes, HepG2, BEC (Figure 3.6A, and B), and fibroblasts (Figure 3.7B) and 
absent in Huh 7.5 (Figure 3.6A).  Of note mRNA for GLUT5 was more abundantly 
expressed in NASH (Figure 3.5B), ALD (Figure 3.5C) and PBC livers (Figure 3.5D) 
when compared to normal.   
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Figure 3.7: Analysis of GLUT receptor expression in human liver non-epithelial 
cells and PBMCs by quantitative qPCR analysis 
(A) mRNA expression of glucose transporters GLUT1-13 in HSEC (B) fibroblasts 
and (C) PBMCs using a fluidigm qPCR array
®
.  Results are expressed as means of 
four HSEC, four fibroblasts and two PBMCs +/- SEM, run on triplicate arrays and 
normalized to pooled endogenous controls β-actin and GAPDH log transformed using 
2-Δct.  
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3.3.5 Immunohistochemical detection of GLUT protein expression in normal 
and diseased livers  
Next we wished to determine whether our mRNA expression patterns were reflected 
by protein expression in liver tissue sections. Ideally antibodies for all isoforms would 
have been screened, but commercial availability restricted our analysis to GLUT1, 
GLUT2, GLUT4, GLUT9 and GLUT10.    
 
GLUT1 protein was expressed in normal, steatotic, NASH, ALD and PBC livers 
(Figure 3.8).  In particular there was uniform strong membranous staining in the 
hepatocytes of normal liver, and staining of bile ducts (Figure 3.8A).  There was a 
tendency for increased staining for GLUT1 in hepatocytes in Zones 2 and 3 in normal 
liver whilst in the steatotic liver, occasional patches of intense staining were noted 
(shown by arrow Figure 3.8B).  The ALD and NASH livers again showed a typical 
membranous hepatocyte-staining pattern, although the intensity of staining was 
greater (Figure 3.8D).  The ALD and NASH livers also showed staining in some 
periportal inflammatory cells (Figure 3.8C and D). This was also present in the PBC 
livers, but here the uniform intense membranous pattern of hepatocyte staining was 
not present (Figure 3.8E) and instead staining was localized to occasional areas of 
parenchyma. Isotype-matched control antibody staining was negative for all liver 
diseases (see representative example from NASH liver in 3.8F). 
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Figure 3.8: Immunohistochemical analysis of GLUT1 protein expression in 
normal human and diseased livers 
Immunohistochemical staining for GLUT1 in acetone fixed frozen sections from (A) 
normal, (B) steatotic, (C) NASH, (D) ALD, (E) PBC and (F) staining of isotype 
matched control antibody in NASH liver.  Fields were captured at 10X original 
magnification with inset pictures captured at 40X original magnification.  Images 
shown are representative of N=3 for each disease and arrows in (B) indicate patches 
of intense staining whilst arrows in (C) indicate staining of periportal inflammatory 
cells. 
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GLUT2 was also present in all livers with clear membranous hepatocyte staining of 
central lobular areas in particular (Figure 3.9A, B, D and E).  Interestingly this typical 
membranous staining pattern was lost in NASH livers, which showed a more diffuse 
cytoplasmic staining pattern where the protein appeared to be localized within the 
hepatocytes (Figure 3.9C).  The BEC were negative for GLUT2 staining indicated by 
arrows in Figure 3.9B and only some inflammatory cells were positively stained. 
Isotype-matched control antibody staining was negative for all liver diseases (see 
representative example from steatotic liver in Figure 3.9F). 
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Figure 3.9: Immunohistochemical analysis of GLUT2 protein expression in 
normal and diseased livers 
Immunohistochemical staining of GLUT2 in paraffin embedded  (A) normal, (B) 
steatotic, (C) NASH, (D) ALD, (E) PBC and (F) staining of isotype matched control 
antibody.  Fields were captured using at 20X original magnification.  Images shown 
are representative from N=3 for each disease and arrows in (A) indicate membranous 
staining in central lobular areas, whilst arrows in (B) indicate no staining in bile ducts 
and arrows in (C) indicate diffuse cytoplasmic staining in hepatocytes.    
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GLUT4 staining in normal livers was generally found to be weak and diffuse with, a 
cytoplasmic localization in hepatocytes (Figure 3.10A).  The hepatocyte staining 
appeared more intense in NASH (Figure 3.10C) and ALD (Figure 3.10D) livers.  
GLUT4 expression was also noted around vessels within the liver. Isotype-matched 
control antibody staining was negative for all liver diseases (see representative 
example from steatotic liver in Figure 3.10F).  BEC did not express GLUT4 but there 
was some staining in infiltrating inflammatory cells.  Confirmatory 
immunofluorescent staining for GLUT4 in PCLS from normal liver confirmed the 
diffuse hepatocyte-staining pattern for GLUT4 (Figure 3.11).   
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Figure 3.10: Immunohistochemical analysis of GLUT4 protein expression in 
normal and diseased livers 
Immunohistochemical staining of GLUT4 in paraffin embedded (A) normal, (B) 
steatotic, (C) NASH, (D) ALD (E) PBC and (F) staining of isotype matched control 
antibody.  Fields were captured at 10X original magnification with inset pictures 
captured at 40X original magnification.  Images shown are representative from N=3 
for each disease and arrow in (D) indicates diffuse cytoplasmic staining in 
hepatocytes. 
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Figure 3.11: Immunofluorescence analysis of GLUT4 protein expression in 
normal liver 
(A) Immunofluorescent staining for GLUT4 in PCLS from a resected normal liver 
and (B) staining of isotype matched control antibody. Fields were captured at 20X 
original magnification.  Images shown are representative from N=3 livers 
 
 
 
 
 
 
 
A 
B 
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Similar to GLUT4, GLUT9 was expressed in all livers (Figure 3.12) with a diffuse 
cytoplasmic staining pattern, and tendency for increased expression in periportal 
hepatocytes in disease. We also noted some degree of endothelial staining in normal 
liver (arrows Figure 3.12A). Whilst our isotype matched controls were negative, we 
did observe some non-specific staining of RBCs within tissue on occasion (Figure 
3.12B).  GLUT10 was expressed diffusely in hepatocytes in all livers examined 
(Figure 3.13) with some strong endothelial staining observed (indicated by arrows in 
Figure 3.13C and D. We also observed some staining on BECs in normal liver 
(indicated by arrows in Figure 3.13A) and also in steatotic liver (indicated by arrows 
in Figure 3.13B), and found some staining in infiltrating cells.  Isotype-matched 
control antibody staining was negative for all liver diseases (see representative 
example from steatotic liver in Figure 3.13F).   
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Figure 3.12: Immunohistochemical analysis of GLUT9 protein expression in 
normal and diseased livers 
Immunohistochemical staining of GLUT9 in paraffin embedded (A) normal, (B) 
steatotic, (C) NASH, (D) ALD, (E) PBC and (F) staining of isotype matched control 
antibody.  Fields were captured at 20X original magnification.  Images shown are 
representative from N=2 for each disease and arrows in (A) indicate endothelial 
staining. 
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Figure 3.13: Immunohistochemical analysis of GLUT10 protein expression in 
normal and diseased livers 
Immunohistochemical staining of GLUT10 in paraffin embedded (A) normal, (B) 
steatotic, (C) NASH, (D) ALD, (E) PBC and (F) staining of isotype matched control 
antibody.  Fields were captured at 20X original magnification.  Images shown are 
representative from N=2 for each disease and arrows in (A) and (B) indicate bile duct 
staining, whilst arrow in (C) and (D) indicate endothelial staining.    
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3.3.6 Microarray analysis reveals expression of lipid trafficking proteins in 
human liver 
Next we examined the expression patterns of lipid trafficking proteins in human liver.  
As before we began by using microarrays to measure gene expression in normal liver, 
HSEC and hepatocytes.  Heat maps were generated using GeneSpring (GX.12.5) and 
transcripts for FABPs 1-7, FATPS 1-5, CAV1, CD36, LRP1, and LRP8 were found in 
normal liver (Figure 3.14).  We also saw transcripts for the same genes in HSEC and 
Huh7.5, in addition to FATP6 and LRP2 (Figure 3.15).  Of note, the hepatocytes 
abundantly expressed FABP1 with little FABP4 whilst the reverse was true for 
HSEC, which also had more FATP1 than the hepatocytes.  For each heatmap the 
color code is shown as before (Figure 3.15C).   
 
We found that expression of 14 of our key genes significantly (P<0.05) differed by 
more than two-fold between HSEC and Huh.7.5.  Thus FABP1, 28912.47fold 
(p<7.49E-08), FABP3 1.35fold (p<4.09E-04), LRP1 6.45fold (p<0.003), LRP2 
20.24fold (p<2.00E-04), LRP8 2.23fold (p<0.006), were down regulated on HSEC 
compared to hepatocytes and FABP4 1412.32fold (p<5.26E-05), FABP5 4.71fold 
(p<7.61E-06), CAV1 31.86fold (p<6.44E-06), CD36 67.99fold (p<2.50E-04), FATP1 
57.57fold (p<1.05E-05), FATP3 6.12fold (p<0.002), FATP4 1.52 fold (p<2.86E-04), 
FATP5 2.40fold (p<1.77E-06), were more abundant in HSEC (Figure 3.16).  
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Figure 3.14: Microarray analysis of lipid trafficking receptor expression in 
normal liver 
(A) RNA was extracted from normal livers using Qiagen RNeasy mini kit and 
assessed for purity and integrity using an Agilent bioanalyser before being run on 
human oligo arrays (Agilent array ID 014850).  Extracted data was analyzed using 
Gene Spring (GX.12.5). Column represents liver type and rows are the gene of 
interest for FABP1-7, CAV1, CD36, LRP1, and LRP8, (B) FATP1-5, data is 
expressed relative to the median expression of a given gene in all samples tested. (C) 
Color key indicates log values (log base 2) were zero indicates median expression of 
all genes across all samples whilst blue coloration indicates expression lower than 
median expression and red coloration indicates expression higher than the median. 
Data representative from N=14 normal livers.   
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Figure 3.15: Microarray analysis of lipid trafficking receptor expression in 
HSEC and Huh7.5 
(A) RNA was extracted from HSEC and Huh7.5 using Qiagen RNeasy mini kit and 
assessed for purity and integrity using an Agilent bioanalyser before being run on 
human oligo arrays (Agilent array ID 014850).  Extracted data was analyzed using 
Gene Spring (GX.12.5). Columns represent cell type and rows are the gene of interest 
for FABP1-7, CAV1, CD36, LRP1, LRP2 and LRP8, (B) FATP1-6, data is expressed 
relative to the median expression of a given gene in all samples tested. (C) Color key 
indicates log values (log base 2) were zero indicates median expression of a given 
gene across all samples whilst blue coloration indicates expression lower than median 
expression and red coloration indicates expression higher than the median.   
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Figure 3.16: Lipid trafficking receptors are differential regulated in HSEC and 
Huh7.5  
RNA was extracted from HSEC and Huh7.5 using Qiagen RNeasy mini kit and 
assessed for purity and integrity using an Agilent bioanalyser before being run on 
human oligo arrays (Agilent Array ID 014850).  Extracted data was analyzed using 
Gene Spring (GX.12.5), (A) Table of fatty acid trafficking transporters and (B) Table 
of FATPs which were >2-fold and p<0.05 different between HSEC compared to 
Huh7.5 using one way ANOVA with Benjamini Hochberg correction, data 
representative from N=5 HSEC and N=3 Huh7.5. 
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3.3.7 qPCR confirms expression of FABP receptors in human liver 
Then qPCR was used to measure mRNA transcript levels of the fatty acid trafficking 
proteins FABP1-7, CAV1, CD36, LRP1, LRP2 and LRP8 in normal and diseased 
liver.  mRNA for all FABPs was present in normal liver (Figure 3.17) with the 
exception of FABP6 and FABP7 which were not expressed (Figure 3.17). The fold 
change in gene expression of the fatty acid trafficking proteins when compared to 
normal revealed only one transporter, LRP2 to be up regulated in steatotic livers (fold 
change 1.48, Figure 3.18A).  In contrast in diseased and inflamed livers (e.g. NASH 
and ALD) the majority of fatty acid trafficking proteins were highly up regulated.  
FABP4, FABP5, FABP6, CAV1, LRP2 and LRP8 were up regulated in NASH (fold 
change 34.17, 2.98, 3.26, 2.94, 5.67, and 4.42 respectively, Figure 3.18B) and in ALD 
FABP2, FABP4, FABP5, FABP6, CAV1, LRP2 and LRP8 were up regulated (fold 
change 3.73, 51.9, 4.31, 3.79, 4.99, 4.34, and 8.21 respectively, Figure 3.18C).  In 
contrast FABP2, FABP6, LRP8 were up regulated in PBC (fold change 4.38, 8.32 and 
4.07 respectively, Figure 3.18D).  
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Figure 3.17: Analysis of fatty acid trafficking protein receptor expression in 
human liver by quantitative qPCR analysis 
mRNA expression of the fatty acid trafficking proteins, FABPs1-7, CAV1, CD36, 
LRP1, LRP2 and LRP8 in normal human liver using a fluidigm qPCR array
®
.  Results 
are expressed as means of five normal livers, +/- SEM, run on triplicate arrays and 
normalized to pooled endogenous controls β-actin and GAPDH and log transformed 
using 2-ΔCt 
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Figure 3.18: Analysis of fatty acid trafficking protein receptor expression in 
human liver by quantitative qPCR analysis 
(A) mRNA expression of the fatty acid trafficking proteins, FABP1-7, CAV1, CD36, 
LRP1, LRP2 and LRP8 in steatotic liver, (B) NASH, (C) ALD and (D) PBC, using a 
fluidigm qPCR array
®
 and run on triplicate arrays.  Results are expressed as the mean 
fold change in gene expression normalized to pooled endogenous controls β actin and 
GAPDH relative to normal livers defined as 1 +/- SEM with means from four normal 
livers, four steatotic, three NASH, four ALD and four PBC.  Dotted line represents 
normal expression at 1.  Significance expressed as **p<0.01, ***p<0.001 using a one 
way ANOVA with Bonferroni correction.   
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3.3.8 Liver epithelial cells express FABP 
Next we investigated the expression of these transporters in cultured liver epithelial 
and non-epithelial cells.  In primary hepatocytes, FABP1, FABP5, CAV1 and LRP1 
(Figure 3.19A) were most abundantly expressed.  The hepatocyte cell lines had 
similar expression except for CAV1, which was not abundantly expressed in HepG2.  
Primary hepatocytes also expressed FABP4 and FABP3, in contrast to the cell lines 
except for a negligible amount of FABP3 in Huh7.5 (Figure 3.19A).  However both 
the cell lines expressed more LRP8, Huh7.5 expressed more LRP2 and HepG2 more 
FABP2 and CD36 than primary hepatocytes (Figure 3.19A).  In contrast BEC were 
found only to express FABP5, CAV1, LRP1 and to a lesser extent LRP8 (Figure 
3.19B).     
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Figure 3.19: Analysis of fatty acid trafficking protein receptor expression in 
human liver epithelial cells by quantitative qPCR analysis 
(A) mRNA expression of the fatty acid trafficking proteins, FABPs1-7, CAV1, CD36, 
LRP1, LRP2 and LRP8 in primary hepatocytes, Huh7.5 and HepG2 and (B) BEC, 
using a fluidigm qPCR array
®
.  Results are expressed as means of three primary 
hepatocytes, three Huh7.5, three HepG2 and three BEC +/- SEM, run on triplicate 
arrays and normalized to pooled endogenous controls β-actin and GAPDH and log 
transformed using 2-ΔCt. 
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3.3.9 FABP receptor profile in non-epithelial cells  
Finally non-epithelial cells were examined (Figure 3.20).  In comparison to primary 
hepatocytes, HSEC and liver derived fibroblasts showed increased expression of 
FABP4, CD36, and LRP8 (Figure 3.20A and B), whilst HSEC expressed more 
FABP5 and fibroblasts expressed more FABP3.  HSEC, fibroblasts and PBMCs did 
not express FABP6, FABP7 or LRP2 and in contrast to hepatocytes did not express 
FABP1.  Fibroblast had increased expression for FABP3 in comparison to 
hepatocytes whilst it was not expressed in all other cell types.  The cellular expression 
data was in agreement with our microarray data (Figure 3.15), confirming FABP1 
expression is higher in Huh7.5 compared to HSEC.  Similarly there was little FABP4 
expression in Huh7.5 cells compared to HSEC. 
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Figure 3.20: Analysis of fatty acid trafficking protein receptor expression in 
human liver non-epithelial cells and PBMCs by quantitative qPCR analysis 
(A) mRNA expression of the fatty acid trafficking proteins, FABPs1-7, CAV1, CD36, 
LRP1, LRP2 and LRP8 in HSEC, (B) fibroblasts and (C) PBMCs using a fluidigm 
qPCR array
®
.  Results are expressed as means of four HSEC, four fibroblasts and two 
PBMCs +/- SEM, run on triplicate arrays and normalized to pooled endogenous 
controls β-actin and GAPDH and log transformed using 2-ΔCt. 
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3.3.10 Immunohistochemical detection of fatty acid trafficking protein 
expression in normal and diseased livers.   
We were then able to investigate whether some of these proteins were also expressed 
at the protein level by immunohistochemical analysis.  CAV1 protein expression was 
found in all livers (Figure 3.21) in support of our qPCR data.  In particular there was 
strong sinusoidal staining in the normal livers and weaker staining around the 
hepatocyte membrane (Figure 3.21A). There was also stronger staining around the 
smooth muscle of vessels.  The steatotic livers had less staining for CAV1 compared 
to normal (Figure 3.21B) and the NASH, ALD and PBC showed intense expression of 
CAV1 in portal and scarred areas (Figure 3.21C, D and E). Interestingly we saw little 
staining of bile ducts.  Protein expression for FABP1, 4 and LRP8 was found in all 
livers.  In particular there was intense staining for all three in NASH livers and a 
decrease in expression in the steatotic livers.  There was an increase in expression 
around the portal area and no staining on bile ducts for FABP1 whilst there was 
increased expression around the central vein in normal liver for LRP8 (Figure 3.21-
3.24).    
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Figure 3.21: Immunohistochemical analysis of Caveolin 1 protein expression in 
normal human and diseased livers 
Immunohistochemical staining for Caveolin 1 in acetone fixed frozen sections from 
(A) normal, (B) steatotic, (C) NASH, (D) ALD, (E) PBC and (F) staining of isotype 
matched control antibody. Fields were captured at 10X original magnification.  
Images shown are representative from N=3 for each disease and arrow in (D) 
indicates no bile duct staining whilst arrow in (E) indicates intense staining in scarred 
areas.    
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Figure 3.22: Immunohistochemical analysis of FABP1 protein expression in 
normal human and diseased livers 
Immunohistochemical staining for FABP1 in paraffin embedded sections from (A) 
normal, (B) steatotic, (C) NASH, and (D) staining of isotype matched control 
antibody. Fields were captured at 10X original magnification.  Images shown are 
representative from N=4 for each disease and red arrow in (C) indicates no bile duct 
staining whilst black arrow indicates intense staining around the portal area.   
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Figure 3.23: Immunohistochemical analysis of FABP4 protein expression in 
normal human and diseased livers 
Immunohistochemical staining for FABP4 in paraffin embedded sections from (A) 
normal, (B) steatotic, (C) NASH, and (D) staining of isotype matched control 
antibody. Fields were captured at 10X original magnification.  Images shown are 
representative from N=4 for each disease.   
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Figure 3.24: Immunohistochemical analysis of LRP8 protein expression in 
normal human and diseased livers 
Immunohistochemical staining for LRP8 in paraffin embedded sections from (A) 
normal, (B) steatotic, (C) NASH, and (D) staining of isotype matched control 
antibody. Fields were captured at 10X original magnification.  Images shown are 
representative from N=4 for each disease and arrow in (A) indicates intense staining 
around central vein.   
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3.3.11 qPCR confirms expression of FATPs in human liver  
We also examined the mRNA profile of the FATPs 1-6.  We found expression of 
FATP1-5 in normal liver (Figure 3.25) with FATP2 and FATP5 most abundantly 
expressed in normal whilst FATP6 was not expressed.  We examined the fold change 
in gene expression compared to normal and found that FATPs were up regulated in 
the NASH and ALD livers (Figure 3.26B and C).  In NASH FATP1, FATP2, FATP3, 
FATP4, FATP5 and FATP6 were up regulated (fold change 3.03, 1.33, 3.99, 2.63, 
1.22 and 3.60 respectively, Figure 3.26B).  In the ALD livers FATP1, FATP2, 
FATP3, FATP4, FATP5 and FATP6 were up regulated (fold change 3.22, 1.11, 4.37, 
2.44, 1.47 and 2.48 respectively, Figure 3.26C).   
 
Figure 3.25: Analysis of FATP expression in human liver by quantitative qPCR 
analysis 
mRNA expression of the FATPs 1-6 in normal human liver using a fluidigm qPCR 
array
®
.  Results are expressed as means of five normal livers, +/- SEM, run on 
triplicate arrays and normalized to pooled endogenous controls β-actin and GAPDH 
and log transformed using 2-ΔCt 
 
 127 
 
Figure 3.26: Analysis of FATP receptor expression in human liver by 
quantitative qPCR analysis 
(A) mRNA expression of FATPs 1-6 in steatotic liver (B) NASH, (C) ALD and (D) 
PBC using a fluidigm qPCR array
®
 and run on triplicate arrays.  Results are expressed 
as the mean fold change in gene expression normalized to pooled endogenous 
controls β-actin and GAPDH relative to normal livers defined as 1 +/- SEM with 
means from four normal livers, four steatotic, three NASH, four ALD and four PBC.  
Dotted line represents normal expression at 1. Significance expressed as * p<0.05, 
***p<0.001 using a one way ANOVA with Bonferroni correction.   
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3.3.12 Liver epithelial cells express FATP receptors 
We examined the liver epithelial expression of FATP and found that primary 
hepatocytes expressed FATP1-5  (Figure 3.27A) with FATP2 and FATP4 most 
abundantly expressed.  Huh7.5 also abundantly expressed FATP4.  The HepG2 cells 
in contrast had more FATP1 and FATP4 (Figure 3.27A) whilst BEC only expressed 
FATP1 and FATP4 (Figure 3.27B).  
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Figure 3.27: Analysis of FATP receptor expression in human liver epithelial cells 
by quantitative qPCR analysis 
(A) mRNA expression of FATPs in primary hepatocytes, Huh7.5 and HepG2 and (B) 
BEC using a fluidigm qPCR  array
®
.  Results are expressed as means of three primary 
hepatocytes, three Huh7.5, three HepG2 and three BEC +/- SEM, run on triplicate 
arrays and normalized to pooled endogenous controls β-actin and GAPDH and log 
transformed using 2-ΔCt. 
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3.3.13 Liver non-epithelial cells express FATP receptors  
The non-epithelial cells such as HSEC expressed FATP1, FATP3 and FATP4 to the 
highest extent (Figure 3.28A), whilst fibroblasts contained abundant FATP1 and 
FATP4 with a smaller amount of FATP3 (Figure 3.28B).  PBMCs expressed FATP1, 
FATP3 and FATP4 (Figure 3.28C).  This confirms the microarray data (Figure 3.15B) 
suggesting more FATP1 in HSEC than in Huh 7.5 and increased expression of 
FATP2 in Huh7.5 compared to HSEC. 
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Figure 3.28: Analysis of FATP receptor expression in human liver non-epithelial 
cells and PBMCs by quantitative qPCR analysis 
(A) mRNA expression of FATPs 1-6 in HSEC, (B) fibroblasts and (C) PBMCs using 
a fluidigm qPCR array
®
.  Results are expressed as means off four HSEC, four 
fibroblasts and two PBMCs +/- SEM, run on triplicate arrays and normalized to 
pooled endogenous controls β-actin and GAPDH and log transformed using 2-ΔCt. 
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3.4 Discussion 
Increasing incidence of liver disease in the western world and in particular NAFLD 
and NASH is a growing concern for healthcare providers.  With uncertainty in disease 
progression many initiating factors are under investigation with a primary concern 
being the accumulation of lipids, which can either remain benign, or trigger the 
cascade of events causing NASH.  As discussed previously hepatocyte steatosis can 
result directly from accumulation of FAs or through de novo synthesis from substrates 
including the carbohydrates glucose and fructose, which make their journey into the 
cell via specific facilitator proteins.  However the expression patterns of these 
transporters in normal and diseased liver has received little attention.  
 
Therefore we began this thesis by using genomic and immunohistochemical 
approaches to document hepatocellular expression of a diverse array of carbohydrate 
and fatty acid transporter proteins in normal and diseased liver and whether changes 
in disease were attributable to a specific subset of cells.  To our knowledge this is the 
first time such a study has been performed with human tissue and is reflected by our 
published review of the literature (Karim et al., 2012).  Our results show that normal 
liver expresses all GLUTs 1-13 with the exception of GLUT7.  Simple steatosis was 
characterized by a similar expression pattern where as in more advanced disease 
where steatosis progresses to inflammation and fibrosis we noted an up regulation in 
receptor expression. Thus NASH was associated with increased GLUTS 
1,3,5,6,8,9,12 mRNA; ALD GLUTS 1,3,5 and 12 and GLUT1 at the protein level, 
particularly on immune cells.  GLUT 2,4,9 and 10 were expressed on hepatocytes 
whilst GLUT4 was up in NASH and ALD at the protein level.  GLUT9 was expressed 
on HSEC and GLUT10 on HSEC and BEC.  We found PBC, which is also 
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characterized by fibrosis and inflammation, was the most different from the normal 
situation with an up regulation of GLUT5 expression on BEC, fibroblasts and 
PBMCs.  We noted that on a cellular level whilst many receptors were common there 
are some specific differences, which could contribute to global changes in disease for 
example BEC most abundantly expressed GLUTS 1,3 and 6, HSEC 1,3,6,8 and 12, 
fibroblasts 1,3,6 and 10 and PBMCs 1,2,5,7,8 and 12. 
 
In addition we document expression of FABPs 1-6, CAV1, CD36, LRP1, LRP2 and 
LRP8 in normal liver with a tendency for more expression of FABP1 on hepatocytes 
and FABP4 on HSEC.  Again simple steatosis was associated with little change in 
receptor expression whilst NASH and ALD were associated with increased 
expression of FABP1, FABP4 (most abundant), FABP5 and FABP6, CAV1, and 
LRP8. In common with our findings for carbohydrate receptors, the profiles of lipid 
transporters in PBC were most different from the normal situation with changes in 
FABP2, FABP4, LRP8 and particularly FABP6. Our pilot immunohistochemistry 
experiments confirmed protein upregulation in NASH for FABP1, FABP4, CAV1 
and LRP8.  All cells expressed FABP5, CAV1, CD36, LRP1 and LRP8 whilst 
FABP4 expression was restricted to HSEC, fibroblasts and immune cells and FABP3 
to fibroblasts.    
 
In relation to FATP expression, simple steatosis and PBC were associated with 
downregulation of all FATPs except FATP6 in PBC, whilst NASH and ALD had 
increased expression for all and in particular FATPs 1,3,4 and 6.  Primary hepatocytes 
and hepatocyte cell lines expressed FATP1-5 and all cells expressed FATP1, whilst 
BEC did not express FATP3.   
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Whilst some of these receptor proteins such as FABP4 and FABP5 have previously 
been shown to be up regulated in NALFD (Westerbacka et al., 2007), to our 
knowledge, no studies to date have documented the full expression patterns of any of 
the carbohydrate or fatty acid trafficking proteins in the liver.  One reason for the lack 
of investigation may be the long held view that the passage of glucose and lipids 
largely involves passive diffusion rather than facilitated transport (Bradbury, 2006), 
(Bonen et al., 2007) however this longstanding view has been challenged by 
identification of specific transporters and recent findings which suggest that transport 
is not merely a passive process. Specific proteins are up regulated in disease for 
example FABP4 and FABP5 (Westerbacka et al., 2007) and some are involved in 
active FA uptake for example CD36 (Zhou et al., 2008).  Since disease onset and 
progression can be fueled by many different and specific substrates, and because 
uptake of these may be driven by an increase in specific receptor expression as part of 
disease pathogenesis, we felt it was important to characterize hepatocellular 
expression in health and disease.   
 
3.4.1 Hepatocellular expression of GLUT proteins  
The completion of the human genome project has meant that to date, 14 members of 
the GLUT family have been identified (Karim et al., 2012).  We have found mRNA 
transcripts for 13 GLUTS in the human liver; we have documented expression in 
specific cultured cell types and have supporting protein expression data for GLUT1, 
GLUT2, GLUT4, GLUT9 and GLUT10.  Previous studies have shown GLUT2 to be 
the predominant GLUT isoform in the liver (Nordlie et al., 1999) also some evidence 
of GLUT1 (Wu et al., 2008), GLUT9 (Keembiyehetty et al., 2006) and GLUT10 
expression (McVie-Wylie et al., 2001) have been documented.  These findings 
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support our studies, which further demonstrate chronic disease specific increases in 
expression of GLUT1, GLUT3, GLUT5 and GLUT12 in particular and a marked 
decrease in hepatocellular expression of many transporters in steatosis.   
 
GLUT1 is ubiquitously expressed in all tissue and cells (Mueckler et al., 1985), 
(Takata et al., 1990), (Mueckler, 1990) and indeed this was reflected in our study with 
abundant mRNA in all livers and protein expression around the hepatocyte membrane 
and strongly in endothelial cells and in infiltrating cells.  We demonstrate 
parenchymal expression in both primary hepatocytes and abundantly in hepatocyte 
cell lines (Amann et al., 2009), which fits with reported elevated hepatocyte 
expression in HCC which is linked to advanced stage in tumor progression (Amann et 
al., 2009).  Interestingly silencing of GLUT1 in tumor cells leads to a reduction in 
glucose uptake and HCC cell migration (Amann et al., 2009), confirming the 
functional importance of this receptor even in the presence of GLUT2. As expected 
GLUT2, was expressed both at the mRNA level and also at protein level in all liver 
types.  There was strong membranous staining in the hepatocytes in normal, steatotic, 
ALD and PBC livers.  Interestingly in two cases of NASH we found diffuse 
cytoplasmic staining for GLUT2 with loss of membrane staining. This phenomenon 
of GLUT2 internalization has also been reported in enterocytes of mice caused by the 
action of insulin (Tobin et al., 2008).  Other factors have also shown to cause this 
internalization such as corticoids, stress and Glucagon-Like Peptide-2 (GLP-2) 
(Kellett and Brot-Laroche, 2005).  Further more in support of our findings GLUT2 
internalization has also been documented in mice, were insulin stimulation has been 
shown to cause IR and GLUT2 cointernalization and colocalization in hepatocytes 
(Eisenberg et al., 2005), (Gonzalez-Rodriguez et al., 2008).  Thus it is likely that an 
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insulin-dependent mechanism may also underlie enhanced cytoplasmic localization in 
human NASH liver. 
 
We have additionally documented GLUT3, GLUT5 and GLUT12 expression in 
human liver, all of which were highly up regulated in NASH and ALD, with GLUT5 
also particularly abundant in PBC.   To date, GLUT3 protein expression in the liver 
has only been associated with hepatic tumor biology by Kurata et al (Kurata et al., 
1999), and indeed Ciaraldi et al speculated that the low level of expression in the 
normal liver was due to restriction to a specific sub set of cells.  Our qPCR data 
confirms expression in malignant hepatocyte lines, and for the first time we have 
shown the presence of mRNA transcripts in HSEC, BEC and fibroblasts. Thus 
enhanced expression in fibrotic and cholestatic diseases may relate to increased 
relative abundance of biliary and fibroblastic cells in disease. GLUT5 is abundantly 
expressed in muscle tissue and functions as a fructose transporter (Corpe et al., 2002) 
but it has previously been shown to be expressed in cytoplasmic regions of 
hepatocytes (Godoy et al., 2006). Other data suggests it is barely detectable in porcine 
livers implying both tissue specific and species differences in distribution 
(Aschenbach et al., 2009). Interestingly increased expression of this protein is also 
associated with IR in diabetes (Litherland et al., 2004) again pointing to common 
regulatory mechanisms in NASH.   
 
Similarly subcellular distribution for GLUT12 has been reported to be influenced by 
insulin (Stuart et al., 2009) and whilst mRNA has been reported in whole liver (Miller 
et al., 2005b) we found it to be one of the least abundant isoforms in the primary 
hepatocytes, Huh7.5, fibroblasts and PBMCs.  It was not expressed in HepG2 cells or 
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BEC and compared to other cell types, was most abundantly expressed in HSEC.  
This was supported by our microarray data were we found significantly more 
expression in HSEC than Huh7.5. We were unable to quantify or detect its cellular 
expression during this investigation, but a recent report points to protein expression 
within normal and cirrhotic human liver lysates (http://www.abcam.com/GLUT12-
antibody-ab100993.pdf).   
 
GLUT4 is the main insulin sensitive member of the GLUT family, and thus is 
abundantly expressed in muscle and adipose tissue. We demonstrate mRNA and 
protein expression in normal, steatotic, NASH, ALD and PBC livers, with protein 
expression around the smooth muscle of vessels as expected but also abundant 
cytoplasmic localization in hepatocytes with no distinct membrane positivity. Control 
staining in adipocytes confirmed the specificity of our reagent and mRNA expression 
in HepG2 and Huh7.5 and to lesser extent primary hepatocytes, confirmed this. 
Interestingly we also noted endothelial expression, as suggested by other studies 
(Tsukioka et al., 2007) as well as smaller amounts in, fibroblasts and PBMCs. 
Previous studies of patients with liver cirrhosis, who have a tendency for reduced 
insulin responses have documented maintained skeletal expression of GLUT4 (Shan 
et al., 2011) but cirrhotic animals also hint at reduced responsiveness to insulin 
(Jessen et al., 2006).  To our knowledge, ours is the first study to consider hepatic 
expression in cirrhosis.   
 
We also found a modest increase in GLUT6, GLUT8, GLUT9 and GLUT10 mRNA 
expression in NASH and ALD. GLUT6 was present in hepatocytes, cell lines were its 
previously been reported (Kayano et al., 1990) and in BEC, HSEC and fibroblasts 
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were it has not been previously reported but was most abundantly expressed, thus 
increased expression of this transporter in disease may reflect the energy demands of 
non parenchymal cells more than parenchymal.  
 
GLUT8 was expressed in all cell types with high abundance in primary hepatocytes 
and the hepatocyte cell lines, although it has been detected in porcine liver and mouse 
hepatocytes there are no known reports in human liver (Gorovits et al., 2003), 
(Aschenbach et al., 2009).  Its significance in NASH and ALD may reflect increase 
expression of this transporter in perivenous hepatocytes were its been reported to be 
involved in regulating glycolytic flux (Gorovits et al., 2003).    
 
GLUT9 and GLUT10 were highly expressed in primary hepatocytes and in HepG2, 
expression of GLUT9 in HepG2 fits with previously reported expression in malignant 
tissue (Godoy et al., 2006).  However its expression patterns have not been 
documented in diseased livers.  Since it was most abundantly expressed in 
hepatocytes and was one of the least abundant isoforms expressed in all other cell 
types, disease specific increase in expression is most likely due to hepatocytes.  
Moreover protein expression of GLUT9 and GLUT10 was similar to GLUT4 were it 
was diffused and cytoplasmic in the hepatocytes, this data supports previous GLUT9 
expression in HCC (Godoy et al., 2006), furthermore we document intense staining 
pattern for GLUT10 in the NASH and strong endothelial staining in the ALD livers, 
which was confirmed by our qPCR findings, this suggests disease and cell specific 
increase in expression, cellular distribution has not been reported previously.  
Although the precise function of GLUT10 is unknown it has a reported role in 
transporting antioxidant vitamin C (Lee et al., 2010) thus increased expression in 
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NASH and ALD may be a protective mechanism to protect the liver from ROS 
induced damage.  It must be noted we found staining in RBCs of ALD livers and this 
may suggest this is non specific staining, however our IgG control was negative for 
staining and kidney tissue stained positive, were GLUT9 is known to be expressed.  
There are no reports linking GLUT9 and RBC expression.  
 
The true extent of expression of GLUT7 is difficult to gauge since we found mRNA 
in only one case of normal liver out of four and in 2 cases of ALD.  We are confident 
that out reported absences in some patients were genuine since transcripts were 
detected appropriately in our universal human standard control in the qPCR 
experiments. Similarly studies with porcine livers support little or no hepatic 
expression (Aschenbach et al., 2009).  However since PBMCs expressed GLUT7, it is 
possible that hepatic expression reflects the extent of inflammation in some patients. 
GLUT11 and GLUT13 expression remained relatively unchanged in diseased liver 
compared to normal suggesting minimal functional roles. However in malignant 
melanoma GLUT8 and GLUT11 expression has been linked to cell proliferation 
(McBrayer et al., 2012). Since we see enhanced expression in the tumor cell lines 
compared to primary hepatocytes this role may be more widespread.   
 
3.4.1.1 Functional Significance of GLUT proteins in liver disease  
As discussed previously NASH and ALD are cirrhotic liver diseases, which are 
associated with inflammation, hypoxia and stress, and where patients may exhibit 
impaired insulin responses (Shan et al., 2011).  We have seen increased expression of 
GLUT1 and GLUT3 in NASH and ALD and have also reported expression of GLUT1 
in PBMCs.  Thus an increase in mRNA expression in the NASH and ALD livers in 
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part may be attributed by the presence of inflammatory cells, or by hypoxia in NASH 
since its been found that hypoxia induces GLUT1 expression (Amann et al., 2009) 
and recently increased expression of GLUT3 mRNA and protein in macrophages was 
found in hypoxic atherosclerotic lesions (Li et al., 2012) suggesting GLUT 1 and 
GLUT3 expression can be increased in hypoxic conditions.  Moreover the 
significance of GLUT3 increased expression in NASH and ALD may be that it 
functions as one of the main GLUT transporters in hypoxic conditions or when 
glucose is the only available energy source its expression increases when glucose is 
used in the synthesis of lipids.  This is supported by findings, which show that when 
GLUT3 is knocked down in macrophages there is a decrease in glucose uptake and 
lipid accumulation when there are no other exogenous lipids present (Li et al., 2012). 
This fits with the insulin resistant, hyperglycemic environment, which characterizes 
NASH.   
 
Some GLUTS may also be upregulated in diseased liver as a protective mechanism.  
For example we saw increased expression of GLUT10 in endothelial cells of ALD 
livers.  Mitochondrial GLUT10 in smooth muscle cells has been shown to have a 
functional role in protecting cells from oxidative damage caused by ROS (Lee et al., 
2010), furthermore in adipocytes it has been shown to be insulin stimulated were it 
can translocate from the Golgi to the mitochondria were its involved in the uptake of 
vitamin C (Lee et al., 2010) which is also an antioxidant.  As metabolism of alcohol 
and fructose leads to the generation of ROS, which ultimately leads to cellular 
damage, the increase in expression of GLUT10 in HSEC and also diseased liver may 
be a mechanism to protect the cell from further damage.  Furthermore increased 
expression of GLUT12 could be a compensatory mechanism in the NASH and ALD 
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liver when other GLUTS become defective to improve insulin sensitivity and glucose 
clearance rates as in mice, over expression of GLUT12 has been shown to improve 
whole body insulin sensitivity and glucose clearance rates (Purcell et al., 2011).  
Interestingly we also found internalization of GLUT2 a bidirectional transporter in 
NASH livers this also may be a protective mechanism in the NASH liver when 
exogenous insulin and glucose levels are high thus preventing glucose release from 
hepatocytes.   Since insulin promotes hepatic lipogenesis its understandable that 
GLUT2 would internalize to prevent glucose release.  Whether the insulin receptor is 
also internalized with GLUT2 needs further investigation.   
 
The role of GLUT5, a fructose transporter in health and disease has recently received 
great attention and this is mainly due to increase consumption of high fructose corn 
syrup, which is used in the manufacturing of food and drinks in the western world. 
Furthermore in the context of fatty liver and NASH, fructose is very important since it 
can be utilized for DNL. The significance of increased GLUT5 expression in NASH 
and ALD is very important in the transition from NALFD to NASH, as an increase in 
receptor expression would result in an increase in fructose uptake.  Hepatic 
metabolism of fructose can lead to inflammation via the production of free radicals 
which when the detoxifying mechanisms of the cell are overwhelmed can cause lipid 
peroxidation, necroinflammtion as observed in NASH and eventually fibrosis and 
cirrhosis (Lim et al., 2010) through the activation of HSCs and KC.  Furthermore 
GLUT9 can also transport fructose, in addition metabolism of fructose leads to 
increase synthesis of uric acid (Stirpe et al., 1970) which is also transported by 
GLUT9.  The significance of this in context of NASH, which is commonly associated 
with the MetS is that uric acid levels have been shown to predict obesity and 
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hypertension (Masuo et al., 2003).  Furthermore in rats with the MetS induced by 
fructose, an inhibitor of uric acid Allopurinol reversed and prohibited the MetS 
(Nakagawa et al., 2006).  In addition Vilà et al have shown in male rats who ingested 
fructose in their drinking water leptin signaling was impaired leading to 
hypertriglyceridemia and hepatic steatosis (Vila et al., 2008).  Furthermore the 
metabolism of alcohol and fructose is similar and we also see an increase in GLUT5 
expression in ALD.  
 
GLUT4, GLUT8, GLUT10 and GLUT12 have all been reported to be insulin 
sensitive.  For example insulin stimulated translocation of GLUT8 has been shown in 
acrosomes of sperm (Schurmann et al., 2002) and mice preimplatation blastocysts 
(Carayannopoulos et al., 2000), GLUT10 in adipocytes (Lee et al., 2010) and 
GLUT12 in normal muscle (Stuart et al., 2009), with translocation being dependent 
on Phosphoinositide 3-Kinase (PI3-K) activation (Stuart et al., 2009).  Although there 
are no reports of insulin stimulated GLUT expression in the liver in our study, the 
presence of GLUT4 and GLUT10 in the liver within cytoplasmic droplets suggests 
they may translocate to the cell membrane upon stimulation.   Such stimuli could be 
insulin or the activity of VAP-1, a protein that is increased in liver inflammatory 
diseases such as ALD and NASH.  For example in isolated rat adipocytes, activation 
of VAP-1 (Enrique-Tarancon et al., 1998), (Marti et al., 1998) causes GLUT4 
mobilization to the cell surface, and in cultured vascular smooth muscle cells 
(VSMCs) VAP-1 substrates such as methylamine have been shown to regulate 
glucose uptake.  Such mechanisms may also act on transporters other than GLUT4, 
such as GLUT1, (El Hadri et al., 2002) since GLUT4 is not expressed in VSMCs 
(Low et al., 1992).  Furthermore in rat’s leptin signaling has been shown to enhance 
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GLUT4 mediated glucose uptake in HSCs (Tang and Chen, 2010) leading to HSC 
activation, which may contribute to fibrogenesis in NAFLD.  Also VAP-1 and CD36 
are found together in caveolae in adipocytes (Souto et al., 2003), (Pilch et al., 2007), 
and there is speculation caveolae are involved in GLUT4 trafficking (Scherer et al., 
1994), (Gustavsson et al., 1996), (Ros-Baro et al., 2001), (Karlsson et al., 2002) 
suggesting that regulation of glucose and lipid uptake is closely linked.   
 
Furthermore sinusoidal endothelium has been shown to express IRS and its been 
suggested that endothelial responses to insulin could be a rate limiting factor in 
glucose uptake (Yang et al., 1989). However the increased expression of GLUT12 in 
NASH with expression being most abundant in HSEC, suggests that other non-
parenchymal cells may play a role in disease pathogenesis.  Since hepatocytes and 
HSEC are physiologically in close contact it is possible that substrates taken up by 
HSEC may be passed through the sinusoidal endothelial fenestrations and hence 
exacerbate disease pathogenesis.  Additionally GLUT8 and GLUT12 may work 
jointly, since enterocytes from GLUT8 KO mice fed on a high fructose diet showed 
increased fructose uptake compared to WT mice and this was associated with 
increased levels of GLUT12. GLUT8 also inhibits fructose uptake in the jejunum 
(DeBosch et al., 2012).  Thus GLUT8 suppresses fructose uptake and KO models 
show increased expression of GLUT12 which causes fructose uptake thus GLUT8 
controls GLUT12 expression in a fructose induced manner in enterocytes (DeBosch et 
al., 2012).  This suggests that the activity of some GLUTS directly affects other 
isoforms and that regulation is closely linked, which is likely the case in NASH.  
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The functional significance of GLUT7 in disease needs further investigation, however 
GLUT7 has high sequence homology to GLUT5 and can also transport glucose and 
fructose however the capacity for these substrates is low and thus its been 
hypothesized (Cheeseman, 2008) that GLUT7 may prefer other as yet unidentified 
substrates, similar to GLUT9 which transports urate.  Its been suggested to be in the 
hepatic ER and its functional role has been reported to be in the release of glucose 
produced during gluconeogenesis and glycogenolysis (Gould and Holman, 1993, 
Waddell et al., 1992).  
 
3.4.1.2 Regulation of GLUT expression in disease 
In all it is interesting to note that in simple steatosis many of the GLUT receptors 
were downregulated.  This is perhaps logical since a cell, which has ample fuel, stored 
in the form of lipid droplets, does not require excess carbohydrate fuel and so GLUT 
receptors are downregulated.  In contrast most receptors were upregulated in both 
NASH and ALD.  A possible reason for this is that many patients with NASH/ALD 
(Smits et al., 2013),  (Strand et al., 2012) also have the MetS, and are IR.  Firstly IR 
would promote an increase in systemic insulin levels this may cause an upregulation 
of specific transporters such as GLUT4, GLUT8, GLUT10 and GLUT12 which have 
been reported to be insulin sensitive in an effort to remove the glucose from 
circulation and improve glucose clearance rates.  Secondly the IR state would mean 
that postprandial circulating levels of many sugars would be high which could induce 
expression of transporters.  Also many of the transporters, as discussed, are also 
upregulated in hypoxic conditions seen in NASH and ALD.  Furthermore systemic IR 
leads to increased hepatic lipogenesis and thus its plausible that GLUT receptors 
would be upregulated in an attempt to firstly remove sugars from the bloodstream and 
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secondly to convert them to lipids via lipogenesis for storage, causing further 
lipotoxicity and oxidative stress through lipid peroxidation and ROS generation.   
 
These changes are likely to be specific for chronic liver diseases associated with 
metabolic disturbances since our data suggests that GLUT expression is very different 
in PBC.  One reason for this may be that unlike NASH and ALD it is not a metabolic 
disease.  PBC is a chronic autoimmune disease, which ultimately leads to the 
destruction of bile ducts. This contrasts with NASH and ALD which are metabolically 
very similar, and hard to distinguish histologically. We also noted key differences in 
GLUT expression between hepatocytes and the two-hepatocyte cell lines studied, 
which are both, derived from differentiated HCCs.  It was not surprising to see that 
many GLUT receptors were highly expressed in the cell lines compared to primary 
hepatocytes since as discussed previously tumor cells have an increased demand for 
energy for growth which is fulfilled by an upregulation of GLUT receptors.  
 
3.4.2 Hepatocellular expression of fatty acid trafficking proteins  
We have shown for the first time disease specific alterations in lipid transporters.  
Normal liver expressed FABP1-5, CAV1, CD36, LRP1, LRP2 and LRP8 mRNA and 
this was similar in simple steatotic livers.  In contrast the inflamed and fibrotic livers 
(NASH, ALD, PBC) again demonstrated altered expression patterns the significance 
of which is discussed below.   
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3.4.2.1 FABP expression in the liver 
FABP1 was strongly expressed cytoplasmically in hepatocytes of normal liver at the 
protein level and expression decreased in steatotic liver but increased in NASH. 
Furthermore at the mRNA level it was one of the most abundant isoforms in the 
primary hepatocytes and cell lines, with no expression in all other cell types studied. 
This corroborates previous immunohistochemical studies showing hepatocyte staining 
in individuals with simple steatosis (Charlton et al., 2009b) but contrasts data in the 
same investigation showing decrease in progressive forms of NASH with little 
expression in individuals with severe NASH (Charlton et al., 2009b).   This finding is 
not in agreement with our results, although the cases shown in the Charlton 
investigation suggest that steatosis was still evident in their ‘severe’ samples. Thus we 
would hypothesize that steatosis leads to a decrease in expression, which may not be 
maintained in individuals, transplanted for end stage disease where extensive 
cirrhosis, but little steatosis is present. In contrast we found FABP2 and FABP3, 
expression in NASH to be similar to that in normal, whilst FABP2 was upregulated in 
ALD and PBC. FABP2 overexpression in cell lines has been linked to reduced 
lipoprotein export, and is downregulated by insulin but upregulated by Epidermal 
Growth Factor (EGF) and steroid administration (Levy et al., 2009).  Since cirrhotic 
patients have elevated circulating EGF levels (Tanabe et al., 2008) and may have 
received treatment with steroidal anti-inflammatory drugs prior to transplantation, this 
could explain enhanced FABP2 expression in PBC and ALD.  
 
In particular we found the adipocyte (Makowski and Hotamisligil, 2004), (Boord et 
al., 2002) and macrophage specific FABP4 (Pelton et al., 1999), highly upregulated 
compared to normal in NASH and ALD livers at the mRNA level and  also at the 
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protein level in NASH, particularly on sinusoidal endothelium, with a decrease in 
steatotic livers.  Endothelial expression is in agreement with identification of this 
molecule as a useful endothelial phenotypic marker (Herbert et al., 2008), and its 
regulation by VEGF-A has been demonstrated in cultured endothelial cells, 
furthermore FABP4 has been shown to be a positive regulator of endothelial cell 
proliferation (Elmasri et al., 2009a). We did not find any expression in PBMCs 
although its been reported to be expressed in macrophages where it regulates 
inflammatory function (Makowski et al., 2005).    A single study has reported mRNA 
expression for FABP4, FABP5 and FATP5 in livers of NAFLD patients with the 
suggestion that expression of FABP4 and FABP5 increases with percentage of liver 
fat, (Westerbacka et al., 2007). Of note, livers with NASH or other chronic cirrhotic 
injuries were not examined in this study and we did not find similar results linked to 
steatosis in our findings.  Others have shown an inverse relationship between FABP4 
expression in adipose tissue and liver in obesity (Queipo-Ortuno et al., 2012) and 
FABP4 and CD36 have also reported to be positively correlated with liver fat content 
in NAFLD (Greco et al., 2008). It is interesting to note that in our study we found 
reduced expression of FABP4 in steatotic livers and a strikingly high up regulation in 
NASH and ALD livers, which are associated with inflammation and fibrosis.  FABP4 
is also found in the circulation were its shed from adipose tissue (Xu et al., 2007), (Xu 
et al., 2006) furthermore Xu et al and others have shown plasma FABP4 levels as an 
early indicator in the development of the MetS independent of obesity and IR (Xu et 
al., 2007), (Tso et al., 2007), (Stejskal and Karpisek, 2006). Given the reported 
regulation of adipocyte FABP4 expression by PPARϒ (Li and Gu, 2012), (Rival et 
al., 2004), and the acquisition of an adipocyte-like phenotype by hepatocytes during 
steatotic liver injury concurrent with PPARϒ activation (Larter et al., 2008) it is 
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possible that similar regulatory mechanisms govern expression of FABP4 in 
hepatocytes.  
 
A similar level of expression was seen in NASH and ALD livers for FABP5, FABP6 
and Caveolin 1, all of which were up regulated compared to normal livers.  In 
particular we found FABP6 a bile acid transporter most abundantly expressed in PBC 
whilst FABP7 expression only in PBC livers and not in any isolated cell types studied 
including BEC. FABP5 binds LCFA with high affinity and has a lower affinity for 
short chain FAs and those containing double bonds (www.uniprot.org).  Increased 
expression has been associated with progression of intrahepatic cholangiocarcinomas 
(Jeong et al., 2012), HFD induced rodent liver injury (Peng et al 2010) and the 
development of atherosclerotic lesions (Babaev et al., 2011). Furthermore 
polymorphisms in the FABP5 gene have been associated with type II diabetes (Bu et 
al., 2011), and again the gene is regulated by PPARγ.  
 
Association with or functioning of FABP6 in PBC has not previously been reported 
but regulation of expression has been linked to ligation of the Farnesoid X Receptor 
by bile salts (Liu et al., 2008), and thus a similar mechanism may operate in 
cholestatic liver injury. In contrast we noted a marked absence of FABP7 mRNA 
under most circumstances. The protein is found in murine KC where expression 
decreases in response to Lipopolysaccharide (LPS) (Abdelwahab et al., 2003), and 
blockade of function in murine hepatoma cell lines, leads to decreased lipid 
accumulation (Ahn et al., 2012). Thus there is a precedent for hepatocellular 
expression and so our data either points to species-specific changes in expression or 
possible deficiencies in our genomic analyses.   
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3.4.2.1.1 Functional Significance of FABPs in liver disease  
FABPs are capable of binding FA and either directing them for storage or oxidation in 
mitochondria.  Furthermore some FABP gene polymorphisms have been associated 
with risk of developing NAFLD, for example for FABP1 (Peng et al., 2012a) and the 
Ala54Thr polymorphism of FABP2 (Baier et al., 1995), (Levy et al., 2001), (Musso et 
al., 2009), (Peng et al., 2009).  Links between variant expression patterns and function 
have yet to be fully defined, however Aller et al suggest that in patients with NAFLD 
the Ala54Thr polymorphism is not associated with histological changes, or IR.  (Aller 
et al., 2009), Whilst other studies link FABP1 with a new mechanism of lipotoxicity 
in NAFLD (Charlton et al., 2009b) where expression is mediated by levels of 
cholesterol (Charlton et al., 2011).  Upregulated FABP1 could contribute to NASH by 
increasing the uptake of LCFA, which it can transport to the nucleus and cause 
activation of PPARα (Adida and Spener, 2002) thus increasing expression of genes 
involved in lipid metabolism; however it is also involved in esterification of lipids to 
TAG (Veerkamp and van Moerkerk, 1993), (Zimmerman and Veerkamp, 2002), 
whilst the T94A polymorphism of FABP1 has been shown to have a reduced affinity 
for LCFAs (Gao et al., 2010) and thus would lead to decreased ligand activation of 
PPARα leading to increased lipid buildup (Peng et al., 2012a).   
 
The significance of increased expression of FABP4 in NASH and ALD is currently 
unknown, but could relate to exacerbation of the immune response, regulation of 
cholesterol handling, obesity and IR.  Thus in macrophages FABP4 has been shown 
to regulate cholesterol traffic and is also involved in the cytokine responses during the 
inflammatory response (Makowski et al., 2005). In addition mice deficient in FABP4 
do not develop diet-induced IR (Hotamisligil et al., 1996) and  demonstrate reduced 
 150 
TNFα expression, again linking obesity and IR (Hotamisligil et al., 1996). Thus 
increased expression of FABP4 in diseased liver could lead to increased uptake of FA 
further damaging the cell. Since soluble forms of FABP4 have been shown as an early 
indicator in the development of the MetS, the protein has merit both as a potential 
biomarker in detecting MetS and therapeutic target for ameliorating NASH.  As 
adipocytes from FABP4 KO mice have decreased lipolysis (Coe et al., 1999, Scheja 
et al., 1999), therapeutic approaches directed against this isoform, may also improve 
whole body insulin sensitivity.  However it is important to note that whilst FABP4 
and FABP5 double KO mice show increased protection from fatty liver, type II 
diabetes, obesity and IR, (Maeda et al., 2005).  In contrast the single KO mice did not 
demonstrate protection against fatty liver or obesity even though modest increases in 
insulin sensitivity were noted (Hotamisligil et al., 1996), (Maeda et al., 2003). This 
reiterates the complex interplay between lipid receptors and suggests that therapeutic 
approaches may need to consider blockade of multiple pathways for maximal effect.   
 
It would be interesting to see if NASH patients have increase circulating levels of 
FABP4 in the blood. Soluble forms of other isoforms have also been reported as 
biomarkers for certain disease, for instance FABP3 Heart (Pelsers et al., 2005), 
FABP1, hepatocellular injury after transplant (Pelsers et al., 2002), FABP2 intestine 
(Lieberman et al., 1997) and FABP7 brain (Wunderlich et al., 2005).  
 
The increased expression of FABP6 in PBC may be due to the nature of the disease, 
since expression of FABP6 is also regulated by bile acids as the bile ducts are 
damaged this leads to poor drainage of bile acids which can regulate FABP6 
expression.  Furthermore bile acids can regulate DNL and gluconeogenesis through 
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activation of farnesoid X receptor (Halilbasic et al., 2012) which may explain why 
FABP2, FABP4 and LRP8 are also upregulated.   
 
3.4.2.2 FATP expression in the liver 
The second family of lipid transporters we studied was the FATPs, and we found a 
down regulation of all FATPs in steatotic and PBC livers. In contrast NASH and ALD 
livers showed an up regulation of all the FATPs and in particular FATP1, FATP3, 
FATP4 and FATP6 were most abundantly expressed.  We found expression of 
FATP2 and FATP5 in primary hepatocytes and cell lines, which support’s previous 
expression data in the liver, and interestingly these were the least up regulated in 
disease in comparison to the other isoforms. FATP2 is found in the cytoplasm, bile 
canaliculus and peroxisomes of mouse hepatocytes (Falcon et al., 2010), but restricted 
to the ER in malignant human hepatocyte cell lines (Krammer et al., 2011), where it is 
primarily involved in large fluxes of LCFA uptake (Krammer et al., 2011).  FATP5 
has previously been reported in the liver (Auinger et al., 2010) on the plasma 
membrane of hepatocytes facing most proximal to the sinusoids (Musso et al., 2009) 
consistent with a role in uptake of circulating lipids. Its functional significance is 
illustrated by overexpression studies leading to increased hepatic FA uptake (Doege et 
al., 2006), and a 50% reduction in FA uptake in hepatocytes from mice lacking 
FATP5 (Doege et al., 2006).  It is also distinctive from other family members as it 
demonstrates bile acid CoA synthetase (BACS) activity (Musso et al., 2009).  This is 
interesting given our noted reduction in FATP5 in PBC livers, and the observation 
that bile acids can reduce hepatocyte FA uptake in a FATP5-dependent manner (Nie 
et al., 2012).   
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Knockdown of FATP3 in rat hepatocytes results in a decrease in lipogenic 
transcription factors (Bu et al., 2009), but there is very little data on human hepatic 
expression patterns of FATP3.  However mRNA expression has been found in mouse 
mammary glands during lactation (Han et al., 2010) and in the lungs (Hirsch et al., 
1998), (Stahl et al., 2001). FATP1, FATP3 and FATP4 expression has been reported 
to be elevated in mice with fatty liver induced by a methionine choline deficient diet 
whilst FATP2 and FATP5 levels did not change (Rinella et al., 2008).  We report for 
the first time that FATP3 is expressed in the human liver and also highly up regulated 
in NASH and ALD livers.  Since knockdown of FATP3 in rat hepatocytes results in a 
decrease in lipogenic transcription factors (Bu et al., 2009), disease-induced 
upregulation could contribute to steatogenesis. In contrast, although FATP6 has been 
found to colocalise with CD36 in facilitating LCFA uptake in the heart (Gimeno et 
al., 2003), it is reported as being absent in the liver (Gimeno et al., 2003).  Of note we 
found FATP6 mRNA expression upregulated in NASH and ALD livers, but in the 
absence of mRNA expression in the individual cell types we studied.  This may 
suggest that expression is only turned on in disease or it is expressed on cells, which 
we have not studied.   
 
3.4.2.2.1 Functional Significance of FATPs in liver disease 
Up regulation of FATPs in diseased liver may have an impact upon the uptake of 
LCFA, amplifying diet-induced obesity and IR.  This is exemplified by FATP4 which 
has been associated with obesity and IR (Gertow et al., 2004), and evidence that 
polymorphisms in the FATP5 promoter (rs56225452) are linked with IR, increased 
ALT activity and dyslipidemia (Auinger et al., 2010). Furthermore FABP1 and 
FATP4 are overexpressed in rat fatty liver (Feng and Chen, 2005) and in mice livers 
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FATP2 KO results in improved insulin sensitivity and a reduction in hepatic steatosis 
(Falcon et al., 2010). Similar findings have also been reported for FATP5 KO mice 
fed a HFD, which have enhanced insulin sensitivity and do not become obese or 
accumulate TAG (Hubbard et al., 2006). This suggests potential for targeting such 
receptors therapeutically to modify disease activity, and indeed reduction in FATP2 
expression through transcription factor FOXA activity, results in inhibition of TAG 
synthesis, accumulation and release (Moya et al., 2012). This fits well with the 
situation in humans where FOXA1 expression is low in NAFLD (Moya et al., 2012) 
and we have noted reduced FATP2 expression in fatty livers, suggesting FOXA1 may 
govern FATP2 expression. However selection of receptor targets for inhibition is key 
since FATP5 KO mice have defective bile acid conjugation (Hubbard et al., 2006) 
and therefore cholestasis may present as a problem (Musso et al., 2009).  However 
evidence that uptake of LCFA by FATP5 can be reversibly inhibited by the secondary 
bile acids Ursodeoxycholic Acid (UDCA) and Deoxycholic Acid (DCA) (Nie et al., 
2012) suggests these bile acids may serve as a potential treatment for NAFLD (Nie et 
al., 2012).  Certainly some evidence suggests FATP5 expression is higher in patients 
with steatosis than patients with NASH (Mitsuyoshi et al., 2009), and although we did 
not replicate this finding, our evidence of high expression in NASH suggests 
therapeutic interventions involving FATP5 should be considered on the basis of 
disease progression (Mitsuyoshi et al., 2009).  
 
Therapeutic strategies directed against FATPs need to consider the daily nutritional 
variations in patients, and potential functional cooperation between receptors.  Pre and 
post absorptive state specific expression of FATP varies. For example its been 
proposed that FATP1 has more of a role in LCFA uptake in the post-absorptive state 
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when insulin levels are high in muscle and adipose tissue (Doege and Stahl, 2006) and 
that in the pre-absorptive state FATP4 and CD36 are involved in LCFA uptake 
(Doege and Stahl, 2006, Coburn et al., 2001).  In addition FATP1 KO mice do not 
exhibit LCFA uptake stimulated by insulin in adipose or skeletal muscle tissue (Wu et 
al., 2006) and are rather directed to the liver (Wu et al., 2006) hence protecting these 
tissues from diet induced obesity and IR (Wu et al., 2006). The same phenomenon is 
also true for FATP5 where in FATP5 KO mice, the post-absorptive lipid uptake rate 
is decreased and lipids are shunted to tissues, which predominantly express other 
FATPs (Doege et al., 2006).  This suggests, that when there are disruptions in FATPs 
in extra hepatic tissues, circulating lipids are directed to other sites such as the liver, 
and this overload could contribute to disease pathogenesis in the liver.   
 
3.4.2.3 Expression of additional transport and related proteins in the liver  
As expected, we detected mRNA and protein expression for Caveolin 1 a constituent 
protein of caveolae in all liver types and cells studied. In support of our findings, 
Caveolin 1 is involved in lipid metabolism in rat hepatocyte peroxisomes 
(Woudenberg et al., 2010).   Furthermore Caveolin 1 has been associated with tumor 
progression in HCC (Cokakli et al., 2009) and also liver regeneration (Mastrodonato 
et al., 2012). We found strong endothelial staining in the normal livers with some 
weaker staining around the hepatocyte membrane. In contrast expression was reduced 
in simple steatosis while mRNA was up regulated in NASH and ALD livers. 
However in chronic disease, endothelial staining appeared less consistent and 
uniform, whilst in PBC livers particularly, Caveolin 1 localized to areas of fibrosis.  
This supports data from a rat model of cirrhosis where Caveolin 1 protein was 
similarly increased (Shah et al., 1999).  
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CD36 a major lipoprotein scavenger receptor was also present in liver as previously 
reported, and mRNA expression was unchanged in chronically diseased livers but 
down regulated in steatotic livers.  This contrasts other studies, which have reported 
increase in CD36 expression in NASH (Miquilena-Colina et al., 2011), and may 
represent patient diversity.  CD36 expression has been reported to be elevated in 
NAFLD patients, which coincides with fat content in the liver (Greco et al., 2008), 
Our data suggested expression predominates on non-parenchymal cells, which fits 
with reports of scavenger functions on endothelium (Duryee et al., 2005) and 
contributions to cholesterol uptake in KC in NASH (Bieghs et al., 2012).  
 
3.4.2.3.1 Functional Significance of additional transport proteins during liver 
disease 
Caveolae are membrane enclosed, cytoplasmic vesicles containing a number of 
proteins including Caveolin 1 and Caveolin 2, GLUT4, insulin receptors and CD36, 
which play important roles in glucose and lipid signaling.   Hence Caveolin 1 null 
mice do not become obese on a HFD (Razani et al., 2002) and Caveolin 1 KO mice 
have decreased lipid droplet formation in hepatocytes (Fernandez et al., 2006).  
Overexpression of Caveolin 3 in mice reverses a diabetic phenotype and IR by 
interacting with IRS1, increasing tyrosine phosphorylation and hence increased 
insulin receptor signal transduction (Dugail and Postic, 2010).  Caveolin 1 has been 
implicated in liver regeneration (Mastrodonato et al., 2012) were its thought to be 
involved in supplying FAs to regenerating hepatocytes for energy,  and this may be 
mediated though CD36 which is found in caveolae  (Lisanti et al., 1994) and 
interestingly also with VAP-1 (Souto et al., 2003).  Thus this may explain increased 
Caveolin 1 expression in NASH.   
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Rats fed on a high fructose or HFDs have been shown to have increased CD36 mRNA 
expression (Janevski et al., 2012) however this does not relate to an increase in 
hepatic fatty acid composition (Janevski et al., 2012).  In contrast mice fed on a HFD 
have increased CD36 expression and TAG (Koonen et al., 2007), (Handberg et al., 
2012), and  CD36 null mice show increased insulin sensitivity and decreased muscle 
TAG content compared to WT (Goudriaan et al., 2003), (Hajri et al., 2002), which is 
associated with increased plasma NEFA and hepatic IR and TAG, (Goudriaan et al., 
2003). Here it was postulated that these NEFA were shunted to the liver where the 
FABP and FATP family are involved in uptake since CD36 expression is low in 
hepatocytes (Goudriaan et al., 2003).  Furthermore increased CD36 expression in 
NASH has been associated with increased steatosis (Miquilena-Colina et al., 2011) 
and onset of inflammation (Bieghs et al., 2012).  Thus, the increased expression of 
LRPs we have reported in NASH and ALD liver may be a compensatory mechanism 
to increase import of lipoproteins and export of HDL in an IR state.  Certainly in the 
post absorptive state, hepatic LRP1 has been shown to increase clearance of 
chylomicron remnants when it translocates to the plasma membrane in response to 
insulin (Laatsch et al., 2009).  Furthermore in hepatocytes from mice lacking LRP1, 
HDL export is reduced (Basford et al., 2011) and LRP8 polymorphisms have been 
associated with onset of coronary artery disease and myocardial infarction (Shen et 
al., 2007).   
 
3.4.3 Mechanisms explaining changes in lipid transporter proteins 
In all, we found a majority of fatty acid trafficking proteins down regulated in simple 
steatosis except LRP2, which was modestly elevated probably in an attempt to 
remove HDL cholesterol from the circulation.  In particular many of the fatty acid 
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trafficking proteins were upregulated in NASH and ALD livers.  As discussed earlier 
IR is a predominant factor in patients with NASH/ALD.  Since IR promotes inhibition 
of adipose tissue lipolysis and increases hepatic lipogenesis, this would result in high 
serum levels of FFA, which would be taken up by the liver, resulting in lipid storage, 
and increased hepatic lipogenesis would further overwhelm the cells storage ability.  
An overload of FA would ultimately lead to hepatocyte cell damage via lipid 
peroxidation, oxidative stress, and generation of ROS through ER stress and 
mitochondrial dysfunction.  The release of cytochrome C from damaged cells would 
result in apoptosis/necrosis, thereby activating hepatic KC and HSCs.  This cascade of 
events, which would ultimately overwhelm the detoxifying mechanism of the cell, 
would add further injury to the liver.  The release of cytokines and other inflammatory 
mediators would result in hepatic upregulation of some of these FABPs, which bind 
FA.  Furthermore cytosolic localization of some receptors may aid FA transport to 
nuclear receptors such as PPARs and NF-κB hence regulating genes, which are 
involved in metabolic and inflammatory processes.  In addition we found that disease 
was associated with upregulation of many of the FATPs. This is perhaps expected 
since for FA to be directed for storage or oxidation in cells they need to be activated 
via FATPs by their ACS activity.  However these receptors are also involved in the 
transport of LCFA.  The increased uptake of FFA beyond the cells storage capability 
would mean that FATPs would need to be upregulated in an attempt to activate FA 
and direct them for oxidation however their dual function in transporting LCFA 
would further exacerbate lipid loading and cellular damage.  Increased expression in 
disease may be due to presence of ligands such as FAs, which can activate nuclear 
receptors PPAR, which control expression of these genes (Madrazo and Kelly, 2008).   
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Interestingly PBC livers demonstrated a distinct pattern of transporter expression with 
FABP6 highly upregulated.  This may be explained by the fact that bile acids can 
regulate FABP6 expression (Liu et al., 2008).  FABP expression in cell lines was 
more similar to primary hepatocytes than the GLUTs and this may be due to 
preference of cell lines for glucose as fuel rather than lipid.  Furthermore as 
previously discussed activated VAP-1 can modulate glucose uptake via insulin 
sensitive GLUT4, other GLUTs have also been reported to be insulin sensitive such 
as GLUT8, GLUT10, GLUT12 and also FATP1 and LRP1, which may also 
translocate in response to activated VAP-1 hence take up lipids and add further 
damage to the cell.   Elevated expression patterns for many of the transporters in this 
study may be related to the chronically diseased liver environment, which consists of 
ROS, hypoxia, cytokines, and elevated VAP-1 activity, which may lead to induction 
of these mediators leading to, altered expression patterns.  
 
3.4.4 Future work 
In all, we have described for the first time the specific hepatocellular expression of 
key receptors involved in glucose and lipid homeostasis, and have shown that key 
transporters are up regulated in diseased liver.  The upregulation patterns of multiple 
specific GLUTS and fatty acid trafficking transporters, confirms that the processes 
regulating carbohydrate and lipid homeostasis are not simple ones, but rather involve 
many different receptors which are deregulated in disease. Whist we have made 
significant progress documenting patterns of expression, the functional significance of 
these needs further investigation.   
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We were able to support our microarray findings, with confirmatory qPCR findings, 
which were supported by protein expression where possible.   Matching patient tissue 
was used for both immunohistochemical studies and qPCR analysis and additional 
samples were used for the microarray analysis. Thus our use of multiple patient 
samples for each condition strengthens our confidence in the altered expression 
patterns we report in disease.  However using a larger sample number for protein 
expression and staining (eg for those already tested such as GLUT 9 and 10) would 
support and validate our findings further. Furthermore the limited availability of a 
number of antibodies for GLUTS and some fatty acid trafficking proteins such as the 
FATP has meant that we have not been able to identify all of our transporters at the 
protein level.  Thus protein expression for many transporters remains to be confirmed, 
and it would be prudent to consider additional techniques such as 
immunoprecipitation, western blotting and dual staining with phenotypic markers to 
validate the expression patterns. We also observed key differences between primary 
hepatocytes and cell lines in transporter expression. Whilst this may reflect 
malignancy-induced changes it would be important to study greater numbers of 
primary hepatocytes isolated from different patients, and to consider the impact of 
disease on hepatocyte phenotype.  It is also important to note that our ‘simple 
steatosis’ samples were obtained from fatty donor livers, which were rejected for 
transplant, and much of our ‘normal’ tissue was collected as uninvolved, non-diseased 
margins from tumor resection surgery.  
 
Our qPCR analyses were based around the use of Taqman probes, which have been 
reported to have 100% efficiency in amplification (http://rtsf.msu.edu/Efficiency-
AN.pdf) and the use of multiple house keeping genes allowed for accurate 
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quantification and normalization.   All probes and samples were spotted twice on 
plates and run in triplicate generating at least 18 technical replicates.  A human 
universal standard containing RNA from all organs in the body was also run in 
parallel with our samples to ensure our probes were working as expected. Thus we are 
confident that the data generated from this analysis is genuine. However of note, we 
restricted our cell type analysis to key cell populations but did not consider KC, 
HSCs, or tissue-derived immune cell populations which contribute to the disease-
specific changes observed.  For example we did not find expression of FATP6 on any 
of the cells we studied, however expression was observed in diseased liver.  An 
explanation for this may be that this gene is only switched on in disease, and our 
cultured cells may not recreate the diseased phenotype in vitro, or the expression is 
restricted to a cell type we did not study. This is exemplified by the experiments 
where we used PBMCs isolated from peripheral blood for expression analysis. Whilst 
this data is novel and has implications for immune modulation and leukocyte 
metabolism, the expression patterns we report may not accurately reflect that of 
infiltrating cells in the diseased liver as monocytes and lymphocytes differentiate into 
tissue specific resident cells within the local environment.   
 
Of particular importance is the question of whether increases in mRNA and protein 
expression leads to an increase in glucose/fructose or indeed lipid uptake in the liver?  
Therefore functional studies are needed to quantify the functional impact of our 
reported expression patterns.  KO mouse models for selected GLUT and FA 
trafficking proteins are available and would allow us to assess their importance in 
disease and energy balance. Cultured cells from diseased livers could also be used in 
functional assays to assess whether metabolic responses change in disease. In order to 
 161 
do this however it would be necessary to check whether primary cells in vitro such as 
hepatocytes and fibroblasts from NASH livers for example, reflect the pattern of 
expression seen in diseased tissue.  Polymorphisms for some fatty acid transporters 
exist such as FABP1 and have been associated with increased disease risk (Charlton 
et al., 2009b) and thus it would be interesting to see whether patients have 
polymorphisms in specific isoforms for example such as  FABP1, FABP2 and 
FABP5.  Similarly it would be interesting to investigate possible changes in 
transporter expression at the different stages of NASH progression from mild, 
moderate to severe to determine whether any key biomarkers or pathogenic signals 
emerge.  This would be particularly important since some of these proteins are found 
in the serum and have been shown to be elevated in NAFLD for example FABP4 
(Koh et al., 2009), thus representing potential diagnostic markers.  Availability of 
liver tissue and difficulties in isolating and culturing primary hepatocytes has made 
cell lines attractive and are routinely used in laboratories for research.  However there 
are differences between cell lines and primary hepatocytes as shown by our data and 
thus the use of primary cells and even whole tissue slices representing a mini organ 
system encompassing a multicellular environment are attractive models for future 
functional studies in liver research.   
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CHAPTER 4 
 
4 IS THERE A ROLE FOR VAP-1 IN GLUCOSE 
HOMEOSTASIS IN THE LIVER? 
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4.1 Introduction  
A contribution of VAP-1 and its substrates to regulation of glucose uptake has been 
widely documented in the context of adipocytes and smooth muscle cells.  For 
example in isolated rat adipocytes, the SSAO substrates benzylamine and tyramine 
have been shown to stimulate glucose transport in the presence of vanadate (Enrique-
Tarancon et al., 1998).  In contrast, in isolated human adipocytes the response to 
methylamine and benzylamine can occur in the absence of vanadate (Morin et al., 
2001).  SSAO activity can also enhance glucose uptake in VSMCs (El Hadri et al., 
2002) and F422A cells (Fontana et al., 2001).  In many cases the mechanism 
underlying enhanced glucose uptake has been linked to hydrogen peroxide as a 
metabolite produced during the deamination of amines (Enrique-Tarancon et al., 
1998), (Marti et al., 1998), (El Hadri et al., 2002), and is based on tyrosine 
phosphorylation of IRS-1 and IRS-3 and activation of PI3-K, (Enrique-Tarancon et 
al., 2000).  Furthermore the SSAO stimulated glucose uptake is dependent on 
translocation of GLUT4 to the cell membrane in rat adipocytes (Enrique-Tarancon et 
al., 1998) and in VSMCs an increase of GLUT1 at the cell membrane (El Hadri et al., 
2002). Importantly this suggests that SSAO activity may regulate different GLUTS in 
different cells. Of note, SSAO colocalizes in intracellular vesicles with GLUT4 in rat 
adipocytes, rat skeletal muscle and 3T3-L1 adipocytes (Enrique-Tarancon et al., 
1998) suggesting a specific role in glucose uptake. These pathways are summarized in 
Figure 4.1. 
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4.1.1 Could VAP-1 activity be of significance in hepatic glucose homeostasis? 
Modulation of SSAO activity has proven impacts on systemic hyperglycaemia and 
glucose tolerance. Hence SSAO substrates, have anti-diabetic effects in vivo in 
streptozotocin-induced diabetic rats, where benzylamine reduces hyperglycemia and 
improves glucose tolerance (Marti et al., 2001). Overexpression of VAP-1 in mice 
also improved glucose uptake however this was associated with several diabetic 
complications (Stolen et al., 2004a).  
 
Our group has published pilot data showing that levels of sVAP-1 and hepatic VAP-1 
increase in NASH (Claridge L C, 2009) and also that elevated sVAP-1 is found in 
many chronic inflammatory liver diseases (Kurkijarvi et al., 1998).  Thus it is prudent 
to investigate whether a similar SSAO-dependent regulation of glucose homeostasis 
operates in the liver, and to measure whether hepatic cells respond to SSAO activity 
in the manner reported for other cell types. VAP-1 has potential to contribute to the 
development of NAFLD and exacerbate disease pathogenesis as observed in NASH 
both through modulation of glucose function and via effects upon leukocyte 
recruitment and fibrogenesis (Weston and Adams, 2011). 
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Figure 4.1: Schematic showing VAP-1/SSAO related glucose uptake 
Deamination of primary amines by VAP-1/SSAO leads to the production of hydrogen 
peroxide, which causes tyrosine phosphorylation of insulin substrates and activation 
of PI3-K leading to GLUT4 mobilization to the cell surface and uptake of glucose in 
rat adipocytes (Enrique-Tarancon et al., 1998).   There is also presence of both 
SSAO/VAP-1 and GLUT4 in intracellular vesicles.  Furthermore SSAO/VAP-1 
derived hydrogen peroxide also leads to an accumulation of GLUT1 at the cell 
membrane in VSMCs (El Hadri et al., 2002). 
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Thus we hypothesis VAP-1 and its substrates may regulate glucose uptake in the liver 
by regulating specific GLUTS. Therefore the major aims of this chapter were: 
 
(I) To develop methodology/an ex vivo based model to investigate the role of VAP-1 
in regulation of glucose uptake in whole liver and cultured hepatic cells. 
 
(II) To investigate the mechanisms underlying SSAO-dependent hepatic responses. 
 
(III) To investigate whether SSAO activity modulates GLUT transporter expression 
or cellular localization. 
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4.2 Methods  
For methods pertinent to this chapter please refer to the general methods p49-50, p54-
59. 
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4.3 Results  
4.3.1 VAP-1 expression and functional activity is increased in diseased liver 
Since this thesis sets out to examine the potential role of VAP-1 in glucose and lipid 
homeostasis in the human liver we began by identifying the expression pattern of this 
protein, and that of related oxidase enzymes in normal and diseased liver.  At the 
mRNA level we found increased expression in NASH, ALD and PBC livers and a 
decrease in expression in the steatotic livers compared to normal (Figure 4.2).  On a 
cellular level, primary hepatocytes and BEC did not express VAP-1 mRNA whilst 
cell lines HepG2 and Huh7.5, HSEC, fibroblasts and PBMCs did (Figure 4.3 and 4.4). 
We also examined the mRNA expression pattern of other oxidases such as MAOA, 
MAOB and LOX in the same samples.  We generally found an increase in expression 
of MAOA, MAOB and LOX in NASH and ALD and a decrease in expression in 
steatotic and PBC livers except for LOX in PBC, which was also, upregulated 
compared to normal (Figure 4.2).  Primary hepatocytes, BEC, HSEC, fibroblasts and 
PBMCs expressed all three enzymes with hepatocytes most abundantly expressing 
MAOA; BEC LOX, and HSEC and fibroblasts MAOA and LOX, (Figure 4.3 and 
Figure 4.4). 
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Figure 4.2: Analysis of SSAO and MAO by quantitative qPCR analysis 
mRNA expression of MAO and SSAO in normal, steatotic, NASH, ALD and PBC 
livers using a fluidigm qPCR array
®
, run on triplicate arrays.  Results are expressed as 
the mean fold change in gene expression normalized to pooled endogenous controls 
β-actin and GAPDH relative to normal livers defined as 1 +/- SEM with means from 
five normal livers, four steatotic, three NASH, four ALD and four PBC.  Dotted line 
represents normal expression set at 1.  Significance expressed as ***p<0.001 using a 
one way ANOVA with Bonferroni correction.   
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Figure 4.3: Analysis of SSAO and MAO in human liver epithelial cells by 
quantitative qPCR analysis 
(A) mRNA expression of SSAO and MAO in primary hepatocytes, Huh7.5, HepG2 
and (B) BEC determined using a fluidigm qPCR array
®
.  Results are expressed as 
means of three primary hepatocytes, three Huh7.5, three HepG2 and three BEC +/- 
SEM, run on triplicate arrays and normalized to pooled endogenous controls (β-actin 
and GAPDH) log transformed using 2-ΔCt. 
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Figure 4.4: Analysis of SSAO and MAO in human liver non-epithelial cells and 
PBMCs by quantitative qPCR analysis 
(A) mRNA expression of SSAO and MAO in HSEC (B) fibroblasts (C) PBMCs using 
a fluidigm qPCR array
®
.  Results are expressed as means of four HSEC, four 
fibroblasts and two PBMCs +/- SEM, run on triplicate arrays and normalized to 
pooled endogenous controls (β-actin and GAPDH) log transformed using 2-ΔCt. 
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Immunohistochemical detection of VAP-1 localization revealed sinusoidal staining in 
all livers (shown by arrow in normal liver, Figure 4.5A) and perivascular staining in 
portal areas.  Expression increased in the NASH, ALD and PBC livers in the fibrotic 
regions (shown by arrows in, Figure 4.5C and E) as well as in the sinusoidal areas, 
particularly in ALD livers (shown by arrow, Figure 4.5D).  We wanted to assess 
whether the increase in VAP-1 protein in diseased liver paralleled an increase in 
activity, thus we assessed VAP-1 activity in standardized protein tissue lysates 
(8mg/ml) from normal and diseased livers using the Amplex red assay and the 
specificity of our assay was confirmed by addition of BEA see Figure 4.6A.  We 
found an increase in activity in NASH, ALD and PBC livers compared to normal and 
steatotic livers (Figure 4.6B).  
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Figure 4.5: Immunohistochemical analysis of VAP-1 protein expression in 
normal and diseased livers 
Immunohistochemical staining of VAP-1 in acetone fixed frozen sections from (A) 
normal, (B) steatotic, (C) NASH, (D) ALD, and (E) PBC livers and (F) is 
representative staining with isotype matched control antibody in PBC liver.  Fields 
were captured at 10X original magnification with inset pictures captured at 40X 
original magnification.  Images shown are representative from N=3 for each disease 
and arrows in (A) indicate sinusoidal staining, arrows in (C) and (E) indicate staining 
in fibrotic regions and arrows in (D) indicate strong sinusoidal endothelial staining. 
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Figure 4.6: Analysis of SSAO activity in normal and diseased human liver lysates 
(A) Detection of SSAO activity in lysates from normal and diseased tissue. 8mg/ml of 
equilibrated protein lysates prepared from indicated liver types were added to a 96 
well flat bottom plate.  Benzylamine (2mM) was added in the presence or absence of 
the specific VAP-1 inhibitor BEA (400μM). The fluorometric reaction was initiated 
by the addition of the Amplex red reagent consisting of 1/100 Amplex ultra red and 
1/100 HRP.  The reaction was measured continuously in a fluorescence microplate 
reader for approximately 3 hours using excitation of 530nm and emission detection at 
590nm.  Data is represented as the mean fluorescence reading up to a time point of 
100 minutes in ALD with specific inhibition of VAP-1 with BEA shown in red and 
(B) the mean fluorescence reading at 30 minutes, N=3 for each disease +/- SEM. 
Significant elevation of SSAO activity in diseased livers expressed as * p<0.05, 
***p<0.001.  
 
 175 
4.3.2 VAP-1 and its substrate methylamine regulate glucose uptake in Hepatic 
cells  
The activity of VAP-1 has been shown to regulate glucose uptake in adipose and 
smooth muscle cells thus, next we went on to assess whether the activity of VAP-1 
was able to modulate glucose hemostasis in isolated hepatic cells.  Insulin was used as 
a positive control and Figure 4.7A shows a significant uptake of glucose following 
insulin treatment of HSEC. Furthermore, pretreatment of HSEC with MA, MA+VAP-
1 and hydrogen peroxide all enhanced glucose uptake compared to control in HSEC. 
Importantly, glucose uptake in response to MA+VAP-1 was significantly reduced in 
the presence of the specific SSAO inhibitor BEA (Figure 4.7A). 
 
We noted that the glucose responses in HSEC from different donors and at different 
passages were very variable, which we considered likely to reflect variable amounts 
of VAP-1 in these cells. Therefore we over expressed VAP-1 in HSEC and repeated 
the glucose uptake experiments.  We transfected HSEC with viral constructs 
overexpressing enzymatically active or inactive VAP-1 and used empty vector 
containing LACZ alone as an additional control.  The enzyme activity of these vectors 
has previously been confirmed (Liaskou et al., 2011).  The expression of VAP-1 after 
transfection was confirmed by flow cytometric analysis (Figure 4.7B).  We only 
observed an increase in glucose uptake following methylamine treatment, in HSEC 
transfected with the active VAP-1 (Figure 4.7C).   
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Figure 4.7: Assessment of glucose uptake after VAP-1 stimulation in HSEC 
(A) Uptake of radiolabelled glucose after stimulation of HSEC with either insulin 
0.10 IU, MA 200μm, VAP-1 500ng, H2O2 10μM, or in combination with MA+VAP-
1, MA+VAP-1+BEA, for approximately 2 hours and 30 minutes and then 30 minutes 
with radiolabelled glucose.  Cells were lysed and radioactivity measured.  N=7 +/- 
SEM, significance expressed as * p<0.05, ***p<0.001 (B) FACS plot demonstrating 
surface expression of VAP-1 on transduced cells, representative image from N=3 cell 
isolates. HSEC were transfected with either an enzymatically active construct for 
VAP-1 (blue line), inactive construct (green line), or an empty vector containing 
LACZ (red line).  (C) Uptake of radiolabelled glucose in transduced HSEC after 
stimulation. Cells transduced as described above and non-transfected HSEC were pre 
treated with MA 200μm for 2 hours and 30 minutes and then 30 minutes with 
radiolabelled glucose.  Cells were lysed and radioactivity measured.  N=3 +/- SEM, 
significance expressed as  **p<0.01.   
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We conducted similar glucose uptake experiments using Huh7.5 and HepG2 cells.  In 
Huh7.5 cells we found when cells were pre treated with MA, MA+VAP-1 there was a 
significant increase in glucose uptake compared to control.  Furthermore the addition 
of MA+VAP-1+BEA significantly reduced glucose uptake compared to MA+VAP-1 
treated cells (Figure 4.8A).  Hydrogen peroxide also enhanced glucose uptake but this 
effect was not significant.   
 
Interestingly when we compared the responses of the two cell lines we found that 
HepG2 cells had higher basal glucose uptake.  Pretreatment of HepG2 with MA 
resulted in increased glucose uptake compared to control and MA+VAP-1/ hydrogen 
peroxide alone significantly increased glucose uptake whilst addition of MA+VAP-
1+BEA significantly reduced glucose uptake compared to MA+VAP-1 treated cells 
(Figure 4.8B). 
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Figure 4.8: Assessment of glucose uptake after VAP-1 stimulation in Huh7.5 and 
HepG2 cells   
(A) Uptake of radiolabelled glucose after stimulation of Huh7.5 or (B) HepG2.  Cells 
were pretreated with either insulin 0.10 IU, MA 200μm, VAP-1 500ng, H2O2 10μM, 
or in combination with MA+VAP-1, MA+VAP-1+BEA, for approximately 2 hours 
and 30 minutes and then 30 minutes with radiolabelled glucose.  Cells were lysed and 
radioactivity measured. For Huh7.5 N=3 +/- SEM, significance expressed * p<0.05, 
**p<0.01, ***p<0.001 and for HepG2 N=4 +/- SEM, significance expressed * 
p<0.05, ***p<0.001. 
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4.3.3 Use of PCLS to model glucose and lipid homeostasis in human liver    
Rather than limit our analyses to cultured cell lines, which may not accurately reflect 
the in vitro situation, we sought to investigate whether SSAO activity might modulate 
glucose uptake in a more physiological, multicellular context.  Thus we developed a 
model based upon organ culture of human liver specimens.  Normal resected tissue 
and on occasion cirrhotic tissue was used to generate 8mm tissue cores (Figure 4.9C), 
which were aseptically cut to generate 240μm thick PCLS (Figure 4.9D) using a 
Krumdieck tissue slicer (Figure 4.9A).  We began by optimizing our culture methods 
and testing performance of the system.  
   
Figure 4.9: Generation of PCLS using a Krumdieck tissue slicer 
(A) Image of a functional Krumdieck tissue slicer, (arrow indicates collection of 
PCLS in the collecting tube), (B) Magnified image of Krumdieck tissue slicer 
collecting tube (arrow indicates collection of PCLS in the collecting tube), (C) Tissue 
cores obtained from explanted liver (D) Representative images of PCLS in a petri 
dish.   
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PCLS weights were generally consistent between different experiments (Figure 
4.10A), and use of MTT confirmed that slices retained viability in culture for up to 48 
hours. However there was a significant reduction in viability between 24 and 48 hours 
(Figure 4.10B).  Morphological assessment of cryosections cut from PCLS after H&E 
staining (Figure 4.11) suggested maintenance of intact tissue morphology in culture. 
Functional activity of tissue was demonstrated by albumin production (Figure 4.12A), 
although we noted a decrease at 24 hours. Similarly Hoechst staining (Figure 4.12C) 
was suggestive of maintenance of nuclear integrity at 24 hours in static culture, with a 
decline thereafter.  This was confirmed by quantification using Image J (Figure 
4.12B), which also showed that a loss of nuclear integrity was noted in central areas 
after prolonged culture (Figure 4.12B and image in Figure 4.12C).  Importantly PCLS 
retained the ability to respond to insulin (Figure 4.12D) after 24 hours in culture and 
maintained the presence of glycogen granules. However these too decreased with 
increasing culture time (Figure 4.12E) (Karim et al., 2013). 
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Figure 4.10: Assessment of PCLS reproducibility and viability  
(A) XY scatter plot of mean PCLS weights, bold line represents the mean and thinner 
lines represent the mean +/- SEM, typical slice weights from N=6 41 slices, +/- SEM. 
(B) Viability of PCLS in culture using the MTT assay. MTT signal was normalized 
per 500mg of tissue and data is represented as % viability compared to control at 0 
hours.  Data generated from N=4 from resected normal livers with 27 replicate slices 
in total +/- SEM.  Significance represented as *** p<0.001.   
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Figure 4.11: H&E staining of Cultured PCLS confirms loss of morphology over 
time 
(A) H&E stained image of PCLS at 0 hours, (B) 24 hours and (C) 48 hours.  Fresh 
PCLS or PCLS cultured in media for 24 or 48 hours were fixed and cryosectioned for 
H&E staining.  Representative images are shown from N=3 resected/donor livers, 
10X original magnification.    
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Figure 4.12: Functional assessment of cultured PCLS 
(A) Production of albumin by PCLS, measured by captured ELISA, N=3 with 6 
replicate slices, (B) Image J quantification of nuclear integrity of PCLS cultured for 
up to 48 hours, sections were stained with Bisbenzimide to visualize nuclear integrity, 
and images were taken of representative fields of view, data represented as the % area 
stained positive in five high power fields +/- SEM and N=4 with 2 replicate slices.  
Statistical analysis revealed a significant reduction in nuclear number at 48 hours 
p<0.01, (C) Representative image of PCLS cultured for 48 hours and stained with 
Bisbenzimide and arrows indicate loss in nuclear integrity in the central area 
compared to periphery, bar represents 100μm. (D) Uptake of radiolabelled glucose 
after insulin treatment of PCLS, data represents +/- SEM from 6 replicate slices and 
(E) Representative Images of PCLS cultured for 24 and 48 hours and stained with 
Periodic Acid Schiff stain, arrows indicate presence of glycogen which stains reddish 
purple and bar represents 50μm.  
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Next we wanted to ensure our ex vivo system was specifically optimised for our 
glucose uptake assays which require use of low glucose DMEM instead of Williams E 
Media.  Thus we performed viability assays to ensure our PCLSs would be viable in 
this media.  Our MTT assays confirmed a similar level of viability for both medias at 
all time points with a general decrease in viability over time as before (Figure 4.13).  
 
 
 
Figure 4.13: Assessment of PCLS viability in different media 
Viability of PCLS after culture in low glucose DMEM or Williams E media using the 
MTT assay. The MTT signal was normalized per 500mg of tissue and data are 
represented as % viability compared to control at 0 hours.  N=2 from resected normal 
livers 6 replicate slices in total. +/- SEM, significance represented as **p<0.01.   
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4.3.4 VAP-1 and its substrate methylamine regulate glucose uptake in liver 
tissue 
Next we used our PCLS model, for glucose uptake experiments. We found that by 
supplying an exogenous substrate (methylamine, MA) to endogenous VAP-1 in the 
PCLS, or exogenous VAP-1 for possible endogenous substrates, we increased glucose 
uptake compared to control.  Furthermore the combination of MA+VAP-1 
significantly increased glucose uptake compared to control and more than when either 
were added in alone; this response was inhibited by BEA, an inhibitor of SSAO 
activity, which had a modest effect when used alone. Furthermore, addition of 
hydrogen peroxide one of the metabolites produced when VAP-1 interacts with its 
substrates also significantly enhanced glucose uptake compared to control (Figure 
4.14A).   
 
Since we observed a significant increase in glucose uptake in PCLS when pretreated 
with MA+VAP-1, we wanted to see whether the activity of SSAO had any effects on 
trafficking of GLUT4.  Thus we stained for GLUT4 in our treated PCLS using 
immunofluorescent protocols.  In the control slices we observed diffuse cytoplasmic 
staining for GLUT4 in hepatocytes, and following MA+VAP-1 treatment there 
appeared to be a relocalisation into cytoplasmic vesicles (shown by arrows, Figure 
4.14B) with a tendency to appear more concentrated at the periphery of the cells.  
These droplets disappeared when the slices were treated with MA+VAP-1 in the 
presence of BEA (Figure 4.14B).  We did note some background staining of cells 
within the sinusoids in all samples, but we did not see any change in this staining 
following treatment (Figure 4.14B).  
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Figure 4.14: Assessment of glucose uptake after VAP-1 stimulation in PCLS   
(A) Uptake of radiolabelled glucose after VAP-1 stimulation. PCLS were pretreated 
with either insulin 0.10 IU, methylamine 200μm, VAP-1 500ng, H2O2 10μM, BEA 
400μm, or in combination with methylamine+VAP-1, methylamine+VAP-1+BEA, 
for approximately 2 hours and 30 minutes and then 30 minutes with radiolabelled 
glucose.  PCLS were lysed, radioactivity was measured and signal normalized per 
500mg of tissue.  N=3 from resected normal livers +/- SEM.  Significance expressed 
as * p<0.05 (B) Localization of GLUT4 in PCLS which were pretreated for 2 hours 
and 30 minutes with either methylamine+VAP-1 or methylamine+VAP-1+BEA, 
PCLSs were then fixed and cryosectioned and stained using GLUT4 antibody.  
Representative images from N=3 resected livers.  Arrows in control indicate possible 
immune cell staining, and arrows in methylamine+VAP-1 PCLS sample indicate 
presence of large droplets at the periphery of the cell.   
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4.3.5 SSAO activity causes activation of NF-κB in PCLS 
Our group has previously demonstrated that the SSAO activity of VAP1 leads to PI3-
K dependent activation of NF-κB in cultured hepatic cells (Lalor et al., 2007). Thus 
we used a human NF-κB signaling pathway PCR array to determine whether we 
observed similar activation in PCLS following treatment.  In PCLS treated with 
MA+VAP-1 compared to control we found many genes associated with the NF-κB 
signaling pathway altered.  These included NF-κB1, IL6, IL8, IL10, ICAM-1 and 
TLR4 (Figures 4.15 and 4.16).  
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Figure 4.15: Analysis of NF-κB signaling pathway after VAP-1 treatment in 
PCLS 
mRNA profiles of the expression of key genes related to NF-κB mediated signal 
transduction after VAP-1 stimuli treatment, involved in (A) Activation of NF-κB 
pathway and (B) NF-κB cascade.  PCLS were treated with methylamine 
200μm+VAP-1 500ng for approximately 2.5 hours.  RNA was extracted and mRNA 
expression was carried out using a Human NF-κB Signaling Pathway RT²Profiler™ 
PCR Array.  Results are expressed as the mean fold change in gene expression 
normalized to endogenous control GAPDH relative to control livers defined as 1.  
N=1 
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Figure 4.16: Analysis of NF-κB signaling pathway after VAP-1 treatment in 
PCLS 
mRNA profiles of the expression of key genes related to NF-κB mediated signal 
transduction after VAP-1 stimuli treatment, involved in (A) NF-κB responsive genes 
and (B) other factors involved in NF-κB pathway.  PCLS were treated with 
methylamine 200μm+VAP-1 500ng for approximately 2.5 hours.  RNA was extracted 
and mRNA expression was carried out using a Human NF-κB Signaling Pathway 
RT²Profiler™ PCR Array.  Results are expressed as the mean fold change in gene 
expression normalized to endogenous control GAPDH relative to control livers 
defined as 1.  N=1 
 
 
 
 190 
4.3.6 VAP1 and its substrate methylamine may alter the expression of GLUT 
proteins in PCLS 
Next we used qPCR to investigate whether mRNA transcript levels for the GLUT 
transporters 1-13 were altered by MA pretreatment of PCLS.  Results were 
normalized to the house keeping genes β-actin and GAPDH and expressed relative to 
control PCLS, which were set as 1.  Pretreatment of PCLS with methylamine alone 
resulted in an increase in mRNA expression of GLUT4, GLUT10 and GLUT13, 
GLUT1, GLUT2, GLUT3 and GLUT7 remain unchanged compared to normal and all 
others were down regulated (Figure 4.17).  
 
 
Figure 4.17: Analysis of GLUT mRNA in PCLS after VAP-1 stimulation by 
quantitative qPCR analysis 
PCLS were treated with methylamine 200μm for approximately 4.5 hours.  RNA was 
extracted and mRNA expression was carried out using a fluidigm qPCR array
®
 run on 
triplicate arrays.  Results are expressed as the mean fold change in gene expression 
normalized to pooled endogenous controls (β-actin and GAPDH) relative to control 
livers defined as 1 +/- SEM with means from two normal resected livers.  
Significance expressed as * p<0.05, **p<0.01, ***p<0.001 using a one way ANOVA 
with Bonferroni correction. 
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4.3.7 VAP-1 null mice show altered glucose responses   
Finally we generated PCLS from WT and VAP-1 KO mice fed on a normal diet in 
order to assess glucose response in these animals.  Initially it was difficult to obtain 
reproducible PCLS from a multi lobed liver, but we were able to generate slices by 
stacking the liver and coring.  Insulin was used as a positive control and indeed 
treatment of WT slices caused a robust increase in glucose uptake, which was less 
marked in the KO animals. Interestingly the KO animals also had a higher basal 
glucose uptake than the WT controls.  In the WT mice we observed an increase in 
glucose uptake when the PCLS were pre treated with MA, VAP-1, MA+VAP-1, and 
hydrogen peroxide, although this was only significant with hydrogen peroxide (Figure 
4.18A).  Furthermore combination with BEA reduced the effect of MA+VAP-1 
treatment. In the KO mice in contrast, we did not observe an increase in glucose 
uptake when slices were pretreated with MA, VAP-1, or MA+VAP-1, although 
hydrogen peroxide again enhanced uptake (Figure 4.18B).   
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Figure 4.18: Assessment of glucose uptake after VAP-1 stimulation in PCLS 
from livers of WT and VAP-1 KO mice   
(A) Uptake of radiolabelled glucose after stimulation of PCLS from WT mice and (B) 
VAP-1 KO mice.  PCLS from WT and VAP-1 KO were pretreated with either insulin 
0.10 IU, methylamine 200μm, VAP-1 500ng, H2O2 10μM, BEA 400μm, or in 
combination with methylamine+VAP-1, methylamine+VAP-1+BEA, for 
approximately 2 hours and 30 minutes and then 30 minutes with radiolabelled 
glucose.  PCLS were lysed and radioactivity measured and signal normalized to per 
500mg of tissue.  N=3 +/- SEM.  Significance expressed as **p<0.01, ***p<0.001 
(mouse livers obtained from Lee Claridge).   
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4.4 Discussion  
VAP-1 is highly expressed in adipose tissue where it has been shown to regulate 
glucose uptake. Since this protein has also been shown to be upregulated in 
inflammatory liver disease and diabetes, this chapter set out to examine whether it has 
a role in hepatic glucose homeostasis.  Firstly we report increased expression of VAP-
1/SSAO in NASH and ALD livers.  We then performed functional studies using a 
novel ex vivo model of liver culture.  We show for the first time global activation of 
hepatic NF-κB and transcription of target genes in response to activation of VAP-1.  
Importantly we demonstrated that VAP-1/SSAO activity stimulated glucose uptake 
with possible mobilization of hepatic GLUT4 and enhanced expression of GLUT10 
and GLUT13.   
 
4.4.1 VAP-1/SSAO expression and functional activity is upregulated in 
diseased livers 
We found expression of VAP-1 to be upregulated in chronically inflamed NASH, 
ALD and PBC livers supporting previous findings from our group (Claridge L C, 
2009).  Stolen et al have previously shown increased VAP-1 expression in transgenic 
mice encoding human VAP-1 (hVAP-1) is associated with increase in SSAO activity 
in the liver (Stolen et al., 2004a) and others have correlated serum SSAO activity with 
sVAP-1 concentration in patients with liver disease (Kurkijarvi et al., 2000, 
Kurkijarvi et al., 1998).  Kurkijarvi et al showed increase SSAO activity in chronic 
liver disease for example in ALD and PBC (Kurkijarvi et al., 2000).  In agreement 
with these observations, our increase in mRNA and protein for VAP-1 in liver disease 
equated to increased SSAO activity in liver homogenates and could be inhibited by 
BEA a specific inhibitor of VAP-1/SSAO activity.  
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In contrast we found a down regulation of protein and mRNA in steatotic livers but no 
significant change in SSAO activity when compared to normal livers.  Whilst to our 
knowledge this is the first study to report this finding in steatotic human liver, fatty 
adipose tissue biopsies from obese men (Body Mass Index (BMI) 32.6) in comparison 
to lean men (BMI 23.3) also show that VAP-1/SSAO activity remains unchanged 
(Visentin et al., 2004).  Since the authors did not show VAP-1 protein expression in 
this study, the unchanged SSAO activity may be reflective of similar protein 
expression or altered activity in the presence of altered expression.  In our study, we 
saw decreased VAP-1 mRNA but no change in SSAO activity or histological protein 
expression in steatosis.  This may suggest that duration of expression or recycling of 
VAP-1 protein is modified during steatosis and so transcription of new VAP-1 protein 
may be reduced to minimize activity.  However it must be noted that the samples we 
classed as steatotic in our study were fatty donor samples rather than true 
pathologically graded NAFLD samples. Analysis of VAP-1 expression and 
subcellular localization in normal and correctly classified NAFLD samples would 
therefore be important. 
 
At the cellular level VAP-1 was expressed in HSEC as previously reported (Salmi et 
al., 1993), (McNab et al., 1996).  In addition VAP-1 expression on HSEC increased in 
diseased livers for example in NASH and ALD, and interestingly our group has 
previously shown serum from ALD patients increases expression of VAP-1 on HSEC 
(Lalor et al., 2002) suggesting either a soluble stimulatory factor or presentation of 
sVAP-1 by HSEC.  In support of previous data (Claridge L C, 2009) we also found 
that VAP-1 was expressed at the mRNA level in liver fibroblasts and protein 
colocalized to fibrotic regions and sinusoidal areas in tissue sections. This is 
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consistent with sinusoidal expression on HSCs, which is increased upon 
differentiation to activated myofibroblast cells in fibrosis.  
 
One key finding from this chapter was that we did not see VAP-1 protein expression 
in hepatocytes in sections, however we document mRNA expression in HepG2 cells 
and Huh7.5. Although VAP-1 expression has been reported in rat hepatocytes 
(Martelius et al., 2000) these cells have generally been considered not to express 
VAP-1. This may suggest that the malignant transformation of hepatocytes in cancer 
could be associated with ability to express VAP-1, and certainly HCC is associated 
with particularly high sVAP-1 levels (Kemik et al., 2010).  Additionally a role for 
VAP-1 in tumor angiogenesis has been reported where SSAO activity leads to 
recruitment of myeloid cells to tumors (Marttila-Ichihara et al., 2009), (Marttila-
Ichihara et al., 2010), (Ferjancic et al., 2013) and numbers of these cells are reduced 
by small molecule inhibitors of VAP-1 (Marttila-Ichihara et al., 2010). Our group has 
also shown (Yoong et al., 1998) that inflammatory cells are recruited into tumors 
using VAP-1. Thus VAP-1 likely plays important roles in tumor biology, and it is 
likely that expression is altered in this context.      
 
4.4.2 The role of amine oxidases in the pathogenesis of NASH   
4.4.2.1 MAO 
The deamination of amines by VAP-1 and other amine oxidases such as MAOA, 
MAOB and LOX results in the production of ammonia, aldehyde and hydrogen 
peroxide, (O'Sullivan et al., 2004), (Carpene et al., 2005) thus we felt it was important 
to study the expression patterns of all of these amine oxidases in the liver in addition 
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to VAP-1.  The expression of MAOA and MAOB has previously been confirmed in 
fetal (Lewinsohn et al., 1980) and adult livers (Rodriguez et al., 2001).  However 
disease specific expression has not been reported.  Interestingly we found a decrease 
in all AO in the steatotic livers, which again supports data from adipose tissue where 
MAO activity is reduced in obese men compared to lean men (Visentin et al., 2004).  
It is possible that this downregulation may reflect changes in substrate availability 
with obesity/steatosis or mitochondrial dysfunction (Visentin et al., 2004). Regardless 
of cause, this suggests that the onset of oxidative stress which may trigger progression 
from simple steatosis to NASH may not be linked to MAO activity, or that a 
compensatory downregulation of expression is designed to protect against oxidative 
stress in this context. However, with advanced disease, expression increases and we 
found AO mRNAs upregulated in NASH and ALD and at the cellular level we have 
shown mRNA expression for MAOA and MAOB in hepatocytes and BEC.  This has 
previously been reported at the protein level (Rodriguez et al., 2001) and in patients 
with NASH (Nocito et al., 2007).  The mechanism leading to alterations in MAO 
expression with disease stage need to be characterized, but evidence from other 
organs such as the uterus (Zhang et al., 2011a) and cells such as platelets (Zellner et 
al., 2011) point to hormonal regulation, high protein diet, homocysteine levels and 
B12 deficiency. This has interesting implications for NASH in particular where 
homocystein levels are reduced and linked to metabolism of vitamin B12 (Polyzos et 
al., 2012).   
 
Elevated MAO expression in NASH is of relevance because a study has shown that 
patients with NASH experience depression and anxiety (Elwing et al., 2006), and 
there is an established link between MAO and depression, with MAOA inhibitors 
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providing therapeutic efficacy. Interestingly depression has also been linked to 
markers of inflammation (Penninx et al., 2003), (Miller et al., 2003), (Sutherland et 
al., 2003) providing further evidence linking depression and the pathogenesis of 
NASH.  Thus in the present study we provide evidence for elevated hepatic 
expression of MAO which may lead to depression in individuals, with implications 
including lack of motivation and a change in appetite.  This could increase calorific 
intake and providing further substrates to fuel disease pathogenesis. Thus MAO 
inhibitors may have dual benefit by targeting psychological and pathological 
mechanisms and indeed administration of chlorgyline to animals with NASH induced 
by methionine-choline deficient diets improved both pathology and circulating liver 
enzymes (Nocito et al., 2007).   
 
4.4.2.2 LOX 
We report elevated expression of LOX in chronically inflamed and fibrotic NASH, 
ALD and PBC livers.  Oxidation of lysine by, LOX leads to cross linking of collagen 
and elastin and remodeling of the extracellular matrix (Smith-Mungo and Kagan, 
1998), and thus it makes sense that we see elevated expression associated with 
fibrotic injuries.  LOX has previously been found in human liver (Kagan and Li, 
2003) and in rat liver with an increase in activity associated with fibrosis and injury 
(Siegel et al., 1978), (Perepelyuk et al., 2013) furthermore serum activity levels of this 
enzyme have been indicated as markers for detecting liver fibrosis (Murawaki et al., 
1991).  However disease specific expression has only been reported for PBC (Vadasz 
et al., 2005) with no reported expression in NASH or ALD.   
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We found LOX was more abundant in NASH and ALD than PBC and this may be 
reflective of the local environment in these disease specific conditions since specific 
cytokines such as Transforming Growth Factor-β (TGFβ) have been shown to 
regulate LOX activity.  At the cellular level it was expressed in all cells studied with 
particular abundance in HSEC, fibroblasts and hepatocyte cell lines.  This is in 
agreement with reported expression in rat HSCs, portal fibroblasts, human 
hepatocytes and BEC (Perepelyuk et al., 2013), (Vadasz et al., 2005), (Wakasaki and 
Ooshima, 1990).  Of note our elevated expression in the two hepatocyte cell lines may 
again be linked to the malignant origin of these cells since LOX is also elevated in 
tumors (Xiao and Ge, 2012) and a reduction in tumor mass can occur through its 
inhibition (Kanapathipillai et al., 2012).   
 
4.4.3 Activation of VAP-1 stimulates glucose uptake in hepatic cells   
We report for the first time that pretreatment of HSEC with MA, MA+VAP-1 or 
hydrogen peroxide stimulates glucose uptake, although similar responses have 
previously been reported in other cells for example rat and human adipocytes 
(Enrique-Tarancon et al., 1998), (Morin et al., 2001), VSMCs (El Hadri et al., 2002) 
and F422A cells (Fontana et al., 2001).  Of note this effect was observed in the 
absence of vanadate, which has been required in addition to substrates of VAP-1 in 
other cells to stimulate glucose uptake (Enrique-Tarancon et al., 1998).  We noticed 
when exogenous VAP-1+MA was added this resulted in a marked increase in glucose 
uptake, which was inhibited on addition of BEA suggesting specificity for VAP-1.  
Furthermore we found the addition of VAP-1+MA had a more potent effect in 
stimulating glucose uptake than when hydrogen peroxide was added in alone.  One 
reason for this may be that a single dose of exogenously added hydrogen peroxide 
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may be less effective in causing the mobilization of insulin stimulated GLUTS and 
hence uptake of glucose than locally generated oxidants produced by VAP-1 
catalysis.  It is also likely that our hydrogen peroxide would be broken down by 
endogenous peroxidases.  Certainly in other studies from our group, upregulation of 
Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) by hydrogen peroxide 
when modeling products of VAP-1 catalysis required multiple re-stimulations over an 
incubation period for maximal effect (Liaskou et al., 2011). We found variable 
responses in HSEC which could be due to patient variability, for example whether 
cells were isolated from a diseased liver like ALD where endothelial VAP-1 
expression is high or from a normal liver were expression is low, or due to loss of 
expression in culture.  However we are confident that VAP-1 stimulates glucose 
uptake in HSEC in a manner dependent upon SSAO activity, since overexpression of 
enzymatically competent VAP-1 using virally encoded constructs led to increased 
glucose uptake upon exposure to substrate.   
 
Glucose uptake in response to SSAO activity in rat adipocytes has been reported as 
being GLUT4-dependent (Enrique-Tarancon et al., 1998) and GLUT1 dependent in 
VSMCs (El Hadri et al., 2002) were in some cases the mechanism is based on 
tyrosine phosphorylation of IRS-1 and IRS-3 and activation of PI3-K (Enrique-
Tarancon et al., 2000). Although we have not shown which GLUT is responsible for 
the observed effect.   We feel this effect may have a possible contribution from the 
four insulin stimulated transporters GLUT4, GLUT8 (Schurmann et al., 2002),  
(Carayannopoulos et al., 2000), GLUT10 (Lee et al., 2010) or GLUT12 (Stuart et al., 
2009) all of which we have shown to be expressed in HSEC (see Chapter 3) as they 
may be sensitive to signals likely to be replicated by VAP-1.  
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Interestingly, despite evidence, which suggests that hepatocyte-cells lack VAP-1, we 
observed similar effects with the two cell lines Huh7.5 and HepG2.  However we 
found that HepG2 cells had higher basal glucose uptake.  The higher basal glucose 
uptake seen in HepG2 may be reflective of the nature of this tumor-derived cell line 
and its demand for energy.  The methylamine- driven stimulation of glucose uptake in 
these cells may be due to the presence of endogenous VAP-1, which was more 
abundant at message level in this cell line (Figure 4.3A).  It would be important to try 
and reproduce these effects in isolated primary hepatocytes, but the data suggest that 
should a local source of VAP-1 and endogenous substrate be present within the liver 
microenvironment, proximal hepatocytes can respond in a manner similar to that 
reported for other cell types.  
 
4.4.4 Development of an ex vivo human model of liver for the functional study 
of VAP-1 in glucose and lipid homeostasis 
Although cell lines are easily available and can be expanded without restrictions and 
are used in many studies there are differences between cell lines and primary cells as 
shown by our current study and by others (Pan et al., 2009), (Tolosa et al., 2013).  
Thus whole animal models are commonly used in the study of liver disease 
pathogenesis (reviewed in (Billerbeck et al., 2013), (Ko et al., 2013), (Takahashi et 
al., 2012)).  These models too are inherently different from human liver disease and 
do not completely reconstitute disease patterns seen in humans for example in the 
methionine choline deficient model the metabolic profile does not constitute the 
human NASH metabolic profile with peripheral insulin sensitivity and weight 
decrease (Takahashi et al., 2012).  Thus since it is important to recreate the 
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multicellular interactions present in the human liver we sought to develop an ex vivo 
based model to study the effects of VAP-1 activity in a multicellular, physiologically 
relevant human model.   
 
Previous studies have used human PCLS to investigate hepatic metabolism and 
hepatotoxicity (Connors et al., 1990), (Wishnies et al., 1991), (Price et al., 1996), 
(Kirby et al., 2004), (Guyot et al., 2007), however the functional activity of PCLS in 
culture has not been addressed by many studies and thus we felt it was vital to fully 
characterize the functional capability of PCLS in culture before performing any 
interventions. 
 
We report that our PCLS culture system retains viability for up to 48 hours, and this is 
supported by albumin secretion, glucose uptake, MTT reduction, glycogen storage 
and morphological evidence in terms of visual integrity (Karim et al., 2013).  
Furthermore we adapted this system to our functional assays for measuring glucose 
uptake.  Importantly we incorporate visual assessment of PCLS integrity, which is not 
carried out in all published studies, and our PCLS culture system is amenable to 
culture for up to 48 hours which extends the time point suggested by many studies 
using human and rodent PCLS for metabolic and toxicological studies (Connors et al., 
1990), (Price et al., 1996), (Mortensen and Dale, 1995, Price et al., 1996, Naik et al., 
2004).   However we did note a gradual decrease in viability between 24 and 48 hours 
and this was accompanied with a decrease in albumin secretion and formation of 
glycogen droplets, loss of morphological structure and nuclear integrity.   We also 
observed necrosis in the center of these slices compared to the periphery (Karim et al., 
2013). This was probably because the periphery of PCLS where able to maintain 
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gaseous exchange and media perfusion.  Similar studies have also reported loss in 
expression over time in culture for example of cytochrome P450 (Martin et al., 2003).  
This model could be further enhanced to improve tissue integrity and architecture at 
48 hours as well as maintain viability over 48 hours by introducing a dynamic flow 
perfusion system for example using microchamber perfusion devices (van Midwoud 
et al., 2010a), (van Midwoud et al., 2010b) or immobilizing PCLS in inserts and 
allowing gaseous exchange in rotary culture (Clouzeau-Girard et al., 2006), (Guyot et 
al., 2007), (Klassen et al., 2008), (Schaffert et al., 2010).  However within the 
confines of the current study all our functional experiments were carried out within 24 
hours to ensure maximal viability of PCLS (Karim et al., 2013), (Liaskou et al., 
2011).  
 
4.4.5 Activated VAP-1 regulates glucose uptake in PCLS  
Our group has previously confirmed that activation of SSAO activity drives activation 
of NF-κB in endothelial cells and induces transcription of IL-8, ICAM-1 and E-
selectin (Lalor et al., 2007).  Thus, in order to check whether our PCLS would 
respond to stimulation of VAP-1 we performed an analysis of NF-κB activity using a 
custom qPCR array.  This included genes, which were up in the NF-κB activation 
pathway, cascade and NF-κB responsive genes IL8, IL6, IL10, ICAM1 and TLR4 
which are involved in the inflammatory response and fits with the picture observed in 
NAFLD.  Thus this data suggests stimulation of VAP-1 in PCLS is successful.  
 
We report for the first time, hepatic glucose uptake in response to methylamine 
treatment of PCLS.  This was due to activation of endogenous VAP-1 within tissue, 
which was likely expressed on HSEC, HSCs and possibly on fibroblastic cells.  
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However since the tissue predominantly used in the generation of PCLS was from 
resected non-fibrotic, normal liver the major contribution would likely be from HSEC 
and HSCs.  Presence of shed sVAP-1 should also be considered since biological stress 
for example from the cutting procedure, may lead to shedding of catalytically active 
VAP-1 from HSEC or other cells.  For example experimentally induced diabetes leads 
to shedding of VAP-1 from HSEC (Stolen et al., 2004a).  Thus shed VAP-1 from 
systemic blood or hepatic cells could have local insulinomimetic effects on 
hepatocytes and other liver cells.   
 
Although other studies have shown VAP-1 substrates to stimulate glucose in cells (El 
Hadri et al., 2002), (Fontana et al., 2001), (Enrique-Tarancon et al., 1998), (Morin et 
al., 2001) this is the first study that has shown methylamine to stimulate glucose 
uptake in firstly the human liver and secondly in a multicellular environment using an 
ex vivo based model. Of note, despite our cellular expression data we obviated the 
need to use inhibitors for other amine oxidases in the PCLS system by choice of 
substrate, since methylamine is not deaminated by the other AO (Lyles, 1996), (Yu, 
1990).  Our observation of an increase in glucose uptake when VAP-1 was added 
alone to PCLS suggests the presence of endogenous ligands.  These could be 
endogenous amines such as methylamine, which is found in food and cigarette smoke 
or from the oxidation of adrenaline by MAO (O'Sullivan et al., 2004). Or amines such 
as leucine and valine which are metabolized by the liver (Holecek et al., 1998).   
 
The addition of endogenous methylamine and VAP-1 resulted in a marked increase in 
glucose uptake, which returned to control levels on addition of BEA and was 
recapitulated on addition of hydrogen peroxide a metabolite known to mimic the 
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effects of insulin (Mahadev et al., 2001) as previously shown in different systems 
(Enrique-Tarancon et al., 1998), (Marti et al., 1998), (El Hadri et al., 2002).  The 
presence of a large amount of exogenous VAP-1 in our system means there is an 
abundance of the enzyme available for the catalytic conversion of methylamine to 
hydrogen peroxide hence stimulating glucose uptake.  Even so we found variable 
responses with different PCLS in this system, which may reflect donor genetic 
differences or variables such as tissue age and processing time prior to 
experimentation. Thus whilst we have confirmed that activation of SSAO activity 
increases glucose uptake by normal liver specimens, it would be interesting to see the 
responses of PCLS from steatotic and NASH patients, particularly in light of our 
observations on basal glucose transporter expression in these situations.  
 
4.4.6 The role of GLUT4 and other glucose transporters in VAP-1 stimulated 
glucose transport 
We then went on to examine whether the enhanced uptake of glucose as a result of 
VAP-1 activity was linked to activity of GLUT4, which has been shown previously in 
rat adipocytes (Enrique-Tarancon et al., 1998).  We noted the appearance of large 
cytoplasmic GLUT4-containing droplets concentrated towards the periphery of 
hepatocytes in PCLS treated with VAP-1+MA.  This effect was not seen in the 
control or VAP-1+MA+BEA treated PCLS and thus we are confident that this effect 
is a genuine observation as a result of VAP-1 activation.  Certainly in adipocytes 
GLUT4 becomes enriched in membrane fractions after VAP-1 substrate stimulation 
(Enrique-Tarancon et al., 1998) and thus a similar mechanism may be in operation. 
We did notice some staining in the IgG control-treated PCLS, but this did not have 
the appearance of large cytoplasmic droplets.  Thus the staining observed in the IgG 
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control could be due to autofluorescence of selected cells within the PCLS or non-
specific binding of staining reagents.  The bright cells in the sinusoids are likely to be 
macrophages or similar which bind antibody non-specifically.  
 
It is interesting that the responsive cells are the hepatocytes which we have not found 
VAP-1 protein expression for and thus lack VAP-1 yet we see possible changes in 
GLUT4 in PCLS thus this implies that activation of VAP-1 by another cell caused the 
response in hepatocytes.  Although we did not use specific cell labeling antibodies to 
identify for example the hepatocytes, morphologically these cells do appear to be 
hepatocytes.  Interestingly we did not see the presence of these GLUT4 droplets in 
HSEC. This may be because the sections were to thin so hard to visualize or the 
HSEC were non responsive because the PCLS were bathed in treatment rather than it 
being delivered through the vasculature.  A further explanation could be that we may 
have missed the endothelial response and rather saw the subsequent hepatocyte 
response due to a longer time point used, for example in adipocytes GLUT4 
recruitment is seen within 1 hour of treatment (Enrique-Tarancon et al., 1998).   
However other studies have shown that changes in protein expression for example 
GLUT1 can be detected as early as 1 hour and persist as long as the cells are exposed 
to the amine (El Hadri et al., 2002).   
 
Furthermore it most be noted that in addition to GLUT4 there are other insulin 
sensitive transporters which may be sensitive to signals likely to be replicated by 
insulinomimetic response of VAP-1 as suggested earlier for example GLUT8 
(Schurmann et al., 2002), (Carayannopoulos et al., 2000), GLUT10 (Lee et al., 2010) 
and GLUT12.   Our data confirms that human liver expresses these insulin- sensitive 
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transporters (see Chapter 3) and so VAP-1 activity may also stimulate glucose uptake 
by regulating the expression of these proteins. Thus future experiments should 
consider confocal staining for these GLUTS in isolated cells and treated liver sections 
to quantify cellular distribution.  GLUT4-independent responses to VAP-1 
stimulation have been demonstrated in VSMCs. Here SSAO activity causes the 
accumulation of GLUT1 at the cell membrane and not GLUT4 (El Hadri et al., 2002) 
as it does in other cells (Enrique-Tarancon et al., 1998) confirming that VAP-1 
stimulates different GLUTS in different cells.  Furthermore in some cells it can 
increase expression of multiple GLUTS for example GLUT1 and GLUT4 in 3T3 
F442A cells (Fontana et al., 2001).  We document elevated expression for GLUT8, 
GLUT10 and GLUT12 in NASH and ALD compared to normal livers and 
importantly these livers also have elevated levels of VAP-1.  This suggests that VAP-
1 may be implicated in their expression and also implies that GLUT8, GLUT10 and 
GLUT12 could be more important than GLUT-4 for VAP-1 stimulated glucose 
uptake in the diseased liver. However this would need further investigation.  
 
One line of evidence supporting this hypothesis is that we have demonstrated 
increased expression of message for GLUT4, GLUT10, and GLUT13 in human PCLS 
following methylamine treatment.  We also found increase in expression of GLUT1 in 
one sample studied.  Increased expression for GLUT4 and GLUT1 by other amines 
such as tyramine and benzylamine has previously been reported in 3T3 F442A cells 
(Fontana et al., 2001) and also GLUT1 in VSMCs (El Hadri et al., 2002).   
 
It was interesting to note that methylamine increased expression of GLUT10 which 
may be involved in protecting the cell from oxidative stress which arises as a direct 
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result of activated VAP-1 generating hydrogen peroxide or through lipid peroxidation. 
Certainly mitochondrial GLUT10 in smooth muscle cells has been shown to have a 
functional role in protecting cells from oxidative damage (Lee et al., 2010). Of note 
the NF-κB array data also showed that we induced activation of NF-κB1 and its target 
gene IL-10, both of which have anti-inflammatory roles for example IL-10 can 
prevent transcription of inflammatory cytokines (Cao et al., 2006), and inhibits IL-2 
production in T lymphocytes thus inhibiting their growth (de Vries, 1995), whilst NF-
κB1 has been shown to reduce the expression of TNFα and hence infiltration of 
immune cells (Oakley et al., 2005).  In addition GLUT13 a H
+
/myo-inositol co 
transporter (Zhao and Keating, 2007), (Uldry et al., 2001), (Scheepers et al., 2004) 
was also upregulated.   Inositol can act as an insulin sensitizer (Giordano et al., 2011) 
which could precipitate glucose uptake in the context of IR. Additionally dietary 
supplementation with inositol has been shown to improve features of the MetS, for 
example a decrease in serum TAG and blood pressure (Giordano et al., 2011). Thus 
whilst VAP-1 activity has clear metabolic consequences, and can drive tissue 
inflammation in the context of disease (Lalor et al., 2007), and can regulate 
expression of ICAM-1 and IL-8 (Figure 4.15 and 4.16), there is also a suggestion that 
activation of protective mechanisms linked to antioxidant responses and anti-
inflammatory gene expression are also induced.   
 
4.4.7 VAP-1 KO mice show altered glucose responses  
Our data from the human system suggests that VAP-1 activity has a profound ability 
to modify glucose uptake. To interrogate this further we used tissue from C57BL/6 
mice lacking the VAP-1 gene to compare glucose responses in ex vivo murine PCLS.  
This strain of mice irrespective of diet develops obesity and IR with age (Anstee and 
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Goldin, 2006) and exhibit increased SSAO activity when compared to other mouse 
strains (Yu and Deng, 1998). Interestingly we found VAP-1 KO mice had a higher 
basal glucose uptake compared to WT, which may be a compensatory mechanism.  
Furthermore the addition of MA did not stimulate glucose uptake in contrast to WT 
animals. This confirms the specificity of our MA responses in the human tissue, and 
the requirement for endogenous VAP-1 to drive MA stimulated glucose uptake.  
Interestingly in the VAP-1 KO PCLS most other treatments did not enhance glucose 
uptake even when exogenous VAP-1 was added.  This suggests that in the murine 
system, endogenous VAP-1 is more effective at recruiting GLUTS and driving 
glucose uptake than exogenous VAP-1. This may reflect an inability of murine 
ligands to respond to human VAP-1, but these proteins are conserved between mouse 
and human and thus unlikely.  Importantly when we supplied hydrogen peroxide 
directly to the PCLS, we saw responses in both WT and VAP-1-deficient tissue, 
which suggests that signaling machinery downstream of VAP-1 is intact in both 
animals. Certainly mouse tissues engineered to overexpress human GLUT-4 show 
enhanced glucose uptake and fatty acid metabolism (Belke et al., 2001).  Whilst this 
data strengthens the role of hepatic VAP-1 in glucose uptake, it must be noted that the 
responses were very variable in this system. This may simply reflect limitations in our 
ex-vivo assay for studies using mouse tissues.  For example media constituents may 
need altering and optimizing for mouse tissues, and it was more difficult to slice the 
multi-lobed mouse livers than human samples.  However it is important to remember 
that mice have high metabolic rates (Andrikopoulos et al., 2008) and different 
immune systems (Liu et al., 2013) than humans and a tendency to ingest calories at 
night (Andrikopoulos et al., 2008) all of which might alter responses in our assays.  
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4.4.8 The Functional significance of VAP-1 in chronic liver disease  
In all this is the first study to document the role of VAP-1 in stimulation of glucose 
uptake in hepatic cells and the human and mouse liver using a novel ex-vivo model.  
Many patients diagnosed with NASH exhibit cardinal features collectively grouped 
together under the MetS, which include IR.  Our data supports the hypothesis that in 
an IR patient suffering from NASH or other chronic inflammatory disease, an 
increase in VAP-1 expression is concomitant with levels of insulin in an attempt to 
regulate blood glucose levels.  For example Salmi et al showed elevated levels of 
sVAP-1 in diabetic patients and this appeared to be regulated by levels of insulin 
which increased the shedding of VAP-1 (Salmi et al., 2002).  In addition induction of 
experimental diabetes in mice overexpressing VAP-1 levels leads to elevated levels of 
sVAP-1 (Stolen et al., 2004a).  Thus VAP-1 may be overexpressed in cells in an 
attempt to make them insulin sensitive.  However it can be argued that this may not be 
restricted to VAP-1 since the deamination of amines by other AO can also result in 
the formation of hydrogen peroxide, which is key to mimic the insulin like effects.    
However we have shown MA, which is specific for VAP-1, stimulates glucose uptake 
in hepatic cells and PCLS, and further evidence suggesting VAP-1 colocalizes in 
intracellular vesicles with GLUT4 points to a specific role in glucose transport 
(Enrique-Tarancon et al., 1998).  Thus VAP-1 has positive effects on diabetes by 
enhancing muscle glucose utilization however it is also associated with late 
complications of diabetes for example glomerulosclerosis and atherosclerosis, (Stolen 
et al., 2004a).  Furthermore the extra fuel in the form of glucose could be used for 
DNL and hence drive steatosis, whilst activation of NF-κB may lead to inflammation 
and fibrosis in NASH.    
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In addition we have shown the liver expresses specific insulin-sensitive GLUTS, 
which are also upregulated in NASH and ALD livers.  Thus it is possible that 
activated VAP-1 may also regulate glucose uptake through GLUT8, GLUT10 and 
GLUT12 in the diseased liver.  Furthermore the enhanced expression of GLUT10 and 
GLUT13 by methylamine as shown by this study may represent a compensatory 
mechanism to protect against oxidative stress similar to that of GLUT10 in smooth 
muscle cells (Lee et al., 2010).  GLUT13 can ameliorate conditions associated with 
the metabolic syndrome by transporting inositol which has roles in insulin signaling 
(Larner, 2002) and as an insulin sensitizer (Giordano et al., 2011).  Although we did 
not find this transporter upregualted in NASH it was in ALD and thus may be 
associated with disease severity or exhibit disease specific expression.  A schematic 
illustrating the roles of each GLUT discussed is below.    
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Figure 4.19: Schematic showing VAP-1/SSAO related glucose uptake in the 
human liver 
We have shown activated VAP-1 leads to glucose stimulation through GLUT4, 
however in the liver it is not limited to GLUT4 but may include GLUT8, GLUT10 
and GLUT12 which are elevated in disease.  Addition of methylamine to PCLS leads 
to enhanced expression of GLUT13, which transports inositol and could have roles in 
sensitizing the insulin resistant liver in NASH and GLUT10, which protects the cell 
from oxidative damage as observed in NASH.   
 
Finally it is important to acknowledge that excess uptake of glucose drives 
lipogenesis and such further evidence to support the insulinomimetic effects of VAP-
1 have been described in adipocytes (Fontana et al., 2001), (Morin et al., 2001).  Thus 
could the  ‘adipocyte like’ differentiation of hepatocytes to make them store TAG a 
possible consequence of VAP-1 activity. Whether this occurs in the liver, and may 
cause or exacerbate disease pathogenesis needs further investigation.  Thus the 
contribution of VAP-1 to lipid storage by the liver is investigated in the next chapter. 
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CHAPTER 5 
 
5 IS THERE A ROLE FOR VAP-1 IN 
HEPATIC LIPID HOMEOSTASIS? 
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5.1 Introduction  
Our studies thus far have demonstrated that activation of hepatic VAP-1 in whole 
liver and isolated cells leads to activation of NF-κB-dependent signaling cascades, 
translocation of GLUT-4 and enhanced glucose uptake.  Of note VAP-1/SSAO-
dependent deamination of amines not only regulates glucose uptake in cells but has 
also been shown to posses other insulin-like effects and can modify lipid metabolism 
(Morin et al., 2001), increase TAG storage (Fontana et al., 2001) and drive adipocyte 
differentiation (Morin et al., 2001). For example, chronic administration of VAP-
1/SSAO substrates such as methylamine, leads to a development of fatty streaks in the 
aortae in mice fed on a high cholesterol diet (Yu et al., 2002) and these substrates 
have also been shown to activate differentiation in adipocytes (Fontana et al., 2001), 
(Carpene et al., 2006), (Mercier et al., 2001), (Subra et al., 2003), (Bour et al., 2005) 
as well as stimulating lipogenesis (Carpene et al., 2006).  Treatment of diabetic rats 
with benzylamine and vanadate also causes a 45% increase in adipose tissue fat 
deposition (Marti et al., 2001), and transgenic mice overexpressing VAP-1/SSAO 
chronically supplemented with methylamine have increased BMI and abdominal fat 
pad weight (Stolen et al., 2004a).  These data imply that VAP-1 has a potent ability to 
regulate not only glucose homeostasis but also the storage and distribution of lipids. 
 
Our initial findings suggest that NASH and chronic liver diseases are associated with 
marked changes in hepatocellular lipid transport proteins, as has been noted in some 
other investigations and discussed in our initial chapter. Whilst speculations as to the 
mechanisms underlying these responses have been made, and links with disease 
susceptibility and progression have been noted (Westerbacka et al., 2007), (Doege et 
al., 2006), to our knowledge no one has considered the impact of amine oxidase 
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activity on liver lipid traffic. It is surprising that the link between obesity, VAP-
1/SSAO and more strikingly fatty liver has received little attention. Of note, the 
increased dietary consumption patterns in western world have likely increased the 
availability of substrates such as methylamine which are abundantly found in food 
(Pirisino et al., 2001), cigarette smoke (Zhang et al., 2012) and are formed 
endogenously from the metabolism of adrenaline (Yu et al., 1997). This coupled with 
the direct portal connection between the gut and liver, may deliver increasing 
concentrations of substrate to the hepatic environment (Liaskou et al., 2011) and 
impact upon local production of hydrogen peroxide and other SSAO metabolites.  
Since hydrogen peroxide has insulinomimetic effects it could regulate lipid 
transporters for example CD36 and FATP1 (Stahl et al., 2002), (Schwenk et al., 
2010), which are reported to be insulin sensitive and hence contribute to lipid 
accumulation, oxidative stress and further damage to the cell.  Furthermore hydrogen 
peroxide could potentially drive endogenous lipogenesis and inhibit lipolysis just like 
insulin.  
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Thus the major aims of this chapter were:  
 
(I) To develop in vitro and ex-vivo based models to investigate the role of VAP-1 in 
regulating lipid accumulation in the liver. 
 
(II) To investigate the role of VAP-1 in regulating lipid accumulation in hepatic cells 
in culture 
 
(III) To investigate the impact of SSAO activity on lipid  transporter expression   
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5.2 Methods  
For methods pertinent to this chapter please refer to the general methods p51-54. 
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5.3 Results 
5.3.1 Quantification of lipid accumulation in cultured cells 
Since excess lipid accumulation has reported toxic effects (Malhi et al., 2006), (Ricchi 
et al., 2009), (Malhi et al., 2007) we began by performing pilot experiments to test 
effects of different doses of both saturated and unsaturated FFAs on cultured Huh7.5 
and HSEC.  Cells were treated with varying concentrations of OA and PA (250μm, 
500μm, 1500μm) for 3, 6 and 24 hours, the lipid was visualized by ORO a dye that 
stains neutral TAG and lipids red and images were taken of cells (see representative 
images in Figure 5.1).  The ORO dye was then solubilized and quantified.  We found 
in the Huh7.5 cells there were increased lipid accumulations with increasing 
incubation time with OA and accumulation appeared more pronounced with OA than 
PA see images in Figure 5.1 and Figure 5.2 ORO values, however this was also 
associated with increased cell loss with time (see images in Figure 5.1).  Furthermore 
there appeared to be presence of both macro and microvesicular accumulation of 
lipids in cells, (macrovesicular steatosis shown by black arrow and microvesicular 
shown by blue arrow in Figure 5.1).  Raw ORO values revealed that at 6 hours there 
was a significant increase in OA accumulation at all concentrations.  
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Figure 5.1: Accumulation of free fatty acids in Huh7.5 cells 
Accumulation of FFAs and ORO staining in Huh7.5 cells.  Cells were treated with 
OA or PA at 250μm, 500μm and 1500μm for 6 or 24 hours.  Cells were fixed, and 
stained with ORO.  Representative pictures from N=4, black arrow in oleic acid 
treated at 500μm for 24 hours indicates presence of macrovesicular steatosis and blue 
arrow indicates microvesicular steatosis.  Pictures captured at 40X original 
magnification.    
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Figure 5.2: Dose and time dependent accumulation of free fatty acids in Huh7.5 
Huh7.5 cells were treated with OA or PA at 250μm, 500μm and 1500μm for 3, 6 or 
24 hours.  Cells were fixed, and stained with ORO.  ORO was then solubilized and 
quantified on a spectrophotometer.  Representative graphs from N=3 +/- SEM.  
Significance expressed as * p<0.05, **p<0.01, ***p<0.001.  
 
 
The same response was noted for endothelium, which incorporated a smaller amount 
of lipid than the hepatocytes but still exhibited toxicity at high concentrations (see 
representative images for OA uptake in Figure 5.3). Here raw ORO values revealed 
an increase in uptake with time which was significant at 250μm for 24 hours, 500μm 
3 hours and 1500μm 3 and 6 hours (Figure 5.4).  HSEC were also treated with PA 
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however this was associated with toxicity even at the lowest dose 250μm at all time 
points (data not shown).  
 
Figure 5.3: Accumulation of oleic acid in HSEC 
Accumulation of OA and ORO staining in HSEC.  (A) control, (B) 250μm and (C) 
500μm OA treatment for 24 hours. Cells were fixed and stained with ORO.  
Representative pictures from N=4.  Pictures captured at 40X original magnification  
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Figure 5.4: Dose and time dependent accumulation of oleic acid in HSEC 
HSEC cells were treated with OA at 250μm, 500μm and 1500μm for 3, 6 or 24 hours.  
Cells were fixed, and stained with ORO.  ORO was then solubilized and quantified on 
a spectrophotometer.  Representative graphs from N=3 +/- SEM.  Significance 
expressed as * p<0.05, **p<0.01, ***p<0.001.  
 
Although the raw ORO values allowed us to see that OA was more potent in 
accumulating in cells than PA, our visual assessment (Figure 5.1) clearly revealed cell 
loss and thus these results made it necessary for us to incorporate assessment of cell 
number into our FFA accumulation assays to permit normalization to number of cells.  
Therefore we constructed cell number calibration curves for cells grown at densities 
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ranging from 8000 to 100,000 cells per well and labeled with Hoechst dye.  Graphs of 
cell number versus fluorescent signal were generated and then used to check cell 
numbers following treatments to permit adjustment for any loss of cells.  
Representative calibration curves for Huh7.5 and HSEC are shown in Figure 5.5. 
 
Figure 5.5: Determination of cell number using Hoechst dye 
(A) Huh7.5 or (B) HSEC cells were seeded at densities ranging from 8000 to 100,000 
cells per well for 24 hours.  Cells were fixed and stained with Hoechst dye. A 
standard curve was generated as above and only used if the R
2
 value was ≥ 0.9.  
Representative graphs from N=3 +/- SEM.   
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Next we treated Huh7.5 with 250μm, 500μm and 1500μm OA or PA for up to 3, 6 
and 24 hours to determine normalized lipid accumulation within the cells. The 
corrected ORO values for Huh7.5 (obtained using Hoechst dye calibration curves) 
treated with OA show that there is an increase in OA uptake with time and 
concentration and at 500μm there seems to be a reduction in lipid uptake compared to 
250μm at 24hours in the PA treated Huh7.5 (Figure 5.6B).  This was not clear from 
the raw ORO values obtained earlier (Figure 5.2).  For all concentrations the greatest 
uptake seems to be at 24 hours (Figure 5.6, data for 1500μm not shown).  A similar 
trend was seen were OA appeared to be more potent in accumulating in cells than PA 
(Figure 5.6).  The corrected ORO values for HSEC suggest there is greater 
accumulation of OA at 250μm and 500μm for 24 hours (Figure 5.7) and although the 
images in Figure 5.3 show cell loss, HSEC do appear to have lipid in them (see 
images in Figure 5.3).   
 
Thus for all subsequent experiments we choose 250μm as our concentration as there 
was minimal cell death and good accumulation of FFAs with a time point of 6 and 24 
hours for either functional assays or gene analysis.  
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Figure 5.6: Quantification of free fatty acids in Huh7.5 
Huh7.5 cells were treated with (A) OA or (B) PA at 250μm or 500μm for 3, 6 or 24 
hours.  Cells were fixed and stained with ORO or Hoechst dye.  ORO was solubilized 
and quantified on a spectrophotometer and fluorescent readings taken of Hoechst dye 
treated plates. The ORO values were then manipulated to express the amount of ORO 
taken per 100,000 cells using the Hoechst dye readings.  Representative graphs from 
N=3 +/- SEM.  Significance expressed as p<0.001*** using a two way ANOVA. 
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Figure 5.7: Quantification of oleic acid in HSEC 
HSEC cells were treated with OA or PA at 250μm, 500μm for 3, 6 or 24 hours.  Cells 
were fixed and stained with ORO or Hoechst dye.  ORO was solubilized and 
quantified on a spectrophotometer and fluorescent readings taken of Hoechst dye 
treated plates. The ORO values were then manipulated to express the amount of ORO 
taken per 100,000 cells using the Hoechst dye readings.  Representative graphs from 
N=4 +/- SEM.  Significance expressed as p<0.001*** using a two way ANOVA. 
 
 
5.3.2 Expression of Lipid transporters alters after treatment of cells with free 
fatty acids 
We have demonstrated that 24 hours treatment with either OA or PA treatment at 
250μm results in accumulation of lipid in cells and minimal cell death OA>PA 
(Figures 5.6 and 5.7).  Thus we collected RNA from Huh7.5 treated with either 
250μm OA or PA for 24 hours and used qPCR to measure transcript levels of FATPs 
1-6, FABPs 1-7, CAV1, CD36, LRP1, LRP2 and LRP8.  Results were normalized to 
the house keeping genes β-actin and GAPDH and expressed relative to untreated 
Huh7.5, which was set as 1.  Pretreatment of Huh7.5 with unsaturated FA (OA) 
resulted in significant increase in CAV1, LRP1, LRP2, LRP8 and FATP6 mRNA 
(Figure 5).  In contrast use of saturated FA (PA) resulted in mRNA for most 
transporter proteins being downregulated or unchanged, except FATP6 and FATP3 
(Figure 5.8B). A notable exception was FATP6, which was highly upregulated by 
both FA. 
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Figure 5.8: Analysis of fatty acid trafficking proteins in Huh7.5 after treatment 
with free fatty acids by quantitative qPCR analysis 
mRNA expression of (A) FABP1-7, CAV1, CD36, LRP1, LRP2, LRP8 and (B) 
FATP1-6 after FFA treatment.  Huh7.5 were treated with OA or PA at 250μm for 24 
hours.  RNA was extracted and mRNA expression was carried out using a fluidigm 
qPCR array
®
 and run on triplicate arrays.  Results are expressed as the mean fold 
change in gene expression normalized to pooled endogenous controls β-actin and 
GAPDH relative to control Huh7.5 defined as 1.  N=3 +/- SEM.  Significance 
expressed as * p<0.05, **p<0.01, ***p<0.001 using a one way ANOVA with 
Bonferroni post correction.  
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5.3.3 VAP-1 regulates lipid accumulation in Huh7.5 
Next we tested whether VAP-1 enzyme activity was able to modulate the way Huh7.5 
responded to supply of exogenous FAs. We chose to test only OA in these 
experiments, since the pilot studies (Figure 5.1 and Figure 5.6A) suggested this had 
the greatest and most reliable effect on lipid accumulation. Therefore Huh7.5 were 
pretreated with MA, VAP-1 and hydrogen peroxide, and combinations of specific 
enzyme inhibitors for MAO and LOX prior to provision of OA for 6 hours.  Figure 
5.9 shows that methylamine+VAP-1, and the by-product of SSAO activity hydrogen 
peroxide all result in enhanced lipid accumulation in hepatocyte cells. This is 
confirmed by the representative images in Figure 5.10.  Specific inhibition of SSAO 
using BEA had only a modest inhibitory effect, but interestingly when the inhibitors 
for MAOA and MAOB were added in combination with methylamine+VAP-1 there 
was a significant increase in lipid accumulation.  Furthermore combination of 
methylamine+VAP-1+BAPN resulted in a decrease in OA uptake when compared to 
methylamine+VAP-1 alone.  
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Figure 5.9: Assessment of oleic acid accumulation after VAP-1 stimuli  
Accumulation of OA after VAP-1 stimulation.  Huh7.5 were pretreated with either 
methylamine 200μm, H2O2 10μM, BEA 400μm, BAPN 250μm, or in combination 
with methylamine+VAP-1, methylamine+VAP-1+BEA, methylamine+VAP-1+C+P 
(C+P at 200μm), methylamine+VAP-1+BAPN, methylamine+VAP-
1+BEA+C+P+BAPN for approximately 18 hours and then 6 hours with 250μm OA.  
Huh7.5 cells were fixed and stained with either ORO or Hoechst dye.  ORO was 
solubilized and signal normalized to per 100,000 cells.  N=3 from +/- SEM.  
Significance expressed as * p<0.05, **p<0.01.  
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Figure 5.10: Visual assessment of oleic acid accumulation after VAP-1 
stimulation 
Huh7.5 were pretreated with either H2O2 10μM, BEA 400μm, BAPN 250μm, or in 
combination with methylamine (200μm)+VAP1 (500ng), methylamine+VAP-1+C+P 
(C+P at 200μm), methylamine+VAP-1+BEA+C+P+BAPN for approximately 18 
hours and then 6 hours with 250μm OA.  Huh7.5 cells were fixed and stained with 
ORO and representative images were captured at 40X original magnification.  N=3. 
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5.3.4 Lipid deposits can be visualized in freshly harvested tissue specimens 
Before we assessed the role of VAP-1 in lipid accumulation in our novel ex-vivo 
model we began by identifying the morphological appearance of normal and diseased 
tissue (normal, steatotic, NASH, ALD and PBC) using H&E and visualization of lipid 
deposits by ORO.  H&E staining revealed normal liver architecture in the normal 
liver (hepatocytes shown by arrow, Figure 5.11).  In contrast, the steatotic liver shows 
presence of macro (shown by black arrow, Figure 5.11) and microvesicular steatosis 
(shown by red arrow, Figure 5.11), which was confirmed with ORO (macrovesicular 
steatosis shown by black arrow and microvesicular steatosis, shown by blue arrow, 
Figure 5.11).  The NASH and ALD livers show presence of inflammatory cells 
(shown by black arrows, Figure 5.11) and steatosis (shown by red arrows, Figure 
5.11).  PBC livers revealed loss of normal liver architecture and presence of bile in 
the liver parenchyma (shown by arrow, Figure 5.11).  In Sirius red stained NASH, 
ALD and PBC livers, arrows indicate presence of large fibrotic tissue. In support of 
this, Image J analysis revealed significant more lipids in steatotic, NASH, ALD and 
PBC livers compared to normal based on the sampled area in five fields of view for 
each disease (Figure 5.12).   
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Figure 5.11: Morphological appearance of normal and diseased liver tissue. 
Histological staining on acetone fixed frozen normal, steatotic, NASH, ALD and PBC 
livers with H&E, ORO staining and Sirius red staining. Images were captured at 20X 
original magnification.  Images shown are representative from N=4 for ALD and N=3 
for all other diseases.  Arrows in H&E stained normal liver represents normal 
hepatocytes, in steatotic liver black arrow indicates macrovesicular steatosis and red 
arrow microvesicular, black arrows in NASH and ALD show inflammatory cells, red 
arrows indicate presence of steatosis.   In PBC livers black arrow indicates bile.  
Black arrow in ORO stained steatotic liver indicates macrovesicular steatosis and blue 
arrow indicates microvesicular steatosis, black arrows in all other diseases indicate 
presence of steatosis.  In Sirius red stained NASH, ALD and PBC livers arrows 
indicate presence of large fibrotic tissue.   
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Figure 5.12: Image J analysis of lipid in normal and diseased tissue 
Normal, steatotic, NASH, ALD and PBC livers were stained with ORO. Images were 
taken of representative fields of view, and amount of ORO staining was quantified by 
threshold analysis using Image J. Data represented as the % area stained positive in 
five high power fields, from N=4 for ALD and N=3 for all other diseases +/- SEM. 
Significance expressed as ***p<0.001. 
 
 
5.3.5 Use of PCLS to model lipid homeostasis in human liver 
5.3.5.1 PCLS can accumulate lipid in culture  
Since this thesis set out to examine potential regulators of lipid accumulation we 
wanted to ensure our novel ex-vivo system responded to lipids.  We chose to use OA 
only in these initial experiments, since our earlier data suggested this had the greatest 
and most reliable effect on lipid accumulation.  Thus we added exogenous OA to the 
PCLS culture media and assessed whether we could regulate accumulation.  MTT 
assay revealed viability of slices was not reduced following incubation with either 
250μm or 500μm OA and if anything we observed an increase (Figure 5.13).  
Viability was maintained after treatment with OA at 500μm and of note also increased 
significantly compared to control (Figure 5.13B).  ORO staining and solubilisation of 
fixed PCLS revealed significant uptake of 250μm OA at 6 and 24 hours which 
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increased with time (Figure 5.14A), similarly OA at 500μm also caused significant 
uptake compared to control at 3 and 24 hours, however 500μm of OA at 6 hours 
resulted in less uptake compared to the other two time points (Figure 5.14B). 
Maintenance of viability following treatment was confirmed by morphological 
assessment of PCLS. Figure 5.15 shows, that architecture of tissue were maintained at 
3, 6 and 24 hours after 250μm OA treatment.  Furthermore ORO staining revealed 
that although endogenous lipid was present in the liver samples (shown by arrow, 
Figure 5.15) there was presence of microvesicular droplets at 6 hours (shown by 
arrows, Figure 5.15) and both micro (shown by blue arrow, Figure 5.15) and macro 
vesicular droplets at 24 hours (shown by black arrow, Figure 5.15). In addition when 
PCLS were treated with 500μm OA the presence of large lipid filled vacuoles were 
evident (shown by arrows on H+E stains in, Figure 5.16).  This accumulation of lipid 
following treatment was confirmed by ORO staining (shown by black arrows, Figure 
5.16) and quantification (Figure 5.14B) suggesting increase in accumulation at both 
250μm and 500μm at 24 hours with indication of earlier accumulation at 3 hours with 
500μm OA.  
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Figure 5.13: Viability of PCLS after free fatty acid treatment  
Viability of PCLS in culture after treatment with OA at (A) 250μM and (B) 500μM 
OA for 3, 6 and 24 hours using the MTT assay.  MTT signal normalized to per 500mg 
of tissue and data represented as % viability compared to control at 0 hours.  N=3 
from resected normal livers +/- SEM. Significance expressed as * p<0.05, ** p<0.01, 
***p<0.001. 
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Figure 5.14: Assessment of lipid accumulation in PCLS  
(A) Accumulation of OA at 250μM and (B) 500μM for 3, 6 and 24 hours.  PCLS 
were cultured with OA with the indicated time points.  PCLS were fixed and stained 
with ORO.  ORO was solubilized and signal normalized to per 500mg of tissue.  N=3 
from resected normal livers +/- SEM.  Significance expressed as * p<0.05, 
***p<0.001.   
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Figure 5.15: Morphological appearance of PCLS after 250μm oleic acid 
treatment 
Histological staining of PCLS at time 0 (control), 3, 6 and 24 hours treated with 
250μm OA and stained with H&E and ORO.  Control stained with ORO, arrow 
indicates presence of endogenous lipid.  Black arrows at 6 hours and blue arrow at 24 
hours indicate microvesicular steatosis and also macrovesicular steatosis at 24 hours 
indicated by black arrow.  Representative images were captured at 20X original 
magnification from N=3 resected livers.   
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Figure 5.16: Morphological appearance of PCLS after 500μm oleic acid 
treatment  
Histological staining of PCLS at time 0 (control), 3, 6 and 24 hours treated with 
500μm OA and stained with H&E and ORO.  Arrow in H&E stained PCLS at 6 hours 
indicates loss of cellular architecture and arrow at 24 hour indicates presence of large 
vacuoles confirmed as macrovesicular steatosis with ORO staining, shown by arrows. 
Representative images were captured at 20X original magnification from N=3 
resected livers 
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5.3.5.2 VAP-1 and its substrate methylamine modify lipid accumulation in 
PCLS 
Next we used the FA exposure model to test whether VAP-1 enzyme activity had any 
impact upon hepatic lipid accumulation. We began by using histology to confirm that 
our treatments were not toxic. Figure 5.17 confirms maintenance of tissue architecture 
in a representative normal liver following treatment with recombinant VAP-1 or 
methylamine or in combination with VAP-1+methylamine.   
 
Figure 5.17: Morphological appearance of Cultured PCLS after VAP-1 
stimulation 
PCLS were cultured with either methylamine 200μm or VAP-1 500ng alone or in 
combination with methylamine and VAP-1 for approximately 18 hours. Controls were 
cultured in media alone for 18 hours. They were then fixed and cryosectioned for 
H&E staining. Images were captured at 20X and 40X original magnification.  
Representative images from N=3 resected/donor livers.   
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We tested the optimal time for which we should expose slices to FFAs after 
stimulation with VAP-1 reagents (since this may be different in a multi cellular 
environment than our single cell based system earlier) in order to determine effects on 
lipid accumulation. Both OA and PA were examined at 250μm for 3, 6 and 24 hours, 
Figure 5.18 shows that there was a significant increase in lipid accumulation 
compared to control after pretreatment with VAP-1 or a combination of VAP-1+MA 
at 6 hours for both OA and PA (Figure 5.18), this effect disappeared following longer 
lipid exposures (24 hours, data not shown).  Treatment with methylamine alone had 
little effect on lipid accumulation at 6 or 24 hours, but we did note an effect at very 
early time points (3 hours, data not shown), which also occurred if VAP-1 was used in 
isolation.  
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Figure 5.18: Assessment of 250μm oleic and palmitic acid accumulation after 
VAP-1 stimulation. 
(A) Accumulation of 250μm OA and (B) PA after stimulation for 6 hours.  PCLS 
were pretreated with either methylamine 200μm or VAP-1 500ng or a combination of 
VAP-1+methylamine for approximately 18 hours and then for 6 hours with 250μm 
OA or PA.  PCLS were fixed, and stained with ORO.  ORO was solubilized and 
signal normalized to per 500mg of tissue.  N=3 from resected normal livers +/- SEM.  
Significance expressed as * p<0.05, **p<0.01, ***p<0.001.  
 
The specificity of this response was then tested by exposing PCLS to substrates for 
VAP-1 (MA: methylamine and BA: benzylamine), by products of VAP-1 enzyme 
activity (hydrogen peroxide) and specific inhibitors of both VAP-1/SSAO (BEA), 
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(BAPN: LOX inhibitor), and other MAOs Chlorgyline (C) and Pargyline  (P) 
(inhibitors of MAOA and B respectively).  Insulin treatment was also used as a 
positive control to stimulate lipogenesis within the PCLS.  
 
Figure 5.19 shows that OA and insulin pretreatment leads to lipid accumulation in 
PCLS.  BA appeared to be more potent in accumulating lipid than MA (Figure 5.19, 
panel A and B).  VAP-1 added in alone appeared to be very potent at driving lipid 
accumulation and although MA/BA+VAP-1 treatment led to greater accumulation 
when compared to OA alone there was an interesting reduction versus VAP-1 alone.  
BEA specifically inhibited the MA/BA+VAP-1 response, and hydrogen peroxide had 
a modest effect.  Furthermore pretreatment with MA/BA+VAP-1 with either BAPN 
or C and P did not result in an inhibition and if anything we saw an increase in 
accumulation with MA/BA+VAP-1+C+P (Figure 5.19 panel A and B).  Interestingly 
when the inhibitors were added in alone there was an increase in lipid uptake 
compared to OA (Figure 5.19, panel C).   
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Figure 5.19: Assessment of oleic acid accumulation after VAP-1 activation   
Accumulation of OA after VAP-1 stimulation using (A) methylamine, (B) 
benzylamine or (C) inhibitors alone.  PCLS were pretreated with either insulin 0.10 
IU, methylamine 200μm, benzylamine 200μm, VAP-1 500ng, H2O2 10μM, BEA 
400μm, BAPN 250μm, C+P both at 200μm or in combination with 
methylamine+VAP-1, methylamine+VAP-1+BEA, methylamine+VAP-1+BAPN, 
methylamine+VAP-1+C+P, benzylamine+VAP-1, benzylamine+VAP-1+BEA, 
benzylamine+VAP1+BAPN, benzylamine+VAP-1+C+P for approximately 18 hours 
and then 6 hours with 250μm OA.  PCLS were fixed, and stained with ORO.  ORO 
was solubilized and signal normalized to per 500mg of tissue.  N=3 from resected 
normal livers +/- SEM.  Significance expressed as * p<0.05, **p<0.01, ***p<0.001.  
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Interestingly when we used the saturated FA, PA we found that there was a small 
effect of VAP-1 alone compared to when unsaturated OA was used, however there 
was still a significant accumulation of lipid versus PA alone (Figure 5.20).  
Furthermore we found that BAPN and not BEA or C+P inhibited the VAP-1+MA 
response and interestingly we found that when BA was used as the substrate in 
combination with VAP-1+BA+BAPN or VAP-1+BA+C+P there was a significant 
increase in lipid accumulation compared to when VAP-1+BA was added in alone.  
Thus we tested whether the inhibitors themselves had any effect on lipid 
accumulation (Figure 5.19 panel C and Figure 5.20 Panel C), and interestingly we 
found that BAPN and C+P enhanced lipid accumulation compared to either OA or PA 
added in alone and that OA effects were more potent, however this effect was 
significant in PA treated PCLS only.  Overall when comparing the pretreatment of 
PCLS with VAP-1 and its substrates/metabolites and subsequent stimulation of OA 
and PA we found that those treated with OA resulted in the largest accumulation 
(Figure 5.19).   
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Figure 5.20: Assessment of palmitic acid accumulation after VAP-1 activation   
Accumulation of PA after VAP-1 stimulation using (A) methylamine, (B) 
benzylamine or (C) inhibitors alone.  PCLS were pretreated with either insulin 0.10 
IU, methylamine 200μm, benzylamine 200μm, VAP-1 500ng, H2O2 10μM, BEA 
400μm, BAPN 250μm, C+P both at 200μm or in combination with 
methylamine+VAP-1, methylamine+VAP-1+BEA, methylamine+VAP-1+BAPN, 
methylamine+VAP-1+C+P, benzylamine+VAP-1, benzylamine+VAP-1+BEA, 
benzylamine+VAP1+BAPN, benzylamine+VAP-1+C+P for approximately 18 hours 
and then 6 hours with 250μm PA.  PCLS were fixed, and stained with ORO.  ORO 
was solubilized and signal normalized to per 500mg of tissue.  N=3 from resected 
normal livers +/- SEM.  Significance expressed as * p<0.05, **p<0.01, ***p<0.001.  
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5.3.5.3 Quantification of triglyceride secretion in PCLS after VAP-1 
stimulation  
In order to assess whether the increase in accumulation after VAP-1 and its stimuli 
was due to a decrease in triglyceride secretion we carried out a triglyceride secretion 
assay.  We tested supernatants from samples where FFA accumulation had been 
tested with PA and pretreatment with MA, VAP-1, hydrogen peroxide or combination 
of VAP-1+MA, VAP-1+MA+BEA, VAP-1+MA+C+P, VAP-1+BA.   We found that 
compared to control in all treatments tested there was a decrease in triglyceride 
secretion and addition of specific inhibitors for example in VAP-1+MA+BEA treated 
samples there appeared to be more triglyceride secretion compared to VAP-1+MA 
this is supportive of our earlier data (see Figure 5.20A) were there is a small decrease 
in accumulation when comparing VAP-1+MA and VAP-1+MA+BEA.  Furthermore 
supernatants from VAP-1+MA and VAP-1+MA+C+P had similar levels of 
triglyceride secretion again supporting our earlier data (see Figure 5.20A).   
 
Figure 5.21: Assessment of triglyceride secretion after VAP-1 stimulation in 
PCLS 
PCLS were pretreated with either, methylamine 200μm, VAP-1 500ng, H2O2 10μM, 
or in combination with methylamine+VAP-1, benzylamine+VAP-1, 
methylamine+VAP-1+BEA, methylamine+VAP-1+C+P, for approximately 18 hours 
and then 6 hours with 250μm PA.  Supernatants were collected after treatments and 
triglyceride secretion quantified.  N=3 from resected normal livers +/- SEM.   
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5.3.6 VAP-1 deficient animals exhibit reduced steatosis in response to a high fat 
diet 
Next we wanted to check whether VAP-1 deficient mice had altered lipid 
accumulation compared to WT mice fed on a HFD.  Interestingly ORO staining and 
quantification of WT and VAP-1 KO mice revealed a significant reduction of lipid in 
the VAP-1 deficient mice (Figure 5.22A) and this was also evident visually (Figure 
5.22B).    
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Figure 5.22: Assessment of lipid accumulation in WT and VAP-1 KO mice 
Accumulation of lipid in WT and VAP-1 KO mice fed on a high fat diet for 12 weeks.  
(A) Livers from WT and VAP-1 KO mice were stained with ORO, which was then 
solubilized and expressed relative to protein concentration for each group of mice, +/- 
SEM.  Significance expressed as **p<0.01.  (B) ORO images of WT and VAP-1 KO 
mice, representative images from N=3  (Mouse samples obtained from Lee Claridge). 
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5.3.7 VAP-1 and methylamine alter the expression of fatty acid trafficking 
proteins in PCLS 
In order to begin to determine the mechanism by which VAP-1 and methylamine 
resulted in increased lipid accumulation in tissue slices after FA exposure we used 
qPCR to measure the mRNA transcript levels of the FATP1-6, FABP1-7, CAV1, 
CD36, LRP1, LRP2 and LRP8 in PCLS after treatment (VAP-1 interventions only).  
Results were normalized to the house keeping genes β-actin and GAPDH and 
expressed relative to control PCLS, which were set as 1.  Pretreatment of PCLS with 
methylamine resulted in an increase in mRNA expression of FABP2 and LRP1 and 
there was a trend for downreguation of all other transporters except FABP4, which 
remained unchanged (Figure 5.23), methylamine also caused an increase in mRNA 
expression for FATP3 and FATP6, with a suggestion of increased FATP4.  
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Figure 5.23: Analysis of fatty acid trafficking proteins in PCLS after 
methylamine treatment by quantitative qPCR analysis 
mRNA expression of the fatty acid trafficking proteins (A) FABP1-7, CAV1, CD36, 
LRP1, LRP2 and LRP8 and (B) FATP1-6 after VAP-1 stimulation with methylamine.  
PCLS were treated with methylamine 200μm for approximately 4.5 hours.  RNA was 
extracted and mRNA expression was carried out using a fluidigm qPCR array
®
 run on 
triplicate arrays.  Results are expressed as the mean fold change in gene expression 
normalized to pooled endogenous controls β-actin and GAPDH relative to control 
livers defined as 1 +/- SEM with means from two normal resected livers.  
Significance expressed as ***p<0.001 using a one way ANOVA with Bonferroni post 
correction.  
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5.4 Discussion  
VAP-1 has been shown to have a role in storage and distribution of lipids (Yu et al., 
2002), (Carpene et al., 2006), (Marti et al., 2001), (Stolen et al., 2004a) thus this 
thesis set out to examine the potential contribution of VAP-1 in accumulating lipid in 
the liver.  In this chapter we show that VAP-1 has the ability to regulate lipid 
accumulation in Huh7.5 cells and in human PCLS.  Furthermore VAP-1 deficient 
mice show reduced steatosis fed on a HFD and endogenous activation of VAP-1 by 
its substrate MA enhances expression of FABP2, LRP1, FATP2, FATP3, FATP4 and 
FATP6 in liver tissue. 
 
5.4.1 Free fatty acids induce altered levels of steatosis  
The hallmark of NAFLD is the presence of TAG in the liver and although the roots of 
these lipids is unknown there have been many speculations that the pathophysiology 
of NAFLD and NASH is due to an influx of FFA from adipocytes (Chen et al., 1987), 
(Frayn, 2001) as result of inhibition of lipolysis in the IR state or from increase flux of 
FFA from the diet.  In particular two FFA the monounsaturated OA and saturated PA 
have been found at high levels in NAFLD and NASH patient serum (de Almeida et 
al., 2002), (Araya et al., 2004) and are abundantly available in serum and via the diet, 
thus we wanted to study the effects of these two FFA in particular.     
 
We found that there was a clear time and dose dependent increase in FFA 
accumulation in Huh7.5 cells however this was associated with increasing cell loss 
with, increasing time and concentration for example at 1500μm. These toxic effects 
have been reported previously (Malhi et al., 2007), (Malhi et al., 2006), (Ricchi et al., 
2009). Furthermore using our basic ORO colorimetric method and visual assessment 
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OA appeared to be more steatogenic and less toxic than PA.  These findings support 
others where PA has been shown to induce apoptosis in cells (Ahn et al., 2013), and 
has been shown to poorly incorporate lipid in droplets (Mei et al., 2011).  Furthermore 
combined treatment of OA and PA has been shown to protect cells from apoptosis 
(Ahn et al., 2013) suggesting a protective role for OA.  In support of this PCLS 
treated with OA, if anything have an increase in viability (Figure 5.13). Interestingly 
we noticed presence of both macro and microvesicular steatosis in Huh7.5 treated 
with OA and this finding is consistent with clinical features of NAFLD and NASH 
and may be due to the presence of PAT proteins which have been associated with 
different sizes of lipid droplets (Straub et al., 2008).  
 
We also looked at the effects of OA on HSEC since HSEC and hepatocytes are in 
close proximity in vivo and their unique fenestrations allows passage of materials to 
hepatocytes they have the ability to exacerbate disease pathogenesis.  We found for 
the first time that human HSEC accumulated lipid with minimal toxicity at the lowest 
dose tested for the longest time point.  Overall lipid accumulation was less than that 
seen in hepatocytes which may suggest that FAs would normally be rapidly utilized or 
possibly passed on to underlying cells via the fenestrations. Studies suggest that 
uptake of lipids by endothelium is sensitive to VEGFB (Hagberg et al., 2010), which 
would be abundant in the liver environment, and subsequently passed onto the 
surrounding tissue for use for example Hagberg et el showed that VEGFB regulates 
the transcription of FATP through PI3-K dependent pathway and thus the subsequent 
uptake of LCFA, in addition they showed VEGFB KO mice showed reduced lipid 
accumulation in the liver, heart, muscle, and brown adipose tissue and that surplus 
lipids were shunted to white adipose tissue (Hagberg et al., 2010).    
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5.4.2 FFA induce expression of fatty acid trafficking proteins in Huh7.5 
FFAs provide fuel for the accumulation of TAG in the liver and pathogenesis of 
NAFLD and NASH, and so understanding the regulation of their uptake may have 
clinical relevance. We found that OA induced expression of FABP2, CAV1, LRP1, 
LRP2, LRP8 and FATP4 whilst both OA and PA induced expression of FATP3, 
FATP5 and FATP6, and in contrast FABP3 was down regulated by OA.  To our 
knowledge this is the first study to document the effects of OA or PA on fatty acid 
trafficking proteins in Huh7.5 cells.  However OA induced expression of LRP1 has 
been reported in adipocytes were OA activates PPARγ-induced expression of LRP1 
(Gauthier et al., 2003).  FABPs have the ability to partition lipids intracellularly to 
various metabolic fates for example FABP2 has been suggested to have a role in TAG 
synthesis (Hardwick et al., 2009), whilst FABP3 has a role in β-oxidation (Hardwick 
et al., 2009) and FATP4 in TAG synthesis and β-oxidation (Hardwick et al., 2009).  
This fits with our observations where OA increased expression of FABP2 resulting in 
intracellular accumulation of TAG and in contrast FABP2 was down regulated in PA 
treated Huh7.5 cells which had poor accumulation of TAG. The down regulation of 
FABP3 fits with storage of lipid rather than oxidation.  In contrast FATP4 may 
initially regulate TAG synthesis, which then switches to β-oxidation when the cell 
requires energy.  FATP3, FATP5 and FATP6 were upregulated by both OA and PA 
but the functions of these are unknown. However it is speculated that FATP3 may be 
involved in FA activation rather than transport (Pei et al., 2004), whilst FATP5 
increase expression has been shown to increase hepatic FA uptake (Doege and Stahl, 
2006), this fits with our results were we see increase expression of FATP5 and hence 
more intracellular lipid accumulation in OA treated cells compared to PA. Of note in 
Chapter 3 we found FATP6 mRNA expression upregulated in NASH and ALD livers, 
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but in the absence of mRNA in the cultured cell types we studied.  We speculated that 
expression is only turned on in disease or restricted to cells, which we have not 
studied. However here we show that both OA and PA acid induced expression of 
FATP6 in Huh7.5. Since FATP6 has been shown to have a role in LCFA transport 
(Gimeno et al., 2003) this suggests that its directly implicated in disease pathogenesis 
via FA induced expression.   
 
5.4.3 The activity of VAP-1 regulates lipid accumulation in Huh7.5 
Since sVAP-1 levels are elevated in liver disease it is possible that circulating sVAP-1 
and amines could have local insulinomimetic effects in hepatocytes.  During hepatic 
steatosis it is the hepatocytes which become fatty, and since our initial data in Chapter 
3 indicated there was a possibility Huh7.5 could express VAP-1 we felt it was prudent 
to use Huh7.5 as a test cell type to investigate the role of VAP-1 activity. We found 
that an exogenous supply of VAP-1+MA and the by-product of VAP-1 activity 
hydrogen peroxide all enhanced lipid accumulation in Huh7.5 cells.  This is supported 
by other studies which have shown a role for VAP-1 in lipid accumulation for 
example in the 3T3-L1 pre adipocyte cell line were administration of methylamine 
promotes adipocyte differentiation (Mercier et al., 2001) and in 3T3 F442A 
preadipocyte cells VAP-1 substrates have been shown to enhance lipid accumulation 
(Fontana et al., 2001).  Further studies have also shown antilipolytic effects of 
activated VAP-1 (Morin et al., 2001) which would also lead to accumulation within 
cells.   Interestingly we found that this effect was only modestly reduced on addition 
of BEA. Here it could be argued that BEA is not as potent an inhibiter as for example 
such as semicarbazide. However we have shown it effectively blocks VAP-1 activity 
in our glucose assays (Chapter 4) and its potency and specificity have been confirmed 
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by others (Yu et al., 2001).  Thus to rule out contribution from other AO we used 
specific inhibitors for these, and found that on addition of C+P to our samples we saw 
a further increase in lipid accumulation. This increased accumulation when MAO-A 
and B are inhibited suggested that these amine oxidases probably do not contribute to 
lipid uptake upon deamination of methylamine.  These inhibitors could instead be 
increasing viability of cells, as reported for other MAO inhibitors (Johnson et al., 
2010) or causing a compensatory upregulation of VAP-1.  Of note however, 
inhibition of LOX with BAPN resulted in a decrease in VAP+MA stimulated lipid 
accumulation.  This could suggest that LOX can deaminate MA, but this is not 
supported by evidence in the literature and rather LOX has more of a role in 
remodeling of the extracellular matrix by oxidation of lysine (Smith-Mungo and 
Kagan, 1998).  However the variability in effects of enzyme inhibitors in isolation, 
and when combined in the presence of exogenous VAP-1 suggests that alternate 
approaches with exclusively specific inhibitors and substrates, or selective KO of key 
enzymes would be worthwhile. 
 
The other important issue to clarify is the modest effects of methylamine when used 
in isolation. This may suggest a lack of endogenous VAP-1 expression by Huh7.5 
cells, which disagrees with our qPCR findings but would fit with lack of hepatocyte 
staining in liver tissue. It is possible that other endogenous or model amines such as 
benzylamine or tyramine are better substrates for VAP-1 in this system, or it may well 
be that an acute treatment of 18 hours is not sufficient to see effect. Certainly a more 
chronic treatment, for example between 7-8 days may be more potent as shown by 
some studies, which have used 3T3 F442A and 3T3-L1 cells to measure TAG content 
(Fontana et al., 2001), (Mercier et al., 2001).  
 255 
5.4.4 The role of VAP-1 in altering lipid accumulation in PCLS  
Our staining data confirmed as expected that normal/resected livers contained 
minimal endogenous lipid thus these livers were used for functional experiments.  
Treatment with either exogenous FFAs increased viability which could be due to 
enhanced proliferation of cells as has been reported previously, (Wicha et al., 1979), 
(Maedler et al., 2001).  Certainly the degree of lipid accumulation in PCLS 
corresponded with viability. It must be noted that there are problems in using 
physiological specimens for analysis of mechanisms leading to fat accumulation since 
it can be hard to distinguish between endogenous and newly synthesized lipids.  
Nevertheless we are confident this method worked well since we observed presence 
of both micro and macrovesicular steatosis after OA treatment. Future studies using 
BODIPY labeled FFA would allow us to distinguish between endogenous and 
exogenous lipids and our use of MALDI imaging and GC in the next chapter is also 
informative. 
 
We found both MA and BA enhanced lipid accumulation in PCLS and this was most 
likely due to activation of endogenous VAP-1.  These results are the first to be 
reported in the liver although VAP-1/SSAO substrate effects have been reported in 
single cell systems as discussed earlier (Mercier et al., 2001), (Fontana et al., 2001), 
(Morin et al., 2001).  Importantly similar results have been reported in vivo where 
benzylamine and vanadate causes a 45% increase in adipose tissue fat deposition in 
diabetic rats (Marti et al., 2001), and transgenic mice overexpressing VAP-1/SSAO 
chronically supplemented with methylamine have increased BMI and abdominal fat 
pad weight (Stolen et al., 2004a).  This supports the idea that the SSAO activity of 
VAP-1 influences the disposal of lipid at a variety of sites. 
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Interestingly we found that BA appeared to be more potent than MA, suggesting that 
BA may have a higher specificity/affinity for VAP-1 than MA as has been shown for 
other substrates (Yraola et al., 2006).  In agreement, MA has been proposed as having 
the lowest affinity of some endogenous substrates such as histamine, dopamine and 
also synthetic BA for VAP-1 (Lyles, 1995).  Certainly benzylamine is used in in vitro 
experiments because of its potency, but it is not a physiological ligand and thus this is 
why MA was used as it’s found in cigarette smoke and food and thus may be in the 
liver from the gut.  We noticed that when extra VAP-1 was added into the PCLS 
system there was a stark increase in lipid accumulation, which suggests the presence 
of unidentified endogenous substrates, which have higher affinity over MA for 
example such as tyramine, histamine or dopamine (Lyles, 1995). However when both 
VAP-1+MA are added, the excess of MA may permit it to function as a preferential 
substrate or a competitor with higher affinity over endogenous substrates, but is not 
able to induce the most potent effects.  This is analogous to studies by Salmi et al who 
have shown that addition of BA reduces VAP-1-dependent lymphocyte binding to 
endothelial cells. Thus they suggested BA was a competitor for the actual endogenous 
substrate for VAP-1 (Salmi et al., 2001).  However regardless of substrate specificity 
in our experiments the finding that BEA specifically inhibited the MA/BA+VAP-1 
effect, confirms that VAP-1 is altering lipid accumulation in PCLS.  Furthermore 
hydrogen peroxide elicited an effect, albeit modest, and as reiterated earlier this may 
be because of lack of bioavailability in the tissue media due to evaporation, 
breakdown by peroxidases or that a single dose of exogenously added hydrogen 
peroxide may be less effective in causing the mobilization of insulin stimulated fatty 
acid trafficking proteins and hence accumulation of lipid than locally generated 
oxidants produced by VAP-1 catalysis.   
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Further evidence that the observed lipid accumulation is due to VAP-1 and not other 
AO arose through addition of BAPN, C or P in combination with MA/BA+VAP-1. 
These inhibitors did not lead to inhibition of lipid accumulation, and if anything 
caused an increase.  We observed the same effect in Huh7.5 with MA suggesting 
substrate, FFA and possibly cell specific effects of inhibitors.  Interestingly when the 
inhibitors BAPN/C/P were added in alone we found an increase in lipid accumulation 
compared to OA alone.  These effects have not been reported previously but its 
possible as suggested earlier that blocking of AO leads to upregulation of VAP-1 
activity, or these inhibitors may be causing allosteric effects in VAP-1 thus increasing 
enzyme activity and hence increasing lipid accumulation. Of note, presence of the 
LOX inhibitor BAPN did cause a small decrease in lipid accumulation in PCLS and 
Huh7.5 in the presence of MA but not BA. This may suggest either that SSAO-
dependent deamination of MA is also inhibited by BAPN, that LOX can use MA as a 
substrate or that there are other non-specific effects of BAPN. Since administration of 
BAPN does not reduce weight gain in rat models (Mercier et al., 2009), its seems 
unlikely that LOX is involved in lipid accumulation  which points to substrate 
specific, off-target effects of BAPN.    
  
Importantly the net accumulation of lipids after VAP-1 interventions fits with our 
triglyceride export data, which shows reduced triglyceride secretion after VAP-1 
interventions and this fits with Aalto et al study who showed an inverse relationship 
between VAP-1 and triglyceride levels in serum (Aalto et al., 2012).   Thus the likely 
cell fate of lipids may be that they are either being oxidized or stored within the cell.   
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The strongest evidence for a role of VAP-1 in lipid homeostasis was supplied by our 
VAP-1 null mouse experiments. Here we found reduced steatosis when VAP-1-/- 
mice were fed on a HFD compared to WT mice. This fits with studies where specific 
inhibition of VAP-1/SSAO activity leads to a decrease in subcutaneous fat deposition 
in obese Zucker rats (Prevot et al., 2007) and that inhibition of both MAO and VAP-
1/SSAO reduces calorific intake, weight gain and also fat accumulation (Carpene et 
al., 2007). Similarly blockade of VAP-1/SSAO activity with potent inhibitors and 
semicarbazide in mice leads to a reduction in weight gain (Yu et al., 2004), (Mercader 
et al., 2011). Here the authors speculated that reduced weight gain was linked to both 
reduced glucose uptake and lipogenesis, which fits well with both our glucose uptake 
data and this chapter.  Furthermore fatty streaks in aortae developed due to chronic 
treatment with methylamine in mice fed on a high cholesterol diet are decreased when 
these mice are administered with inhibitors of SSAO activity (Yu et al., 2002).  In 
addition VAP-1/SSAO inhibitors in mice have been shown to decrease the levels of 
the toxic aldehyde malondialdehyde (MDA) which is elevated in diabetes and causes 
protein cross linking (Slatter et al., 2000).  It is a marker of oxidative stress and also a 
by product of lipid oxidation (Yu et al., 2002) mainly derived from arachidonic acid 
(Esterbauer et al., 1990). 
 
5.4.5 Activity of VAP-1 alters expression of lipid trafficking proteins  
In order to begin to understand the possible mechanism by which VAP-1 may be 
altering lipid accumulation in PCLS we assessed the levels of various fatty acid 
trafficking proteins, which we previously documented in Chapter 3.  Since VAP-1 has 
insulinomimetic effects its possible that VAP-1 activity may be accumulating lipid by 
translocation of either FATP1 or LRP1 which are both insulin sensitive transporters 
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(Stahl et al., 2002) and we have shown Huh7.5 express both.  Furthermore FATP1 has 
been reported to be expressed in the endoplasmic reticulum in Huh7.5 cells (Krammer 
et al., 2011) an organelle were the bulk of neutral lipid synthesis occurs (Sturley and 
Hussain, 2012).  Furthermore as discussed earlier OA induces expression of a number 
of fatty acid trafficking proteins for example FABP2.  
 
Similarly for the PCLS system we assessed changes in transporter expression after 
MA treatment in the absence of exogenous FAs thereby minimizing confounding 
effects from exogenously added lipid. We found FABP2, LRP1, FATP2, FATP3, 
FATP4 and FATP6 were upregulated in response to MA treatment.  As discussed in 
Chapter 3 many of these proteins have implications in the development of fatty liver. 
For example the Ala54Thr polymorphism of FABP2 has been associated with 
increased risk of fatty liver disease.  In mice livers, FATP2 KO results in improved 
insulin sensitivity and a reduction in hepatic steatosis (Falcon et al., 2010).  Similarly 
FATP4 which has been associated with obesity and IR (Gertow et al., 2004), is 
overexpressed in rat fatty liver (Feng and Chen, 2005).  Furthermore in hepatocytes 
from mice lacking LRP1, HDL export is reduced (Basford et al., 2011) and in 
adipocytes lacking LRP1 lipid uptake is impaired and lipids are directed to the liver 
resulting in hepatosteatosis (Terrand et al., 2009).  Thus it is possible that in the in 
vivo environment LRP-1 in the liver is upregulated in an attempt to remove VLDLP 
rich in TAG in the IR state.   
 
Thus a possible mechanism explaining VAP-1 derived lipid accumulation could be 
that upregulation of LRP1 leads to endocytosis and breakdown of TAG rich VLDLP 
and chylomicron remnants (Terrand et al., 2009) leading to cellular accumulation of 
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lipid.  However with almost 40 ligands for LRP1 (Herz and Strickland, 2001) further 
work would be needed to examine which ligand binds as a result of VAP-1 activity.  
Certainly in the post absorptive state, hepatic LRP1 has been shown to increase 
clearance of chylomicron remnants when it translocates to the plasma membrane in 
response to insulin (Laatsch et al., 2009).  In addition upregulation of FATP2 and 
FATP6 leads to enhanced uptake of LCFA (Gimeno et al., 2003), (Krammer et al., 
2011).  The subsequent FA would then need to be activated via FATPs by their ACS 
leading to targeting for storage or β-oxidation to the mitochondria. For example 
FATP3 has been reported to have a preferential role in activation of FA (Pei et al., 
2004). Since knockdown of FATP3 in rat hepatocytes results in a decrease in 
lipogenic transcription factors (Bu et al., 2009) disease-induced upregulation could 
contribute to steatogenesis.  The activated FA destined for storage is then associated 
with FABP2 or FATP4 which have reported roles in TAG synthesis (Hardwick et al., 
2009), with a role in β oxidation for FATP4 (Hardwick et al., 2009).  Furthermore 
FABP2 overexpression in cell lines has been linked to reduced lipoprotein export 
(Levy et al., 2009) probably due to defective trafficking of FA to regions of 
lipoprotein assimilation (Levy et al., 2009).  Of note, we found that many of these 
transporters were upregulated in NASH and ALD livers (Chapter 3).   
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Figure 5.24: Schematic showing the hypothesized role of lipid transporters in 
liver, which are elevated as a result of VAP-1 activity 
Membrane bound VAP-1-dependent catalysis of methylamine leads to production of 
hydrogen peroxide, which possibly stimulates tyrosine phosphorylation of insulin 
receptors.  This leads to LRP1 translocation to the cell membrane in a manner similar 
to insulin were it picks up chylomicron remnants and VLDLPs rich in TAG.  The 
activity of VAP-1 also leads to upregulation of FATP2, FATP6 and FABP2 which 
take up FA, these are then activated by FATP3 and targeted to either β-oxidation or 
storage were FABP2 and FATP4 have a role in formation of TAG synthesis.  
Activated FA can also be transported to nuclear receptors such as PPARs and NF-κB 
hence regulating genes, which are involved in metabolic and inflammatory processes.  
sVAP-1 and membrane bound VAP-1 production of hydrogen peroxide may also 
have local insulinomimetic effects on neighboring cells.  
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In all we have shown that the activity of VAP-1 alters development of hepatic 
steatosis in mice and, has a role in lipid accumulation in Huh7.5 and human PCLS, 
with changes in transporter expression induced by both FFA and VAP-1 activity.  In 
Chapter 4 we have shown that VAP-1 regulates glucose uptake in isolated hepatic 
cells and PCLS thus taking these Chapters together it suggests that VAP-1 in the liver 
may have the ability to drive endogenous lipogenesis through glucose uptake and 
modification of fat uptake and disposal thus exacerbating disease pathogenesis.  There 
are glucose and lipid transporters such as GLUT4, 8, 10, 12, FATP1 and LRP1 that 
are insulin sensitive, and it is likely that the activity of VAP-1 would be able to 
regulate these transporters in a manner similar to insulin.  In addition there is evidence 
to suggest these proteins work together to achieve glucose and lipid homeostasis, for 
example GLUT4 and its association with FATP1 and CD36 suggest glucose and lipid 
transport is closely regulated (Stahl et al., 2002), (Schwenk et al., 2010).  Interestingly 
SSAO, CD36, and Caveolin 1 have been found as major constituents of caveolae 
(Pilch et al., 2007), (Souto et al., 2003) and there is speculation caveolae are involved 
in GLUT4 trafficking (Scherer et al., 1994), (Gustavsson et al., 1996), (Ros-Baro et 
al., 2001), (Karlsson et al., 2002).  This provides evidence of parallel regulation of 
pathways for glucose and lipid uptake as well as driving endogenous lipogenesis from 
excess imported glucose.  It would be interesting to see whether there are differences 
in the lipid composition of VAP-1 deficient mice and PCLS treated with VAP-1 and 
their possible anatomical location and thus these are investigated in the next chapter.   
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CHAPTER 6 
 
6 USE OF MASS SPECTROMETRY AND MALDI 
IMAGING TO DETECT PATHOLOGICAL 
CHANGES IN NASH 
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6.1 Introduction  
NAFLD and NASH are a growing concern with approximately 25%-30% of the 
general population in western countries said to be suffering from the condition (Bhala 
et al., 2013), with prevalence of NASH in 3%-5% in the general population (Vernon 
et al., 2011) thus understanding of the key regulatory mechanisms is of vital 
importance, especially with difficulties in identifying and discriminating between 
these conditions.  In the preceding chapters we have illustrated the pathological 
appearance of livers from patients with NASH and quantified associated changes in 
glucose transporter molecules and components of the lipid transporter pathway.  We 
have also confirmed that the SSAO activity of VAP-1 can modulate hepatic glucose 
uptake and lipid accumulation and that livers from VAP-1 null mice have reduced 
steatosis on a HFD compared to WT controls. 
 
Alterations in transporter expression and activity of VAP-1/SSAO may result in an 
altered lipid composition and deposition in the diseased liver.  For example steatosis 
consists of both micro and macrovesicular steatosis (Kleiner et al., 2005), with 
macrovesicular steatosis associated with a poorer donor recipient outcome (de Graaf 
et al., 2012) and IR.  Whilst some lipids for example TAG are reported as “good fats” 
(Yamaguchi et al., 2007) and others as pathologically “bad fats” for example 
sphingolipids ceramide and unsaturated FA (Fujiwaki et al., 2006), (Ma et al., 2007), 
(Cowart, 2009), (Huwiler and Pfeilschifter, 2009), (Stachowska et al., 2004).  Thus 
we wanted to use techniques firstly to characterize what is happening in NASH versus 
simple steatosis and then how SSAO activity may impact on this, and thus these may 
provide potential for biomarker discovery.   
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Thus in this chapter we have performed pilot, proof of concept experiments to assess 
the validity of mass spectrometric approaches such as gas chromatography (GC), 
Matrix Assisted Laser Desorption Ionization Mass Spectrometry (MALDI-MS) and 
Matrix Assisted Laser Desorption Ionization Mass Spectrometry Imaging (MALDI-
MSI) to identify the lipidomic profiles of normal, Steatotic, NASH, ALD and PBC 
livers. We have also determined whether SSAO activity results in quantifiable 
changes in hepatic lipid profiles. We begin with some background to the technology 
used.  
 
6.1.1 MALDI 
MALDI (Karas and Hillenkamp, 1988) is a technology which provides a means for 
fast, high throughput analysis of biomolecules within a sample with high sensitivity 
and spatial resolution (Koeniger et al., 2011).  It is a combinatorial technique 
encompassing MALD-MS, which allows identification of component profiles in 
sample mixtures, and MALDI-MSI which provides information as to their spatial 
localization in thin tissue sections by desorption and ionization of samples 
(Zimmerman et al., 2008).  MALDI-MS/MSI are powerful techniques, which have 
been used to find disease biomarkers in brain for Alzheimer’s disease, epithelial 
ovarian cancer and IgA nephropathy (Rohner et al., 2005), (Huang et al., 2012), 
(Surin et al., 2013).  Importantly, MALDI-MSI allows the unbiased visualization and 
direct analysis of biomolecules within tissue (Reyzer and Caprioli, 2007), (Bunch et 
al., 2004), (Fonville et al., 2013) without disrupting cellular integrity and architecture 
and thus avoids the need for extraction and purification of samples, which is essential 
for MALDI-MS (Shrivas et al., 2010).  In comparison to conventional 
immunohistochemistry MALDI-MSI allows the detection of multiple targets in a 
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single test without the need for labeling (Bunch et al., 2004), (Caprioli et al., 1997), 
(Chaurand et al., 1999).  Furthermore these two techniques can be combined to 
correlate spectral data to histological features in a given tissue and by using this 
combined approach has led to the identification of novel protein and lipid biomarkers 
in disease (Chaurand et al., 2006), (Johnson et al., 2006), (Sparvero et al., 2012). 
However we are specifically interested in lipids in this chapter.  The most common 
lipids detected in MALDI experiments to date are the phospholipids as they easily 
ionize and are the most abundant in physiological specimens (Carter et al., 2011).  
 
6.1.1.1 Sample collection and preparation  
Sample collection for MALDI generally involves the immediate preservation and 
storage of samples by flash freezing in liquid nitrogen in order to prevent the 
degradation of tissue and rearrangement of species of interest.  For MALDI-MS a 
specialized method for extracting lipids from tissue is employed (Folch et al., 1957) 
and can be optimized for the extraction of lipids for some tissues (Abbott et al., 2013), 
(Kulkarni et al., 2012).  For MALDI-MSI tissue blocks are not digested and are 
usually mounted intact on to a cryostat cutting block using water rather than the 
conventional method of using OCT since this interferes with ion formation and mass 
spectra (Schwartz et al., 2003).  Thin tissue sections are then cut and mounted on to 
MALDI target plates.  At its simplest, sample preparation for MALDI experiments 
involves mixing the sample with an organic matrix and causing co-crystallization of 
both substances, also referred to as ‘dried droplet’ analysis in MALDI-MS. In contrast 
in the case of MALDI-MSI the matrix is usually deposited on top of a thin tissue 
section using an air brush (Hayasaka et al., 2009) as well as other methods such as 
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electrospray, inkjet printing and the use of automated acoustic multispotters (Baluya 
et al., 2007), (Aerni et al., 2006), (Altelaar et al., 2006).  The matrix-sample complex 
is then irradiated using either ultraviolet (Holle et al., 2006) or infrared lasers (Park 
and Murray, 2012), which causes ionization of molecules.  Ionization of molecules 
generally leads to protonated positive [M+H]
+
 and negative ions [M+H]
- 
which can 
include matrix ions and matrix-sample ions, however [M+Na]
+
, [M+Na]
- 
and [M+K]
+
 
[M+K]
- 
ions can also be formed due to salts or other compounds within the sample 
(Schwartz et al., 2003).  These ions are then detected using a mass spectrometer, 
usually a time of flight mass spectrometer (ToF-MS), (Chaurand et al., 2005) based 
on their mass to charge (m/z).  Thus a typical mass spectrometer has three basic 
components, an ionization source, m/z analyzer and a detector (Zimmerman et al., 
2008).   
 
Sample ions can be identified using several approaches. The simplest is by comparing 
the m/z of a test ion to that of a known control compound ionized under identical 
conditions. This can also be supported by the use of molecular mass, mass 
spectrometry MS/MS which involves the fragmentation of the parent ion to further 
characterize the component parts of complex chemicals.  This method can also be 
used to identify novel species.  In particular MS/MS can be combined with MALDI-
MSI (also referred to as tandem MSI) to form a very powerful technique for example 
to track the distribution of drugs and their metabolites (Khatib-Shahidi et al., 2006).   
 
The successful formation of ions depends on the type and thickness of matrix used, 
the tissue surface and the formation of good quality homogenous crystals (Pol et al., 
2011) thus all these parameters are usually optimized before any MALDI experiments 
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are carried out.  There are several commonly used matrices employed in MALDI, 
which include 3,5-dimethoxy-4-hydroxycinnamic acid (SA) used in the study of 
proteins and peptides (Low et al., 2004), 2-5,dihydroxybenzoic acid (DHB), for the 
study of small oligo nucleotides, glycopeptides and glycoproteins (Andersson et al., 
2008) and finally α-cyano-4-hydroxycinnamic acid (CHCA) which is used in the 
study of small proteins, peptides and glycoproteins (Gorka et al., 2012).   
 
6.1.1.2 Data collection and processing  
In MALDI-MSI, the mass spectrum of a given tissue is taken at each pixel location 
thus generating a large amount of raw data (Zimmerman et al., 2008). This data can 
be converted to produce an Analyze 7.5 dataset (Zimmerman et al., 2008) to aid 
analysis and data handling.  This information can then used to form ion images of 
interest using specific software packages such as Matlab (Clerens et al., 2006) 
(Stoeckli et al., 2002) or Biomap.  Although MALDI-MSI is a qualitative method 
(Koeniger et al., 2011) due to problems in sample homogeneity, for some molecules 
quantitative evaluation has been reported by normalization of signal to an internal 
standard (Ostrowski et al., 2007), (Goodwin et al., 2010). 
 
In order to infer differences between normal and diseased samples with such large 
data sets the use of statistical, data clustering methods such as PCA, is essential 
(Zimmerman et al., 2008).  PCA, which is commonly used for large sets of genomic 
information (Parsonage et al., 2003) allows the reduction and graphical visualization 
of the data set (Zaima et al., 2009) and has been successfully used in MALDI 
experiments to identify biomarkers (Zaima et al., 2009).   
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A further technique which can also be used to separate components of mixtures is GC 
which allows the rapid identification of volatile compounds and can serve as a non 
invasive tool for the analysis of disease biomarkers for example in breath (Dadamio et 
al., 2012), and serum (Hasokawa et al., 2012). For example in a recent study several 
compounds were identifiable in patients with liver cirrhosis which were not present in 
control subjects using GC (Dadamio et al., 2012).  Briefly for lipid analysis using GC 
lipids are derived in to their methyl esters and injected in to the GC apparatus where 
they interact with the GC column and are retained until the inert gas carrier elutes 
them. The RT of lipids is based upon their chemical properties, and data is acquired as 
a chromatogram representing peaks for the different RT.  These are then compared to 
RT to a known standard to assign a lipid identity to each peak; furthermore GC can 
separate isomers.   
 
6.1.2 Use of mass spectrometry in the study of human liver disease 
The ability for rapid unbiased assessment of compounds within valuable material 
from patients has led to an increase in the number of studies using mass spectrometry 
to assess liver disease pathogenesis. For example in a recent study several compounds 
were identifiable in patients with liver cirrhosis which were not present in control 
subjects using GC (Dadamio et al., 2012).  Similarly descriptions of such techniques 
for identifying novel biomarkers in NASH have been reported (Solga et al., 2006), 
(Feldstein et al., 2004), (Feldstein et al., 2003), (Ratziu et al., 2000) with a specific 
focus on indicators of inflammation, oxidative stress and fibrosis. Furthermore some 
studies have identified circulating lipid profiles in NASH using MS (Feldstein et al., 
2010). However to our knowledge little evidence of hepatic localization of potential 
biomarkers using MALDI-MSI has been reported (Wattacheril et al., 2013).  
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Therefore in this chapter we have used such technology to confirm whether patients 
with NASH have distinct lipidomic profiles, whether it is possible to use MALDI-
MSI to localize species expression, and whether this technology can be used to assess 
any contribution of SSAO activity to lipidomic profiles. 
 
Thus the major aims of this chapter were:  
 
(I) To describe the lipidomic profiles of normal and diseased liver tissue using mass 
spectrometry techniques  
 
(II) To assess the validity of using MALDI-MSI on human liver tissue 
 
III) To identify the lipidomic profiles of WT and VAP-1/SSAO KO mice fed on a 
high fat diet 
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6.2 Methods  
For methods pertinent to this chapter please refer to the general methods p67-70.   
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6.3 Results  
6.3.1 Identification of lipid species in normal and diseased livers using Gas 
Chromatography  (GC)  
In the previous chapters we have reported altered profiles of lipid trafficking proteins 
in disease in combination with altered amounts of steatosis within our tissue samples. 
This steatotic accumulation of TAG along with native lipids such as signaling lipids 
and membrane phospholipids will constitute the lipid signature of each tissue.   Thus 
initially we wanted to identify the profile of lipids in the normal human liver and to 
see how this changes in disease. This would form the basis to inform our 
understanding of how signaling via SSAO activity may alter this lipidomic signature.  
Thus we extracted lipids from lysates made of whole liver tissue and used GC to 
examine the profile of lipids present in normal and diseased liver. Figure 6.1 
represents an overview of this.   
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Figure 6.1: Schematic representation of workflow and of data acquired by gas 
chromatography 
Normal and diseased liver were used for the extraction of lipids.  (A) Small pieces of 
liver approximately 2cm
3/
2cm
3
 were collected from freshly harvested livers and 
immediately snap frozen. Upon requirement samples were mechanically disrupted 
and homogenized, (B) lipids were then extracted using the Folch method, this mixture 
of lipids (C) was then injected in to the Gas Chromatograph (D). The methyl ester 
derivatives of the lipids interacted with the walls of the column inside the Gas 
Chromatograph causing the lipids to elute at different time points.  The retention time 
data acquired is shown as a chromatogram (E) with peaks for the different retention 
times of individual lipids, these are then compared to retention times of a known 
standard analyzed under identical conditions to assign a lipid identity to each peak.   
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Our pilot GC analysis of lipid extracts from normal and diseased livers confirmed that 
this method was useful for analysis of human samples and revealed some key 
differences in lipid composition. Figure 6.2A shows a representative chromatogram 
from normal liver with red circles highlighting species present in normal but not 
NASH liver, see chromatogram in Figure 6.2B. For example the saturated FA 
myristate and the polyunsaturated FA gamma linolenate were detected in only 
steatotic livers, as well as a further lipid with a RT of 20.83 (Figure 6.2C).  
Furthermore a lipid with RT of 20.48/20.49 was only detected in normal livers 
(Figure 6.2C).  Interestingly we found a lipid species with an RT of 32.6, which was 
present in all liver samples except NASH. Unfortunately these lipids with RT of 
20.83, 20.48/20.49 and 32.6 could not be assigned as they, were not present in the 
standards we used (Figure 6.2C).  We were only able to perform this analysis on 
limited numbers of samples and interestingly we found some lipid species, which 
were not detected in both samples from the same disease state.  For example 
palmitoleate and a lipid with an RT of 24.53 were detected in normal liver 1 only and 
Gamma linolenate was detected in only one steatotic sample. (Figure 6.2C).    
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Figure 6.2: Analysis of fatty acid components of lipids in normal and diseased 
livers using GC   
Lipid extracts of normal, steatotic, NASH, ALD and PBC livers were derived to 
methyl esters and analysis of lipid components was carried out using GC. Typical 
examples of GC chromatograms from normal (A) and NASH liver lipid extracts are 
shown. Red circles in the normal chromatogram (A) indicate peaks, which are present 
in normal but not NASH liver.  A standard solution containing 37 methyl esters was 
also run along side the liver extracts and the RT time for each eluate (normal and 
diseased) was assigned to lipids by comparing with the standard. A summary table of 
RT of FA in normal and diseased livers with their lipid assignments is also shown 
(C). RT indicated in red are those found in the particular disease state.  Data shown 
are from several livers (normal N=2, Steatotic N=2, NASH N=1, ALD N=1 and PBC 
N=1) with triplicate values determined for each sample.   
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6.3.2 Can Gas Chromatography identify any lipid compositional change in 
PCLS treated with VAP-1? 
 
Our data in chapter 5 (Figures 5.19 and 5.20) showed that SSAO activity resulted in 
accumulation of lipid within liver slices and that VAP-1 null animals had reduced 
steatosis on a HFD.  Next we wanted to examine whether the activity of SSAO was 
able to alter the composition of lipid species observed in the diseased livers.  We 
found on the whole that there were very few compositional differences between 
treatments. However in PCLS treated with H202 we found a lipid species with an RT 
of 9.59, which was absent from the other samples. Again this lipid was not 
represented in our generic standard and therefore could not be assigned. Similarly a 
lipid species with an RT of 24.62, which was detected in both MA and MA+VAP-
1+BEA treated PCLS could not be assigned.  Of note, we again found that there was 
variability between samplings of extracts made from the same liver samples in this 
analysis, for example the unique lipid species detected in the H202 treated sample was 
not detected in all repeats (Figure 6.3). 
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Figure 6.3: GC analysis of fatty acid components in PCLS after stimulation of 
VAP-1 
PCLS were pretreated with either methylamine 200μm, VAP-1 500ng, H2O2 10μM, 
or a combination of methylamine+VAP-1, and methylamine+VAP-1+BEA for 
approximately 18 hours and then for 6 hours with 250μm PA.  PCLS were then fixed 
and lipid was extracted using Folch method, derived to methyl esters and analysis of 
lipid components was carried out using GC. A standard containing 37 methyl esters 
was run alongside the liver extracts and RT times for each eluate (control and treated) 
was assigned to lipids by comparing to the standard. Typical GC chromatogram of 
lipid extracts from control PCLS (A) and slices after exposure to either VAP-1+MA 
(B) or H202 (C) are shown. The red circle in the H2O2 chromatogram (C) indicates a 
peak, which is absent in the control sample.  A Table of RT with lipid assignments for 
FA in PCLS treated with all stimuli (D) is also shown. Here RT indicated in red are 
those found in a particular treatment only.  Data shown is from triplicate analyses for 
a single donor liver.   
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6.3.3 Identification of lipid species in normal and diseased livers using Matrix 
Assisted Laser Desorption Ionization-Mass Spectrometry (MALDI-MS)  
Whilst our pilot chromatographic analyses hinted at compositional differences in 
treated liver samples, and showed promise for detection of disease-specific signatures, 
we were limited by availability of standard lipids and inter-sample variation. We were 
also unable to define the cellular origin of identified lipids. MALDI-MS allows the 
analysis of the full spectrum of lipids in a sample based upon structural information 
and can be combined with imaging to begin to assign species to cellular origin. Thus 
we continued our analysis using these approaches and Figure 6.4 represents an 
overview of this.   
 279 
 
Figure 6.4: Schematic representation of workflow and of data acquired using 
MALDI-MS and MALDI-MSI 
Normal or diseased livers were used for the extraction of lipids or for generation of 
tissue sections.  Lipids were extracted using the Folch method and spotted on to a 
steel MALDI target plate or thin tissue sections were cut onto a MALDI target (A). 
The matrix CHCA was applied on top of the lipid extracts using a pipette, whilst an 
artist’s brush was used to apply a homogenous layer of matrix onto tissue sections 
(B).  The samples were pulsed with a laser which causes the generation of positively 
charged ions which can arise in a variety of positively charged forms such as the H
+
, 
Na
+
 and K
+
 ions (C) These ions were detected by the spectrometer which generates 
m/z spectra allowing identification of differences between normal and diseased livers. 
Further structural information was also obtained by fragmenting a particular ion via 
MS/MS (D).  MALDI-MSI allows the generation of ion images where the number of 
counts for each m/z peak are, displayed pixel wise according to location of sample 
origin on the section.   
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In order to analyze our samples using MALDI-MS we firstly optimized conditions 
necessary to run the experiment.  A range of different matrix components, were 
analyzed to see which would give the highest ion counts in the lipid range of the 
spectra by MALDI-MS.  We found that the CHCA matrix gave the highest ion counts 
and thus this matrix was employed for all future experiments (data not shown).  The 
most commonly detected phospholipids (Astigarraga et al., 2008) in positive ion 
mode by MALDI-MS are phosphocholine-containing species, which are detected in 
the m/z 700-900 region.  Furthermore MALDI-MS can give rise to three different 
ionic states of the same lipids detected in a sample, the [M+H]
+
, [M+Na]
+
 and 
[M+K]
+
 forms.  An example of a typical MALDI-MS spectrum we obtained from a 
normal liver is represented in Figure 6.5A, with an enlargement of the 700-840 region 
containing commonly detected phosphocholine-containing species (Astigarraga et al., 
2008), which were also abundant in our specimens, phospholipids are highlighted on 
the spectrum and indicated in a table  (Figure 6.5B and 6.5C).   
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Figure 6.5: Typical analysis of abundantly detected phosphocholines in normal 
liver lipid extracts using MALDI-MS 
Folch extract samples of normal liver were spotted on to a multi well MALDI target 
plate, overlaid with a matrix solution (CHCA) and samples were analyzed on a hybrid 
TOF-MS and data were acquired in positive reflectron mode. (A) Representative 
spectra from normal liver in the m/z 50-1000 range with inset box indicating the m/z 
700-840 region (B) enlarged spectrum of the m/z 700-840 region with symbols 
indicating typical phosphocholine lipids as shown in (C) a table of abundantly 
detected phosphocholine lipids in human liver. Data shown is representative spectra 
from normal livers N=2, with 10 replicate spots for each sample.   
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Next, Folch extracts from samples of normal and diseased liver were spotted onto the 
MALDI target plate and representative MALDI-MS spectra from normal, steatotic, 
NASH, ALD and PBC are presented in Figure 6.6. The inset pictures highlight the 
spectra from the lipid region (m/z 700-900), and whilst many peaks are apparent in all 
samples, there are clear differences between disease types.  Our initial analysis 
revealed that there was some key compositional differences observed between 
samples, which included peaks at m/z 304 (Arachidonyl amine), 326 (10-nitro-
9Z,12Z,octadecadienoic acid), 478 (glycerophospholipid), 502, 
(glycerophospholipid), 734 (glycerophospholipid), and 810 (Acetyl Co-A) (326 
indicated on spectrum, Figure 6.6), which will be discussed in more detail below. 
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Figure 6.6: Analysis of normal and diseased liver lipid extracts using MALDI-
MS 
Folch extract samples of liver were spotted on to a multi well MALDI target plate, 
overlaid with a matrix solution (CHCA) and samples were analyzed on a hybrid TOF-
MS and data were acquired in positive reflectron mode. MALDI-MS spectra shown 
represent phospholipids in (A) normal, (B) steatotic, (C) NASH, (D) ALD and (E) 
PBC liver extracts. Data shown are spectra from m/z region 50-1000 with inset 
regions at m/z 700-900 and are representative spectra from normal N=2, Steatotic 
N=2, NASH N=1, ALD N=1 and PBC N=1 livers with 10 replicate spots for each 
sample.   
 
 
 284 
The ability to discriminate these and other species, which distinguish disease types, 
led us to perform PCA on our dataset. Restricting analysis to the first principle 
component showed that normal livers could be completely separated from the 
diseased livers (steatotic, NASH, ALD and PBC, see Figure 6.7A) and if analysis was 
extended to three components diseased livers were clearly separable from each other 
(Figure 6.7B).  Importantly diseases that are difficult to discriminate histologically 
(NASH and ALD) were separable, and there was clear distinction between simple 
steatosis and NASH. An example of some of the data, which contributed to this 
analysis, is shown in Figure 6.8. We found that peaks for m/z 326 and 304 were most 
abundantly detected in normal livers compared to diseased livers whilst peaks m/z 478 
and 502 were abundantly detected in NASH and Figure 6.8 and 6.9 show overlay of 
the mass spectra for m/z 326, 304, 478 and 502 in normal and diseased livers.  
 
We then analyzed the spectrum for normal and disease states specifically in the region 
700-900 since most phosphocholine-containing lipids are detected in this region. 
Interestingly we found a peak at m/z 734, which was more abundant in NASH and 
ALD liver than steatotic and normal samples. This is demonstrated by an overlay of 
m/z 734 in normal and diseased livers (Figure 6.10A), in order to try and identify this 
peak we carried out MS/MS fragmentation analysis to try and obtain some structural 
information we found presence of m/z 184 and m/z 86 in MS/MS fragmentation 
analysis (see inset in Figure 6.10A) suggesting this peak is a phosphocholine lipid, 
which contains two palmitic acid side chains. In addition we found peak m/z 810 was 
more abundant in NASH, ALD and PBC livers.  
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Figure 6.7: Principle component analysis of normal and diseased liver lipid 
extracts 
PCA was performed on data generated from MALDI-MS spectra of normal, steatotic, 
NASH, ALD and PBC lipid liver extracts.  Folch extract samples were spotted on to a 
multi well MALDI target plate, overlaid with matrix solution (CHCA) and analyzed 
on a hybrid TOF-MS, data acquired was in positive reflectron mode and data shown 
are from normal N=2, Steatotic N=2, NASH N=1 (established cirrhosis), ALD N=1 
and (established cirrhosis with type II diabetes), PBC N=1 (biliary cirrhosis), with 10 
replicate spots for each sample. (A) PCA analysis of normal and diseased liver based 
on the first two-principle components (B) PCA analysis of normal and diseased lipid 
liver extracts based on the first three principle components.  PCA analysis was 
performed by Alan M Race. 
 286 
 
Figure 6.8: Analysis of m/z peak 304 and 326 in normal and disease lipid extracts 
using MALDI-MS 
Folch extract samples from each disease state were spotted on to a multi well MALDI 
target plate, overlaid with matrix solution (CHCA) and analyzed on a hybrid TOF-
MS, data acquired was in positive reflectron mode. (A) Overlay of mass spectra for 
peak m/z 326 in normal, steatotic, NASH, ALD and PBC lipid liver extracts, Overlay 
spectra shows more abundance of this ion in normal (B) Overlay of mass spectra for 
peak m/z 304 in normal, steatotic, NASH, ALD and PBC lipid liver extracts, Overlay 
spectra shows more abundance of this ion in normal.  Data shown are representative 
spectra from normal N=2, steatotic N=2, NASH N=1, ALD N=1 and PBC N=1 livers 
with 10 replicate spots for each sample 
 
 +TOF MS: 30 MCA scans from Sample 4 (NL211106 4) of Normal Vs Disease extracts_24_02_2011SET1.wif...
a=3.56473558766324010e-004, t0=-3.71960707223915960e+001
Max. 4.0e4 counts.
304.10 304.15 304.20 304.25 304.30 304.35 304.40 304.45 304.50
m/z, Da
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
In
t
e
n
s
it
y
, 
c
o
u
n
t
s
304
Normal 
Steatotic 
NASH 
ALD 
PBC 
 
A 
B 
R
e
la
ti
v
e
 I
n
te
n
si
ty
 %
 
m/z  
 +TOF MS: 30 MCA scans from Sample 4 (NL211106 4) of Normal Vs Disease extracts_24_02_2011SET1.wif...
a=3.56473558766324010e-004, t0=-3.71960707223915960e+001
Max. 4.0e4 counts.
326.1 326.2 326.3 326.4 326.5 326.6 326.7
m/z, Da
0%
20%
40%
60%
80%
100%
R
e
l.
 I
n
t
. 
(
%
)
326
m/z  
R
e
la
ti
v
e
 I
n
te
n
si
ty
 %
 
Normal 
PBC 
Steatotic 
NASH 
ALD 
 287 
 
Figure 6.9: Analysis of m/z peak 478 and 502 in normal and disease lipid extracts 
using MALDI-MS 
Folch extract samples from each disease state were spotted on to a multi well MALDI 
target plate, overlaid with matrix solution (CHCA) and analyzed on a hybrid TOF-
MS, data acquired was in positive reflectron mode. (A) Overlay of mass spectra for 
peak m/z 478 in normal, steatotic, NASH, ALD and PBC lipid liver extracts, (B) 
overlay spectrum for ion m/z 502.  Data shown are representative spectra from normal 
N=2, Steatotic N=2, NASH N=1, ALD N=1 and PBC N=1 livers with 10 replicate 
spots for each sample.   
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Figure 6.10: Analysis of m/z peak 734 and 810 in normal and disease lipid 
extracts using MALDI-MS 
Folch extract samples from each disease states were spotted on to a multi well 
MALDI target plate, overlaid with matrix solution (CHCA) and analyzed on a hybrid 
TOF-MS, data acquired was in positive reflectron mode. (A) Overlay of mass spectra 
for peak m/z 734 in normal, steatotic, NASH, ALD and PBC lipid liver extracts, with 
inset spectrum showing MS/MS data for this ion suggesting this peak is a 
phosphocholine lipid and (B) Overlay spectrum for ion m/z 810.  Data shown are 
representative spectra from normal N=2, steatotic N=2, NASH N=1, ALD N=1 and 
PBC N=1 livers with 10 replicate spots for each sample.   
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6.3.4 Identification of lipid species in wild type and VAP-1 KO mice using 
Matrix Assisted Laser Desorption Ionization-Mass Spectrometry 
(MALDI-MS)  
Our pilot data from human tissue suggested that MALDI-MS could be used to assess 
global compositional changes in hepatic lipid profiles in disease and that we could 
identify some of the component lipids by MS/MS. Next we wanted to evaluate the 
livers from our VAP-1 null animals on a HFD to see if reduced steatosis was 
accompanied by compositional change in resident lipids. We also wondered whether 
these studies would show whether livers from mice fed a HFD reflect the picture seen 
in human steatosis or NASH.  
 
Figure 6.11 shows a typical mass spectrum generated from normal mouse liver fed on 
a HFD with key phosphocholine containing lipids indicated and highlighted in the 
table.  Of note again the most abundant species identified are the same as those found 
in the human livers and several ionic forms of each are present.  
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Figure 6.11: MALDI-MS Analysis of phosphocholine lipids present in normal 
mouse liver lipid extracts 
Folch extract samples were spotted on to a multi well MALDI target plate, overlaid 
with matrix solution (CHCA) and analyzed on a hybrid TOF-MS, data acquired was 
in positive reflectron mode. (A) A representative spectra from the lipid region (m/z 
700-880) of normal mouse liver fed on a HFD, with symbols indicating key 
phosphocholine lipids, which are highlighted in the table below (B) Data shown is 
representative of spectra from normal mouse liver (N=3), with 10 replicate spots for 
each sample spotted.   
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Interestingly by examination of spectra obtained from WT and VAP-1 KO mice fed 
on a HFD we found key differences between the samples. Thus some m/z peaks were 
present in WT but not VAP-1 KO mice and some m/z peaks were present in VAP-1 
KO but not WT mice. These findings are summarized in Table 6.1 and also on spectra 
as highlighted see Figure 6.12 and 6.13.  Furthermore the peak at m/z 326, which we 
observed to be most abundant in normal compared to other diseases in human 
specimens, was only detected in VAP-1 KO mice (highlighted on spectrum with a red 
circle, Figure 6.12B).  We also identified a peak at m/z 782, which was present in 
VAP-1 KO mice only.  Finally we performed PCA analysis on the entire MALDI-MS 
datasets, which showed that the two groups could not be separated (Figure 6.14A) and 
MALDI-MSI image of m/z 782 did not reveal any clear differences between WT and 
VAP-1 KO mice (Figure 6.14B).   
 292 
                          
Table 6.1: Table of m/z peaks present in WT and VAP-1 KO mice 
Table of m/z peaks indicating those which are present in WT mice but absent from 
VAP-1 KO mice or those present in VAP-1 KO but absent in WT mice. Folch extract 
samples of each mouse group were spotted on to a multi well MALDI target plate, 
followed by a matrix solution (CHCA) and samples were analyzed on a hybrid TOF-
MS, data acquired was in positive reflectron mode. Data shown are m/z values 
obtained from representative spectra from WT N=3 and VAP-1 KO N=3 with 10 
replicate spots for each sample spotted. 
 
T
A
G
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Figure 6.12: MALDI-MS analysis of hepatic lipid composition of WT and VAP-1 
KO mice in m/z region 50-1000  
Folch extract samples from each mouse group were spotted on to a multi well 
MALDI target plate, overlaid with matrix solution (CHCA) and analyzed on a hybrid 
TOF-MS, data acquired was in positive reflectron mode. Images show entire MALDI-
MS spectra from m/z region 50-1000 in (A) WT and (B) VAP-1 KO mice lipid liver 
extracts. Data shown are representative spectra from wild type N=3 and VAP-1 KO 
N=3 livers with 10 replicate spots for each sample. The black circles in (A) indicate 
m/z peaks which are only present in WT mice and in (B) m/z peaks which are only 
present in VAP-1 KO mice, and the red circle in (B) indicates peak with m/z 326 
which is only present in VAP-1 KO and was most abundant in normal human livers.  
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Figure 6.13: MALDI-MS analysis of hepatic lipid composition of wild type and 
VAP-1 KO mice in m/z region 400-880 
Folch extract samples from each mouse group were spotted on to a multi well 
MALDI target plate, overlaid with matrix solution (CHCA) and analyzed on a hybrid 
TOF-MS, data acquired was in positive reflectron mode. Images show enlarged 
MALDI-MS spectra from m/z region 400-880 in (A) WT and (B) VAP-1 KO mice 
lipid liver extracts. Data shown are representative spectra from WT N=3 and VAP-1 
KO N=3 livers with 10 replicate spots for each sample. Black circles in (A) indicate 
m/z peaks, which are only present in WT mice and in (B) m/z peaks, which are only 
present in VAP-1 KO mice.   
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Figure 6.14: Principle component analysis of wild type and VAP-1 KO mice liver 
lipid extracts 
Tissue sections from WT and VAP-1 KO mouse livers were placed on a MALDI 
target plate, overlaid with matrix solution (CHCA) and analyzed on a hybrid TOF-
MS, data acquired was in positive reflectron mode. Ion images for m/z 782 were 
generated using oMALDI 5.1 (AB Sciex). PCA was performed on data generated 
from WT and VAP-1 KO liver lipid extracts.  (A) PCA analysis of WT and VAP-1 
KO mice lipid liver extracts based on the first two principle components, (B) ion 
images showing localization of m/z 782.35 in WT and VAP-1 KO mouse livers. Data 
shown was generated from representative spectra and images from WT N=3 and 
VAP-1 KO N=3 livers with 10 replicate spots for each sample in the MALDI-MS 
analysis.  PCA analysis was performed by Alan M Race.    
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6.3.5 Imaging of lipid species in normal and diseased livers using Matrix 
Assisted Laser Desorption Ionization-Mass Spectrometry Imaging 
(MALDI-MSI)  
Finally we wanted to examine whether we would be able to spatially locate the 
origins of the m/z peaks using MALDI-MSI where the spatial distribution of a 
particular peak can be visualized by plotting the intensity of that peak to generate an 
ion image.  We were particularly interested in the MALDI-MS peak at m/z 734 since 
it was most abundant in NASH compared to normal liver.  Thus MALDI-MSI images 
of m/z 772 (the most abundant peak in extracts is the [M+H]
+ 
state which corresponds 
to m/z 734 whilst in tissue the most abundant peak is the [M+K]
+ 
state which 
corresponds to m/z 772)
 
were generated for normal, steatotic, NASH, ALD and PBC 
livers (Figure 6.15B).  Panel A shows the spectra for this peak in all tissues and again 
confirms the abundance in NASH liver and presence in all liver samples. The inset 
shows the MS/MS fragmentation analysis. This molecule is identified as PC: 32:0 
[M+H]
+
. 
 
The normal liver tissue distribution appeared homogenous for this peak with some 
intense signals in the perivascular areas of the steatotic specimen (indicated by arrows 
in Figure 6.15B). In contrast in the NASH liver there was intense detection of this 
peak within fibrotic regions (indicated by arrow in Figure 6.15B), which was also 
reciprocated in the ALD and PBC livers (indicated by arrows in Figure 6.15.B for 
each disease state), although not to the extent seen in the NASH sample. If we 
combined and overlaid the ion image of m/z 772 in NASH liver with an optical image 
of a serial H&E stained section, we noted excellent correlation (indicated by black 
arrow in ion image of 772 in NASH, white arrow in H&E stained NASH, and white 
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arrow in NASH H&E and ion image overlay, Figure 6.15C) of the ion localization 
and obvious gross histological features. These co-localizations are in an orientation 
suggestive of areas of extensive fibrosis in the NASH specimens (see Figure 5.11, 
Chapter 5) and of note tend to be the same areas where we see extensive VAP-1 
protein expression (Figure 4.5, Chapter 4). 
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Figure 6.15: MALDI-MS and MALDI-MSI analysis of m/z 734 peak in normal 
and diseased liver extracts 
Folch extracts from each liver were spotted on to a multi well MALDI target plate, 
overlaid with matrix solution (CHCA) and analyzed on a hybrid TOF-MS.  Data 
acquired was in positive reflectron mode, and then MS/MS fragmentation analysis 
was carried out on this ion. Ion images were generated by mounting tissue sections 
onto a MALDI target plate, CHCA matrix was applied with an artistic brush and 
tissue sections were analyzed using a TOF-MS (oMALDI 5.1 (AB Sciex).  (A) Shows 
the overlay of mass spectra for peak m/z 734 in normal, steatotic, NASH, ALD and 
PBC lipid liver extracts, with inset spectrum showing MS/MS data for this ion. (B) 
Shows representative MALDI-MSI images for this ion in normal and diseased livers 
and (C) is an overlay of MALDI-MSI for ion 772 generated using GNU image 
manipulation program 2.6, and a H&E image of a serial section of NASH liver. The 
arrows in (B) highlight areas with high intensity for this ion and the white arrows in 
overlay images (C) shows good correlation with histological features.  Data shown are 
representative spectra and images from normal N=2, Steatotic N=2, NASH N=1, 
ALD N=1 and PBC N=1 livers with 10 replicate spots for each sample for the 
MALDI-MS analysis.  Image manipulation, was performed by Dr Josephine Bunch.   
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6.4 Discussion 
Thus far this thesis has established a role for VAP-1 in glucose uptake and lipid 
accumulation and altered expression of both glucose and lipid transporters, which 
may give, rise to a distinct lipid signature in diseased tissues with different basal 
VAP-1 activities, or in tissues where we have triggered VAP-1 activity exogenously.  
Therefore we were interested to investigate whether there were any compositional 
lipid differences in PCLS treated with VAP-1 or from livers from VAP-1 KO and WT 
mice and whether pathological changes could be detected in this chapter using mass 
spectrometry.  In summary using MS we detected compositional differences between 
normal and diseased tissue and in WT and VAP-1 KO mice fed on a HFD using GC 
and MALDI-MS. In particular MALDI-MSI allowed visualization of m/z 734 
phosphocholine containing lipid species distinctly located in fibrotic regions of 
NASH.  
 
6.4.1 Gas chromatography reveals compositional lipid differences in normal 
and diseased livers.   
To begin we used GC to examine the compositional lipid differences in normal and 
diseased tissue.  We found that GC was effective in providing qualitative differences 
between tissues.  GC identified the saturated FA Myristate and the polyunsaturated 
gamma linolenate to be present only in steatotic livers.  Interestingly gamma 
linolenate which was only present in one steatotic liver has been previously shown to 
be elevated in NAFLD and NASH (Puri et al., 2009) and has also been shown to 
suppress weight regain in previously obese individuals (Schirmer and Phinney, 2007). 
Salt esters of palmitic, stearic, oleic and arachidonic acid were present in normal and 
diseased livers.  Stearic acid has been shown to increase markers of ER stress (Zhang 
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et al., 2011b), whilst PA has been shown to induce ER stress and apoptosis (Wei et 
al., 2006), (Listenberger et al., 2001) which is reduced by the presence of some lipids 
for example α-Linolenic and Oleate acid (Zhang et al., 2011b), (Wei et al., 2006).  
These findings suggest there are distinct lipid species between normal and diseased 
livers, however these may reflect changes in the liver during organ collection or tissue 
processing, and support the abundance of PA and OA in tissue and our use in in vitro 
uptake assays. 
 
Puri et al have shown arachidonic acid to be decreased in NASH (Puri et al., 2007) 
and its oxidized products are elevated  (Puri et al., 2009). We found it was present in 
normal and NASH however we could not quantify it and thus it could be less in 
NASH livers.  Furthermore in support of our data a HFD on obese mice resulted in an 
increase in palmitic, stearic and oleic acid identified using GC/MS (Kim et al., 2011).  
GC can be used to identify quantitative differences however appropriate calibration of 
GC needs to be carried out which was beyond the scope of this investigation.  Thus 
although we have not quantified the levels of these FA we propose there may be a 
complex interplay between the different quantities of these FAs, which may change as 
a result of affording the cell protection or damage.  It is important to note that there 
were four unidentified species, which were present only in steatotic or normal livers 
or not present in NASH as the standard used in this assay was unable to assign lipids 
to some retention times, as they were not present in the standard.  Similar difficulties 
in identifying lipid species has been reported previously (Kim et al., 2011) and 
highlight the importance of standard selections in such technologies.  
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The Advantages of using GC are that it is fast, only a small amount of sample is 
needed thus this method with the appropriate set up would be excellent in a hospital 
setting in the non invasive diagnosis of NASH. In this investigation we have used 
liver tissue, however we would need to check blood for correlates however it is 
important to check for markers via all routes in pilot investigations to look for good 
serological markers.  Diagnosis of NASH in many cases requires biopsy and 
histological examination (Brunt et al., 1999), (Kleiner et al., 2005) which in some 
cases can be associated with complications (Bravo et al., 2001), (Piccinino et al., 
1986).  Certainly a recent report has successfully used GC and exhaled breath samples 
to discriminate between patients with NASH and those without (Verdam et al., 2013).  
Thus GC of blood or other easily collected samples may provide a rapid and non-
invasive method for the diagnosis of NASH in conjunction with other non invasive 
methods such as ultrasonography, transient elastography and FibroMeter (Festi et al., 
2013).   
 
6.4.2 Gas chromatography reveals compositional lipid differences in PCLS 
treated with VAP-1 and its metabolites  
Next we wanted to examine whether we could identify compositional lipid differences 
resulting from VAP-1/SSAO activity in PCLS.  On the whole we found that there 
were very few compositional differences which could reflect the short time point used 
in this study in comparison to other studies looking at a role for SSAO in lipid 
homeostasis which have used more chronic exposures (Marti et al., 2001), (Fontana et 
al., 2001), (Mercier et al., 2001), (Stolen et al., 2004a) and could also be reflective of 
the FA used as a source in these experiments.  Nevertheless we did observe presence 
of two separate species one which was present in the hydrogen peroxide treated 
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sample only and the second that was only present in VAP-1+MA and VAP-
1+MA+BEA treated PCLS, since hydrogen peroxide can also be produced by other 
reactions careful interpretation is needed.  In addition the species detected in 
hydrogen peroxide treated samples was not detected in all repeats thus this result 
would need to be further validated, and again limitations in the standard used means 
that the identity of these species remains unknown.  However this data suggests that 
interventions using PCLS can be detected and examined using GC.   
 
6.4.3 Use of MALDI-MS to detect pathological changes in normal and diseased 
livers 
We found that the matrix CHCA gave the highest ion counts in comparison to other 
commonly employed MALDI matrices used in lipid analysis (Schiller et al., 2001), 
(Schiller et al., 2007) this suggests that tissues from different organs or species give 
variable ion counts based on different matrix used.  We found that our samples 
contained abundantly detected phosphocholine phospholipids as shown previously 
(Emerson et al., 2010).  Interestingly MALDI-MS also revealed there were some 
compositional differences between normal and diseased livers for example normal 
liver most abundantly expressed peaks at m/z 326 and m/z 304 compared to all other 
diseases tested.  Although these peaks could not be quantified, overlay spectra did 
show clear abundance reflective of ion counts. It is interesting to note that m/z 326 is a 
10-nitro-9Z, 12Z, octadecadienoic acid. Other octadecadienoic acids such as 13-oxo-
9-11-octadecadienoic acid have been shown to decrease hepatic TAG in obese mice 
by acting as a PPARα agonist (Kim et al., 2012) and it is interesting to speculate 
whether our species with m/z 326 could behave in a similar manner.  Furthermore we 
then analyzed spectra in the region 700-900 since most phosphocholine containing 
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lipids are detected in this region and almost 65% of the TAG pool is said to be 
derived from phosphatidylcholines (van der Veen et al., 2012) which may have 
implications in NASH pathogenesis.  We were able to identify peaks with increased 
abundance in NASH, which hints at distinct lipodomic profiles in NASH identifiable 
via MALDI-MS.  For example m/z 810 may be Acetyl Co-A, an intermediate 
metabolite of both glucose and lipid metabolism, which was abundantly, detected in 
the NASH, ALD and PBC livers.  Furthermore the MALDI-MSI peak of m/z 772  has 
also recently been detected by Wattacheril et al in NASH (Wattacheril et al., 2013).   
 
The ms/ms analysis of m/z 734 revealed this was a phosphocholine lipid containing 2 
PA side chains.  This is interesting to note since activation of the inflammasome in 
macrophages/kupffer cells has recently been shown to be jointly activated by palmitic 
acid and Toll Like Receptor 2 (TLR2) and hence contributing to the development of 
NASH (Miura et al., 2013).  Furthermore incubation of hepatocytes with PA has been 
shown to increase expression of IL-8 giving further support for the role of PA in the 
inflammatory process in NASH (Joshi-Barve et al., 2007). It must be noted that 
phospholipids are the most abundantly detected lipids in tissue since they are major 
constituents of lipid membranes. However these have also been shown to suppress 
signal from other lipids in MALDI analysis (Petkovic et al., 2001), thus its possible 
that we may not be detecting some mechanistically important lipids in these samples.  
Amendments to the current protocol for example using phospholipase treatment, may 
overcome this problem (Sparvero et al., 2012) and further lipid analysis could be 
improved by using additives such as nitrates (Griffiths and Bunch, 2012).   
 
 304 
Regardless of our current technical limitations, PCA analysis on our data set allowed 
complete separation of normal and diseased livers. This confirms that there are 
distinct lipodomic profiles between normal and diseased liver and in addition between 
each disease state (e.g steatosis and NASH were separable).  However it must be 
noted factors such as age and sex of donors as well as grade of fibrosis or cirrhosis 
may influence the separation of data in the PCA analysis.  Although our results are 
preliminary and we acknowledge our samples numbers would need to be greatly 
enhanced before any clear distinctions can be made, it is clear that MALDI-MS can 
be used to identify distinct lipidomic profiles in NASH and hence possibly be used in 
disease diagnosis as reported previously (Zaima et al., 2009).  Although our analysis 
has focused on invasive procedure involving tissue biopsy a less invasive method for 
example blood collecting would improve the utility of MALDI-MS as a clinical tool. 
For example other MS techniques have been used with non-invasively collected 
methods such as breath samples in both humans and animal models for distinguishing 
NASH (Millonig et al., 2010), (Aprea et al., 2012).  
 
6.4.4 Use of MALDI-MSI to detect changes in lipid species in wild type and 
VAP-1 knock out mice  
Using MALDI-MSI we were able to identify a number of lipid species, which 
differed between WT and VAP-1 KO mice, suggesting that the presence of VAP-1 
not only alters lipid levels as shown in Chapter 5 but also the composition of lipids.  
This is consistent with other MS studies, which have shown altered lipid composition 
in NAFLD and NASH patients for example Wattacheril et al showed altered 
abundance of PC (Wattacheril et al., 2013), whilst Feldstein et al have shown 
increased oxidized lipid products in plasma of patients with NASH (Feldstein et al., 
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2010).  Furthermore we identified m/z peaks, which were present in WT but not VAP-
1 KO mice, which suggests that VAP-1 activity may lead to oxidation or metabolism 
of parent lipids, which is possibly why we do not see them in the VAP-1 KO mice.  
Certainly some studies have reported presence of oxidized lipid in blood collected 
from NASH patients (Feldstein et al., 2010), however the origins of blood lipids and 
identification of oxidized lipids in the liver remains to be clarified. VAP-1 may 
provide a mechanistic link explaining sources of oxidized lipids and lipid metabolites.  
Certainly the presence of peaks in VAP-1 KO mice but not WT (for example m/z 326, 
which was also abundant in normal liver), suggest that VAP-1 could be suppressing 
key lipid species, or metabolizing them which could generate pathogenic derivatives 
or act as a protective mechanism against injury.  For example we found m/z 326, a 
possible sodium adduct of arachidonic acid, to be present in VAP-1 KO but not WT 
mice and levels of its oxidized product 11-HETE have been shown to be elevated in 
NASH (Puri et al., 2009).  
 
Whilst we were able to identify individual compositional changes, our PCA analysis 
revealed that the WT and VAP-1 KO livers could not be separated. This may reflect 
the ranking system used for the PCA, and high variability between individual 
samples. This type of analysis works best with samples with low signal to noise 
ratios, large variances and is a non-parametric analysis system. It is possible that 
stricter selection of the components could lead to a significant difference with PCA in 
future studies.  However a disadvantage of using PCA is that complicated 
relationships may be missed.  Furthermore TAGs are neutral molecules and hard to 
ionize thus it is possible we may be missing some lipid species in our analysis, which 
would significantly enhance sample separation by PCA.   
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6.4.5 MALDI-MSI allows visualization of lipid species in distinct anatomical 
locations in normal and diseased livers 
Finally we analyzed the spatial distribution of peaks identified by our MALDI 
analysis. In particular here we focussed on m/z 734 (corresponds to peak m/z 772 in 
MALDI-MS) using MALDI-MSI since this was most abundant in NASH.  As stated 
earlier this was a phosphocholine lipid containing 2 palmitic acid side chains, and 
MALDI-MSI confirmed this lipid species was most abundant in NASH and in 
particular in fibrotic regions of NASH, ALD and PBC livers.  Of note these are also 
areas for which we have reported extensive VAP-1 expression (see Chapter 4), 
(Claridge L C, 2009).  Thus it is clear from the MALDI-MS and MALDI-MSI data 
that this lipid species in particular is abundant and distinctly located in NASH as 
shown also by Wattacheril et al (Wattacheril et al., 2013).  Here it is possible that 
ROS generated as a result of VAP-1 activity attack cellular lipids (for example the 
lipid species in question), which could lead to activation of the inflammatory response 
for example in kupffer cells which PA has been shown to induce (Miura et al., 2013).  
Its interesting to note that other studies using MS approaches have identified oxidized 
lipid products distinct in NASH (Feldstein et al., 2010) and have speculated these may 
be a result of free radicals.  Thus whether oxidized products of this species are 
detected in NASH would need further investigation.  Furthermore there is growing 
evidence of distinct localization of various lipids in NAFLD and NASH (Le Naour et 
al., 2009, Wattacheril et al., 2013) suggesting cellular damage in NASH may be an 
orchestrated event related to the type of fat and proteins present in particular 
anatomical locations.   
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This technique serves as a powerful tool for detecting pathological changes in NASH 
as recently shown by (Wattacheril et al., 2013) and thus may aid in biomarker 
discovery for NASH treatment.  In contrast to MALDI-MS, MALDI-MSI avoids the 
need for extraction and purification of samples and the ability to perform tandem MS 
or fragmentation of the ionized samples may permit identification of molecules 
without recourse to standard preparations. Thus biopsy samples taken from NASH 
patients could help identify whether there are key disease biomarkers present. 
Furthermore in contrast to standard histology the identity of hundreds of proteins can 
be observed in a single measurement, reducing time constraints and requirement for 
pre-available detection reagents.   
  
In all it is clear from our study and those of others that these applications can provide 
useful insight into possible disease pathogenesis, progression and diagnosis of 
NAFLD and NASH (Gorden et al., 2011), (Feldstein et al., 2010), (Verdam et al., 
2013), (Wattacheril et al., 2013). With a recent report suggesting the potential of 
using a single section of tissue for both lipid and protein analysis (Steven and Bunch, 
2013), MS represents  a powerful technique reducing time and material requirements.  
Although there are some limitations to these technologies, for example identification 
of molecules is often based on known libraries of species which may not include 
every species detected thus some molecules are not identified for example in our 
study and by other investigators (Zaima et al., 2009), and statistical analysis which are 
often required for such large multivariate data sets may shone some differences we 
feel the advantages outweigh the disadvantages.   
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Future experiments should include identifying for example the glucose and fatty acid 
trafficking proteins which we have shown altered in disease, in a single measurement 
by color coding m/z spectra as shown in a recent method by Fonville et al (Fonville et 
al., 2013).  Furthermore identification of the lipidomic profiles of isolated cells from 
NAFLD or NASH patients would aid in identifying which cells are responsible for the 
disease signature and use of laser microdissection of specific regions of liver would 
be beneficial in assessing disease pathogenesis since phospholipid zonation has been 
suggested to be associated with NASH pathogenesis (Wattacheril et al., 2013).  This 
could be applied to using MALDI-MSI to detect possible localization of lipid species 
after VAP-1 intervention in PCLS.  Furthermore with growing evidence that oxidative 
stress and ROS species lead to development of NASH, and with some MS studies 
linking volatile organic compounds in NASH (Verdam et al., 2013), it would be 
interesting to see of these are VAP-1-derived since VAP-1 is elevated in NASH.  
Thus identifying ROS generated by VAP-1 and their resultant lipid peroxidation 
products could be useful in biomarker discovery and diagnosis for NASH.   
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7 CONCLUSIONS & FUTURE WORK 
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7.1 Overview  
VAP-1 has a well established role in glucose (Enrique-Tarancon et al., 1998), (Morin 
et al., 2001), (El Hadri et al., 2002), (Fontana et al., 2001), (Marti et al., 1998) and 
lipid homeostasis (Morin et al., 2001), (Fontana et al., 2001), (Yu et al., 2002), 
(Carpene et al., 2006), (Mercier et al., 2001), (Subra et al., 2003), (Bour et al., 2005), 
(Marti et al., 2001), (Stolen et al., 2004a) as well as in inflammation (Salmi et al., 
1993), (Tohka et al., 2001), (Merinen et al., 2005), (Lalor et al., 2002), (Lalor et al., 
2007).  VAP-1 levels are increased in NASH, (see Chapter 4), (Claridge L C, 2009) 
but its roles in hepatic glucose and lipid homeostasis were unknown up until this 
thesis (Figures 4.14, 5.19 and 5.20).  In the liver it is able to recruit specific subset of 
cells during the inflammatory process. For example CD16+ monocytes are targeted to 
inflamed and fibrotic locations (Aspinall et al., 2010), whilst it  also supports 
transcellular migration of CD4 lymphocytes  (Shetty et al., 2011).  Furthermore VAP-
1 has potential roles in fibrosis for example sVAP-1 levels correlate with fibrosis 
scores (Claridge L C, 2009) and VAP-1 has been implicated in extracellular matrix 
remodeling by activating HSCs (unpublished observations, Centre for Liver 
Research).  We have shown stimulation of VAP-1 leads to global activation of hepatic 
NF-κB and transcription of target genes (Figures 4.15 and 4.16), and in support of 
data in this thesis, our laboratory has shown that VAP-1 null mice have reduced 
steatosis and fibrosis after exposure to a high fat diet or CCL4 injury (unpublished 
observations, Centre for Liver Research).  Hence VAP-1 has multiple roles in liver 
disease.  NF-κB activation drives inflammatory and fibrotic liver disease, since it has 
been coupled to HSC activation (Elsharkawy et al., 1999) and Watson et al have 
shown that inhibition of NF-κB signaling leads to HSC apoptosis and reversal of 
fibrosis (Watson et al., 2008). Increased NF-κB activation has been reported in ALD 
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patients (Ribeiro et al., 2004) where it is associated with inflammation and fibrosis.  
Our data for VAP-1 activation of NF-κB suggests regulation of key genes such as 
ICAM-1, IL-6 and IL-10 which are associated with the activated HSC phenotype 
(Mann and Smart, 2002).  Hence VAP-1 is a potential regulator of chronic disease 
through modulation of inflammation and fibrosis in addition to the metabolic 
consequences we describe in this thesis. 
 
7.1.1 Physiological relevance of VAP-1 derived glucose and lipid accumulation 
in NASH 
Since this multifunctional protein may do many things in long-term disease processes, 
it presents an interesting therapeutic target. It may initially afford protection to the 
cell, since VAP-1 signaling leads to accumulation of FFAs in PCLS, and TAG 
accumulation in the liver. Hepatocytes may be able to respond directly, or more likely 
we propose sVAP-1 or membrane bound VAP-1 on neighboring cells could promote 
local insulinomimetic effects on hepatocytes in this context. Furthermore it could also 
be recruiting in regulatory T cells (Shetty et al., 2011) or resolution promoting cells 
(Bonder et al., 2005), which can clear up acute inflammatory responses.  
 
In NAFLD upregulation of hepatic VAP-1 could mimic or replace ineffective insulin 
signaling when hepatic IR prevails due to toxic ceramides and diacylglycerol (Samuel 
et al., 2010), in an attempt to regulate and restore glucose and lipid homeostasis 
systemically.  Thus targeting of VAP-1 could potentially be used in ameliorating IR 
in adipose and muscle tissue by using cell directed therapy, or VAP-1 substrates could 
be used in the formulation of anti-diabetic drugs (Bonaiuto et al., 2010).  However 
careful consideration needs to be taken since overexpression of VAP-1 is also 
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associated with diabetes like complications (Stolen et al., 2004a). The supply of 
exogenous lipids and FA from the diet or from adipose tissue depot overloads in an IR 
state could mean there is an increased requirement for VAP-1 activity to mop up 
excess and drive storage.  Glucose would either be used for glycogen synthesis or 
storage, however when glycogen stores are overwhelmed glucose may enter 
glycolysis producing acetyl Co-A and hence used for DNL were the FA may enter 
further oxidation or storage and have potential in causing liver damage.  The 
intermediate metabolite acetyl Co-A intricately links these two pathways.   Increase in 
FFA influx and DNL using glucose as a substrate could potentially add further 
lipotoxicity to the cell.  This would lead to generation of ROS, lipid peroxidation 
products, ER, and oxidative stress (Sanyal et al., 2001), (Neuschwander-Tetri, 2010), 
(Fu et al., 2011).  Furthermore autophagy can lead to liberation of FA from lipid 
droplets (Singh et al., 2009), whilst glucose itself has been shown to induce apoptosis 
in hepatic cells (Chandrasekaran et al., 2010).  Activation of HSCs and NF-κB would 
initiate the immune response, which would eventually lead to fibrosis, cirrhosis and 
even HCC (Feldstein, 2010), (De Minicis et al., 2013), (White et al., 2012), (Fares 
and Peron, 2013), although HCC is associated with cirrhosis, VAP-1 itself has been 
implicated in tumor angiogenesis (Marttila-Ichihara et al., 2009), (Marttila-Ichihara et 
al., 2010), (Ferjancic et al., 2013).  Thus could this process cause upregulation of 
VAP-1 in hepatocytes, fuelling malignant transformation and growth thus linking 
NASH and HCC; this may explain why we have noted Huh7.5 and HepG2 display 
VAP-1 expression and not primary hepatocytes and thus may increase the risk for 
liver failure and mortality.   
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Figure 7.1: The hypothesized role of VAP-1 in the spectrum of NAFLD 
Extra hepatic IR leads to excess FFA to the liver, which can eventually become IR, 
VAP-1 acts as a compensator to insulin by modulating glucose and lipid homeostasis, 
this eventually leads to further lipid loading in the liver, activation of NF-κB not only 
recruits inflammatory mediators but also promotes HSC activation and subsequent 
fibrosis which can eventually lead to HCC were VAP-1 can also increase recruitment 
of myeloid cells.   
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Thus VAP-1 may represent a valuable hepatic therapeutic target against lipid-induced 
damage by ROS, inflammation, and fibrosis, which ultimately progresses, to NASH, 
cirrhosis and HCC.  Additionally blockade of VAP-1 may have beneficial effects in 
other tissues and interestingly some of these tissues are involved in late complications 
of diabetes. For example VAP-1 is expressed in brain (Hernandez-Guillamon et al., 
2012) and associated with brain damage, eye (Almulki et al., 2010) where it is 
involved in diabetic retinopathy (Noda et al., 2009), kidney with involvement in 
nephropathy (Stolen et al., 2004a) and the heart and circulatory system (Salmi and 
Jalkanen, 2006) where its been shown to have a role in atherosclerosis (Stolen et al., 
2004a).  This widens the pool of organs where anti-VAP-1 therapy could be targeted, 
for example VAP-1 inhibition has been shown to prevent endotoxin induced uveitis 
(Noda et al., 2008). Thus the use of VAP-1 in therapy could be exploited by using cell 
directed therapy with vectors targeting VAP-1.  Since the activation of NF-κB is 
important during fibrosis (Sunami et al., 2012), (Xiao et al., 2013) direct blocking of 
VAP-1 will also inhibit fibrosis and inflammation and targeting key genes in the NF-
κB pathway may dampen down key responses.   
  
However careful consideration for treatment needs to be considered since if a patient 
with fibrosis was targeted with therapeutics directed against VAP-1, these may also 
block the influx of resolution-promoting macrophages. Certainly in our lab clinical 
trials testing impact of anti-VAP-1 therapy are being planned.  In one, PBC transplant 
patients will be administered with a bolus of VAP-1 antibody to prevent early 
leukocyte recruitment to the graft, outcomes linked to allograft rejection will be 
assessed along with safety endpoints.  In a similar vein, small molecule inhibitors of 
VAP-1 reduce recruitment of myeloid cells to tumors (Marttila-Ichihara et al., 2010) 
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and clinical trials involving oral administration of VAP-1 antagonist in psoriasis and 
rheumatoid arthritis have begun 
(http://www.proximagen.com/docs/Proximagen%20VAP-1.pdf). The trials to date 
have focused on small molecule inhibitors or humanized monoclonal antibodies for 
therapy, but a recent study reports new thiazole derivatives for inhibiting VAP-1 in 
the treatment of diabetic macula edema (Inoue et al., 2013).  
 
Our data also supports enhanced expression of MAO other than VAP-1 during liver 
disease (Figure 4.2). These enzymes have been linked to depression and inhibitors 
such as selegiline, which targets MAOB, are used in the treatment of depression and 
Parkinson’s disease.  Thus treatment for NAFLD and NASH could be combined with 
existing MAO inhibitors to improve psychological ie: improve sedentary lifestyle and 
pathological mechanisms (Nocito et al., 2007) and possibly MAO derived glucose and 
lipid uptake (Gres et al., 2013).   
 
We accept there are limitations to our study, for example use of PCLS from patients 
or donors where external factors such as insulin state, recent meal patterns and 
whether the person was a deceased organ donor, may impact upon our biological 
readouts.  Furthermore we found variable responses to hydrogen peroxide, which 
could be a deficiency in our experimental design where the use of repeated dosing 
may have overcome local antioxidant defense or it may be that other metabolites of 
VAP-1 which this study has not investigated may initiate responses for example a 
recent report has found similar responses, and have shown oxidation products of 
serotonin such as 5-hydroxyindoleacetic acid (HIAA) have the ability to bind to 
PPARϒ and regulate genes involved in lipid and glucose handling such as FABP4, 
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CD36 and GLUT1 thus leading to lipid storage in adipose tissue (Gres et al., 2013). 
This suggests other AO, and oxidation products other than hydrogen peroxide have 
the ability to regulate glucose and lipid handling in extra hepatic tissue and impact on 
the pathogenesis of NAFLD and NASH.   
 
7.1.2 Hepatic expression of glucose and fatty acid trafficking transporter 
proteins and implications in NASH  
We have documented differential expression of carbohydrate transporters (GLUTS), 
FABPs, FATPs, CAV-1 and members of the LRP receptor family in NASH and ALD 
and in particular in isolated hepatic cells (Chapter 3) which have roles in LCFA 
uptake, FA activation, TAG synthesis, β-oxidation, which may contribute to global 
changes in disease.  Although protein identification for some remains to be confirmed 
this suggests that there are distinct GLUT and lipid trafficking protein signatures for 
hepatic cells and thus disease pathogenesis may not be restricted to one cell alone.   
Thus this study provides a basic framework for future studies focusing on metabolic 
aspects of liver disease looking in to mechanistic links and also as therapeutic targets.    
 
In addition this study identified presence of several GLUTS and fatty acid trafficking 
proteins upregulated in NASH, which in Chapters 4 and 5 were not upregulated due to 
VAP-1 activation.  This suggests mechanisms independent of VAP-1 alter transporter 
proteins, which could be adding further damage to the liver and exacerbating disease 
pathogenesis. Thus these transporters may serve as potential therapeutic or diagnostic 
targets. For example GLUT5 may serve as an attractive therapeutic target in NAFLD 
and NASH since its substrate fructose is widely used in the manufacturing of food 
and drinks and has the potential to induce disease progression from NAFLD to 
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NASH. Fructose metabolism leads to formation of free radicals, and fructose 
consumption has been implicated in NAFLD (Vila et al., 2008), (Ouyang et al., 2008), 
(Zelber-Sagi et al., 2007) and fibrosis severity (Abdelmalek et al., 2010). Fructose 
affects transcription factors ChREBP and SREBP-1c by activating and increasing 
expression of key enzymes involved in DNL thus promoting hepatic steatogenesis 
(Lim et al., 2010).  Specific pharmacological inhibitors are not available, however 
interestingly a dietary supplement (Anthocyanin) prepared from some berries has 
been shown to reduce expression of fructose transporters GLUT5 and GLUT2 (F. 
Alzaid, 2010).  This serves as an effective treatment strategy for preventing fructose-
induced steatosis.  Furthermore blockade of GLUTS could not only hinder onset of 
HCC but also progression due to decreased fuel intake, which is a requirement for 
tumor growth since tumors require a lot of fuel and this enters through GLUT 
transporters, thus blocking these would potentially hinder HCC progression.   
 
Furthermore FABP1 and FABP4 expression was increased in NASH and ALD 
patients and thus may serve as a potential diagnostic biomarkers since these two 
proteins are found in the circulation (Xu et al., 2007), (Xu et al., 2006), (Pelsers et al., 
2002).  In addition FABP1 may be useful in distinguishing NAFLD from NASH since 
its elevated levels in serum have been reported to be related to hepatocellular damage 
(Pelsers et al., 2002).  Also FABP4 has been reported as an early indicator for MetS 
(Xu et al., 2007), (Tso et al., 2007), (Stejskal and Karpisek, 2006).  To note this 
transporter may be beneficial as both a diagnostic and therapeutic target since 
adipocytes lacking FABP4 have reduced lipolysis (Coe et al., 1999) this means that 
blocking this transporter would result in a decrease in FFA flux to the liver.  Giving 
this exciting avenue care must be taken since single KO mice for FABP4 and FABP5 
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only show modest sensitivity to insulin and do not protect from fatty liver (Maeda et 
al., 2003), (Hotamisligil et al., 1996) whilst double KO mice for FABP4 and FABP5 
show increased protection from fatty liver (Maeda et al., 2005).  Therapies, using 
small inhibitor molecules against FABP4 in mice have already proven to be 
successful against type II diabetes and atherosclerosis (Furuhashi et al., 2007).  Thus 
mechanisms such as VAP-1 activity, which may underlie regulation of FABPs, could 
have potential for therapy.   
 
Similarly elevated expression for FATPs in NASH may be therapeutically relevant, 
since for example knockdown of FATP3 in rat hepatocytes results in a decrease in 
lipogenic transcription factors (Bu et al., 2009) and thus disease-induced upregulation 
could contribute to steatogenesis.  However care must be taken before strategies 
targeting these proteins are tested since inhibition for example of FATP5 may lead to 
cholestasis (Musso et al., 2009) since FATP5 deficient mice have been shown to have 
defective bile acid conjugation (Hubbard et al., 2006).  
 
Therefore standard current clinical diagnosis protocols could be used in combination 
with serum detection of some of these soluble proteins we report to, improve 
stratification of patients with hepatic disease. sVAP-1 levels already show promise for 
potential as a serological marker of fibrosis stage (Claridge L C, 2009). FABP-1 could 
distinguish between NAFLD and NASH, FABP4 expression may identify individuals 
at risk of developing NAFLD and LOX, which is reported to be elevated in disease, 
could be used as a serum marker together with sVAP-1 for detecting liver fibrosis 
(Murawaki et al., 1991).  In the clinical setting these proteins could be easily detected 
in serum using GC. 
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7.1.3 Use of GC and MALDI-MS/MSI in diagnosis and biomarker discovery in 
NASH 
This study has shown that MS techniques have the potential to identify differences 
between diseases, in particular the histologically hard to distinguish NASH and ALD. 
To date our analysis has been restricted to the use of liver samples and further studies 
would need to search for serological correlates, which could be screened with non-
invasively collected material.  Our sample numbers need to be increased further to 
assess the validity of our approach but these techniques have much potential for use in 
diagnostics and also biomarker discovery.  For example using these techniques two 
protein biomarkers Carbamoyl phosphate synthase 1 (CPS1) and 78kDa glucose- 
regulated protein (GRP78) have been identified as differentially expressed in NASH 
(Rodriguez-Suarez et al., 2010).  Furthermore our analysis and reported studies 
(Wattacheril et al., 2013) has identified the m/z 772 species specifically targeted to 
fibrous septae areas were we find extensive VAP-1 expression.  It would be 
interesting to see if this species is detected in serum.  Thus this species could be a 
signaling molecule and its functional importance needs further investigation.  
Furthermore isolated cells, PCLS, and MALDI-MSI could be combined to find 
markers or mechanisms linked to spectrum progression in NAFLD.   
 
To conclude, the progression from NAFLD to NASH involves multiple, complex 
mechanisms. However the hallmark is oxidative stress and ROS generation, which 
arise due to lipid overload in the hepatocytes. We propose VAP-1 as a likely 
contributor to this process since in the liver its expression and activity are increased in 
NASH, thus VAP-1 is the “moral molecule” with bad side effects.  On the one hand it 
attempts to do “good” by regulating systemic glucose and lipid homeostasis by 
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mimicking insulinomimetic effects and at the same time activating protective 
mechanisms for example GLUT10, NF-κB1 and IL-10 which have anti-inflammatory 
and ROS mopping up roles.  On the other hand the “bad” side of VAP-1 function 
leads to lipotoxicity to the cell, which ultimately leads to cellular damage, and in the 
long-term liver failure. These findings suggest an interesting role for VAP-1 in the 
liver and future studies will shed more light on this multifunctional protein. 
 
Investigations, which are a direct consequence of our current data, are outlined below.   
 
7.1.4 Future work  
Use of our ex-vivo model to study the effects of VAP-1 intervention in PCLS  
 It would be interesting to see how PCLS from NASH and ALD patients would 
respond to an exogenous supply of VAP-1 and to examine glucose and FA 
transporter expression within them after treatment.  We observed differences 
in basal glucose uptake in VAP-1 null animals and it would be useful to know 
if similar changes in baseline responses are evident in human disease. 
 Silencing of specific transporters highlighted in the present study as a result of 
VAP-1 activation. We need to determine whether the changes we noted are 
functionally relevant. Thus if we knock key genes down do we impair our 
effects of VAP-1 stimulation? 
 It would be interesting to see if the activity of VAP-1 is increasing levels of 
enzymes involved in DNL in PCLS.   
 Use of fructose in glucose uptake assays, and to examine if it drives 
endogenous lipogenesis in the absence of lipid in the liver.  The metabolism of 
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fructose is of key importance in the western diet-induced increase in NAFLD 
and our assays could provide an important means to dissect these effects. 
 Using our ex-vivo model (Karim et al., 2013) our studies could be taken 
further by studying inter organ interactions by taking tissue slices from 
adipose and liver tissue or even muscle.  In a manner similar to a recently 
published report using liver and intestinal slices (van Midwoud et al., 2010b).   
 Efficacy of potential drugs or antibodies targeted against VAP-1 could be 
studied directly in the liver or other organs by using our novel ex-vivo model.  
 
Use of MALDI in diagnostic and biomarker discovery for NASH  
 Using our ex-vivo model and combining it with Liquid Extraction Surface 
Analysis Mass Spectrometry LESA-MS for identification of lipids and protein 
biomarker discovery.  For example we could use MALDI-MSI to validate our 
qPCR data at the protein level in a single measurement, furthermore we could 
analyze serum from patients with normal liver, with NASH, or diabetes and 
then follow this with PCA and see if we can find a discriminator which 
predicts NAFLD or NASH such as FABP4 which has been shown to predict 
MetS.  
 LESA-MS analysis of liver to see if glucose and lipid transporters are 
expressed relative to the zonation of liver.   
 Identification of lipidomic profiles of cells isolated from NAFLD and NASH 
patients to identify cells with specific disease signature.    
 Labeling of FFA and using MALDI-MSI to identify where FFA are 
distributed and incorporated into PCLS after VAP-1 intervention.   
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Other studies  
 It would be interesting to see if there are elevated levels of VAP-1 and sVAP-
1 in the pediatric population where there have been reported cases of NASH 
(Baldridge et al., 1995), (Rashid and Roberts, 2000).  This would further 
provide direct evidence for a link between VAP-1 and NASH.   
 Further more it would be of interest to see if VAP-1 colocalizes with any of 
the glucose or fatty acid trafficking proteins highlighted in this thesis.   
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